Annual ReportMARCH 2023
Dear Shareholders,
2022 was a year of achievement and
evolution for Johnson & Johnson.
We delivered solid financial performance and enhanced
value for our shareholders. We made progress in
two significant undertakings: preparing Johnson &
Johnson to operate as a faster, more focused two-
sector company, and initiating the separation of our
Consumer Health business, Kenvue. We did all of this
in a year when every industry felt the effects of high
inflation, geopolitical tension, and continued supply
chain disruption.
Joaquin Duato
Chairman and CEO
Times like these remind me how privileged I am to
lead Johnson & Johnson as the eighth Chairman
and CEO in our history. Our company has navigated Our total shareholder return (TSR) for 2022
through many economic cycles while addressing outperformed both our Competitor Composite
healthcare’s most important unmet needs for 137 and the S&P 500, contributing to our TSR of nearly
years. Over that time, we have learned how to make 13% compounded annual growth rate over the last
decisions for the long-term. ten years. This significant value creation was made
possible by both our long-term strategic focus
Our deep commitment to Our Credo values, and outstanding execution from teams in all three
and determination to use our size for good, have segments of our business.
long made us a global leader in health. Focusing on
patient and customer needs reinforces our sense MEDTECH
of purpose and urgency. Thanks to the 150,000
We performed in line or ahead of our competitive
employees who embody these ideals—and the
composite for the past two years. Growth was driven
breadth and diversification of our business—2022
by our focused commercial strategies, the successful
was a successful year.
launch of differentiated products, and improvements in
global procedure recovery.
Performance and Priorities
• We delivered on our innovation agenda by
In 2022, we achieved full-year operational sales accelerating the cadence of new products and
growth of more than 6%*. Adjusted net earnings significantly enhancing our MedTech pipeline, which
were $27 billion* and adjusted diluted net earnings included more than 20 programs with over $100
per share were $10.15*, representing increases of million of net present value potential in 2022.
3.2% and 3.6% respectively, compared to 2021. On
• MedTech delivered operational sales growth* across
an operational basis, adjusted diluted net earnings per
all businesses in 2022: Orthopaedics, Surgery,
share increased by 9.2%*.
Interventional Solutions, and Vision.
We invested nearly $15 billion in R&D, deployed • The acquisition of Abiomed positions us as the global
more than $17 billion toward acquisitions, increased leader in heart recovery, immediately enhances our
our dividend for the 60th consecutive year, and MedTech revenue growth, and further diversifies our
returned capital to shareholders through our share portfolio (which now includes 12 priority platforms with
repurchase program. over $1 billion in annual revenue).
Chairman’s Letter 1PHARMACEUTICAL
We strengthened our position as a leading Delivering for the world
pharmaceutical company by delivering our 11th
consecutive year of above-market adjusted
operational sales growth, excluding our #2 $52
COVID-19 vaccine. rank million
in the Access to committed to programs
• Our growth was driven by several of our oncology
Medicine Index, focused on closing
and immunology medicines, including DARZALEX,
reflecting our decades- the racial health gap
ERLEADA, STELARA, and TREMFYA.
long strategy to as part of Our Race to
• We continue to investigate new indications and maximize access to our Health Equity initiative,
transformative regimens to reach even more innovative medicines with investments in
and technologies community health
patients, including DARZALEX in front-line multiple
centers, health
myeloma, ERLEADA in early-stage prostate cancer,
literacy education,
TREMFYA in Crohn’s disease and ulcerative colitis, and $5+
and increasing racial
RYBREVANT in combination with lazertinib in front-line, billion
diversity in the
non-small-cell lung cancer with EGFR mutations.
global impact spend healthcare talent
• Investment in our pipeline further strengthened our with small and pipeline and workforce
portfolio of multiple myeloma medicines. In addition diverse suppliers
to the launches of CARVYKTI, our first cell therapy,
10
and TECVAYLI, a first-in-class bispecific antibody, we African
5
submitted a BLA for talquetamab, an investigational, consecutive countries
off-the-shelf bispecific antibody.
years
where a $15 million
of recognition with commitment from the
CONSUMER HEALTH
a CDP A-List rating Johnson & Johnson
We made significant strides toward the separation of for our leadership in Foundation to the Africa
the business into an independent company while also climate action Frontline First Catalytic
delivering solid performance for the year. Fund is providing
support to community
• We rolled out the Kenvue name and brand, reflective of 12 health workers
weeks
both Johnson & Johnson’s storied history and Kenvue’s
bright future as a standalone organization. of paid parental leave
2.2
for qualified Johnson billion
• We appointed leadership, including Thibaut Mongon as
& Johnson employees
CEO Designate, Paul Ruh as CFO Designate, and Larry
around the world doses of VERMOX
Merlo, former Chairman and CEO of CVS, as Non- donated since 2006 to
Executive Chair Designate of Kenvue. facilitate treatment of
100% intestinal worms
• Starting in 2023, we began operating our consumer
business as a company within a company. Earlier this
renewable
year, Kenvue filed a Form S-1 with the SEC, giving us
electricity
the option to pursue an IPO as a potential step in the
separation, and we remain on track to complete the secured for our
process during 2023. operations in Brazil
through a Direct
We know that to have the greatest impact on patients, Power Purchase
we must continue prioritizing the most promising Agreement
opportunities. Our ongoing emphasis on building starting in 2023
digital capabilities, including AI, data science, and
intelligent automation, will fuel the next wave of
innovation at the intersection of science and technology.
2 Chairman’s LetterDelivering for investors
60 $17.7 #1
straight years billion rank
of increased dividends invested in mergers onFortune’s Most Admired
and acquisitions Companies list for the
Pharmaceutical industry
3
number of 29
companies ~65%
brands and platforms
in the world with a AAA
credit rating, including with more than $1 billion of 10-year free cash flow*
Johnson & Johnson in sales in 2022 returned to shareholders
* Cash flow from operating activities less
additions to property plant and equipment
$14.6
billion
invested in R&D
The Opportunity and Responsibility to Lead As the world evolves, Johnson & Johnson will evolve
ahead of it. We know we can do this because we’ve
As I met with customers, partners, government officials,
done it so many times before. Putting patients at the
and employees around the world during my first year
center of all that we do keeps us looking forward and
as CEO, I was constantly reminded of what the world
open to opportunity.
expects from us. We are a partner of choice. People
depend on us to deliver, and they want us to succeed. We have achieved success for more than a century
Johnson & Johnson is held in the highest regard and by staying true to our mission of serving patients
held to the highest standards—as we should be. This and families, doctors and nurses, our employees and
affirms our purpose and motivates us every day. communities, and all others who depend on us. We
have so much more we can do for the world, and
These standards were set in no small part by my
there’s no time to waste.
predecessor, Alex Gorsky. I am deeply honored to
serve as Chairman and CEO following his retirement.
Alex laid a strong foundation for the future, anchored in
Sincerely,
the people of Johnson & Johnson. They have always
been our greatest strength, and their commitment to
Our Credo fills me with confidence and inspiration
every day.
Joaquin Duato
Chairman and CEO
2023 will be one of the most important years in our
history—a new chapter not just for one, but two leading
global companies. Johnson & Johnson is uniquely
positioned to lead our industry through a fast-moving
healthcare landscape.
*Non-GAAP Measures: Operational sales growth excludes the effect of translational currency. Adjusted net earnings and adjusted net earnings per share excludes
special items and intangible asset amortization expense. Adjusted operational net earnings per share excludes special items, intangible asset amortization expense
and the effect of translational currency. See Non-GAAP reconciliation in this Annual Report.
Chairman’s Letter 3UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
Í ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT
OF 1934
ForthefiscalyearendedJanuary1,2023
or
‘ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934 for the transition period from to
Commissionfilenumber1-3215
JOHNSON & JOHNSON
(Exactnameofregistrantasspecifiedinitscharter)
NewJersey 22-1024240
(Stateofincorporation) (I.R.S.EmployerIdentificationNo.)
OneJohnson&JohnsonPlaza
NewBrunswick,NewJersey 08933
(Addressofprincipalexecutiveoffices) (ZipCode)
OneJohnson&JohnsonPlaza
NewBrunswick,NewJersey08933
(Addressofprincipalexecutiveoffices)
Registrant’stelephonenumber,includingareacode:(732)524-0400
SECURITIESREGISTEREDPURSUANTTOSECTION12(b)OFTHEACT
Titleofeachclass TradingSymbol Nameofeachexchangeonwhichregistered
CommonStock,ParValue$1.00 JNJ NewYorkStockExchange
0.650%NotesDueMay2024 JNJ24C NewYorkStockExchange
5.50%NotesDueNovember2024 JNJ24BP NewYorkStockExchange
1.150%NotesDueNovember2028 JNJ28 NewYorkStockExchange
1.650%NotesDueMay2035 JNJ35 NewYorkStockExchange
Indicatebycheckmarkiftheregistrantisawell-knownseasonedissuer,asdefinedinRule405oftheSecurities
Act. Yes Í No ‘
IndicatebycheckmarkiftheregistrantisnotrequiredtofilereportspursuanttoSection13orSection15(d)oftheExchange
Act. Yes ‘ No Í
Indicatebycheckmarkwhethertheregistrant(1)hasfiledallreportsrequiredtobefiledbySection13or15(d)ofthe
ExchangeActduringthepreceding12months(orforsuchshorterperiodthattheregistrantwasrequiredtofilesuch
reports),and(2)hasbeensubjecttosuchfilingrequirementsforthepast90days. Yes Í No ‘
IndicatebycheckmarkwhethertheregistranthassubmittedelectronicallyeveryInteractiveDataFilerequiredtobesubmitted
pursuanttoRule405ofRegulationS-Tduringthepreceding12months(orforsuchshorterperiodthattheregistrantwas
requiredtosubmitsuchfiles). Yes Í No ‘
Indicatebycheckmarkwhethertheregistrantisalargeacceleratedfiler,anacceleratedfiler,anon-acceleratedfiler,asmaller
reportingcompany,oremerginggrowthcompany.Seethedefinitionsof“largeacceleratedfiler,”“acceleratedfiler”,“smaller
reportingcompany,”and“emerginggrowthcompany”inRule12b-2oftheExchangeAct.
Largeacceleratedfiler Í Acceleratedfiler ‘
Non-acceleratedfiler ‘ Smallerreportingcompany ‘
Emerginggrowthcompany ‘
Ifanemerginggrowthcompany,indicatebycheckmarkiftheregistranthaselectednottousetheextendedtransitionperiod
forcomplyingwithanyneworrevisedfinancialaccountingstandardsprovidedpursuanttoSection13(a)oftheExchange
Act. ‘
Indicatebycheckmarkwhethertheregistranthasfiledareportonandattestationtoitsmanagement’sassessmentofthe
effectivenessofitsinternalcontroloverfinancialreportingunderSection404(b)oftheSarbanes-OxleyAct(15U.S.C.
7262(b))bytheregisteredpublicaccountingfirmthatpreparedorissueditsauditreport. Yes Í No ‘
IfsecuritiesareregisteredpursuanttoSection12(b)oftheAct,indicatebycheckmarkwhetherthefinancialstatementsof
theregistrantincludedinthefilingreflectthecorrectionofanerrortopreviouslyissuedfinancialstatements. ‘
Indicatebycheckmarkwhetheranyofthoseerrorcorrectionsarerestatementsthatrequiredarecoveryanalysisofincentive-
basedcompensationreceivedbyanyoftheregistrant’sexecutiveofficersduringtherelevantrecoveryperiodpursuantto
§240.10D-1(b). ‘
Indicatebycheckmarkwhethertheregistrantisashellcompany(asdefinedinRule12b-2oftheExchange
Act). Yes ‘ No Í
TheaggregatemarketvalueoftheCommonStockheldbynon-affiliatescomputedbyreferencetothepriceatwhichthe
CommonStockwaslastsoldasofthelastbusinessdayoftheregistrant’smostrecentlycompletedsecondfiscalquarter
wasapproximately$472billion.
OnFebruary10,2023,therewere2,604,286,303sharesofCommonStockoutstanding.
DOCUMENTSINCORPORATEDBYREFERENCE
PartsIandIII: Portionsofregistrant’sproxystatementforits2023annualmeetingofshareholdersfiledwithin
120daysafterthecloseoftheregistrant’sfiscalyear(the“ProxyStatement”),areincorporatedby
referencetothisreportonForm10-K(this“Report”).Item Page
PARTI
1 Business 1
General 1
SegmentsofBusiness 1
GeographicAreas 2
RawMaterials 3
Patents 3
Trademarks 3
Seasonality 3
Competition 3
Environment 4
Regulation 4
EmployeesandHumanCapitalManagement 5
AvailableInformation 7
1A. RiskFactors 8
1B. UnresolvedStaffComments 16
2 Properties 16
3 LegalProceedings 17
4 MineSafetyDisclosures 17
ExecutiveOfficersoftheRegistrant 18
PARTII
5 MarketforRegistrant’sCommonEquity,RelatedStockholderMattersandIssuerPurchasesof
EquitySecurities 20
6 (Reserved) 20
7 Management’sDiscussionandAnalysisofResultsofOperationsandFinancialCondition 21
7A. QuantitativeandQualitativeDisclosuresAboutMarketRisk 41
8 FinancialStatementsandSupplementaryData 41
9 ChangesinandDisagreementsWithAccountantsonAccountingandFinancialDisclosure 110
9A. ControlsandProcedures 110
9B. OtherInformation 110
9C. DisclosuresRegardingForeignJurisdictionsThatPreventInspections 110
PARTIII
10 Directors,ExecutiveOfficersandCorporateGovernance 111
11 ExecutiveCompensation 111
12 SecurityOwnershipofCertainBeneficialOwnersandManagementandRelatedStockholder
Matters 111
13 CertainRelationshipsandRelatedTransactions,andDirectorIndependence 112
14 PrincipalAccountantFeesandServices 112
PARTIV
15 ExhibitsandFinancialStatementSchedules 113
16 Form10-KSummary 113
Signatures 114
ExhibitIndex 116CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
ThisAnnualReportonForm10-KandJohnson&Johnson’sotherpubliclyavailabledocumentscontain“forward-looking
statements”withinthemeaningofthesafeharborprovisionsoftheUnitedStatesPrivateSecuritiesLitigationReformAct
of1995.ManagementandrepresentativesofJohnson&Johnsonanditssubsidiaries(theCompany)alsomayfromtimeto
timemakeforward-lookingstatements.Forward-lookingstatementsdonotrelatestrictlytohistoricalorcurrentfactsand
reflectmanagement’sassumptions,views,plans,objectivesandprojectionsaboutthefuture.Forward-lookingstatements
maybeidentifiedbytheuseofwordssuchas“plans,”“expects,”“will,”“anticipates,”“estimates”andotherwordsof
similarmeaninginconjunctionwith,amongotherthings:discussionsoffutureoperations;expectedoperatingresultsand
financialperformance;impactofplannedacquisitionsanddispositions;impactandtimingofrestructuringinitiatives,
includingassociatedcostsavingsandotherbenefits;theplannedseparationoftheCompany’sConsumerHealth
business;theCompany’sstrategyforgrowth;productdevelopmentactivities;regulatoryapprovals;marketpositionand
expenditures.
Becauseforward-lookingstatementsarebasedoncurrentbeliefs,expectationsandassumptionsregardingfutureevents,
theyaresubjecttouncertainties,risksandchangesthataredifficulttopredictandmanyofwhichareoutsideofthe
Company’scontrol.Investorsshouldrealizethatifunderlyingassumptionsproveinaccurate,orknownorunknownrisksor
uncertaintiesmaterialize,theCompany’sactualresultsandfinancialconditioncouldvarymateriallyfromexpectationsand
projectionsexpressedorimpliedinitsforward-lookingstatements.Investorsarethereforecautionednottorelyonthese
forward-lookingstatements.Risksanduncertaintiesinclude,butarenotlimitedto:
RisksRelatedtoProductDevelopment,MarketSuccessandCompetition
• Challengesanduncertaintiesinherentininnovationanddevelopmentofnewandimprovedproductsandtechnologies
onwhichtheCompany’scontinuedgrowthandsuccessdepend,includinguncertaintyofclinicaloutcomes,additional
analysisofexistingclinicaldata,obtainingregulatoryapprovals,healthplancoverageandcustomeraccess,andinitial
andcontinuedcommercialsuccess;
• ChallengestotheCompany’sabilitytoobtainandprotectadequatepatentandotherintellectualpropertyrightsfornew
andexistingproductsandtechnologiesintheUnitedStatesandotherimportantmarkets;
• Theimpactofpatentexpirations,typicallyfollowedbytheintroductionofcompetinggeneric,biosimilarorotherproducts
andresultingrevenueandmarketsharelosses;
• IncreasinglyaggressiveandfrequentchallengestotheCompany’spatentsbycompetitorsandothersseekingtolaunch
competinggeneric,biosimilarorotherproductsandincreasedreceptivityofcourts,theUnitedStatesPatentand
TrademarkOfficeandotherdecisionmakerstosuchchallenges,potentiallyresultinginlossofmarketexclusivityand
rapiddeclineinsalesfortherelevantproductsoonerthanexpected;
• Competitioninresearchanddevelopmentofnewandimprovedproducts,processesandtechnologies,whichcanresult
inproductandprocessobsolescence;
• Competitiontoreachagreementwiththirdpartiesforcollaboration,licensing,developmentandmarketingagreements
forproductsandtechnologies;
• Competitionbasedoncost-effectiveness,productperformance,technologicaladvancesandpatentsattainedby
competitors;and
• AllegationsthattheCompany’sproductsinfringethepatentsandotherintellectualpropertyrightsofthirdparties,which
couldadverselyaffecttheCompany’sabilitytoselltheproductsinquestionandrequirethepaymentofmoneydamages
andfutureroyalties.
RisksRelatedtoProductLiability,LitigationandRegulatoryActivity
• Productefficacyorsafetyconcerns,whetherornotbasedonscientificevidence,potentiallyresultinginproduct
withdrawals,recalls,regulatoryactiononthepartoftheUnitedStatesFoodandDrugAdministration(orinternational
counterparts),decliningsales,reputationaldamage,increasedlitigationexpenseandsharepriceimpact;
• Theimpact,includingdecliningsalesandreputationaldamage,ofsignificantlitigationorgovernmentactionadverseto
theCompany,includingproductliabilityclaimsandallegationsrelatedtopharmaceuticalmarketingpracticesand
contractingstrategies;
• Theimpactofanadversejudgmentorsettlementandtheadequacyofreservesrelatedtolegalproceedings,including
patentlitigation,productliability,personalinjuryclaims,securitiesclassactions,governmentinvestigations,employment
andotherlegalproceedings;
Johnson&Johnson2022AnnualReport •• Increasedscrutinyofthehealthcareindustrybygovernmentagenciesandstateattorneysgeneralresultingin
investigationsandprosecutions,whichcarrytheriskofsignificantcivilandcriminalpenalties,including,butnotlimited
to,debarmentfromgovernmentbusiness;
• Failuretomeetcomplianceobligationsincomplianceagreementswithgovernmentsorgovernmentagencies,which
couldresultinsignificantsanctions;
• PotentialchangestoapplicablelawsandregulationsaffectingUnitedStatesandinternationaloperations,including
relatingto:approvalofnewproducts;licensingandpatentrights;salesandpromotionofhealthcareproducts;access
to,andreimbursementandpricingfor,healthcareproductsandservices;environmentalprotection;andsourcingofraw
materials;
• CompliancewithlocalregulationsandlawsthatmayrestricttheCompany’sabilitytomanufactureorsellitsproductsin
relevantmarkets,includingrequirementstocomplywithmedicaldevicereportingregulationsandotherrequirements
suchastheEuropeanUnion’sMedicalDevicesRegulation;
• Changesindomesticandinternationaltaxlawsandregulations,increasingauditscrutinybytaxauthoritiesaroundthe
worldandexposurestoadditionaltaxliabilitiespotentiallyinexcessofexistingreserves;and
• TheissuanceofneworrevisedaccountingstandardsbytheFinancialAccountingStandardsBoardandregulationsby
theSecuritiesandExchangeCommission.
RisksRelatedtotheCompany’sStrategicInitiatives,HealthcareMarketTrendsandthePlanned
SeparationoftheCompany’sConsumerHealthBusiness
• Pricingpressuresresultingfromtrendstowardhealthcarecostcontainment,includingthecontinuedconsolidation
amonghealthcareprovidersandothermarketparticipants,trendstowardmanagedcare,theshifttowardgovernments
increasinglybecomingtheprimarypayersofhealthcareexpenses,significantnewentrantstothehealthcaremarkets
seekingtoreducecostsandgovernmentpressureoncompaniestovoluntarilyreducecostsandpriceincreases;
• Restrictedspendingpatternsofindividual,institutionalandgovernmentalpurchasersofhealthcareproductsand
servicesduetoeconomichardshipandbudgetaryconstraints;
• ChallengestotheCompany’sabilitytorealizeitsstrategyforgrowthincludingthroughexternallysourcedinnovations,
suchasdevelopmentcollaborations,strategicacquisitions,licensingandmarketingagreements,andthepotential
heightenedcostsofanysuchexternalarrangementsduetocompetitivepressures;
• Thepotentialthattheexpectedstrategicbenefitsandopportunitiesfromanyplannedorcompletedacquisitionor
divestiturebytheCompanymaynotberealizedormaytakelongertorealizethanexpected;
• Thepotentialthattheexpectedbenefitsandopportunitiesrelatedtopastandongoingrestructuringactionsmaynotbe
realizedormaytakelongertorealizethanexpected;
• TheCompany’sabilitytoconsummatetheplannedseparationoftheCompany’sConsumerHealthbusinessonatimely
basisoratall;
• TheCompany’sabilitytosuccessfullyseparatetheCompany’sConsumerHealthbusinessandrealizetheanticipated
benefitsfromtheplannedseparation;and
• TheNewConsumerHealthCompany’sabilitytosucceedasastandalonepubliclytradedcompany.
RisksRelatedtoEconomicConditions,FinancialMarketsandOperatingInternationally
• TherisksassociatedwithglobaloperationsontheCompanyanditscustomersandsuppliers,includingforeign
governmentsincountriesinwhichtheCompanyoperates;
• Theimpactofinflationandfluctuationsininterestratesandcurrencyexchangeratesandthepotentialeffectofsuch
fluctuationsonrevenues,expensesandresultingmargins;
• Potentialchangesinexport/importandtradelaws,regulationsandpoliciesoftheUnitedStatesandothercountries,
includinganyincreasedtraderestrictionsortariffsandpotentialdrugreimportationlegislation;
• Theimpactoninternationaloperationsfromfinancialinstabilityininternationaleconomies,sovereignrisk,possible
impositionofgovernmentalcontrolsandrestrictiveeconomicpolicies,andunstableinternationalgovernmentsandlegal
systems;
• Theimpactofglobalpublichealthcrisesandpandemics,includingthenovelcoronavirus(COVID-19)pandemic;
• Changestoglobalclimate,extremeweatherandnaturaldisastersthatcouldaffectdemandfortheCompany’sproducts
andservices,causedisruptionsinmanufacturinganddistributionnetworks,altertheavailabilityofgoodsandservices
withinthesupplychain,andaffecttheoveralldesignandintegrityoftheCompany’sproductsandoperations;and
• TheimpactofarmedconflictsandterroristattacksintheUnitedStatesandotherpartsoftheworld,includingsocialand
economicdisruptionsandinstabilityoffinancialandothermarkets.
• Johnson&Johnson2022AnnualReportRisksRelatedtoSupplyChainandOperations
• Difficultiesanddelaysinmanufacturing,internally,throughthird-partyprovidersorotherwisewithinthesupplychain,that
mayleadtovoluntaryorinvoluntarybusinessinterruptionsorshutdowns,productshortages,withdrawalsor
suspensionsofproductsfromthemarket,andpotentialregulatoryaction;
• InterruptionsandbreachesoftheCompany’sinformationtechnologysystemsorthoseoftheCompany’svendors,
whichcouldresultinreputational,competitive,operationalorotherbusinessharmaswellasfinancialcostsand
regulatoryaction;
• Relianceonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexandsubjecttoincreasing
regulatoryrequirementsthatmayadverselyaffectsupply,sourcingandpricingofmaterialsusedintheCompany’s
products;and
• Thepotentialthattheexpectedbenefitsandopportunitiesrelatedtorestructuringactionscontemplatedfortheglobal
supplychainmaynotberealizedormaytakelongertorealizethanexpected,includingduetoanyrequiredapprovals
fromapplicableregulatoryauthorities.
InvestorsalsoshouldcarefullyreadtheRiskFactorsdescribedinItem1AofthisAnnualReportonForm10-Kfora
descriptionofcertainrisksthatcould,amongotherthings,causetheCompany’sactualresultstodiffermateriallyfrom
thoseexpressedinitsforward-lookingstatements.Investorsshouldunderstandthatitisnotpossibletopredictoridentify
allsuchfactorsandshouldnotconsidertherisksdescribedaboveandinItem1Atobeacompletestatementofall
potentialrisksanduncertainties.TheCompanydoesnotundertaketopubliclyupdateanyforward-lookingstatementthat
maybemadefromtimetotime,whetherasaresultofnewinformationorfutureeventsordevelopments.
Johnson&Johnson2022AnnualReport •[THISPAGEINTENTIONALLYLEFTBLANK]PART I
Item 1. BUSINESS
General
Johnson&Johnsonanditssubsidiaries(theCompany)haveapproximately152,700employeesworldwideengagedinthe
researchanddevelopment,manufactureandsaleofabroadrangeofproductsinthehealthcarefield.Johnson&Johnson
isaholdingcompany,withoperatingcompaniesconductingbusinessinvirtuallyallcountriesoftheworld.TheCompany’s
primaryfocusisproductsrelatedtohumanhealthandwell-being.Johnson&JohnsonwasincorporatedintheStateof
NewJerseyin1887.
TheExecutiveCommitteeofJohnson&Johnsonistheprincipalmanagementgroupresponsibleforthestrategic
operationsandallocationoftheresourcesoftheCompany.ThisCommitteeoverseesandcoordinatestheactivitiesofthe
Company’sthreebusinesssegments:ConsumerHealth,PharmaceuticalandMedTech(previouslyreferredtoasMedical
Devices).WithinthestrategicparametersprovidedbytheCommittee,seniormanagementgroupsatU.S.andinternational
operatingcompaniesareeachresponsiblefortheirownstrategicplansandtheday-to-dayoperationsofthose
companies.Eachsubsidiarywithinthebusinesssegmentsis,withlimitedexceptions,managedbyresidentsofthecountry
wherelocated.
Segments of Business
TheCompanyisorganizedintothreebusinesssegments:ConsumerHealth,PharmaceuticalandMedTech.Additional
informationrequiredbythisitemisincorporatedhereinbyreferencetothenarrativeandtabulardescriptionsofsegments
andoperatingresultsunder:“Item7.Management’sDiscussionandAnalysisofResultsofOperationsandFinancial
Condition”ofthisReport;andNote17“SegmentsofBusinessandGeographicAreas”oftheNotestoConsolidated
FinancialStatementsincludedinItem8ofthisReport.
ConsumerHealth
TheConsumerHealthsegmentincludesabroadrangeofproductsfocusedonpersonalhealthcareusedintheSkin
Health/Beauty,Over-the-Countermedicines,BabyCare,OralCare,Women’sHealthandWoundCaremarkets.Major
brandsinSkinHealth/BeautyincludetheAVEENO;CLEAN&CLEAR;DR.CI:LABO;NEUTROGENAandOGXproduct
lines.Over-the-Counter(OTC)medicinesincludethebroadfamilyofTYLENOLacetaminophenproducts;SUDAFED
cold,fluandallergyproducts;BENADRYLandZYRTECallergyproducts;MOTRINIBibuprofenproducts;NICORETTE
smokingcessationproductsoutsidetheU.S.;ZARBEE’Sproducts,inspiredbynature,andthePEPCIDlineofacidreflux
products.BabyCareincludestheJOHNSON’SandAVEENOBabylineofproducts.OralCareincludestheLISTERINE
productline.MajorbrandsinWomen’sHealthoutsideofNorthAmericaareSTAYFREEandCAREFREEsanitarypads
ando.b.tamponbrands.WoundCarebrandsincludetheBAND-AIDBrandAdhesiveBandagesandNEOSPORINFirst
Aidproductlines.Theseproductsaremarketedtothegeneralpublicandsoldonline(eCommerce)andtoretailoutlets
anddistributorsthroughouttheworld.
InNovember2021,theCompanyannounceditsintentiontoseparatetheCompany’sConsumerHealthbusiness(Kenvue
asthenamefortheplannedNewConsumerHealthCompany),withtheintentiontocreateanew,publiclytraded
companybytheendofthefiscalyear2023.
Pharmaceutical
ThePharmaceuticalsegmentisfocusedonthefollowingtherapeuticareas:Immunology(e.g.,rheumatoidarthritis,
psoriaticarthritis,inflammatoryboweldiseaseandpsoriasis),InfectiousDiseases(e.g.,HIV/AIDS),Neuroscience(e.g.,
mooddisorders,neurodegenerativedisordersandschizophrenia),Oncology(e.g.,prostatecancer,hematologic
malignancies,lungcancerandbladdercancer),CardiovascularandMetabolism(e.g.,thrombosis,diabetesandmacular
degeneration)andPulmonaryHypertension(e.g.,PulmonaryArterialHypertension).Medicinesinthissegmentare
distributeddirectlytoretailers,wholesalers,distributors,hospitalsandhealthcareprofessionalsforprescriptionuse.Key
productsinthePharmaceuticalsegmentinclude:REMICADE(infliximab),atreatmentforanumberofimmune-mediated
inflammatorydiseases;SIMPONI(golimumab),asubcutaneoustreatmentforadultswithmoderatetosevererheumatoid
Johnson&Johnson2022AnnualReport • 1arthritis,activepsoriaticarthritis,activeankylosingspondylitisandmoderatelyactivetoseverelyactiveulcerativecolitis;
SIMPONIARIA(golimumab),anintravenoustreatmentforadultswithmoderatetosevererheumatoidarthritis,active
psoriaticarthritisandactiveankylosingspondylitisandactivepolyarticularjuvenileidiopathicarthritis(pJIA)inpeople
2yearsofageandolder;STELARA(ustekinumab),atreatmentforadultsandchildrenwithmoderatetosevereplaque
psoriasis,foradultswithactivepsoriaticarthritis,foradultswithmoderatelytoseverelyactiveCrohn’sdiseaseand
treatmentofmoderatelytoseverelyactiveulcerativecolitis;TREMFYA(guselkumab),atreatmentforadultswithmoderate
tosevereplaquepsoriasisandactivepsoriaticarthritis;EDURANT(rilpivirine),PREZISTA(darunavir)andPREZCOBIX/
REZOLSTA(darunavir/cobicistat),antiretroviralmedicinesforthetreatmentofhumanimmunodeficiencyvirus(HIV-1)in
combinationwithotherantiretroviralproductsandSYMTUZA(darunavir/cobicistat/emtricitabine/tenofoviralafenamide),a
once-dailysingletabletregimenforthetreatmentofHIV;CONCERTA(methylphenidateHCl)extended-releasetablets
CII,atreatmentforattentiondeficithyperactivitydisorder;INVEGASUSTENNA/XEPLION(paliperidonepalmitate),forthe
treatmentofschizophreniaandschizoaffectivedisorderinadults;INVEGATRINZA/TREVICTA(paliperidonepalmitate),for
thetreatmentofschizophreniainpatientsaftertheyhavebeenadequatelytreatedwithINVEGASUSTENNAforatleast
fourmonths;RISPERDALCONSTA(risperidonelong-actinginjection),forthetreatmentofschizophreniaandthe
maintenancetreatmentofBipolar1Disorderinadults;ZYTIGA(abirateroneacetate),atreatmentforpatientswithprostate
cancer;ERLEADA(apalutamide),anext-generationandrogenreceptorinhibitorforthetreatmentofpatientswithprostate
cancer;IMBRUVICA(ibrutinib),atreatmentforcertainB-cellmalignancies,orbloodcancersandchronicgraftversushost
disease;DARZALEX(daratumumab),atreatmentformultiplemyeloma;DARZALEXFASPRO(daratumumaband
hyaluronidase-fihj),atreatmentformultiplemyelomaandlightchain(AL)Amyloidosis;XARELTO(rivaroxaban),anoral
anticoagulantforthepreventionofdeepveinthrombosis(DVT),whichmayleadtopulmonaryembolism(PE)inpatients
undergoinghiporkneereplacementsurgery,toreducetheriskofstrokeandsystemicembolisminpatientswith
nonvalvularatrialfibrillation,andforthetreatmentandreductionofriskofrecurrenceofDVTandPEtoreducetheriskof
majorcardiovasculareventsinpatientswithcoronaryarterydisease(CAD)andperipheralarterydisease(PAD),forthe
treatmentandsecondarypreventionofthromboembolisminpediatricpatients,andforthromboprophylaxisinpediatric
patientsfollowingtheFontanprocedure;INVOKANA(canagliflozin),forthetreatmentofadultswithtype2diabetes;
INVOKAMET/VOKANAMET(canagliflozin/metforminHCl),acombinationtherapyoffixeddosesofcanagliflozinand
metforminhydrochlorideforthetreatmentofadultswithtype2diabetes;andINVOKAMETXR(canagliflozin/metformin
hydrochlorideextended-release),aonce-daily,fixed-dosecombinationtherapyofcanagliflozinandmetformin
hydrochlorideextended-release,forthetreatmentofadultswithtype2diabetes;OPSUMIT(macitentan)asmonotherapy
orincombination,indicatedforthelong-termtreatmentofpulmonaryarterialhypertension(PAH);UPTRAVI(selexipag),
theonlyapprovedoralandintravenous,selectiveIPreceptoragonisttargetingaprostacyclinpathwayinPAH.Manyof
thesemedicinesweredevelopedincollaborationwithstrategicpartnersorarelicensedfromothercompaniesand
maintainactivelifecycledevelopmentprograms.
MedTech
TheMedTech(previouslyreferredtoasMedicalDevices)segmentincludesabroadportfolioofproductsusedinthe
InterventionalSolutions,Orthopaedics,SurgeryandVisioncategories.InterventionalSolutionsincludeElectrophysiology
products(BiosenseWebster)totreatcardiovasculardiseases,Neurovascularcare(Cerenovus)thattreatshemorrhagicand
ischemicstrokeandtheHeartRecoveryportfolio(Abiomed)whichincludestechnologiestotreatseverecoronaryartery
diseaserequiringhigh-riskPCIorAMIcardiogenicshock.TheOrthopaedicsportfolio(DePuySynthes)comprisesproducts
insupportofHips,Knees,Trauma,andSpine,Sports&Other.TheSurgeryportfoliosincludeadvancedandgeneralsurgery
offerings(Ethicon),solutionsthatfocusonBreastAesthetics(Mentor),andEar,NoseandThroat(Acclarent)procedures.
Johnson&JohnsonVisionproductsincludeACUVUEBrandcontactlensesandophthalmictechnologiesrelatedtocataract
andlaserrefractivesurgery.Theseproductsaredistributedtowholesalers,hospitalsandretailers,andusedpredominantly
intheprofessionalfieldsbyphysicians,nurses,hospitals,eyecareprofessionalsandclinics.
Geographic Areas
Johnson&Johnsonanditssubsidiaries(theCompany)haveapproximately152,700employeesworldwideengagedinthe
researchanddevelopment,manufactureandsaleofabroadrangeofproductsinthehealthcarefield.TheCompany
conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand
well-being.
Theproductsmadeandsoldintheinternationalbusinessincludemanyofthosedescribedaboveunder“–Segmentsof
Business–ConsumerHealth,”“–Pharmaceutical”and“–MedTech.”However,theprincipalmarkets,productsand
methodsofdistributionintheinternationalbusinessvarywiththecountryandtheculture.Theproductssoldin
internationalbusinessincludethosedevelopedintheU.S.andbysubsidiariesabroad.
2 • Johnson&Johnson2022AnnualReportInvestmentsandactivitiesinsomecountriesoutsidetheU.S.aresubjecttohigherrisksthancomparableU.S.activities
becausetheinvestmentandcommercialclimatemaybeinfluencedbyfinancialinstabilityininternationaleconomies,
restrictiveeconomicpoliciesandpoliticalandlegalsystemuncertainties.
Raw Materials
RawmaterialsessentialtotheCompany’sbusinessaregenerallyreadilyavailablefrommultiplesources.Wherethereare
exceptions,thetemporaryunavailabilityofthoserawmaterialswouldnotlikelyhaveamaterialadverseeffectonthe
financialresultsoftheCompany.
Patents
TheCompany’ssubsidiarieshavemadeapracticeofobtainingpatentprotectionontheirproductsandprocesseswhere
possible.Theyown,orarelicensedunder,asignificantnumberofpatentsintheU.S.andothercountriesrelatingtotheir
products,productuses,formulationsandmanufacturingprocesses,whichintheaggregatearebelievedtobeofmaterial
importancetotheCompanyintheoperationofitsbusinesses.TheCompany’ssubsidiariesfacepatentchallengesfrom
thirdparties,includingchallengesseekingtomanufactureandmarketgenericandbiosimilarversionsoftheCompany’s
keypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproducts.Significantlegal
proceedingsandclaimsinvolvingtheCompany’spatentandotherintellectualpropertyaredescribedinNote19,“Legal
Proceedings—IntellectualProperty”oftheNotestoConsolidatedFinancialStatementsincludedinItem8ofthisReport.
SalesoftheCompany’slargestproduct,STELARA(ustekinumab),accountedforapproximately10.2%oftheCompany’s
totalrevenuesforfiscal2022.Accordingly,thepatentsrelatedtothisproductarebelievedtobematerialtotheCompany.
JanssenBiotech,Inc.,awholly-ownedsubsidiaryofJohnson&Johnson,ownspatentsspecificallyrelatedtoSTELARA.
ThelatestexpiringUnitedStatescompositionofmatterpatentexpiresin2023.ThelatestexpiringEuropeancomposition
ofmatterpatentexpiresin2024.
SalesoftheCompany’ssecondlargestproduct,collectivelyDARZALEX(daratumumab)andDARZALEXFASPRO
(daratumumabandhyaluronidase-fihj),accountedforapproximately8.4%oftheCompany’stotalrevenuesforfiscal2022.
Accordingly,thepatentsrelatedtothisproductarebelievedtobematerialtotheCompany.GenmabA/Sownstwo
patentfamiliesrelatedtoDARZALEX,andJanssenBiotech,Inc.hasanexclusivelicensetothosepatentfamilies.Thetwo
patentfamiliesbothexpireintheUnitedStatesin2029.ThelatestexpiringlicensedEuropeanpatentexpiresin2032.
JanssenBiotech,Inc.ownsaseparatepatentportfoliorelatedtoDARZALEXFASPRO.
Trademarks
TheCompany’ssubsidiarieshavemadeapracticeofsellingtheirproductsundertrademarksandofobtainingprotection
forthesetrademarksbyallavailablemeans.ThesetrademarksareprotectedbyregistrationintheU.S.andothercountries
wheresuchproductsaremarketed.TheCompanyconsidersthesetrademarksintheaggregatetobeofmaterial
importanceintheoperationofitsbusinesses.
Seasonality
Worldwidesalesdonotreflectanysignificantdegreeofseasonality;however,spendinghastypicallybeenheavierinthe
fourthquarterofeachyearthaninotherquarters.Thisreflectsincreasedspendingdecisions,principallyforadvertising
andresearchanddevelopmentactivity.
Competition
Inalloftheirproductlines,theCompany’ssubsidiariescompetewithcompaniesbothlocallyandglobally.Competition
existsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolved.Competitionin
research,bothinternallyandexternallysourced,involvingthedevelopmentandtheimprovementofnewandexisting
productsandprocesses,isparticularlysignificant.Thedevelopmentofnewandinnovativeproducts,aswellasprotecting
theunderlyingintellectualpropertyoftheCompany’sproductportfolio,isimportanttotheCompany’ssuccessinallareas
ofitsbusiness.Thecompetitiveenvironmentrequiressubstantialinvestmentsincontinuingresearch.Inaddition,the
developmentandmaintenanceofcustomerdemandfortheCompany’sconsumerproductsinvolvesignificant
expendituresforadvertisingandpromotion.
Johnson&Johnson2022AnnualReport • 3Environment
TheCompanyissubjecttoavarietyofU.S.andinternationalenvironmentalprotectionmeasures.TheCompanybelieves
thatitsoperationscomplyinallmaterialrespectswithapplicableenvironmentallawsandregulations.TheCompany’s
compliancewiththeserequirementsisnotexpectedtohaveamaterialeffectuponitscapitalexpenditures,cashflows,
earningsorcompetitiveposition.
Regulation
TheCompany’sbusinessesaresubjecttovaryingdegreesofgovernmentalregulationinthecountriesinwhichoperations
areconducted,andthegeneraltrendistowardincreasinglystringentregulationandenforcement.TheCompanyissubject
tocostlyandcomplexU.S.andforeignlawsandgovernmentalregulationsandanyadverseregulatoryactionmay
materiallyadverselyaffecttheCompany’sfinancialconditionandbusinessoperations.IntheU.S.,thedrug,deviceand
cosmeticindustrieshavelongbeensubjecttoregulationbyvariousfederalandstateagencies,primarilyastoproduct
safety,efficacy,manufacturing,advertising,labelingandsafetyreporting.Theexerciseofbroadregulatorypowersbythe
U.S.FoodandDrugAdministration(theU.S.FDA)continuestoresultinincreasesintheamountsoftestingand
documentationrequiredforU.S.FDAapprovalofnewdrugsanddevicesandacorrespondingincreaseintheexpenseof
productintroduction.SimilartrendsarealsoevidentinmajormarketsoutsideoftheU.S.Thenewmedicaldevice
regulatoryframeworkandtheevolvingprivacy,datalocalization,andemergingcybersecuritylawsandregulationsaround
theworldareexamplesofsuchincreasedregulation.FiveU.S.States(California,Connecticut,Colorado,Utahand
Virginia)nowhavecomprehensiveprivacylawsinplaceandChinaintroducedbroadpersonalinformationprotectionand
datasecurityregulationsin2022.Withotherjurisdictionsenactingsimilarprivacylaws,localdataprotectionauthorities
willforcegreateraccountabilityonthecollection,accessanduseofpersonaldatainthehealthcareindustry.
TheregulatoryagenciesunderwhosepurviewtheCompanyoperateshaveadministrativepowersthatmaysubjectittoactions
suchasproductwithdrawals,recalls,seizureofproductsandothercivilandcriminalsanctions.Insomecases,theCompany’s
subsidiariesmaydeemitadvisabletoinitiateproductrecallsregardlessofwhetherithasbeenrequiredordirectedto.
TheU.S.FDAandregulatoryagenciesaroundtheglobearealsoincreasingtheirenforcementactivities.IftheU.S.FDA
weretoconcludethatwearenotincompliancewithapplicablelawsorregulations,orthatanyofourdrugsormedical
devicesareineffectiveorposeanunreasonablehealthrisk,theU.S.FDAcouldbansuchproducts,detainorseize
adulteratedormisbrandedproducts,orderarecall,repair,replacement,orrefundofsuchproducts,refusetogrant
pendingapplicationsformarketingauthorizationorrequirecertificatesofforeigngovernmentsforexports,and/orrequire
ustonotifyhealthprofessionalsandothersthattheproductspresentunreasonablerisksofsubstantialharmtothepublic
health.TheU.S.FDAmayalsoassesscivilorcriminalpenaltiesagainstus,ourofficersoremployeesandimpose
operatingrestrictionsonacompany-widebasis,orenjoinand/orrestraincertainconductresultinginviolationsof
applicablelaw.TheU.S.FDAmayalsorecommendprosecutiontotheU.S.DepartmentofJustice.Anyadverseregulatory
action,dependingonitsmagnitude,mayrestrictusfromeffectivelymarketingandsellingourproductsandlimitourability
toobtainfutureclearancesorapprovals,andcouldresultinasubstantialmodificationtoourbusinesspracticesand
operations.Equivalentenforcementmechanismsexistindifferentcountriesinwhichweconductbusiness.
Thecostsofhumanhealthcarehavebeenandcontinuetobeasubjectofstudy,investigationandregulationby
governmentalagenciesandlegislativebodiesaroundtheworld.IntheU.S.,attentionhasbeenfocusedbystates,
regulatoryagenciesandCongressonprices,profits,overutilizationandthequalityandcostsofhealthcaregenerally.Laws
andregulationshavebeenenactedtorequireadherencetostrictcompliancestandardsandpreventfraudandabusein
thehealthcareindustry.Thereisincreasedfocusoninteractionsandfinancialrelationshipsbetweenhealthcarecompanies
andhealthcareproviders.Varioustransparencylawsandregulationsrequiredisclosuresofpaymentsandothertransfers
ofvaluemadetophysiciansandteachinghospitalsand,beginningwithdisclosuresin2022,tocertainnon-physician
practitioners.Federalandforeignlawsgoverninginternationalbusinesspracticesrequirestrictcompliancewithanti-
briberystandardsandcertainprohibitionswithrespecttopaymentstoanyforeigngovernmentofficial.Payersand
PharmacyBenefitManagers(PBMs)havebecomeamorepotentforceinthemarketplaceandincreasedattentionis
beingpaidtodrugpricingandappropriatedrugandmedicaldeviceutilization.
Ourbusinesshasbeenandcontinuestobeaffectedbyfederalandstatelegislationthataltersthepricing,coverage,and
reimbursementlandscape.Atthefederallevel,inAugust2022,PresidentBidensignedintolawtheInflationReductionAct(IRA),
whichincludesprovisionsthateffectivelyauthorizethegovernmenttoestablishpricesforcertainhigh-spendsingle-sourcedrugs
andbiologicsreimbursedbytheMedicareprogram,startingin2026forMedicarePartDdrugsand2028forMedicarePartB
drugs.Itisnotyetcertainwhichproductsthefederalgovernmentwillselectandsubjecttogovernment-establishedprices,orhow
thefederalgovernmentwillestablishpricesforselectedproducts,astheIRAspecifiesaceilingpricebutnotaminimumprice.One
ormoreofourproductscouldbeselectedandsubjecttothegovernment-establishedprice.
4 • Johnson&Johnson2022AnnualReportTheIRAalsocontainsprovisionsthatimposerebatesifcertainpricesincreaseataratethatoutpacestherateofinflation,
beginningOctober1,2022,forMedicarePartDdrugsandJanuary1,2023,forMedicarePartBdrugs.SeparateIRA
provisionsredesigntheMedicarePartDbenefitinvariousways,includingbyshiftingagreaterportionofcoststo
manufacturerswithincertaincoveragephasesandreplacingthePartDcoveragegapdiscountprogramwithanew
manufacturerdiscountingprogram.FailuretocomplywithIRAprovisionsmaysubjectmanufacturerstovariouspenalties,
includingcivilmonetarypenalties.TheimpactoftheIRAonourbusinessandthebroaderpharmaceuticalindustryremains
uncertain,asthefederalgovernmenthasyettomakevariousIRAimplementationdecisions.
Additionally,weexpectcontinuedscrutinyondrugpricingandgovernmentpricereportingfromCongress,agencies,and
otherbodiesatthefederalandstatelevels.
ThereareanumberofadditionalbillspendinginCongressandhealthcarereformproposalsatthestatelevelthatwould
affectdrugpricing,includingintheMedicareandMedicaidprograms.Thischanginglegallandscapehasbothpositiveand
negativeimpactsontheU.S.healthcareindustrywithmuchremaininguncertainastohowvariousprovisionsoffederal
andstatelaw,andpotentialmodificationorrepealoftheselaws,willultimatelyaffecttheindustry.TheIRAandanyother
federalorstatelegislativechangecouldaffectthepricingandmarketconditionsforourproducts.
Inaddition,businesspracticesinthehealthcareindustryhavecomeunderincreasedscrutiny,particularlyintheU.S.,by
governmentagenciesandstateattorneysgeneral,andresultinginvestigationsandprosecutionscarrytheriskofsignificant
civilandcriminalpenalties.Ofnoteistheincreasedenforcementactivitybydataprotectionauthoritiesinvarious
jurisdictions,particularlyintheEuropeanUnion,wheresignificantfineshavebeenleviedoncompaniesfordatabreaches,
violationsofprivacyrequirements,andunlawfulcross-borderdatatransfers.IntheU.S.,theFederalTradeCommission
hassteppedupenforcementofdataprivacywithseveralsignificantsettlementsandtherehavebeenamaterialincreasein
class-actionlawsuitslinkedtothecollectionanduseofbiometricdata.
Further,theCompanyreliesonglobalsupplychains,andproductionanddistributionprocesses,thatarecomplex,are
subjecttoincreasingregulatoryrequirements,andmaybefacedwithunexpectedchangessuchasthoseresultingfrom
theCOVID-19pandemicandBrexitthatmayaffectsourcing,supplyandpricingofmaterialsusedintheCompany’s
products.Theseprocessesalsoaresubjecttocomplexandlengthyregulatoryapprovals.
Employees and Human Capital Management
AsofJanuary1,2023,andJanuary2,2022,thenumberofemployeeswereapproximately:
2022 2021
Employees1 155,800 144,300
Full-timeequivalent(FTE)positions2 152,700 141,700
1 “Employee”isdefinedasanindividualworkingfull-timeorpart-time,excludingfixedtermemployees,internsandco-opemployees.
Employeedatamaynotincludefullpopulationfrommorerecentlyacquiredcompaniesandindividualsonlong-termdisabilityareexcluded.
Contingentworkers,contractorsandsubcontractorsarealsoexcluded.Abiomedheadcounthasbeenincludedintheabovetable.
2 FTErepresentsthetotalnumberoffull-timeequivalentpositionsanddoesnotreflectthetotalnumberofindividualemployeesas
someworkpart-time.
Employees by region (in percentages)
16.6%
34.2%
29.0%
20.2%
Asia Pacific EMEA
Latin America North America
Johnson&Johnson2022AnnualReport • 5Strategy
TheCompanybelievesthatitsemployeesarecriticaltoitscontinuedsuccessandareanessentialelementofitslong-
termstrategy.ManagementisresponsibleforensuringthatitspoliciesandprocessesreflectandreinforcetheCompany’s
desiredcorporateculture,includingpoliciesandprocessesrelatedtostrategy,riskmanagement,andethicsand
compliance.TheCompany’shumancapitalmanagementstrategyisbuiltonthreefundamentalfocusareas:
• Attractingandrecruitingthebesttalent
• Developingandretainingtalent
• Empoweringandinspiringtalent
Underpinningthesefocusareasareongoingeffortstocultivateandfosteraculturebuiltondiversity,equityandinclusion
(DEI),innovation,health,well-beingandsafety,wheretheCompany’semployeesareencouragedtosucceedboth
professionallyandpersonallywhilehelpingtheCompanyachieveitsbusinessgoals.
CultureandEmployeeEngagement
AttheCompany,employeesareguidedbyOurCredowhichsetsforththeCompany’sresponsibilitiestopatients,
consumers,customers,healthcareprofessionals,employees,communitiesandshareholders.Employeesworldwidemust
adheretotheCompany’sCodeofBusinessConductwhichsetsbasicrequirementsandservesasafoundationforthe
Companypolicies,proceduresandguidelines,allofwhichprovideadditionalguidanceonexpectedemployeebehaviorsin
everymarketwhereitoperates.TheCompanyconductsglobalsurveysthatofferitsemployeestheabilitytoprovide
feedbackandvaluableinsighttohelpaddresspotentialhumanresourcesrisksandidentifyopportunitiestoimprove.In
2022,92%ofglobalemployeesacross77countriesparticipatedinOurCredoSurveywhichwasofferedin36
languages.
GrowthandDevelopment
Tocontinuetoleadinthechanginghealthcarelandscape,itiscrucialthattheCompanycontinuetoattractandretaintop
talent.TheCompanybelievesthatitsemployeesmustbeequippedwiththerightknowledgeandskillsandbeprovided
withopportunitiestogrowanddevelopintheircareers.Accordingly,professionaldevelopmentprogramsandeducational
resourcesareavailabletoallemployees.TheCompany’sobjectiveistofosteralearningculturethathelpsshapeeach
person’suniquecareerpathwhilecreatingarobustpipelineoftalenttodeliverontheCompany’slong-termstrategies.In
furtheranceofthisobjective,theCompanydeploysaglobalapproachtoensuredevelopmentisforeveryone,regardlessof
wheretheyareontheircareerjourney.In2022,46.2%ofemployeesinManagerandabovejobcategorieswhohad
movements(includingupwardpromotionsorlateraltransfers)tookadvantageofcareeropportunitiesbymovingacross
functions,countryorbusinesssegmentlines(excludingemployeesintheresearchanddevelopmentorganizations).The
Company’svoluntaryturnoverratewas9%.
Diversity,Equity,andInclusion(DEI)
TheCompanyiscommittedtoworkplacediversityandtocultivating,fostering,andadvancingacultureofequityand
inclusion.In2022,Johnson&JohnsonintroducedtheCompany’sevolvedenterpriseDiversity,EquityandInclusion
strategy,whichrecognizeshowDEIacceleratestheCompany’sabilitytomeetthechangingneedsofthecommunitiesthe
CompanyservestodeliverOurPurposetoprofoundlychangethetrajectoryofhealthforhumanity.TheCompany’sDEI
visionis:Beyourself,changetheworld.TheCompany’sDEIMissionis:Makediversity,equityandinclusionhowwework
everyday.OurevolvedenterpriseDEIStrategyisalignedtoourDEIVisionandMissionandrestsonfourcorepillars:
• Accelerateourglobalcultureofinclusionwhereeveryindividualbelongs
• Buildaworkforcethatreflectsthediversityofourcommunities
• Transformtalentandbusinessprocessestoachieveequitableaccessandoutcomesforall
• Driveinnovationandgrowthwithourbusinesstoservediversemarketsaroundtheworld
TheCompany’sDEIstrategyisguidedbyinternalandexternalinsights,globalbestpracticesandcontinualemployee
feedbackwhichremindtheCompanythatwhilediversitychangesbylocation,inclusionisthesameeverywhere.
6 • Johnson&Johnson2022AnnualReportCompensationandBenefits
AspartoftheCompany’stotalrewardsphilosophy,theCompanyofferscompetitivecompensationandbenefitstoattract
andretaintoptalent.TheCompanyiscommittedtofairnessandequitabletreatmentinitscompensationandbenefitsfor
employeesatalllevels.TheCompanyobserveslegalminimumwageprovisionsandexceedsthemwherepossible.The
Company’stotalrewardsofferingsincludeanarrayofprogramstosupportitsemployees’well-being,includingannual
performanceincentiveopportunities,pensionandretirementsavingsprograms,healthandwelfarebenefits,paidtimeoff,
leaveprograms,flexibleworkschedulesandemployeeassistanceprograms.InrecognitionoftheCompany’scommitment
tohelpemployeesbalancetheirpersonalandprofessionalresponsibilities,theCompanyextendeditspaidparentalleave
benefitgloballyfrom8to12weeksforalleligibleemployees.IntheU.S.,thebenefitwaseffectiveonJanuary1,2022,
withretroactivecoveragefornewfamilyadditionsasofJuly1,2021.
Health,WellnessandSafety
TheCompany’sinvestmentinemployeehealth,well-beingandsafetyisbuiltonitsconvictionthatadvancinghealthfor
humanitystartswithadvancingthehealthofitsemployees.Withtherightawareness,focus,practicesandtools,the
Companyensuresthatallitsemployeesaroundtheworld,aswellastemporarycontractorsandvisitorstotheCompany’s
sites,canworksafely.TheCompanyhascontinuouslyexpandedhealthandwell-beingprogramsthroughouttheCompany
andacrosstheglobe,incorporatingnewthinkingandtechnologiestokeepitsofferingsbest-in-classandtohelpemployees
achievetheirpersonalhealthgoals.TheprogramsandpracticestheCompanyadvancesfortotalhealth—physical,mental,
emotionalandfinancial—ensureemployeehealthprotectionforemerginghealthrisks.Protectingandsupportingour
employeesastheCOVID-19pandemichasevolvedcontinuestobeatoppriorityandtheCompany’sapproachincludes:
ensuringthehealthandsafetyofouremployeesintheworkplacethroughrobustlayersofprotection;enhancedcleaning
andaccesstocleaningsuppliesandpersonalprotectiveequipment;supportingemployeeswithbenefitsandwell-being
tools.TheCompanycontinuestoaddressouremployeesneedsthroughJ&JFlex,ahybridmodelthatempowersthe
Company’soffice-basedemployeestofindtherightproductivityandbalanceofin-personandremotework.
Available Information
TheCompany’smaincorporatewebsiteaddressiswww.jnj.com.AlloftheCompany’sSECfilingsarealsoavailableonthe
Company’swebsiteatwww.investor.jnj.com/sec.cfm,assoonasreasonablypracticableafterhavingbeenelectronically
filedorfurnishedtotheSEC.AllSECfilingsarealsoavailableattheSEC’swebsiteatwww.sec.gov.
InvestorsandthepublicshouldnotethattheCompanyalsoannouncesinformationat
www.factsaboutourprescriptionopioids.com,www.factsabouttalc.comandwww.LTLManagementInformation.com.
Weusethesewebsitestocommunicatewithinvestorsandthepublicaboutourproducts,litigationandothermatters.Itis
possiblethattheinformationweposttothesewebsitescouldbedeemedtobematerialinformation.Therefore,we
encourageinvestorsandothersinterestedintheCompanytoreviewtheinformationpostedtothesewebsitesin
conjunctionwithwww.jnj.com,theCompany’sSECfilings,pressreleases,publicconferencecallsandwebcasts.
Inaddition,theAmendedandRestatedCertificateofIncorporation,By-Laws,thewrittenchartersoftheAuditCommittee,
theCompensation&BenefitsCommittee,theNominating&CorporateGovernanceCommittee,theRegulatory
Compliance&SustainabilityCommittee,theScience&TechnologyCommitteeandanyspecialcommitteeoftheBoardof
DirectorsandtheCompany’sPrinciplesofCorporateGovernance,CodeofBusinessConduct(foremployees),Codeof
BusinessConduct&EthicsforMembersoftheBoardofDirectorsandExecutiveOfficers,andothercorporate
governancematerials,areavailableatwww.investor.jnj.com/gov.cfmontheCompany’swebsiteandwillbeprovided
withoutchargetoanyshareholdersubmittingawrittenrequest,asprovidedabove.Theinformationonwww.jnj.com,
www.factsaboutourprescriptionopioids.com,www.factsabouttalc.comandwww.LTLManagementInformation.comisnot,and
willnotbedeemed,apartofthisReportorincorporatedintoanyotherfilingstheCompanymakeswiththeSEC.
Johnson&Johnson2022AnnualReport • 7Item1A. RISK FACTORS
AninvestmentintheCompany’scommonstockordebtsecuritiesinvolvesrisksanduncertainties.TheCompanyseeksto
identify,manageandmitigateriskstoourbusiness,butuncertaintiesandrisksaredifficulttopredictandmanyareoutside
oftheCompany’scontrolandcannotthereforebeeliminated.Inadditiontotheotherinformationinthisreportandthe
Company’sotherfilingswiththeSEC,investorsshouldconsidercarefullythefactorssetforthbelow.Investorsshouldbe
awarethatitisnotpossibletopredictoridentifyallsuchfactorsandthatthefollowingisnotmeanttobeacomplete
discussionofallpotentialrisksoruncertainties.Ifknownorunknownrisksoruncertaintiesmaterialize,theCompany’s
business,resultsofoperationsorfinancialconditioncouldbeadverselyaffected,potentiallyinamaterialway.
Risks Related to Our Business, Industry and Operations
TheCompany’sbusinessesoperateinhighlycompetitiveproductmarketsandcompetitivepressurescould
adverselyaffecttheCompany’searnings.
TheCompanyfacessubstantialcompetitioninallthreeoperatingsegmentsandinallgeographicmarkets.TheCompany’s
businessescompetewithcompaniesofallsizesonthebasisofcost-effectiveness,technologicalinnovations,intellectual
propertyrights,productperformance,realorperceivedproductadvantages,pricingandavailabilityandrateof
reimbursement.TheCompanyalsocompeteswithothermarketparticipantsinsecuringrightstoacquisitions,
collaborationsandlicensingagreementswiththirdparties.Competitionforrightstoproductcandidatesandtechnologies
mayresultinsignificantinvestmentandacquisitioncostsandonerousagreementtermsfortheCompany.Competitors’
developmentofmoreeffectiveorlesscostlyproducts,and/ortheirabilitytosecurepatentandotherintellectualproperty
rightsandsuccessfullymarketproductsaheadoftheCompany,couldnegativelyimpactsalesoftheCompany’sexisting
productsaswellasitsabilitytobringnewproductstomarketdespitesignificantpriorinvestmentintherelatedproduct
development.
FortheCompany’sPharmaceuticalbusinesses,lossofpatentexclusivityforaproductoftenisfollowedbyasubstantial
reductioninsalesascompetitorsgainregulatoryapprovalforgenericandothercompetingproductsandenterthemarket.
Similarcompetitioncanbetriggeredbythelossofexclusivityforabiologicalproduct.FortheCompany’sMedTech
businesses,technologicalinnovation,productquality,reputationandcustomerserviceareespeciallyimportantto
competitiveness.Developmentbyothercompaniesofneworimprovedproducts,processesandtechnologiescould
threatentomaketheCompany’sproductsortechnologieslessdesirable,lesseconomicalorobsolete.TheCompany’s
ConsumerHealthbusinessesfaceintensecompetitionfromotherbrandedproductsandretailers’private-labelbrands.If
theCompanyfailstosufficientlydifferentiateandmarketitsbrandnameconsumerproducts,thiscouldadverselyaffect
revenuesandprofitabilityofthoseproducts.
InterruptionsanddelaysinmanufacturingoperationscouldadverselyaffecttheCompany’sbusiness,sales
andreputation.
TheCompany’smanufactureofproductsrequiresthetimelydeliveryofsufficientamountsofcomplex,high-quality
componentsandmaterials.TheCompany’ssubsidiariesoperate89manufacturingfacilitiesaswellassourcingfrom
thousandsofsuppliersaroundtheworld.TheCompanyhasinthepast,andmayinthefuture,faceunanticipated
interruptionsanddelaysinmanufacturingthroughitsinternalorexternalsupplychain.Manufacturingdisruptionscanoccur
formanyreasonsincludingregulatoryaction,productionqualitydeviationsorsafetyissues,labordisputes,labor
shortages,site-specificincidents(suchasfires),naturaldisasterssuchashurricanesandothersevereweatherevents,
rawmaterialshortages,politicalunrest,terroristattacksandepidemicsorpandemics.Suchdelaysanddifficultiesin
manufacturingcanresultinproductshortages,declinesinsalesandreputationalimpactaswellassignificantremediation
andrelatedcostsassociatedwithaddressingtheshortage.
TheCompanyreliesonthirdpartiestomanufacturecertainofourproducts.Anyfailurebyorlossofathird-
partymanufacturercouldresultindelaysandincreasedcosts,whichmayadverselyaffectourbusiness.
TheCompanyreliesonthirdpartiestomanufacturecertainofourproducts.Wedependonthesethird-party
manufacturerstoallocatetousaportionoftheirmanufacturingcapacitysufficienttomeetourneeds,toproduceproducts
ofacceptablequalityandatacceptablemanufacturingyieldsandtodeliverthoseproductstousonatimelybasisandat
acceptableprices.However,wecannotguaranteethatthesethird-partymanufacturerswillbeabletomeetournear-term
orlong-termmanufacturingrequirements,whichcouldresultinlostsalesandhaveanadverseeffectonourbusiness.
Otherrisksassociatedwithourrelianceonthirdpartiestomanufacturetheseproductsincluderelianceonthethirdparty
forregulatorycomplianceandqualityassurance,misappropriationoftheCompany’sintellectualproperty,limitedabilityto
8 • Johnson&Johnson2022AnnualReportmanageourinventory,possiblebreachofthemanufacturingagreementbythethirdpartyandthepossibleterminationor
nonrenewalofthemanufacturingagreementbythethirdpartyatatimethatiscostlyorinconvenientforus.Moreover,if
anyofourthird-partymanufacturerssuffersanydamagetofacilities,losesbenefitsundermaterialagreements,
experiencespoweroutages,encountersfinancialdifficulties,isunabletosecurenecessaryrawmaterialsfromitssuppliers
orsuffersanyotherreductioninefficiency,theCompanymayexperiencesignificantbusinessdisruption.Intheeventof
anysuchdisruption,theCompanywouldneedtoseekandsourceotherqualifiedthird-partymanufacturers,likelyresulting
infurtherdelaysandincreasedcostswhichcouldaffectourbusinessadversely.
Counterfeitversionsofourproductscouldharmourpatientsandhaveanegativeimpactonourrevenues,
earnings,reputationandbusiness.
Ourindustrycontinuestobechallengedbythevulnerabilityofdistributionchannelstoillegalcounterfeitingandthe
presenceofcounterfeitproductsinagrowingnumberofmarketsandovertheInternet.Thirdpartiesmayillegallydistribute
andsellcounterfeitversionsofourproducts,whichdonotmeetourrigorousmanufacturingandtestingstandards.To
distributorsandpatients,counterfeitproductsmaybevisuallyindistinguishablefromtheauthenticversion.Counterfeit
medicinesposearisktopatienthealthandsafetybecauseoftheconditionsunderwhichtheyaremanufactured–oftenin
unregulated,unlicensed,uninspectedandunsanitarysites–aswellasthelackofregulationoftheircontents.
Theindustry’sfailuretomitigatethethreatofcounterfeitmedicinescouldadverselyimpactourbusinessandreputationby
impactingpatientconfidenceinourauthenticproducts,potentiallyresultinginlostsales,productrecalls,andanincreased
threatoflitigation.Inaddition,diversionofourproductsfromtheirauthorizedmarketintootherchannelsmayresultin
reducedrevenuesandnegativelyaffectourprofitability.
Globalhealthcrises,pandemics,epidemics,orotheroutbreakscouldadverselydisruptorimpactcertain
aspectsoftheCompany’sbusiness,resultsofoperationsandfinancialcondition.
Wearesubjecttorisksassociatedwithglobalhealthcrises,epidemics,pandemicsandotheroutbreaks(suchincident(s),
ahealthcrisisorhealthcrises),includingtheglobaloutbreakofcoronavirusanditsvariants(COVID-19).TheCOVID-19
pandemichasadverselyimpacted,andmaycontinuetoadverselyimpact,certainaspectsoftheCompany’sbusiness,
resultsofoperationsandfinancialcondition,includinglowersalesandreducedcustomerdemandandusageofcertainof
ourproducts.ThecontinuedspreadofCOVID-19orotherhealthcrisesmaycausetheCompanytomodifyitsbusiness
practices,andtakefurtheractionsasmayberequiredbygovernmentauthoritiesorastheCompanydeterminesareinthe
bestinterestsofourpatients,customers,employeesandbusinesspartners.WhiletheCompanyhasrobustbusiness
continuityplansinplaceacrossourglobalsupplychainnetworktohelpmitigatetheimpactofhealthcrises,theseefforts
maynotcompletelypreventourbusinessfrombeingadverselyaffectedandfutureimpactsremainuncertain.
WhiletheU.S.andothercountrieshavesubstantiallyreopenedtheireconomies,theextenttowhichCOVID-19,orother
healthcrises,couldimpacttheCompany’sfutureoperationswilldependonmanyfactorswhichcannotbepredictedwith
confidence,includingthedurationofanoutbreakandimpactofvariants.AsurgeinCOVID-19orotherhealthcrisescould
resultintheimpositionofnewmandatesandprolongedrestrictivemeasuresimplementedinordertocontrolthespreadof
disease.TheglobalspreadofCOVID-19orotherhealthcrisescouldadverselyimpacttheCompany’soperations,
including,amongotherthings,ourmanufacturingoperations,supplychain,third-partysuppliers,salesandmarketing,and
clinicaltrialoperations.AnyofthesefactorscouldadverselyaffecttheCompany’sbusiness,financialresults,andglobal
economicconditionsgenerally.
Wealsofaceuncertaintiesrelatedtoourvaccinedevelopmentprograms,includinguncertaintiesrelatedtotheriskthatour
continueddevelopmentprogramsmaynotbesuccessful,commerciallyviableorreceiveapprovalfromregulatory
authorities;risksassociatedwithclinicaltrialandreal-worlddata,includingfurtheranalysesofitsefficacy,safetyand
durability;theriskthatcontinuedevolutionandmutationofdiseaseandthedurationofaparticularoutbreakmayimpedeour
abilitytoconducttrialswithinaspecifiedtimeframe;theriskthatdataaresubjecttodifferinginterpretationsand
assessments,includingduringthepeerreview/publicationprocess,inthescientificcommunitygenerally,andbynational
immunizationtechnicaladvisorygroups(NITAGs)andregulatoryauthorities;disruptionsintherelationshipsbetweenus,our
third-partysuppliers,externalmanufacturers,andotherthirdpartieswithwhomweengage;theriskthatothercompanies
mayproducesuperiororcompetitiveproducts;theriskthatdemandforanyproductswemaydevelopmaynolongerexist;
risksrelatedtotheavailabilityofrawmaterialstomanufactureanysuchproducts;theriskthatwemaynotbeabletorecoup
costsassociatedwithourR&Dandmanufacturingeffortsandrisksassociatedwithanychangesinthewayweapproachor
provideadditionalresearchfundingforpotentialdrugdevelopment;theriskthatwemaynotbeabletocreateorscaleup
manufacturingcapacityonatimelybasis,thatwemaycontinuetoexperiencemanufacturingdelaysonceamanufacturing
siteisactivated,orhaveaccesstologisticsorsupplychannelscommensuratewithglobaldemandforanypotential
approvedvaccineorproductcandidate,whichwouldnegativelyimpactourabilitytosupplytheestimatednumbersofdoses
Johnson&Johnson2022AnnualReport • 9ofourvaccinewithintheprojectedtimeperiodsindicated,andotherchallengesandrisksassociatedwiththepaceofour
vaccinedevelopmentprogram;andpricingandaccesschallengesforsuchproducts,includingintheU.S.
Risks Related to Government Regulation and Legal Proceedings
GlobalsalesintheCompany’sPharmaceuticalandMedTechsegmentsmaybenegativelyimpactedby
healthcarereformsandincreasingpricingpressures.
SalesoftheCompany’sPharmaceuticalandMedTechproductsaresignificantlyaffectedbyreimbursementsbythird-party
payerssuchasgovernmenthealthcareprograms,privateinsuranceplansandmanagedcareorganizations.Aspartof
variouseffortstocontainhealthcarecosts,thesepayersareputtingdownwardpressureonpricesatwhichproductswill
bereimbursed.IntheU.S.,increasedpurchasingpowerofentitiesthatnegotiateonbehalfofMedicare,Medicaid,and
privatesectorbeneficiaries,inpartduetocontinuedconsolidationamonghealthcareproviders,couldresultinfurther
pricingpressures.Inaddition,recentlegislationandongoingpoliticalscrutinyorpricing,coverageandreimbursement
couldresultinadditionalpricingpressures.Specifically,theInflationReductionActof2022(IRA)maysubjectcertain
productstogovernment-establishedpricing,potentiallyimposerebates,andsubjectmanufacturerswhofailtoadhereto
thegovernment’sinterpretationsofthelawtopenalties.OutsidetheU.S.,numerousmajormarkets,includingtheEU,
UnitedKingdom,JapanandChina,havepervasivegovernmentinvolvementinfundinghealthcareand,inthatregard,
directlyorindirectlyimposepricecontrols,limitaccessto,orreimbursementfor,theCompany’sproducts,orreducethe
valueofitsintellectualpropertyprotection.
TheCompanyissubjecttosignificantlegalproceedingsthatcanresultinsignificantexpenses,finesand
reputationaldamage.
Intheordinarycourseofbusiness,Johnson&Johnsonanditssubsidiariesaresubjecttonumerousclaimsandlawsuits
involvingvariousissuessuchasproductliability,patentdisputesandclaimsthattheirproductsales,marketingandpricing
practicesviolatevariousantitrust,unfairtradepracticesand/orconsumerprotectionlaws.TheCompany’smoresignificant
legalproceedingsaredescribedinNote19,“LegalProceedings”underNotestotheConsolidatedFinancialStatements
includedinItem8ofthisReport.Litigation,ingeneral,andsecurities,derivativeaction,classactionandmulti-district
litigation,inparticular,canbeexpensiveanddisruptive.Someofthesemattersmayincludethousandsofplaintiffs,may
involvepartiesseekinglargeand/orindeterminateamounts,includingpunitiveorexemplarydamages,andmayremain
unresolvedforseveralyears.Forexample,theCompanyisadefendantinnumerouslawsuitsarisingoutoftheuseofbody
powderscontainingtalc,primarilyJOHNSON’SBabyPowder,andtheCompany’ssale,manufacturingandmarketingof
opioids.WhiletheCompanybelievesithassubstantialdefensesinthesematters,itisnotfeasibletopredicttheultimate
outcomeoflitigation.TheCompanycouldinthefutureberequiredtopaysignificantamountsasaresultofsettlementsor
judgmentsinthesematters,potentiallyinexcessofaccruals,includingmatterswheretheCompanycouldbeheldjointly
andseverallyliableamongotherdefendants.Theresolutionof,orincreaseinaccrualsfor,oneormoreofthesemattersin
anyreportingperiodcouldhaveamaterialadverseeffectontheCompany’sresultsofoperationsandcashflowsforthat
period.TheCompanydoesnotpurchasethird-partyproductliabilityinsurance;however,theCompanyutilizesawholly
ownedcaptiveinsurancecompanysubjecttocertainlimits.
Productreliability,safetyandeffectivenessconcernscanhavesignificantnegativeimpactsonsalesand
resultsofoperations,leadtolitigationandcausereputationaldamage.
Concernsaboutproductsafety,whetherraisedinternallyorbylitigants,regulatorsorconsumeradvocates,andwhetheror
notbasedonscientificevidence,canresultinsafetyalerts,productrecalls,governmentalinvestigations,regulatoryaction
onthepartoftheU.S.FoodandDrugAdministration(oritscounterpartinothercountries),privateclaimsandlawsuits,
paymentoffinesandsettlements,decliningsalesandreputationaldamage.Thesecircumstancescanalsoresultin
damagetobrandimage,brandequityandconsumertrustintheCompany’sproducts.Productrecallshaveinthepast,
andcouldinthefuture,promptgovernmentinvestigationsandinspections,theshutdownofmanufacturingfacilities,
continuedproductshortagesandrelatedsalesdeclines,significantremediationcosts,reputationaldamage,possiblecivil
penaltiesandcriminalprosecution.
TheCompanyfacessignificantregulatoryscrutiny,whichimposessignificantcompliancecostsand
exposestheCompanytogovernmentinvestigations,legalactionsandpenalties.
Likeothercompaniesinthehealthcareindustry,theCompanyissubjecttoextensiveregulation,investigationsandlegal
actionbynational,stateandlocalgovernmentagenciesintheU.S.andothercountriesinwhichitoperates.Regulatory
issuesregardingcompliancewithcurrentGoodManufacturingPractices(cGMP)(andcomparablequalityregulationsin
foreigncountries)bymanufacturersofdrugs,devicesandconsumerproductscanleadtofinesandpenalties,product
10 • Johnson&Johnson2022AnnualReportrecalls,productshortages,interruptionsinproduction,delaysinnewproductapprovalsandlitigation.Inaddition,the
marketing,pricingandsaleoftheCompany’sproductsaresubjecttoregulation,investigationsandlegalactionsincluding
undertheFederalFood,Drug,andCosmeticAct,theMedicaidRebateProgram,federalandstatefalseclaimsacts,state
unfairtradepracticesactsandconsumerprotectionlaws.Scrutinyofhealthcareindustrybusinesspracticesby
governmentagenciesandstateattorneysgeneralintheU.S.,andanyresultinginvestigationsandprosecutions,carryrisk
ofsignificantcivilandcriminalpenaltiesincluding,butnotlimitedto,debarmentfromparticipationingovernment
healthcareprograms.AnysuchdebarmentcouldhaveamaterialadverseeffectontheCompany’sbusinessandresultsof
operations.Themostsignificantcurrentinvestigationsandlitigationbroughtbygovernmentagenciesaredescribedin
Note19,“LegalProceedings—GovernmentProceedings”underNotestotheConsolidatedFinancialStatementsincluded
inItem8ofthisReport.
ChangesintaxlawsorexposurestoadditionaltaxliabilitiescouldnegativelyimpacttheCompany’s
operatingresults.
Changesintaxlawsorregulationsaroundtheworld,includingintheU.S.andasledbytheOrganizationforEconomic
CooperationandDevelopment,suchastherecentadoptionbytheEU,enactmentbySouthKoreaandtheanticipated
enactmentbyadditionalcountriesofaglobalminimumtax,couldnegativelyimpacttheCompany’seffectivetaxrateand
resultsofoperations.Achangeinstatutorytaxrateorcertaininternationaltaxprovisionsinanycountrywouldresultinthe
revaluationoftheCompany’sdeferredtaxassetsandliabilitiesrelatedtothatparticularjurisdictionintheperiodinwhich
thenewtaxlawisenacted.ThischangewouldresultinanexpenseorbenefitrecordedtotheCompany’sConsolidated
StatementofEarnings.TheCompanycloselymonitorstheseproposalsastheyariseinthecountrieswhereitoperates.
Changestotaxlawsorregulationsmayoccuratanytime,andanyrelatedexpenseorbenefitrecordedmaybematerialto
thefiscalquarterandyearinwhichthelawchangeisenacted.
SeeNote8,“IncomeTaxes”underNotestotheConsolidatedFinancialStatementsincludedinItem8ofthisReportfor
additionalinformation.
TheCompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandisaddressingtaxauditsanddisputes
withmanytaxauthorities.Inconnectionwithvariousgovernmentinitiatives,companiesarerequiredtodisclosemore
informationtotaxauthoritiesonoperationsaroundtheworld,whichmayleadtogreaterauditscrutinyofprofitsearnedin
othercountries.TheCompanyregularlyassessesthelikelyoutcomesofitstaxauditsanddisputestodeterminethe
appropriatenessofitstaxreserves.However,anytaxauthoritycouldtakeapositionontaxtreatmentthatiscontrarytothe
Company’sexpectations,whichcouldresultintaxliabilitiesinexcessofreserves.
Risks Related to Our Intellectual Property
TheCompanyfacesincreasedchallengestointellectualpropertyrightscentraltoitsbusiness.
TheCompanyownsorlicensesasignificantnumberofpatentsandotherproprietaryrightsrelatingtoitsproductsand
manufacturingprocesses.TheserightsareessentialtotheCompany’sbusinessesandmateriallyimportanttothe
Company’sresultsofoperations.Publicpolicy,bothwithinandoutsidetheU.S.,hasbecomeincreasinglyunfavorable
towardintellectualpropertyrights.TheCompanycannotbecertainthatitwillobtainadequatepatentprotectionfornew
productsandtechnologiesintheUnitedStatesandotherimportantmarketsorthatsuchprotections,oncegranted,will
lastaslongasoriginallyanticipated.
CompetitorsroutinelychallengethevalidityorextentoftheCompany’sownedorlicensedpatentsandproprietaryrights
throughlitigation,interferences,oppositionsandotherproceedings,suchasinterpartesreview(IPR)proceedingsbefore
theUnitedStatesPatent&TrademarkOffice(USPTO).Theseproceedingsabsorbresourcesandcanbeprotractedas
wellasunpredictable.Inaddition,challengesthattheCompany’sproductsinfringethepatentsofthirdpartiescouldresult
inaninjunctionand/ortheneedtopaypastdamagesandfutureroyaltiesandadverselyaffectthecompetitivepositionand
salesoftheproductsinquestion.
TheCompanyhasfacedincreasingpatentchallengesfromthirdpartiesseekingtomanufactureandmarketgenericand
biosimilarversionsoftheCompany’skeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscovering
thoseproducts.IntheU.S.,manufacturersofgenericversionsofinnovativehumanpharmaceuticalproductsmay
challengethevalidity,orclaimnon-infringement,ofinnovatorproductsthroughtheAbbreviatedNewDrugApplication,or
ANDA,processwiththeU.S.FDAandrelatedANDAlitigation.TheBiologicsPriceCompetitionandInnovationAct
(BPCIA),enactedin2010,whichcreatedanewregulatorypathwayfortheapprovalbytheU.S.FDAofbiosimilar
alternativestoinnovator-developedbiologicalproducts,alsocreatedmechanismsforbiosimilarapplicantstochallengethe
patentsontheinnovatorbiologics.TheIPRprocesswiththeUSPTOisalsobeingusedbycompetitorstochallenge
patentsassertedinlitigation.
Johnson&Johnson2022AnnualReport • 11IntheeventtheCompanyisnotsuccessfulindefendingitspatentsagainstsuchchallenges,oruponthe“at-risk”launch
bythegenericorbiosimilarfirmofitsproduct,theCompanycanloseamajorportionofrevenuesforthereferenced
productinaveryshortperiodoftime.CurrentlegalproceedingsinvolvingtheCompany’spatentsandotherintellectual
propertyrightsaredescribedinNote19,“LegalProceedings—IntellectualProperty”underNotestotheConsolidated
FinancialStatementsincludedinItem8ofthisReport.
RisksRelatedtoProductDevelopment,RegulatoryApprovalandCommercialization
SignificantchallengesordelaysintheCompany’sinnovationanddevelopmentofnewproducts,
technologiesandindicationscouldhaveanadverseimpactontheCompany’slong-termsuccess.
TheCompany’scontinuedgrowthandsuccessdependsonitsabilitytoinnovateanddevelopnewanddifferentiated
productsandservicesthataddresstheevolvinghealthcareneedsofpatients,providersandconsumers.Developmentof
successfulproductsandtechnologiesisalsonecessarytooffsetrevenuelosseswhentheCompany’sexistingproducts
losemarketshareduetovariousfactorssuchascompetitionandlossofpatentexclusivity.Newproductsintroduced
withinthepastfiveyearsaccountedforapproximately25%of2022sales.TheCompanycannotbecertainwhenor
whetheritwillbeabletodevelop,licenseorotherwiseacquirecompanies,productsandtechnologies,whetherparticular
productcandidateswillbegrantedregulatoryapproval,and,ifapproved,whethertheproductswillbecommercially
successful.
TheCompanypursuesproductdevelopmentthroughinternalresearchanddevelopmentaswellasthroughcollaborations,
acquisitions,jointventuresandlicensingorotherarrangementswiththirdparties.Inallofthesecontexts,developingnew
products,particularlypharmaceuticalandbiotechnologyproductsandmedicaldevices,requiressignificantinvestmentof
resourcesovermanyyears.Onlyaveryfewbiopharmaceuticalresearchanddevelopmentprogramsresultincommercially
viableproducts.Theprocessdependsonmanyfactorsincludingtheabilityto:discernpatients’andhealthcareproviders’
futureneeds;developpromisingnewcompounds,strategiesandtechnologies;achievesuccessfulclinicaltrialresults;
secureeffectiveintellectualpropertyprotection;obtainregulatoryapprovalsonatimelybasis;and,ifandwhentheyreach
themarket,successfullydifferentiatetheCompany’sproductsfromcompetingproductsandapproachestotreatment.
Newproductsorenhancementstoexistingproductsmaynotbeacceptedquicklyorsignificantlyinthemarketplacedue
toproductandpricecompetition,changesincustomerpreferencesorhealthcarepurchasingpatterns,resistanceby
healthcareprovidersoruncertaintyoverthird-partyreimbursement.Evenfollowinginitialregulatoryapproval,thesuccess
ofaproductcanbeadverselyimpactedbysafetyandefficacyfindingsinlargerreal-worldpatientpopulations,aswellas
marketentryofcompetitiveproducts.
Risks Related to Financial and Economic Market Conditions
TheCompanyfacesavarietyoffinancial,economic,legal,socialandpoliticalrisksassociatedwith
conductingbusinessinternationally.
TheCompany’sextensiveoperationsandbusinessactivitythroughouttheworldareaccompaniedbycertainfinancial,
economic,legal,socialandpoliticalrisks,includingthoselistedbelow.
ForeignCurrencyExchange:Infiscal2022,approximately49%oftheCompany’ssalesoccurredoutsideoftheU.S.,with
approximately25%inEurope,6%intheWesternHemisphere,excludingtheU.S.,and18%intheAsia-PacificandAfrica
region.Changesinnon-U.S.currenciesrelativetotheU.S.dollarimpacttheCompany’srevenuesandexpenses.While
theCompanyusesfinancialinstrumentstomitigatetheimpactoffluctuationsincurrencyexchangeratesonitscashflows,
unhedgedexposurescontinuetobesubjecttocurrencyfluctuations.Inaddition,theweakeningorstrengtheningofthe
U.S.dollarmayresultinsignificantfavorableorunfavorabletranslationeffectswhentheoperatingresultsofthe
Company’snon-U.S.businessactivityaretranslatedintoU.S.dollars.
InflationandCurrencyDevaluationRisks:TheCompanyfaceschallengesinmaintainingprofitabilityofoperationsin
economiesexperiencinghighinflationrates.Specifically,theCompanyhasaccountedforoperationsinArgentina,Turkey
andVenezuelaashighlyinflationary,asthepriorthree-yearcumulativeinflationratesurpassed100%.WhiletheCompany
strivestomaintainprofitmarginsintheseareasthroughcostreductionprograms,productivityimprovementsandperiodic
priceincreases,itmightexperienceoperatinglossesasaresultofcontinuedinflation.Inaddition,theimpactofcurrency
devaluationsincountriesexperiencinghighinflationratesorsignificantcurrencyexchangefluctuationscouldnegatively
impacttheCompany’soperatingresults.
IllegalImportationofPharmaceuticalProducts:Theillegalimportationofpharmaceuticalproductsfromcountrieswhere
governmentpricecontrolsorothermarketdynamicsresultinlowerpricesmayadverselyaffecttheCompany’ssalesand
12 • Johnson&Johnson2022AnnualReportprofitabilityintheU.S.andothercountriesinwhichtheCompanyoperates.Withtheexceptionoflimitedquantitiesof
prescriptiondrugsforpersonaluse,foreignimportsofpharmaceuticalproductsareillegalundercurrentU.S.law.
However,thevolumeofillegalimportscontinuestoriseastheabilityofpatientsandothercustomerstoobtainthelower-
pricedimportshasgrownsignificantly.
Anti-BriberyandOtherRegulations:TheCompanyissubjecttovariousfederalandforeignlawsthatgovernitsinternational
businesspracticeswithrespecttopaymentstogovernmentofficials.ThoselawsincludetheU.S.ForeignCorrupt
PracticesAct(FCPA),whichprohibitsU.S.publiclytradedcompaniesfrompromising,offering,orgivinganythingofvalue
toforeignofficialswiththecorruptintentofinfluencingtheforeignofficialforthepurposeofhelpingtheCompanyobtain
orretainbusinessorgainanyimproperadvantage.TheCompany’sbusinessisheavilyregulatedandthereforeinvolves
significantinteractionwithforeignofficials.Also,inmanycountriesoutsidetheU.S.,thehealthcareproviderswho
prescribehumanpharmaceuticalsareemployedbythegovernmentandthepurchasersofhumanpharmaceuticalsare
governmententities;therefore,theCompany’sinteractionswiththeseprescribersandpurchasersaresubjecttoregulation
undertheFCPA.InadditiontotheU.S.applicationandenforcementoftheFCPA,variousjurisdictionsinwhichthe
Companyoperateshavelawsandregulations,includingtheU.K.BriberyAct2010,aimedatpreventingandpenalizing
corruptandanticompetitivebehavior.EnforcementactivitiesundertheselawscouldsubjecttheCompanytoadditional
administrativeandlegalproceedingsandactions,whichcouldincludeclaimsforcivilpenalties,criminalsanctions,and
administrativeremedies,includingexclusionfromhealthcareprograms.
OtherFinancial,Economic,Legal,SocialandPoliticalRisks.Otherrisksinherentinconductingbusinessgloballyinclude:
• localandregionaleconomicenvironmentsandpoliciesinthemarketsthatweserve,includinginterestrates,monetary
policy,inflation,economicgrowth,recession,commodityprices,andcurrencycontrolsorotherlimitationsontheability
toexpatriatecash;
• protectiveeconomicpoliciestakenbygovernments,suchastradeprotectionmeasuresandimport/exportlicensing
requirements;
• compliancewithlocalregulationsandlawsincluding,insomecountries,regulatoryrequirementsrestrictingthe
Company’sabilitytomanufactureorsellitsproductsintherelevantmarket;
• diminishedprotectionofintellectualpropertyandcontractualrightsincertainjurisdictions;
• potentialnationalizationorexpropriationoftheCompany’sforeignassets;
• politicalorsocialupheavals,economicinstability,repression,orhumanrightsissues;and
• geopoliticalevents,includingnaturaldisasters,disruptionstomarketsduetowar,armedconflict,terrorism,epidemicsor
pandemics.
Failuretomaintainasatisfactorycreditratingcouldadverselyaffectourliquidity,capitalposition,
borrowingcostsandaccesstocapitalmarkets.
WecurrentlymaintaininvestmentgradecreditratingswithMoody’sInvestorsServiceandStandard&Poor’sRatings
Services.Ratingagenciesroutinelyevaluateus,andtheirratingsofourlong-termandshort-termdebtarebasedona
numberoffactors.Anydowngradeofourcreditratingsbyacreditratingagency,whetherasaresultofouractionsor
factorswhicharebeyondourcontrol,canincreasethecostofborrowingunderanyindebtednesswemayincur,reduce
marketcapacityforourcommercialpaperorrequirethepostingofadditionalcollateralunderourderivativecontracts.
Therecanbenoassurancethatwewillbeabletomaintainourcreditratings,andanyadditionalactualoranticipated
changesordowngradesinourcreditratings,includinganyannouncementthatourratingsareunderreviewfora
downgrade,mayhaveanegativeimpactonourliquidity,capitalpositionandaccesstocapitalmarkets.
TheRussia-UkraineWar,andactionstakeninresponsetotheRussia-UkraineWar,couldadverselyaffect
ourbusiness,resultsofoperationsorfinancialcondition.
InFebruary2022,RussialaunchedamilitaryinvasionofUkraine.TheongoingRussia-UkraineWarhasprovokedstrong
reactionsfromtheUnitedStates,theUnitedKingdom,theEuropeanUnionandvariousothercountriesandeconomicand
politicalorganizationsaroundtheworld.WehavebeenmonitoringthegeopoliticalsituationinRussiasincethestartofthe
Russia-UkraineWarandhavesuspendedadditionalinvestment,enrollmentofclinicaltrials,andsupplyofourpersonal
careproductsinRussia.Wecontinuetomonitortheneedforhumanitarianreliefintheregionandcontinuetosupplyour
medicines,medicaldevicesandequipmentintheregionincompliancewiththeapplicablesanctions.Wewillcontinueto
monitorthegeopoliticalsituationinRussiaandtoevaluateouractivitiesandfutureoperationsinRussia.
ActionstakeninresponsetotheRussia-UkraineWarincludetheimpositionofexportcontrolsandbroadfinancialand
economicsanctionsagainstRussia,BelarusandspecificareasofUkraine.Additionalsanctionsorothermeasuresmaybe
imposedbytheglobalcommunity,includingbutnotlimitedtolimitationsonourabilitytofile,prosecuteandmaintain
Johnson&Johnson2022AnnualReport • 13patents,trademarksandotherintellectualpropertyrights.Furthermore,theRussiangovernmenthasalreadytakenaction
allowingRussiancompaniesandindividualstoexploitinventionsownedbypatentholdersfromtheUnitedStatesand
manyothercountrieswithoutconsentorcompensationandwemaynotbeabletopreventthirdpartiesfrompracticingour
inventionsinRussiaorfromsellingorimportingproductsinandintoRussia.
Wehaveexperienced,andexpecttocontinuetoexperience,otherrisksrelatedtothebroadeconomicconsequencesof
theRussia-UkraineWar,includingforeigncurrencyvolatility,decreaseddemandforourproductsincountriesaffectedby
theRussia-UkraineWarandchallengestoourglobalsupplychainrelatedtoincreasedcostsofmaterialsandotherinputs
forourproductsandsuppliersoperatinginRussiaandUkraine.Wealsocontinuetomonitorthevarioussanctionsand
exportcontrolsimposedinresponsetotheRussia-UkraineWar.
ThefullimpactoftheRussia-UkraineWar,andactionstakeninresponsetotheongoingconflict,ontheglobaleconomy
andgeopoliticalrelations,ingeneral,andonourbusinessinparticular,remainuncertain.Anyoralloftheforegoingrisks
couldhaveanadverseeffectonourbusiness,resultsofoperationsorfinancialcondition,particularlyastheconflict
continuesforanindefiniteperiodoftime.GiventhatdevelopmentsconcerningtheRussia-UkraineWarareongoingand
havebeenconstantlyevolving,additionalimpactsandrisksmayarisethatarenotpresentlyknowntous.TheRussia-
UkraineWarmayalsohavetheeffectofheighteningmanyoftheotherrisksdescribedinthis“RiskFactors”section.
Risks Related to the Planned Separation of our Consumer Health Business
TheplannedseparationoftheCompany’sConsumerHealthbusinessmaynotbecompletedontheterms
ortimelinecurrentlycontemplated,ifatall,andmaynotachievetheexpectedresults.
InNovember2021,theCompanyannounceditsintentiontoseparatetheCompany’sConsumerHealthbusiness,withthe
intentiontocreateastandalonepubliclytradedcompany,whichwassubsequentlynamedKenvue,Inc.(“Kenvue”).The
plannedseparationisintendedtoqualifyasatax-freetransactionforU.S.federalincometaxpurposes.TheCompanyis
targetingcompletionoftheplannedseparationin2023.Completionoftheplannedseparationwillbesubjecttothe
satisfactionofcertainconditions,including,amongothers,consultationswithworkscouncilsandotheremployee
representativebodies,asrequired,finalapprovalbytheCompany’sBoardofDirectors,thecontinuingeffectivenessand
validityoftheCompany’sprivateletterrulingfromtheInternalRevenueService(“IRS”)andreceiptoffavorableopinionsof
theCompany’sU.S.taxadvisorswithrespecttothetax-freenatureofthetransaction,andthereceiptofotherregulatory
approvals.Therecanbenoassuranceregardingtheultimatetimingoftheplannedseparationorthatsuchseparationwill
becompleted.Unanticipateddevelopmentscoulddelay,preventorotherwiseadverselyaffecttheplannedseparation,
includingbutnotlimitedtodisruptionsingeneralorfinancialmarketconditionsorpotentialproblemsordelaysinobtaining
variousregulatoryandtaxapprovalsorclearances.
Thecoststocompletetheplannedseparationwillbesignificant.Inaddition,theCompanymaybeunable
toachievesomeorallofthestrategicandfinancialbenefitsthatitexpectstoachievefromtheplanned
separationoftheCompany’sConsumerHealthbusiness.
TheCompanyhasincurred,andisexpectedtoincur,significantexpensesinconnectionwiththeplannedseparation.In
addition,theCompanymaynotbeabletoachievethefullstrategicandfinancialbenefitsthatareexpectedtoresultfrom
theplannedseparation.Theanticipatedbenefitsoftheplannedseparationarebasedonanumberofassumptions,some
ofwhichmayproveincorrect.
Followingtheplannedseparation,thepriceofsharesoftheCompany’scommonstockmay
fluctuatesignificantly.
TheCompanycannotpredicttheeffectoftheplannedseparationonthetradingpriceofsharesofitscommonstock,and
themarketvalueofsharesofitscommonstockmaybelessthan,equaltoorgreaterthanthemarketvalueofsharesofits
commonstockpriortotheplannedseparation.Inaddition,thepriceoftheCompany’scommonstockmaybemorevolatile
aroundthetimeoftheplannedseparation.
Theplannedseparationcouldresultinsubstantialtaxliability.
TheCompanyhasreceivedaprivateletterrulingfromtheIRSastothetax-freenatureoftheplannedseparationunderthe
U.S.InternalRevenueCodeof1986,asamended.Theplannedseparationisconditionedon,amongotherthings,the
continuingeffectivenessandvalidityoftheCompany’sprivateletterrulingfromtheIRSandreceiptoffavorableopinionsof
theCompany’sU.S.taxadvisors.Theprivateletterrulingandopinionswillbebasedon,amongotherthings,variousfacts,
assumptions,representationsandundertakingsfromtheCompanyandKenvueregardingthepastandfutureconductof
14 • Johnson&Johnson2022AnnualReportthecompanies’respectivebusinessesandothermatters.Ifanyofthesefacts,assumptions,representationsor
undertakingsareincorrectornototherwisesatisfied,theCompanyanditsshareholdersmaynotbeabletorelyonthe
rulingortheopinionsoftaxadvisors.Notwithstandingtheprivateletterrulingandopinionsoftaxadvisors,ifsubsequentto
theplannedseparationtheIRSdeterminesthatcertainstepsofthetransactiondonotqualifyfortax-freetreatmentfor
U.S.federalincometaxpurposes,theresultingtaxliabilitytotheCompanyanditsshareholderscouldbesubstantial.The
plannedseparationmayalsonotqualifyfortax-freetreatmentinothercountriesaroundtheworld,andasaresultmay
triggersubstantialtaxliabilitytotheCompany.
Other Risks
Ourbusinessdependsonourabilitytorecruitandretaintalented,highlyskilledemployeesandadiverse
workforce.
Ourcontinuedgrowthrequiresustorecruitandretaintalentedemployeesrepresentingdiversebackgrounds,experiences,
andskillsets.Themarketforhighlyskilledworkersandleadersinourindustryisextremelycompetitiveandourabilityto
competedependsonourabilitytohire,developandmotivatehighlyskilledpersonnelinallareasofourorganization.
Maintainingourbrandandreputation,aswellasadiverse,equitableandinclusiveworkenvironmentenablesustoattract
toptalent.Ifwearelesssuccessfulinourrecruitingefforts,orifwecannotretainhighlyskilledworkersandkeyleaders,
ourabilitytodevelopanddeliversuccessfulproductsandservicesmaybeadverselyaffected.Inaddition,effective
successionplanningisimportanttoourlong-termsuccess.Anyunsuccessfulimplementationofoursuccessionplansor
failuretoensureeffectivetransferofknowledgeandsmoothtransitionsinvolvingkeyemployeescouldadverselyaffectour
business,financialcondition,orresultsofoperations.
Climatechangeorlegal,regulatoryormarketmeasurestoaddressclimatechangemaynegativelyaffect
ourbusinessandresultsofoperations.
Climatechangeresultingfromincreasedconcentrationsofcarbondioxideandothergreenhousegasesintheatmosphere
couldpresentriskstoouroperations,includinganadverseimpactonglobaltemperatures,weatherpatternsandthe
frequencyandseverityofextremeweatherandnaturaldisasters.Naturaldisastersandextremeweatherconditions,such
asahurricane,tornado,earthquake,wildfireorflooding,mayposephysicalriskstoourfacilitiesanddisrupttheoperation
ofoursupplychain.Theimpactsofthechangingclimateonwaterresourcesmayresultinwaterscarcity,limitingourability
toaccesssufficienthigh-qualitywaterincertainlocations,whichmayincreaseoperationalcosts.
Concernoverclimatechangemayalsoresultinneworadditionallegalorregulatoryrequirementsdesignedtoreduce
greenhousegasemissionsand/ormitigatetheeffectsofclimatechangeontheenvironment.Ifsuchlawsorregulations
aremorestringentthancurrentlegalorregulatoryobligations,wemayexperiencedisruptionin,oranincreaseinthecosts
associatedwithsourcing,manufacturinganddistributionofourproducts,whichmayadverselyaffectourbusiness,results
ofoperationsorfinancialcondition.Further,theimpactsofclimatechangehaveaninfluenceoncustomerpreferences,
andfailuretoprovideclimate-friendlyproductscouldpotentiallyresultinlossofmarketshare.
Aninformationsecurityincident,includingacybersecuritybreach,couldhaveanegativeimpacttothe
Company’sbusinessorreputation.
Tomeetbusinessobjectives,theCompanyreliesonbothinternalinformationtechnology(IT)systemsandnetworks,and
thoseofthirdpartiesandtheirvendors,toprocessandstoresensitivedata,includingconfidentialresearch,business
plans,financialinformation,intellectualproperty,andpersonaldatathatmaybesubjecttolegalprotection,andensurethe
continuityoftheCompany’ssupplychain.Theextensiveinformationsecurityandcybersecuritythreats,whichaffect
companiesglobally,posearisktothesecurityandavailabilityofthesesystemsandnetworks,andtheconfidentiality,
integrity,andavailabilityoftheCompany’ssensitivedata.TheCompanycontinuallyassessesthesethreatsandmakes
investmentstoincreaseinternalprotection,detection,andresponsecapabilities,aswellasensuretheCompany’sthird-
partyprovidershaverequiredcapabilitiesandcontrols,toaddressthisrisk.Todate,theCompanyhasnotexperiencedany
materialimpacttothebusinessoroperationsresultingfrominformationorcybersecurityattacks;however,becauseofthe
frequentlychangingattacktechniques,alongwiththeincreasedvolumeandsophisticationoftheattacks,thereisthe
potentialfortheCompanytobeadverselyimpacted.Thisimpactcouldresultinreputational,competitive,operationalor
otherbusinessharmaswellasfinancialcostsandregulatoryaction.TheCompanymaintainscybersecurityinsurancein
theeventofaninformationsecurityorcyberincident;however,thecoveragemaynotbesufficienttocoverallfinancial,
legal,businessorreputationallosses.
AsaresultoftheRussia-UkraineWar,therehasbeen,andweexpecttherewillcontinuetobe,anincreasedriskof
informationsecurityorcybersecurityincidents,includingcyberattacksperpetratedbyRussiaorothersatitsdirection.
Johnson&Johnson2022AnnualReport • 15Althoughwehavetakenstepstoenhanceourprotectionsagainsttheseattacks,wemaynotbeabletoaddressthethreat
ofinformationsecurityorcybersecurityincidentsproactivelyorimplementadequatepreventativemeasuresandwemay
notbeabletodetectandaddressanysuchdisruptionorsecuritybreachpromptly,oratall,whichcouldadverselyaffect
ourbusiness,resultsofoperationsorfinancialcondition.Moreover,weareawareofincidentsinwhichourthird-party
partnershavebeenthetargetofinformationsecurityorcybersecurityincidentsasaresultoftheRussia-UkraineWar.
Although,todate,ourITSystemshavenotbeencompromisedbytheseincidents,itispossiblethatfutureinformation
securityorcybersecurityincidentsinvolvingourcustomers,manufacturers,suppliersorotherthird-partypartnerscould
successfullycompromiseourITSystems,whichcouldadverselyaffectourbusiness,resultsofoperationsorfinancial
condition.
Abreachofprivacylawsorunauthorizedaccess,lossormisuseofpersonaldatacouldhaveanegative
impacttotheCompany’sbusinessorreputation.
TheCompanyissubjecttoprivacyanddataprotectionlawsacrosstheglobethatimposebroadcomplianceobligations
onthecollection,use,storage,access,transferandprotectionofpersonaldata.Breachofsuchrequirementscouldresult
insubstantialfines,penalties,privaterightofactions,claimsanddamagetoourreputationandbusiness.Newprivacylaws
areexpectedinotherterritories,togetherwithgreaterprivacyenforcementbygovernmentalauthoritiesglobally,particularly
ondatalocalizationrequirementsandinternationaldataflows.TheCompanyhasestablishedprivacycomplianceprograms
andcontrolsthatourbusinessesworldwidearerequiredtocomplywith,butwithmanytechnologyanddata-driven
initiativesbeingprioritizedacrosstheCompanyandinvolvingmultiplevendorsandthirdparties,therearepotentialrisksof
controlsimposedoncrossborderdataflows,unauthorizedaccess,andlossofpersonaldatathroughinternalandexternal
threatsthatcouldimpactourbusinessoperationsandresearchactivities.
Item 1B. UNRESOLVED STAFF COMMENTS
Notapplicable.
Item 2. PROPERTIES
TheCompany’ssubsidiariesoperate89manufacturingfacilitiesoccupyingapproximately14.9millionsquarefeetoffloor
space.ThemanufacturingfacilitiesareusedbytheindustrysegmentsoftheCompany’sbusinessapproximatelyas
follows:
SquareFeet
Segment (inthousands)
ConsumerHealth 4,562
Pharmaceutical 5,456
MedTech 4,930
WorldwideTotal 14,948
WithintheU.S.,fourfacilitiesareusedbytheConsumerHealthsegment,fivebythePharmaceuticalsegmentand19by
theMedTechsegment.OutsideoftheU.S.,23facilitiesareusedbytheConsumerHealthsegment,13bythe
Pharmaceuticalsegmentand25bytheMedTechsegment.
Thelocationsofthemanufacturingfacilitiesbymajorgeographicareasoftheworldareasfollows:
SquareFeet
GeographicArea NumberofFacilities (inthousands)
UnitedStates 28 4,169
Europe 27 6,016
WesternHemisphere,excludingU.S. 9 1,733
Africa,AsiaandPacific 25 3,030
WorldwideTotal 89 14,948
Inadditiontothemanufacturingfacilitiesdiscussedabove,theCompanymaintainsnumerousofficeandwarehouse
facilitiesthroughouttheworld.
16 • Johnson&Johnson2022AnnualReportTheCompany’ssubsidiariesgenerallyseektoown,ratherthanlease,theirmanufacturingfacilities,althoughsome,
principallyinnon-U.S.locations,areleased.Officeandwarehousefacilitiesareoftenleased.TheCompanyalsoengages
contractmanufacturers.
TheCompanyiscommittedtomaintainingallofitspropertiesingoodoperatingcondition.
Segmentinformationonadditionstoproperty,plantandequipmentiscontainedinNote17“SegmentsofBusinessand
GeographicAreas”oftheNotestoConsolidatedFinancialStatementsincludedinItem8ofthisReport.
Item 3. LEGAL PROCEEDINGS
TheinformationcalledforbythisitemisincorporatedhereinbyreferencetotheinformationsetforthinNote19“Legal
Proceedings”oftheNotestoConsolidatedFinancialStatementsincludedinItem8ofthisReport.
Item 4. MINE SAFETY DISCLOSURES
Notapplicable.
Johnson&Johnson2022AnnualReport • 17EXECUTIVE OFFICERS OF THE REGISTRANT
ListedbelowaretheexecutiveofficersoftheCompany.Therearenofamilyrelationshipsbetweenanyoftheexecutive
officers,andthereisnoarrangementorunderstandingbetweenanyexecutiveofficerandanyotherpersonpursuantto
whichtheexecutiveofficerwasselected.AttheannualmeetingoftheBoardofDirectors,theexecutiveofficersare
electedbytheBoardtoholdofficeforoneyearanduntiltheirrespectivesuccessorsareelectedandqualified,oruntil
earlierresignationorremoval.
InformationwithregardtothedirectorsoftheCompanyisincorporatedhereinbyreferencetothematerialcaptioned
“Item1.ElectionofDirectors”intheProxyStatement.
Name Age Position
VanessaBroadhurst 54 Member,ExecutiveCommittee;ExecutiveVicePresident,Global
CorporateAffairs(a)
JoaquinDuato 60 ChairmanoftheBoard;ChiefExecutiveOfficer(b)
PeterM.Fasolo,Ph.D. 60 Member,ExecutiveCommittee;ExecutiveVicePresident,ChiefHuman
ResourcesOfficer(c)
ElizabethForminard 52 Member,ExecutiveCommittee;ExecutiveVicePresident,General
Counsel(d)
WilliamN.Hait,M.D.,Ph.D. 73 Member,ExecutiveCommittee;ExecutiveVicePresident,Chief
ExternalInnovationandMedicalSafetyOfficer;InterimHead
JanssenR&D(e)
AshleyMcEvoy 52 Member,ExecutiveCommittee;ExecutiveVicePresident,Worldwide
Chairman,MedTech(f)
ThibautMongon 53 Member,ExecutiveCommittee,ExecutiveVicePresident,Worldwide
Chairman,ConsumerHealth(g)
JamesSwanson 57 Member,ExecutiveCommittee;ExecutiveVicePresident,Chief
InformationOfficer(h)
JenniferL.Taubert 59 Member,ExecutiveCommittee;ExecutiveVicePresident,Worldwide
Chairman,Pharmaceuticals(i)
KathrynE.Wengel 57 Member,ExecutiveCommittee;ExecutiveVicePresident,Chief
TechnicalOperations&RiskOfficer(j)
JosephJ.Wolk 56 Member,ExecutiveCommittee;ExecutiveVicePresident,Chief
FinancialOfficer(k)
(a) Ms.V.BroadhurstjoinedtheCompanyin2005asWorldwideVicePresident,Anemia&OncologySupportiveCare.Shethenwent
ontobecomeVicePresidentoftheCardiovascular&InstitutionalFranchisein2008,andPresidentofJanssenTherapeuticsin2011
beforebecomingU.S.President,InternalMedicinein2012.From2013to2017,sheheldGeneralManagerrolesatAmgenin
Inflammation&Cardiovascular,andCardiovascular&Bone.In2017,Ms.BroadhurstrejoinedJohnson&JohnsonasU.S.President,
Cardiovascular&MetabolismandamemberoftheJanssenAmericasLeadershipTeam.Inthisroleshealsoprovidedoperational
oversightofthefullportfolioofJanssenmedicinesinPuertoRicoandCanada.In2018,shewasappointedCompanyGroup
Chairman,GlobalCommercialStrategyOrganization.In2022,Ms.BroadhurstwasnamedExecutiveVicePresident,Global
CorporateAffairsandamemberoftheExecutiveCommittee,leadingtheCompany’sglobalmarketing,communication,GlobalPublic
Healthandphilanthropyfunctions.
(b) Mr.J.DuatobecameChairmanoftheBoardofDirectorsinJanuary2023subsequenttohisappointmentasChiefExecutiveOfficer
andaDirectorinJanuary2022.HejoinedtheCompanyin1989withJanssen-FarmaceuticaS.A.(Spain),asubsidiaryofthe
Company,andheldexecutivepositionsofincreasingresponsibilityinallbusinesssectorsandacrossmultiplegeographiesand
functions.In2009,hewasnamedCompanyGroupChairman,Pharmaceuticals,andin2011,hewasnamedWorldwideChairman,
Pharmaceuticals.In2016,Mr.DuatobecameamemberoftheExecutiveCommitteeandwasnamedExecutiveVicePresident,
WorldwideChairman,Pharmaceuticals.InJuly2018,Mr.DuatowaspromotedtoViceChairmanoftheExecutiveCommittee,where
heprovidedstrategicdirectionforthePharmaceuticalandConsumerHealthsectorsandoversawboththeGlobalSupplyChain,
InformationTechnologyandHealth&Wellnessteams.AsadualcitizenofSpainandtheUnitedStates,Mr.Duato’sinternational
perspectiveandgloballensgiveshimadeepappreciationofdiversethoughtsandopinions.
(c) Dr.P.M.FasolojoinedtheCompanyin2004asWorldwideVicePresident,HumanResourcesintheMedTechsegment,and
subsequentlyservedastheCompany’sChiefTalentOfficer.HeleftJohnson&Johnsonin2007tojoinKohlbergKravisRoberts&
Co.asChiefTalentOfficer.Dr.FasoloreturnedtotheCompanyin2010astheVicePresident,GlobalHumanResources,andin
2011,hebecameamemberoftheExecutiveCommittee.InApril2016,hewasnamedExecutiveVicePresident,ChiefHuman
ResourcesOfficer.Dr.Fasolohasresponsibilityforglobaltalent,recruiting,diversity,compensation,benefits,employeerelationsand
18 • Johnson&Johnson2022AnnualReportallaspectsofthehumanresourcesagendafortheCompany.HealsoservesontheBoardsoftheHumanResourcesPolicy
Association,TuftsUniversityandSavetheChildrenandwasnamedaFellowoftheNationalAcademyofHumanResourcesin2017.
(d) Ms.ElizabethForminardjoinedtheCompanyin2006asVicePresident,Law,ConsumerHealthcareGlobalBusinessUnitand
continuedtoserveinrolesofincreasingresponsibility.In2012,shewaspromotedtoGeneralCounsel,MedicalDevices&
DiagnosticsandbecameGeneralCounsel,ConsumerGroup&SupplyChainin2013.ShewasappointedWorldwideVice
President,CorporateGovernancein2016.From2019to2022,sheservedasGeneralCounsel,Pharmaceuticals.InOctober2022,
shewasnamedExecutiveVicePresident,GeneralCounselandbecameamemberoftheExecutiveCommittee.Ms.Forminardhas
worldwideresponsibilityforthelegalandprivacyfunctions,andleadsthedevelopmentandexecutionoftheCompany’senvironment,
socialandgovernancestrategy.
(e) Dr.W.HaitjoinedtheCompanyin2007asSeniorVicePresident,WorldwideHeadofOncologyResearch.Hethenservedasthe
firstGlobalTherapeuticAreaHeadforOncologyfrom2009to2011,andthenasGlobalHead,JanssenResearch&Development
from2011through2018.From2018to2022,hewasGlobalHead,Johnson&JohnsonGlobalExternalInnovation.In2022,he
becameExecutiveVicePresident,ChiefExternalInnovation,MedicalSafetyandGlobalPublicHealthOfficer,andamemberofthe
ExecutiveCommittee.HeisresponsibleforleadingexternalsourcingandcreationoftransformationalinnovationtohelpJohnson&
JohnsonachieveitsmissiontoimprovehumanhealthutilizingtheCompany’sexcellenceinpharmaceuticals,medicaldevicesand
consumerproducts.HealsohasoversightoverGlobalPublicHealthandtheOfficeoftheChiefMedicalOfficer.AsInterimHeadof
JanssenR&D,Dr.Hait’smissionistofocusthebestresearchanddevelopmentteamsintheworldattheintersectionofunmet
medicalneedandbreakthroughsinscienceandtechnologytomakemedicineswithbenefitforpatientsworldwide.
(f) Ms.A.McEvoyjoinedtheCompanyin1996asAssistantBrandManagerofMcNeilConsumerHealth,asubsidiaryoftheCompany,
advancingthroughpositionsofincreasingresponsibilitiesuntilshewasappointedCompanyGroupChairman,VisionCarein2012,
followedbyCompanyGroupChairman,ConsumerMedicalDevicesin2014.InJuly2018,Ms.McEvoywaspromotedtoExecutive
VicePresident,WorldwideChairman,MedTech,andbecameamemberoftheExecutiveCommittee.Ms.McEvoyhasresponsibility
forthesurgery,orthopaedics,interventionalsolutionsandeyehealthbusinessesacrossEthicon,DePuySynthes,BiosenseWebster,
Abiomed,andJohnson&JohnsonVision.
(g) Mr.T.MongonjoinedtheCompanyin2000asDirectorofMarketingfortheVisionCaregroupinFranceandsubsequentlyheld
positionsofincreasingresponsibilityuntilhetransitionedtothePharmaceuticalsectorin2012,astheGlobalCommercialStrategy
LeaderfortheNeurosciencetherapeuticarea.In2014,hejoinedtheConsumerHealthsectorasCompanyGroupChairmanAsia-
Pacific.In2019,hewaspromotedtoExecutiveVicePresidentandWorldwideChairman,ConsumerHealth,andbecameamember
oftheExecutiveCommittee.Mr.MongonhasresponsibilityfortheglobaldevelopmentofJohnson&Johnson’shealthandwellness
productsandsolutionsinbeauty,OTC,oralcare,babycare,women’shealth,andwoundcare.
(h) Mr.J.SwansonrejoinedtheCompanyin2019asChiefInformationOfficerofJohnson&JohnsonfromBayerCropScience,where
heservedasamemberoftheExecutiveLeadershipTeamandasCIOandHeadofDigitalTransformation.From1996to2005,
Mr.SwansonheldpositionsofincreasingresponsibilityattheCompany,includingProjectManager,DirectorIT,Sr.DirectorITand
VicePresident,ChiefInformationOfficer.Mr.SwansonisresponsibleforenhancingJohnson&Johnson’sbusinessimpactand
shapingitsdirectionthroughthestrategicuseoftechnology.Mr.Swanson,ExecutiveVicePresident,EnterpriseChiefInformation
Officer,joinedtheExecutiveCommitteeeffectiveJanuary3,2022.
(i) Ms.J.L.TaubertjoinedtheCompanyin2005asWorldwideVicePresident,andsheheldseveralexecutivepositionsofincreasing
responsibilityinthePharmaceuticalsector.In2012,shewasappointedCompanyGroupChairman,NorthAmericaPharmaceuticals,
andin2015becameCompanyGroupChairman,TheAmericas,Pharmaceuticals.InJuly2018,Ms.Taubertwaspromotedto
ExecutiveVicePresident,WorldwideChairman,Pharmaceuticals,andbecameamemberoftheExecutiveCommittee.Ms.Taubertis
responsibleforthePharmaceuticalsectorglobally,includingshapingthecompany’sstrategyoftransformationalmedicalinnovation
andforsuccessfullybringingtomarketcriticalnewmedicinesthatsignificantlyimprovethelivesofpatientslivingwithcancer,
immune-relateddiseases,cardiovasculardisease,infectiousdiseases,pulmonaryhypertensionandseriousmentalillness.
(j) Ms.K.E.WengeljoinedtheCompanyin1988asProjectEngineerandEngineeringSupervisoratJanssen,asubsidiaryofthe
Company.DuringhertenurewiththeCompany,shehasheldavarietyofstrategicleadershipandexecutivepositions,includingin
roleswithinoperations,quality,engineering,newproducts,informationtechnology,andothertechnicalandbusinessfunctions.In
2018,shewasnamedExecutiveVicePresident,ChiefGlobalSupplyChainOfficer,andbecameamemberoftheExecutive
Committee.InJanuary2023,shewasappointedExecutiveVicePresident,ChiefTechnicalOperations&RiskOfficer.Ms.Wengel
hasenterprise-wideresponsibilitiesforkeytechnicaloperationsfunctions,includingProcurement,Engineering&PropertyServices,
Sustainabilityandcross-sectorSupplyChainteamsfocusedonstandards,services,strategicprogramsanddatascience,and
servesasChairoftheCompany’sSupplyChainManagementCommittee.Shealsooverseescriticalriskfunctions,including
Quality&Compliance,HealthCareCompliance,EnvironmentalHealth&Safety,GlobalSecurityandGlobalBrandProtection.
(k) Mr.J.J.WolkjoinedtheCompanyin1998asFinanceManager,BusinessDevelopmentforOrtho-McNeil,asubsidiaryofthe
Company,andthroughtheyearsheldavarietyofseniorleadershiprolesinseveralsegmentsandfunctionsacrosstheCompany’s
subsidiaries,inPharmaceuticals,MedicalDevicesandSupplyChain.From2014to2016,heservedasVicePresident,Financeand
ChiefFinancialOfficeroftheJanssenPharmaceuticalCompaniesofJohnson&Johnson.In2016,Mr.WolkbecametheVice
President,InvestorRelations.InJuly2018,hewasappointedExecutiveVicePresident,ChiefFinancialOfficerandbecameamember
oftheExecutiveCommittee.Mr.WolkplaysastrategicroleintheoverallmanagementoftheCompany,andleadsthedevelopment
andexecutionoftheCompany’sgloballong-termfinancialstrategy.
Johnson&Johnson2022AnnualReport • 19PART II
Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED
STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY
SECURITIES
AsofFebruary10,2023,therewere124,211recordholdersofcommonstockoftheCompany.Additionalinformation
calledforbythisitemisincorporatedhereinbyreferencetothefollowingsectionsofthisReport:Note16“Common
Stock,StockOptionPlansandStockCompensationAgreements”oftheNotestoConsolidatedFinancialStatements
includedinItem8;andItem12“SecurityOwnershipofCertainBeneficialOwnersandManagementandRelated
StockholderMatters–EquityCompensationPlanInformation.”
Issuer Purchases of Equity Securities
OnSeptember14,2022,theCompanyannouncedthatitsBoardofDirectorsapprovedasharerepurchaseprogram,
authorizingtheCompanytopurchaseupto$5.0billionoftheCompany’sCommonStock.Sharerepurchasesmaybe
madeatmanagement’sdiscretionfromtimetotimeontheopenmarketorthroughprivatelynegotiatedtransactions.The
repurchaseprogramhasnotimelimitandmaybesuspendedforperiodsordiscontinuedatanytime.
ThefollowingtableprovidesinformationwithrespecttocommonstockpurchasesbytheCompanyduringthefiscalfourth
quarterof2022.Commonstockpurchasesontheopenmarketaremadeaspartofasystematicplantomeettheneeds
oftheCompany’scompensationprograms.Therepurchasesbelowalsoincludethestock-for-stockoptionexercisesthat
settledinthefiscalfourthquarter.
TotalNumberof MaximumNumber(or
Shares(orUnits) ApproximateDollar
PurchasedasPart Value)ofShares(orUnits)
TotalNumber ofPublicly thatMayYetBe
ofShares Avg.Price AnnouncedPlans PurchasedUnderthe
FiscalPeriod Purchased(1) PaidPerShare orPrograms(2) PlansorPrograms(3)
October3,2022throughOctober30,
2022 3,921,949 165.29 3,179,491 —
October31,2022through
November27,2022 1,444,006 173.26 — —
November28,2022throughJanuary1,
2023 2,379,100 178.18 — —
Total 7,745,055 3,179,491 13,876,567
(1) Duringthefiscalfourthquarterof2022,theCompanyrepurchasedanaggregateof7,745,055sharesofJohnson&Johnson
CommonStockinopen-markettransactions,ofwhich3,179,491shareswerepurchasedpursuanttotherepurchaseprogramthat
waspubliclyannouncedonSeptember14,2022,andofwhich4,565,564shareswerepurchasedaspartofasystematicplanto
meettheneedsoftheCompany’scompensationprograms.
(2) AsofJanuary1,2023,anaggregateof15,411,776shareswerepurchasedforatotalof$2.5billionsincetheinceptionofthe
repurchaseprogramannouncedonSeptember14,2022.
(3) AsofJanuary1,2023,themaximumnumberofsharesthatmayyetbepurchasedundertheplanis13,876,567basedontheclosing
priceofJohnson&JohnsonCommonStockontheNewYorkStockExchangeonDecember30,2022of$176.65pershare.
Item 6. Reserved
20 • Johnson&Johnson2022AnnualReportItem 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF
OPERATIONS AND FINANCIAL CONDITION
Organization and Business Segments
DescriptionoftheCompanyandBusinessSegments
Johnson&Johnsonanditssubsidiaries(theCompany)haveapproximately152,700employeesworldwideengagedinthe
researchanddevelopment,manufactureandsaleofabroadrangeofproductsinthehealthcarefield.TheCompany
conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand
well-being.
TheCompanyisorganizedintothreebusinesssegments:ConsumerHealth,PharmaceuticalandMedTech.The
ConsumerHealthsegmentincludesabroadrangeofproductsusedintheBabyCare,OralCare,SkinHealth/Beauty,
Over-the-Counterpharmaceutical,Women’sHealthandWoundCaremarkets.Theseproductsaremarketedtothe
generalpublicandsoldonline(eCommerce)andtoretailoutletsanddistributorsthroughouttheworld.The
Pharmaceuticalsegmentisfocusedonthefollowingtherapeuticareas,includingImmunology,Infectiousdiseases,
Neuroscience,Oncology,PulmonaryHypertension,andCardiovascularandMetabolicdiseases.Productsinthissegment
aredistributeddirectlytoretailers,wholesalers,distributors,hospitalsandhealthcareprofessionalsforprescriptionuse.
TheMedTechsegmentincludesabroadportfolioofproductsusedintheOrthopaedic,Surgery,InterventionalSolutions
(cardiovascularandneurovascular)andVisionfields.Theseproductsaredistributedtowholesalers,hospitalsandretailers,
andusedprincipallyintheprofessionalfieldsbyphysicians,nurses,hospitals,eyecareprofessionalsandclinics.
TheExecutiveCommitteeofJohnson&Johnsonistheprincipalmanagementgroupresponsibleforthestrategic
operationsandallocationoftheresourcesoftheCompany.ThisCommitteeoverseesandcoordinatestheactivitiesofthe
ConsumerHealth,PharmaceuticalandMedTechbusinesssegments.
Inallofitsproductlines,theCompanycompeteswithothercompaniesbothlocallyandglobally,throughouttheworld.
Competitionexistsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolved.
Competitioninresearch,involvingthedevelopmentandtheimprovementofnewandexistingproductsandprocesses,is
particularlysignificant.Thedevelopmentofnewandinnovativeproducts,aswellasprotectingtheunderlyingintellectual
propertyoftheCompany’sproductportfolio,isimportanttotheCompany’ssuccessinallareasofitsbusiness.The
competitiveenvironmentrequiressubstantialinvestmentsincontinuingresearch.Inaddition,thedevelopmentand
maintenanceofcustomerdemandfortheCompany’sconsumerproductsinvolvessignificantexpendituresforadvertising
andpromotion.
Management’sObjectives
With“OurCredo”asthefoundation,theCompany’spurposeistoblendheart,scienceandingenuitytoprofoundly
changethetrajectoryofhealthforhumanity.TheCompanyiscommittedtobringingitsfullbreadthanddepthtoensure
healthforpeopletodayandforfuturegenerations.Unitedaroundthiscommonambition,theCompanyispoisedtofulfillits
purposeandsuccessfullymeetthedemandsoftherapidlyevolvingmarketsinwhichitcompetes.
TheCompanyisbroadlybasedinhumanhealthcare,andiscommittedtocreatingvaluebydevelopingaccessible,high
quality,innovativeproductsandservices.Newproductsintroducedwithinthepastfiveyearsaccountedforapproximately
25%of2022sales.In2022,$14.6billionwasinvestedinresearchanddevelopmentreflectingmanagement’s
commitmenttocreatelife-enhancinginnovationsandtocreatevaluethroughpartnershipsthatwillprofoundlychangethe
trajectoryofhealthforhumanity.
AcriticaldriveroftheCompany’ssuccessisthediversityofits152,700employeesworldwide.Employeesare
empoweredandinspiredtoleadwithOurCredoandpurposeasguides.Thisallowseveryemployeetousethe
Company’sreachandsizetoadvancetheCompany’spurpose,andtoalsoleadwithagilityandurgency.Leveragingthe
extensiveresourcesacrosstheenterpriseenablestheCompanytoinnovateandexecutewithexcellence.Thisensuresthe
Companycanremainfocusedonaddressingtheunmetneedsofsocietyeverydayandinvestforanenduringimpact,
ultimatelydeliveringvaluetoitspatients,consumersandhealthcareprofessionals,employees,communitiesand
shareholders.
Johnson&Johnson2022AnnualReport • 2114.6
snoilliB
nI
$
snoilliB
nI
$
sralloD
nI
Research & Acquisi(cid:2)ons (net Dividends Paid
Development of cash acquired) Per Share
17.7
14.7
4.45 4.19
0.1 0.1
2022 2021 2022 2021 2022 2021
Results of Operations
AnalysisofConsolidatedSales
Fordiscussiononresultsofoperationsandfinancialconditionpertainingtothefiscalyears2021and2020seethe
Company’sAnnualReportonForm10-KforthefiscalyearendedJanuary2,2022,Item7.Management’sDiscussionand
AnalysisofResultsofOperationsandFinancialCondition.
In2022,worldwidesalesincreased1.3%to$94.9billionascomparedtoanincreaseof13.6%in2021.Thesesales
changesconsistedofthefollowing:
Salesincrease/(decrease)dueto: 2022 2021
Volume 6.9% 12.9%
Price (0.8) (0.7)
Currency (4.8) 1.4
Total 1.3% 13.6%
Thenetimpactofacquisitionsanddivestituresontheworldwidesalesgrowthwasanegativeimpactof0.1%in2022and
anegativeimpactof0.6%in2021.
SalesbyU.S.companieswere$48.6billionin2022and$47.2billionin2021.Thisrepresentsincreasesof3.0%in2022
and9.3%in2021.Salesbyinternationalcompanieswere$46.4billionin2022and$46.6billionin2021.Thisrepresents
adecreaseof0.6%in2022andanincreaseof18.2%in2021.
Thefive-yearcompoundannualgrowthratesforworldwide,U.S.andinternationalsaleswere4.4%,4.0%and4.9%,
respectively.Theten-yearcompoundannualgrowthratesforworldwide,U.S.andinternationalsaleswere3.5%,5.0%and
2.2%,respectively.
In2022,salesbycompaniesinEuropeexperiencedadeclineof0.6%ascomparedtotheprioryear,whichincluded
operationalgrowthof11.0%andanegativecurrencyimpactof11.6%.SalesbycompaniesintheWesternHemisphere,
excludingtheU.S.,achievedgrowthof6.5%ascomparedtotheprioryear,whichincludedoperationalgrowthof10.2%,
andanegativecurrencyimpactof3.7%.SalesbycompaniesintheAsia-Pacific,Africaregionexperiencedadeclineof
2.8%ascomparedtotheprioryear,includingoperationalgrowthof6.2%andanegativecurrencyimpactof9.0%.
In2022,theCompanyutilizedthreewholesalersdistributingproductsforallthreesegmentsthatrepresented
approximately16.5%,13.0%and12.0%ofthetotalconsolidatedrevenues.In2021,theCompanyhadthreewholesalers
distributingproductsforallthreesegmentsthatrepresentedapproximately14.0%,11.0%and11.0%ofthetotal
consolidatedrevenues.
22 • Johnson&Johnson2022AnnualReport2022 Sales by Geographic Region (in billions) 2022 Sales by Segment (in billions)
$16.8
$27.4
$6.1
$48.6 $52.6
$23.4 $15.0
Europe Western Hemisphere (ex. U.S.) Consumer Health Pharmaceutical
Asia-Pacific, Africa U.S. MedTech
Note:valuesmayhavebeenrounded
Analysis of Sales by Business Segments
ConsumerHealthSegment
ConsumerHealthsegmentsalesin2022were$15.0billion,adecreaseof0.5%from2021,whichincluded3.6%
operationalgrowthandanegativecurrencyimpactof4.1%.U.S.ConsumerHealthsegmentsaleswere$6.6billion,an
increaseof1.3%.Internationalsaleswere$8.4billion,adecreaseof1.9%,whichincluded5.3%operationalgrowthanda
negativecurrencyimpactof7.2%.In2022,acquisitionsanddivestitureshadanetnegativeimpactof0.3%onthe
operationalsalesgrowthoftheworldwideConsumerHealthsegment.
MajorConsumerHealthFranchiseSales*:
Total Operations Currency
(DollarsinMillions) 2022 2021 Change Change Change
OTC(1) $6,031 5,627 7.2% 11.2% (4.0)%
SkinHealth/Beauty 4,352 4,541 (4.2) (0.4) (3.8)
OralCare 1,505 1,645 (8.5) (4.7) (3.8)
BabyCare 1,461 1,566 (6.7) (2.4) (4.3)
Women’sHealth 904 917 (1.5) 7.0 (8.5)
WoundCare/Other 700 739 (5.3) (3.8) (1.5)
TotalConsumerHealthSales $14,953 15,035 (0.5)% 3.6% (4.1)%
* Certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation
(1) Fiscal2021reflectsapproximately$0.4billionofcertaininternationalOTCproducts,primarilyinChina,whichwerereclassifiedfrom
thePharmaceuticalsegmenttotheConsumerHealthsegmentbasedonoperationalchanges
TheOTCfranchisesalesof$6.0billionincreased7.2%ascomparedtotheprioryear.Operationalgrowthwasprimarily
attributabletoincreasedCough/Cold/Flu,adultandpediatricincidences,priceactionsprimarilyintheU.S.andincreased
consumptioninChinaduetoeasingofCOVID-19restrictions.Growthwaspartiallyoffsetbysupplyconstraints.
TheSkinHealth/Beautyfranchisesalesof$4.4billiondeclined4.2%ascomparedtotheprioryear.Theoperational
declinewasdrivenbysupplyconstraintsintheU.S.partiallyoffsetbypriceactionsandstrongnewproductperformance
intheAsiaPacificandLatinAmericaregion.
TheOralCarefranchisesalesof$1.5billiondeclined8.5%ascomparedtotheprioryear.Theoperationaldeclinewas
duetoportfoliosimplificationintheU.S.,competitivepressuresinEMEAandChina,categorydeclineandpricing
pressuresinEMEA,aswellassuspensionofpersonalcaresalesinRussiaandnegativeCOVID-19impactsinChina.
Johnson&Johnson2022AnnualReport • 23TheBabyCarefranchisesalesof$1.5billiondeclined6.7%ascomparedtotheprioryear.Theoperationaldeclinewas
drivenbycategorydecelerationandcompetitivepressuresintheU.S.,suspensionofpersonalcaresalesinRussiaand
weaknessinIndia.
TheWomen’sHealthfranchisesalesof$0.9billiondeclined1.5%ascomparedtotheprioryear.Operationalgrowth
drivenbylappingprioryearsupplyconstraintsinEMEA,strengthinIndia,andpriceactionsinLATAMwaspartiallyoffset
bysuspensionofpersonalcaresalesinRussiaandnegativecurrencyimpacts.
TheWoundCare/Otherfranchisesalesof$0.7billiondeclined5.3%ascomparedtotheprioryear.Theoperational
declinewasdrivenbylappingstrongprioryearconsumption,competitivepressureintheU.S.,anddecreased
consumptioninChina.
InNovember2021,theCompanyannounceditsintentiontoseparatetheCompany’sConsumerHealthbusiness(Kenvue
asthenamefortheplannedNewConsumerHealthCompany),withtheintentiontocreateanew,publiclytraded
companybytheendofthefiscalyear2023.
24 • Johnson&Johnson2022AnnualReportPharmaceutical Segment
Pharmaceuticalsegmentsalesin2022were$52.6billion,anincreaseof1.7%from2021,whichincludedoperational
growthof6.7%andanegativecurrencyimpactof5.0%.U.S.saleswere$28.6billion,anincreaseof2.3%.International
saleswere$24.0billion,anincreaseof1.0%,whichincluded11.9%operationalgrowthandanegativecurrencyimpact
of10.9%.In2022,acquisitionsanddivestitureshadanetnegativeimpactof0.1%ontheoperationalsalesgrowthofthe
worldwidePharmaceuticalsegment.Adjustmentstoprevioussalesreserveestimateswereapproximately$0.1billionand
$0.7billioninfiscalyears2022and2021,respectively.
MajorPharmaceutical TherapeuticAreaSales*:
Total Operations Currency
(DollarsinMillions) 2022 2021 Change Change Change
TotalImmunology $16,935 16,750 1.1% 4.8% (3.7)%
REMICADE 2,343 3,190 (26.6) (25.3) (1.3)
SIMPONI/SIMPONIARIA 2,184 2,276 (4.0) 1.0 (5.0)
STELARA 9,723 9,134 6.5 10.4 (3.9)
TREMFYA 2,668 2,127 25.4 30.1 (4.7)
OtherImmunology 17 24 (28.2) (28.2) 0.0
TotalInfectiousDiseases 5,449 5,825 (6.5) 0.8 (7.3)
COVID-19VACCINE 2,179 2,385 (8.6) 2.0 (10.6)
EDURANT/rilpivirine 1,008 994 1.5 11.8 (10.3)
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA 1,943 2,083 (6.7) (4.4) (2.3)
OtherInfectiousDiseases(2) 318 363 (12.3) (7.2) (5.1)
TotalNeuroscience 6,893 6,988 (1.4) 3.4 (4.8)
CONCERTA/methylphenidate 644 667 (3.5) 4.1 (7.6)
INVEGASUSTENNA/XEPLION/INVEGATRINZA/TREVICTA 4,140 4,022 3.0 6.9 (3.9)
RISPERDALCONSTA 485 592 (18.1) (13.0) (5.1)
OtherNeuroscience(2) 1,623 1,706 (4.9) 0.4 (5.3)
TotalOncology 15,983 14,548 9.9 16.9 (7.0)
DARZALEX 7,977 6,023 32.4 39.5 (7.1)
ERLEADA 1,881 1,291 45.7 53.0 (7.3)
IMBRUVICA 3,784 4,369 (13.4) (7.6) (5.8)
ZYTIGA/abirateroneacetate 1,770 2,297 (22.9) (13.6) (9.3)
OtherOncology 571 568 0.6 6.0 (5.4)
TotalPulmonaryHypertension 3,417 3,450 (1.0) 3.0 (4.0)
OPSUMIT 1,783 1,819 (2.0) 2.6 (4.6)
UPTRAVI 1,322 1,237 6.9 8.6 (1.7)
OtherPulmonaryHypertension 313 395 (20.8) (13.1) (7.7)
TotalCardiovascular/Metabolism/Other 3,887 4,119 (5.6) (4.0) (1.6)
XARELTO 2,473 2,438 1.4 1.4 —
INVOKANA/INVOKAMET 448 563 (20.4) (17.2) (3.2)
Other(1,2) 966 1,119 (13.6) (9.3) (4.3)
TotalPharmaceuticalSales $52,563 51,680 1.7% 6.7% (5.0)%
* Certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation
(1) InclusiveofPROCRIT/EPREXwhichwaspreviouslydisclosedseparately
(2) Fiscal2021reflectsapproximately$0.4billionofcertaininternationalOTCproducts,primarilyinChina,whichwerereclassifiedfrom
thePharmaceuticalsegmenttotheConsumerHealthsegmentbasedonoperationalchanges
Johnson&Johnson2022AnnualReport • 25Immunologyproductsachievedsalesof$16.9billionin2022,representinganincreaseof1.1%ascomparedtotheprior
year.OperationalgrowthwasdrivenbystronguptakeofSTELARA(ustekinumab)inCrohn’sdiseaseandUlcerative
ColitisandstrengthofTREMFYA(guselkumab)inPsoriasisanduptakeinPsoriaticArthritis.Thiswaspartiallyoffsetby
lowersalesofREMICADE(infliximab)duetobiosimilarcompetition.
BiosimilarversionsofREMICADEhavebeenintroducedintheUnitedStatesandcertainmarketsoutsidetheUnited
Statesandadditionalcompetitorscontinuetoenterthemarket.Continuedinfliximabbiosimilarcompetitionwillresultina
furtherreductioninsalesofREMICADE.
ThelatestexpiringUnitedStatespatentforSTELARA(ustekinumab)willexpireinSeptember2023.STELARA
(ustekinumab)U.S.salesinfiscal2022wereapproximately$6.4billionandtheexpirationofthisproductpatentorlossof
marketexclusivitywillresultinareductioninsales.
Infectiousdiseaseproductssaleswere$5.4billionin2022,representingadeclineof6.5%ascomparedtotheprioryear.
OperationalgrowthwasdrivenbytheCOVID-19vaccineoutsidetheU.SpartiallyoffsetbylowersalesofPREZISTAand
PREZCOBIX/REZOLSTA(darunavir/cobicistat)duetoincreasedcompetitionandlossofexclusivityofPREZISTAin
certaincountriesoutsidetheU.S.
Neuroscienceproductssaleswere$6.9billion,in2022,representingadeclineof1.4%ascomparedtotheprioryear.
TheoperationalsalesgrowthofINVEGASUSTENNA/XEPLION(paliperidonepalmitate)andINVEGATRINZA/TREVICTA
fromnewpatientstartsandpersistenceaswellasthelaunchofINVEGAHAFYERAwasoffsetbynegativecurrency
impactsandlowersalesofRISPERDALCONSTA.
Oncologyproductsachievedsalesof$16.0billionin2022,representinganincreaseof9.9%ascomparedtotheprior
year.ContributionstooperationalgrowthwerestrongsalesofDARZALEX(daratumumab)drivenbysharegainsinall
regions,continuedstrongmarketgrowth,anduptakeofthesubcutaneousformulationaswellasthecontinuedglobal
launchuptakeofERLEADA(apalutamide).ThiswaspartiallyoffsetbydecliningsalesofIMBRUVICA(ibrutinib)dueto
competitivepressuresandmarketsuppressionandZYTIGAduetolossofexclusivityintheEuropeanUnioninthesecond
halfof2022.
PulmonaryHypertensionproductssaleswere$3.4billion,adeclineof1.0%ascomparedtotheprioryear.The
operationalsalesgrowthofOPSUMIT(macitentan)andUPTRAVI(selexipag)duetocontinuedsharegainsandmarket
growthwasoffsetbyCOVID-19relatedimpactsandcontinueddeclinesinOtherPulmonaryHypertension.
Cardiovascular/Metabolism/Otherproductssaleswere$3.9billion,adeclineof5.6%ascomparedtotheprioryear.The
operationaldeclinewasprimarilyattributabletolowersalesofINVOKANA/INVOKAMET(canagliflozin)duetoshare
erosionandPROCRIT/EPREX(epoetinalfa)duetobiosimilarcompetition.
TheCompanyupdateditspolicysothatnoendcustomerwillbepermitteddirectdeliveryofproducttoalocationother
thanthebillinglocation.Thepolicyimpactscontractpharmacytransactionsinvolvingnon-grantee340Bcoveredentities
formostoftheCompany’sdrugs,subjecttomultipleexceptions.Bothgranteeandnon-granteecoveredentitiescan
maintaincertaincontractpharmacyarrangementsunderpolicyexceptions.TheCompanyhasbeenandwillcontinueto
offer340Bdiscountstocoveredentitiesonallofitscoveredoutpatientdrugs,anditbelievesitspolicywillimproveits
abilitytoidentifyinappropriateduplicatediscountsanddiversionprohibitedbythe340Bstatute.The340BDrugPricing
ProgramisaU.S.federalgovernmentprogramrequiringdrugmanufacturerstoprovidesignificantdiscountsoncovered
outpatientdrugstocoveredentities.Thispolicyupdatehaddiscountimplicationswhichpositivelyimpactedsalesto
customersin2022.
26 • Johnson&Johnson2022AnnualReportDuring2022,theCompanyadvanceditspipelinewithseveralregulatorysubmissionsandapprovalsfornewdrugsand
additionalindicationsforexistingdrugsasfollows:
ProductName(Chemical US EU US EU
Name) Indication Approval Approval Filing Filing
aprocitentan Treatmentfordifficulttotreathypertension •
CABENUVA(rilpivirineand HIVtreatmentforadolescents •
cabotegravir)
CARVYKTI(ciltacabtagene TreatmentforpatientswithrelapsedorrefractoryMultiple • •
autoleucel) Myeloma
• •
ERLEADA(apalutamide) Tabletreduction
IMBRUVICA(ibrutinib) TreatmentforPediatricPatientswithChronicGraft-Versus-Host •
Disease
TreatmentforFrontlineChronicLymphocyticLeukemia(I+V •
fixedduration)(GLOW)
niraparib TreatmentofL1Prostatecancermetastaticcastration-resistantin •
combinationwithabirateroneacetateandPrednisone
STELARA(ustekinumab) TreatmentofPediatricPatientswithJuvenilePsoriaticArthritis •
Talquetamab TreatmentofPatientswithRelapsedRefractoryMultipleMyeloma •
teclistamab(BCMA/CD3) TreatmentofPatientswithRelapsedRefractoryMultipleMyeloma • •
Johnson&Johnson2022AnnualReport • 27MedTechSegment**
TheMedTechsegmentsalesin2022were$27.4billion,anincreaseof1.4%from2021,whichincludedoperational
growthof6.2%andanegativecurrencyimpactof4.8%.U.S.saleswere$13.4billion,anincreaseof5.4%ascompared
totheprioryear.Internationalsaleswere$14.1billion,adecreaseof2.3%ascomparedtotheprioryear,whichincluded
operationalgrowthof6.9%andanegativecurrencyimpactof9.2%.In2022,thenetimpactofacquisitionsand
divestituresontheMedTechsegmentworldwideoperationalsalesgrowthwasapositive0.1%.
MajorMedTechFranchiseSales*:
Total Operations Currency
(DollarsinMillions) 2022 2021 Change Change Change
Surgery $9,690 9,812 (1.2)% 3.8% (5.0)%
Advanced 4,569 4,622 (1.1) 3.8 (4.9)
General 5,121 5,190 (1.3) 3.8 (5.1)
Orthopaedics 8,587 8,588 0.0 3.7 (3.7)
Hips 1,514 1,480 2.3 5.8 (3.5)
Knees 1,359 1,325 2.6 6.1 (3.5)
Trauma 2,871 2,885 (0.5) 3.1 (3.6)
Spine,Sports&Other 2,843 2,898 (1.9) 1.9 (3.8)
Vision 4,849 4,688 3.4 9.5 (6.1)
ContactLenses/Other 3,543 3,440 3.0 9.6 (6.6)
Surgical 1,306 1,248 4.6 9.4 (4.8)
InterventionalSolutions 4,300 3,971 8.3 13.7 (5.4)
TotalMedTechSales $27,427 27,060 1.4% 6.2% (4.8)%
* Certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation
** PreviouslyreferredtoasMedicalDevices
TheSurgeryfranchisesaleswere$9.7billionin2022,representingadeclineof1.2%from2021.Theoperationalgrowth
inAdvancedSurgerywasprimarilydrivenbythefollowing:Endocuttermarketrecoveryandnewproductspartiallyoffset
bycompetitivepressuresintheU.S.;Biosurgerymarketrecoveryandthesuccessofnewproductspartiallyoffsetby
strongU.S.marketdemandintheprioryearforinfectionpreventionproducts;andEnergyproductsdrivenbymarket
recoveryandnewproductpenetrationcoupledwithcompetitivesupplychallenges.TheoperationalgrowthinGeneral
Surgerywasprimarilydrivenbymarketrecoveryandtechnologypenetration.
TheOrthopaedicsfranchisesaleswere$8.6billionin2022,whichwasflattotheprioryear.TheOrthopaedicsfranchise
includedoperationalsalesgrowthof3.7%offsetbyanegativecurrencyimpactof3.7%.Theoperationalgrowthinhips
reflectsthemarketrecoverycombinedwithcontinuedstrengthoftheportfolioincludingtheACTISstemandenabling
technologies–KINCISEandVELYSHipNavigation.Thisgrowthwaspartiallyoffsetbyimpactsofvolume-based
procurementinChinaandthetimingoftendersoutsidetheU.S.Theoperationalgrowthinkneeswasprimarilydrivenby
procedurerecovery,strengthoftheATTUNEportfolioandpullthroughrelatedtotheVELYSRoboticassistedsolution.
Thisgrowthwaspartiallyoffsetbyimpactsofvolume-basedprocurementinChinaandtimingoftendersoutsidetheU.S.
TheoperationalgrowthinTraumawasdrivenbyglobalmarketrecoveryanduptakeofnewproducts.Theoperational
growthinSpine,Sports&Otherwasprimarilydrivenbyprocedurerecoveryandnewproductintroductions.Thisgrowth
waspartiallyoffsetbycompetitivepressuresinSpineandimpactsofvolume-basedprocurementinChina.
TheVisionfranchiseachievedsalesof$4.8billionin2022,representinganincreaseof3.4%from2021.TheContact
Lenses/Otheroperationalgrowthwasduetomarketrecovery,priceactions,commercialexecutionandbenefitsfromnew
products.SurgicalVisionoperationalgrowthwasprimarilyduetomarketrecoveryandthesuccessofnewproductsand
waspartiallyoffsetbyahigherprioryearU.S.Refractorymarket.
TheInterventionalSolutionsfranchiseachievedsalesof$4.3billionin2022,representinganincreaseof8.3%from2021.
Operationalgrowthwasdrivenbymarketrecoveryandsuccessofnewproductsandcommercialstrategies.Interventional
solutionsalsoincludessalesfromAbiomed,Inc.(Abiomed)whichwerereflectedasofDecember22,2022.
28 • Johnson&Johnson2022AnnualReportAnalysisofConsolidatedEarningsBeforeProvisionforTaxesonIncome
Consolidatedearningsbeforeprovisionfortaxesonincomewas$21.7billionand$22.8billionfortheyears2022and
2021,respectively.Asapercenttosales,consolidatedearningsbeforeprovisionfortaxesonincomewas22.9%and
24.3%,in2022and2021,respectively.
Earnings Before Provision for Taxes
$22.8
$21.7
24.3%
22.9%
2022 2021
(Dollars in billions. Percentages in chart are as a percent to total sales)
CostofProductsSoldandSelling,MarketingandAdministrativeExpenses:
Cost of Products Sold Selling, Marke(cid:2)ng & Administra(cid:2)ve
$31.1
$29.9 $24.8 $24.7
32.7% 31.8%
26.1% 26.3%
2022 2021 2022 2021
(Dollars in billions. Percentages in chart are as a percent to total sales)
Costofproductssoldincreasedasapercenttosalesdrivenby:
• One-timeCOVID-19vaccinemanufacturingexitrelatedcosts
• CurrencyimpactsinthePharmaceuticalsegment
• CommodityinflationintheMedTechandConsumerHealthsegments
partiallyoffsetby
• SupplychainbenefitsintheConsumerHealthsegment
Theintangibleassetamortizationexpenseincludedincostofproductssoldwas$4.3billionand$4.7billionforthefiscal
years2022and2021,respectively.
Selling,MarketingandAdministrativeExpensesdecreasedasapercenttosalesdrivenby:
• ReductionofbrandmarketingexpensesinthePharmaceuticalandConsumerHealthbusinesses
Johnson&Johnson2022AnnualReport • 29ResearchandDevelopmentExpense:
Researchanddevelopmentexpensebysegmentofbusinesswasasfollows:
2022 2021
(DollarsinMillions) Amount %ofSales* Amount %ofSales*
ConsumerHealth $493 3.3% $459 3.1%
Pharmaceutical 11,622 22.1 11,878 23.0
MedTech 2,488 9.1 2,377 8.8
Totalresearchanddevelopmentexpense $14,603 15.4% $14,714 15.7%
Percentincrease/(decrease)overtheprioryear (0.8)% 21.0%
* Asapercenttosegmentsales
ResearchanddevelopmentactivitiesrepresentasignificantpartoftheCompany’sbusiness.Theseexpendituresrelateto
theprocessesofdiscovering,testinganddevelopingnewproducts,upfrontpaymentsanddevelopmentalmilestones,
improvingexistingproducts,aswellasensuringproductefficacyandregulatorycompliancepriortolaunch.TheCompany
remainscommittedtoinvestinginresearchanddevelopmentwiththeaimofdeliveringhighqualityandinnovativeproducts.
ResearchandDevelopmentdecreasedasapercenttosalesprimarilydrivenby:
• LowermilestonepaymentsinthePharmaceuticalbusiness
In-ProcessResearchandDevelopment(IPR&D):Inthefiscalyear2022,theCompanyrecordedanintangibleasset
impairmentchargeofapproximately$0.8billionrelatedtoanin-processresearchanddevelopmentasset,bermekimab
(JnJ-77474462),aninvestigationaldrugforthetreatmentofAtopicDermatitis(AD)andHidradenitisSuppurativa(HS).
AdditionalinformationregardingefficacyoftheADindicationandHSindicationbecameavailablewhichledtheCompany
tothedecisiontoterminatethedevelopmentofbermekimabforbothADandHS.TheCompanyacquiredallrightsto
bermekimabfromXBiotech,Inc.inthefiscalyear2020.Infiscalyear2021,theCompanyrecordedapartialIPR&Dcharge
of$0.9billionprimarilyrelatedtoexpecteddevelopmentdelaysinthegeneralsurgerydigitalroboticsplatform(Ottava)
acquiredwiththeAurisHealthacquisitionin2019.Theimpairmentchargewascalculatedbasedonrevisionstothe
discountedcashflowvaluationmodelreflectingadelayoffirstinhumanproceduresofapproximatelytwoyearsfromthe
initialacquisitionmodelassumptionofthesecondhalfof2022.TheCompanywillcontinuetomonitortheremaining
$1.5billionOttavaplatformintangibleassetasdevelopmentprogramactivitiesareongoing.
Other(Income)Expense,Net:Other(income)expense,netistheaccountwheretheCompanyrecordsgainsand
lossesrelatedtothesaleandwrite-downofcertaininvestmentsinequitysecuritiesheldbyJohnson&Johnson
Innovation-JJDC,Inc.(JJDC),changesinthefairvalueofsecurities,investment(income)/lossrelatedtoemployeebenefit
programs,gainsandlossesondivestitures,certaintransactionalcurrencygainsandlosses,acquisitionanddivestiture
relatedcosts,litigationaccrualsandsettlements,aswellasroyaltyincome.
Other(income)expense,netforthefiscalyear2022wasunfavorableby$1.4billionascomparedtotheprioryear
primarilyduetothefollowing:
(DollarsinBillions)(Income)/Expense 2022 2021 Change
ConsumerHealthseparationcosts $1.0 0.1 0.9
Litigationrelated(1) 0.9 2.3 (1.4)
Changesinthefairvalueofsecurities 0.7 (0.5) 1.2
One-timeCOVID-19vaccinemanufacturingexitrelatedcosts 0.7 0.0 0.7
Acquisition,IntegrationandDivestiturerelated(2) 0.1 (0.5) 0.6
Restructuringrelated 0.1 0.1 0.0
Employeebenefitplanrelated (1.2) (0.6) (0.6)
Other (0.4) (0.4) —
TotalOther(Income)Expense,Net $1.9 0.5 1.4
(1) 2022wasprimarilyrelatedtopelvicmeshand2021wasprimarilyrelatedtotalcandRisperdalGynecomastia
(2) 2022wasprimarilycostsrelatedtotheacquisitionofAbiomed.2021wasprimarilyrelatedtodivestituregainsoftwopharmaceutical
brandsoutsidetheU.S.
30 • Johnson&Johnson2022AnnualReportInterest(Income)Expense:Interest(income)expenseinthefiscalof2022wasnetinterestincomeof$214millionas
comparedtointerestexpenseof$130millioninthefiscalyear2021primarilyduetohigherratesofinterestearnedon
cashbalances.Cash,cashequivalentsandmarketablesecuritiestotaled$23.5billionattheendof2022,andaveraged
$27.6billionascomparedtothecash,cashequivalentsandmarketablesecuritiestotalof$31.6billionand$28.4billion
averagecashbalancein2021.Thetotaldebtbalanceattheendof2022was$39.7billionwithanaveragedebtbalance
of$36.7billionascomparedto$33.8billionattheendof2021andanaveragedebtbalanceof$34.5billion.Thelower
averagecash,cashequivalentsandmarketablesecuritiesandhigheraveragedebtbalancewereprimarilyduetothe
acquisitionofAbiomedinlateDecemberof2022.
IncomeBeforeTaxbySegment
Income(loss)beforetaxbysegmentofbusinesswereasfollows:
Percentof
IncomeBeforeTax SegmentSales SegmentSales
(DollarsinMillions) 2022 2021 2022 2021 2022 2021
ConsumerHealth(3) $2,930 1,573 14,953 15,035 19.6% 10.5
Pharmaceutical(3) 15,901 17,969 52,563 51,680 30.3 34.8
MedTech 4,607 4,373 27,427 27,060 16.8 16.2
Segmentearningsbeforetax(1) 23,438 23,915 94,943 93,775 24.7 25.5
Less:Expensesnotallocatedtosegments(2) 624 1,072
Less:ConsumerHealthseparationcosts 1,089 67
Worldwideincomebeforetax $21,725 22,776 94,943 93,775 22.9% 24.3
(1) SeeNote17totheConsolidatedFinancialStatementsformoredetails.
(2) Amountsnotallocatedtosegmentsincludeinterest(income)expenseandgeneralcorporate(income)expense.
(3) Prioryearincomebeforetaxofapproximately$0.2billionhasbeenreclassifiedascertaininternationalOTCproducts,primarilyin
China,werereclassifiedfromthePharmaceuticalsegmenttotheConsumerHealthsegmentbasedonoperationalchanges.
ConsumerHealthSegment:In2022,theConsumerHealthsegmentincomebeforetaxasapercentofsaleswas
19.6%versus10.5%in2021.Theincreaseintheincomebeforetaxasapercentofsaleswasprimarilydrivenbythe
following:
• Lowerlitigationexpenseof$0.2billionin2022versus$1.6billion(primarilytalcrelated)in2021
• Reductioninbrandmarketingexpensesin2022versus2021
• Supplychainbenefitsin2022
partiallyoffsetby:
• Commodityinflationin2022
PharmaceuticalSegment:In2022,thePharmaceuticalsegmentincomebeforetaxasapercenttosaleswas30.3%
versus34.8%in2021.Thedecreaseintheincomebeforetaxasapercentofsaleswasprimarilydrivenbythefollowing:
• One-timeCOVID-19vaccinemanufacturingexitrelatedcostsof$1.5billionin2022
• Unfavorablechangesinthefairvalueofsecurities($0.7billionlossin2022vs.$0.5billiongainin2021)
• AnIPR&Dchargeof$0.8billionin2022relatedtobermekimab(JnJ-77474462),aninvestigationaldrugforthe
treatmentofAtopicDermatitis(AD)andHidradenitisSuppurativa(HS)
• Lowerdivestituregainsof$0.1billionin2022versus$0.6billionrelatedtotwopharmaceuticalbrandsoutsidetheU.S.
infiscal2021
• CurrencyimpactsinCostofProductsSold
Johnson&Johnson2022AnnualReport • 31partiallyoffsetby:
• Lowerlitigationrelatedexpenseof$0.1billionin2022versus$0.6billion(primarilyrelatedtoRisperdalGynecomastia)
in2021
• LowerResearch&Developmentmilestonepaymentsin2022
• Lowerbrandmarketingexpensesin2022versus2021
Infiscal2020and2021,theCompanyenteredintoaseriesofcontractmanufacturingarrangementsforvaccine
productionwiththirdpartycontractmanufacturingorganizations.ThesearrangementsprovidedtheCompanywith
supplementalcommercialcapacityforvaccineproductionandpotentiallytransferablerightstosuchproductionifcapacity
isnotrequired.TheCompanycontinuestoevaluateandmonitorbothitsinternalandexternalsupplyarrangements.In
fiscal2022,theCOVID-19Vaccinerelatedcosts(mentionedabove)includedtheremainingcommitmentsand
obligations,includingexternalmanufacturingnetworkexitandrelatedinventorycostsandrequiredclinicaltrialexpenses,
associatedwiththeCompany’smodificationofitsCOVID-19vaccineresearchprogramandmanufacturingcapacityto
levelsthatmeetallremainingcustomercontractualrequirements.
MedTechSegment:In2022,theMedTechsegmentincomebeforetaxasapercenttosaleswas16.8%versus16.2%
in2021.Theincreaseintheincomebeforetaxasapercenttosaleswasprimarilydrivenbythefollowing:
• AnIPR&Dchargeof$0.9billionin2021relatedtothegeneralsurgeryofferingindigitalrobotics(Ottava)acquiredwith
theAurisHealthacquisitionin2019
partiallyoffsetby:
• Higherlitigationrelatedexpenseof$0.6billionin2022,primarilyrelatedtopelvicmeshcostsversus$0.1billionin
2021
• Acquisitionrelatedcostsof$0.3billionin2022relatedtotheAbiomedacquisitionversus$0.1billionin2021
Restructuring:Inthefiscalsecondquarterof2018,theCompanyannouncedplanstoimplementactionsacrossits
GlobalSupplyChainthatareintendedtoenabletheCompanytofocusresourcesandincreaseinvestmentsincritical
capabilities,technologiesandsolutionsnecessarytomanufactureandsupplyitsproductportfolioofthefuture,enhance
agilityanddrivegrowth.TheGlobalSupplyChainactionsincludedexpandingitsuseofstrategiccollaborations,and
bolsteringitsinitiativestoreducecomplexity,improvingcost-competitiveness,enhancingcapabilitiesandoptimizingits
supplychainnetwork.TheCompanyhasachievedapproximately$0.8billioninannualpre-taxcostsavingsasoutlinedin
therestructuringactions.In2022,theCompanyrecordedapre-taxchargeof$0.5billion,whichisincludedonthe
followinglinesoftheConsolidatedStatementofEarnings,$0.3billioninrestructuring,$0.1billioninother(income)
expenseand$0.1billionincostofproductssold.Totalprojectcostsofapproximately$2.2billionhavebeenrecorded
sincetherestructuringwasannounced.Theprogramwascompletedinthefiscalfourthquarterof2022.
SeeNote20totheConsolidatedFinancialStatementsforadditionaldetailsrelatedtotherestructuringprograms.
ProvisionforTaxesonIncome:Theworldwideeffectiveincometaxratewas17.4%in2022and8.3%in2021.
Inthefiscal2022,theCompanyincurredapproximately$0.5billionnetincrementalinternationaltaxcostrelatedtothe
legalseparationoftheConsumerHealthbusiness,andmaycontinuetoincuradditionalcostinfiscal2023.
OnDecember15,2022,theEuropeanUnion(EU)MemberStatesformallyadoptedtheEU’sPillarTwoDirective,which
generallyprovidesforaminimumeffectivetaxrateof15%,asestablishedbytheOrganizationforEconomicCo-operation
andDevelopment(OECD)PillarTwoFrameworkthatwassupportedbyover130countriesworldwide.TheEUeffective
datesareJanuary1,2024,andJanuary1,2025,fordifferentaspectsofthedirective.
Asignificantnumberofothercountriesareexpectedtoalsoimplementsimilarlegislation,includingSouthKoreawhich
approvedlegislationonDecember23,2022withafulleffectivedateofJanuary1,2024.TheCompanyiscontinuingto
evaluatethepotentialimpactonfutureperiodsofthePillarTwoFramework,pendinglegislativeadoptionbyadditional
individualcountries,includingthosewithintheEuropeanUnion.
Fordiscussionrelatedtothefiscal2022provisionfortaxesrefertoNote8totheConsolidatedFinancialStatements.
32 • Johnson&Johnson2022AnnualReportLiquidity and Capital Resources
Liquidity&CashFlows
Cashandcashequivalentswere$14.1billionattheendof2022ascomparedto$14.5billionattheendof2021.
Theprimarysourcesandusesofcashthatcontributedtothe$0.4billiondecreasewere:
(DollarsInBillions)
$14.5 Q42021Cashandcashequivalentsbalance
21.2 cashgeneratedfromoperatingactivities
(12.4) netcashusedbyinvestingactivities
(8.9) netcashusedbyfinancingactivities
$(0.3) effectofexchangerateandrounding
$14.1 Q42022Cashandcashequivalentsbalance
Inaddition,theCompanyhad$9.4billioninmarketablesecuritiesattheendoffiscalyear2022and$17.1billionatthe
endoffiscalyear2021.SeeNote1totheConsolidatedFinancialStatementsforadditionaldetailsoncash,cash
equivalentsandmarketablesecurities.
Cashflowfromoperationsof$21.2billionwastheresultof:
(DollarsInBillions)
$17.9 NetEarnings
7.3 non-cashexpensesandotheradjustmentsprimarilyfordepreciationandamortization,stock-basedcompensation
andassetwrite-downspartiallyoffsetbythedeferredtaxprovision,netgainonsaleofassets/businessesand
creditlossesandaccountsreceivableallowances
(2.0) adecreaseincurrentandnon-currentliabilities
0.7 adecreaseinothercurrentandnon-currentassets
1.1 anincreaseinaccountspayableandaccruedliabilities
(3.8) anincreaseinaccountsreceivableandinventories
$21.2 CashFlowfromoperations
Investingactivitiesuseof$12.4billionofcashwasprimarilyusedfor:
(DollarsInBillions)
$(4.0) additionstoproperty,plantandequipment
(17.7) acquisitions
0.5 proceedsfromthedisposalofassets/businesses,net
9.2 netsalesofinvestments
(0.2) Creditsupportagreementsactivity,net
(0.2) other(primarilylicensesandmilestones)androunding
$(12.4) Netcashusedforinvestingactivities
Johnson&Johnson2022AnnualReport • 33Financingactivitiesuseof$8.9billionofcashwasprimarilyusedfor:
(DollarsInBillions)
$(11.7) dividendstoshareholders
(6.0) repurchaseofcommonstock
7.5 netproceedsfromshortandlongtermdebt
1.3 proceedsfromstockoptionsexercised/employeewithholdingtaxonstockawards,net
$(8.9) Netcashusedforfinancingactivities
AsofJanuary1,2023,theCompany’snotespayableandlong-termdebtwasinexcessofcash,cashequivalentsand
marketablesecurities.AsofJanuary1,2023,thenetdebtpositionwas$16.1billionascomparedtotheprioryearof
$2.1billion.TheincreasewasprimarilyduetotheacquisitionofAbiomed,Inc.inDecember2022.Thedebtbalanceatthe
endof2022was$39.7billionascomparedto$33.8billionin2021.Consideringrecentmarketconditions,theCompany
hasre-evaluateditsoperatingcashflowsandliquidityprofileanddoesnotforeseeanysignificantincrementalrisk.The
Companyanticipatesthatoperatingcashflows,theabilitytoraisefundsfromexternalsources,borrowingcapacityfrom
existingcommittedcreditfacilitiesandaccesstothecommercialpapermarketswillcontinuetoprovidesufficient
resourcestofundoperatingneeds,includingtheCompany’sremainingbalancetobepaidontheagreementtosettle
opioidlitigationforapproximately$2.7billionandtheestablishmentofthe$2.0billiontrustfortalcrelatedliabilities(See
Note19totheConsolidatedFinancialStatementsforadditionaldetails).Inaddition,theCompanymonitorstheglobal
capitalmarketsonanongoingbasisandfromtimetotimemayraisecapitalwhenmarketconditionsarefavorable.
Effectivebeginninginfiscal2022,theU.S.TaxCutsandJobActof2017(TCJA)requirestheCompanytodeductU.S.
andinternationalresearchanddevelopmentexpendituresfortaxpurposesover5to15years,insteadofinthecurrent
fiscalyear.Asaresult,infiscal2022,theCompanyexperiencedanincreaseinannualcashtaxpaymentsofapproximately
$1.2billionabovewhatotherwisewouldhavebeenremittedtotheU.STreasury.TheCompanyconcurrentlyrecordsa
deferredtaxbenefitforthefutureamortizationoftheresearchanddevelopment(R&D)fortaxpurposes.Therequirement
toexpenseR&DasincurredisunchangedforU.S.GAAPpurposesandtheimpacttopre-taxR&Dexpenseisnotaffected
bythisprovision.
OnSeptember14,2022,theCompanyannouncedthatitsBoardofDirectorsapprovedasharerepurchaseprogram,
authorizingtheCompanytopurchaseupto$5.0billionoftheCompany’sCommonStock.Sharerepurchasesmaybe
madeatmanagement’sdiscretionfromtimetotimeontheopenmarketorthroughprivatelynegotiatedtransactions.The
repurchaseprogramhasnotimelimitandmaybesuspendedforperiodsordiscontinuedatanytime.Anysharesacquired
willbeavailableforgeneralcorporatepurposes.TheCompanyintendstofinancethesharerepurchaseprogramthrough
availablecash.ThroughJanuary1,2023,approximately$2.5billionhasbeenrepurchasedundertheprogram.
ThefollowingtablesummarizestheCompany’smaterialcontractualobligationsandtheiraggregatematuritiesasof
January1,2023:Tosatisfytheseobligations,theCompanyintendstousecashfromoperations.
Tax Intereston
Legislation Debt Debt
(DollarsinMillions) (TCJA) Obligations Obligations Total
2023 $1,522 1,551 893 3,966
2024 2,029 1,392 843 4,264
2025 2,536 1,667 789 4,992
2026 — 1,996 744 2,740
2027 — 2,271 736 3,007
After2027 — 19,562 8,772 28,334
Total $6,087 28,439 12,777 47,303
Fortaxmatters,seeNote8totheConsolidatedFinancialStatements.
34 • Johnson&Johnson2022AnnualReportFinancingandMarketRisk
TheCompanyusesfinancialinstrumentstomanagetheimpactofforeignexchangeratechangesoncashflows.
Accordingly,theCompanyentersintoforwardforeignexchangecontractstoprotectthevalueofcertainforeigncurrency
assetsandliabilitiesandtohedgefutureforeigncurrencytransactionsprimarilyrelatedtoproductcosts.Gainsorlosses
onthesecontractsareoffsetbythegainsorlossesontheunderlyingtransactions.A10%appreciationoftheU.S.Dollar
fromtheJanuary1,2023marketrateswouldincreasetheunrealizedvalueoftheCompany’sforwardcontractsby
$0.1billion.Conversely,a10%depreciationoftheU.S.DollarfromtheJanuary1,2023marketrateswoulddecreasethe
unrealizedvalueoftheCompany’sforwardcontractsby$0.1billion.Ineitherscenario,thegainorlossontheforward
contractwouldbeoffsetbythegainorlossontheunderlyingtransaction,andtherefore,wouldhavenoimpactonfuture
anticipatedearningsandcashflows.
TheCompanyhedgestheexposuretofluctuationsincurrencyexchangerates,andtheeffectoncertainassetsand
liabilitiesinforeigncurrency,byenteringintocurrencyswapcontracts.A1%changeinthespreadbetweenU.S.and
foreigninterestratesontheCompany’sinterestratesensitivefinancialinstrumentswouldeitherincreaseordecreasethe
unrealizedvalueoftheCompany’sswapcontractsbyapproximately$1.7billion.Ineitherscenario,atmaturity,thegainor
lossontheswapcontractwouldbeoffsetbythegainorlossontheunderlyingtransaction,andtherefore,wouldhaveno
impactonfutureanticipatedcashflows.
TheCompanydoesnotenterintofinancialinstrumentsfortradingorspeculativepurposes.Further,theCompanyhasa
policyofonlyenteringintocontractswithpartiesthathaveatleastaninvestmentgradecreditrating.Thecounterpartiesto
thesecontractsaremajorfinancialinstitutionsandthereisnosignificantconcentrationofexposurewithanyone
counterparty.Managementbelievestheriskoflossisremote.TheCompanyenteredintocreditsupportagreements
(CSA)withcertainderivativecounterpartiesestablishingcollateralthresholdsbasedonrespectivecreditratingsand
nettingagreements.SeeNote6totheConsolidatedFinancialStatementsforadditionaldetailsoncreditsupport
agreements.
TheCompanyinvestsinbothfixedrateandfloatingrateinterestearningsecuritieswhichcarryadegreeofinterestrate
risk.Thefairmarketvalueoffixedratesecuritiesmaybeadverselyimpactedduetoariseininterestrates,whilefloating
ratesecuritiesmayproducelessincomethanpredictedifinterestratesfall.A1%(100basispoints)changeinspreadon
theCompany’sinterestratesensitiveinvestmentswouldeitherincreaseordecreasetheunrealizedvalueofcash
equivalentsandcurrentmarketablesecuritiesbylessthan$0.1billion.
TheCompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwide.InSeptember2022,the
Companysecuredanew364-dayCreditFacilityof$10billion,whichexpiresonSeptember7,2023.InNovember2022,
theCompanysecuredanadditional364-dayrevolvingCreditFacilityof$10billion,whichhasanexpirationof
November21,2023.InterestchargedonborrowingsunderthecreditlineagreementisbasedoneitherSecured
OvernightFinancingRate(SOFR)ReferenceRateorotherapplicablemarketrateasallowedplusapplicablemargins.
Commitmentfeesundertheagreementarenotmaterial.
Totalborrowingsattheendof2022and2021were$39.7billionand$33.8billion,respectively.Theincreasein
borrowingswasduetotheacquisitionofAbiomed,Inc.In2022,netdebt(cashandcurrentmarketablesecurities,netof
debt)was$16.1billioncomparedtonetdebtof$2.1billionin2021.Totaldebtrepresented34.1%oftotalcapital
(shareholders’equityandtotaldebt)in2022and31.3%oftotalcapitalin2021.Shareholders’equitypershareattheend
of2022was$29.39comparedto$28.16atyear-end2021.
AsummaryofborrowingscanbefoundinNote7totheConsolidatedFinancialStatements.
Dividends
TheCompanyincreaseditsdividendin2022forthe60thconsecutiveyear.Cashdividendspaidwere$4.45persharein
2022and$4.19persharein2021.
OnJanuary3,2023,theBoardofDirectorsdeclaredaregularcashdividendof$1.13pershare,payableonMarch7,
2023toshareholdersofrecordasofFebruary21,2023.
Other Information
CriticalAccountingPoliciesandEstimates
Management’sdiscussionandanalysisofresultsofoperationsandfinancialconditionarebasedontheCompany’s
consolidatedfinancialstatementsthathavebeenpreparedinaccordancewithaccountingprinciplesgenerallyacceptedin
Johnson&Johnson2022AnnualReport • 35theU.S.(GAAP).Thepreparationofthesefinancialstatementsrequiresthatmanagementmakeestimatesand
assumptionsthataffecttheamountsreportedforrevenues,expenses,assets,liabilitiesandotherrelateddisclosures.
Actualresultsmayormaynotdifferfromtheseestimates.TheCompanybelievesthattheunderstandingofcertainkey
accountingpoliciesandestimatesareessentialinachievingmoreinsightintotheCompany’soperatingresultsand
financialcondition.Thesekeyaccountingpoliciesincluderevenuerecognition,incometaxes,legalandself-insurance
contingencies,valuationoflong-livedassets,assumptionsusedtodeterminetheamountsrecordedforpensionsandother
employeebenefitplansandaccountingforstockbasedawards.
RevenueRecognition:TheCompanyrecognizesrevenuefromproductsaleswhenobligationsunderthetermsofa
contractwiththecustomeraresatisfied;generally,thisoccurswiththetransferofcontrolofthegoodstocustomers.The
Company’sglobalpaymenttermsaretypicallybetween30to90days.Provisionsforcertainrebates,salesincentives,
tradepromotions,coupons,productreturns,discountstocustomersandgovernmentalclawbackprovisionsareaccounted
forasvariableconsiderationandrecordedasareductioninsales.
Productdiscountsgrantedarebasedonthetermsofarrangementswithdirect,indirectandothermarketparticipants,as
wellasmarketconditions,includingconsiderationofcompetitorpricing.Rebatesareestimatedbasedoncontractual
terms,historicalexperience,patientoutcomes,trendanalysisandprojectedmarketconditionsinthevariousmarkets
served.TheCompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarilythroughtheanalysisof
wholesalerandotherthird-partysell-throughandmarketresearchdata,aswellasinternallygeneratedinformation.
Salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformation.Productsthatexhibitunusual
salesorreturnpatternsduetodating,competitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas
partoftheaccountingforsalesreturnaccruals.
Salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpiration,destructioninthefield,
orinspecificareas,productrecall.Thesalesreturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarket
asapercenttogrosssales.InaccordancewiththeCompany’saccountingpolicies,theCompanygenerallyissuescredit
tocustomersforreturnedgoods.TheCompany’ssalesreturnsreservesareaccountedforinaccordancewiththe
U.S.GAAPguidanceforrevenuerecognitionwhenrightofreturnexists.Salesreturnsreservesarerecordedatfullsales
value.SalesreturnsintheConsumerHealthandPharmaceuticalsegmentsarealmostexclusivelynotresalable.Sales
returnsforcertainfranchisesintheMedTechsegmentaretypicallyresalablebutarenotmaterial.TheCompany
infrequentlyexchangesproductsfrominventoryforreturnedproducts.ThesalesreturnsreserveforthetotalCompanyhas
beenapproximately1.0%ofannualnettradesalesduringthefiscalyears2022,2021and2020.
Promotionalprograms,suchasproductlistingallowancesandcooperativeadvertisingarrangements,arerecordedinthe
sameperiodasrelatedsales.Continuingpromotionalprogramsincludecouponsandvolume-basedsalesincentive
programs.Theredemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue.
Volume-basedincentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedas
productsaresold.Thesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedas
areductionofrevenue.TheCompanyalsoearnsprofit-sharepaymentsthroughcollaborativearrangementsofcertain
products,whichareincludedinsalestocustomers.Profit-sharepaymentswerelessthan2.0%ofthetotalrevenuesin
fiscalyear2022andlessthan3.0%ofthetotalrevenuesinfiscalyears2021and2020andareincludedinsalesto
customers.
Inaddition,theCompanyentersintocollaborationarrangementsthatcontainmultiplerevenuegeneratingactivities.
Amountsduefromcollaborativepartnersforthesearrangementsarerecognizedaseachactivityisperformedordelivered,
basedontherelativesellingprice.Upfrontfeesreceivedaspartofthesearrangementsaredeferredandrecognizedover
theperformanceperiod.SeeNote1totheConsolidatedFinancialStatementsforadditionaldisclosuresoncollaborations.
Reasonablylikelychangestoassumptionsusedtocalculatetheaccrualsforrebates,returnsandpromotionsarenot
anticipatedtohaveamaterialeffectonthefinancialstatements.TheCompanycurrentlydisclosestheimpactofchanges
toassumptionsinthequarterlyorannualfilinginwhichthereisamaterialfinancialstatementimpact.
36 • Johnson&Johnson2022AnnualReportBelowaretablesthatshowtheprogressionofaccruedrebates,returns,promotions,reservefordoubtfulaccountsand
reserveforcashdiscountsbysegmentofbusinessforthefiscalyearsendedJanuary1,2023andJanuary2,2022.
ConsumerHealthSegment
Balanceat Balanceat
Beginning Payments/ Endof
(DollarsinMillions) ofPeriod Accruals Credits Period
2022
Accruedrebates(1) $287 1,052 (948) 391
Accruedreturns 76 83 (88) 71
Accruedpromotions 387 2,077 (2,008) 456
Subtotal $750 3,212 (3,044) 918
Reservefordoubtfulaccounts 32 5 (3) 34
Reserveforcashdiscounts 15 210 (208) 17
Total $797 3,427 (3,255) 969
2021
Accruedrebates(1) $289 893 (895) 287
Accruedreturns 76 136 (136) 76
Accruedpromotions 428 1,958 (1,999) 387
Subtotal $793 2,987 (3,030) 750
Reservefordoubtfulaccounts 39 0 (7) 32
Reserveforcashdiscounts 12 213 (210) 15
Total $844 3,200 (3,247) 797
(1) Includesreserveforcustomerrebatesof$82millionatJanuary1,2023and$80millionatJanuary2,2022,recordedasacontra
asset.
Pharmaceutical Segment
Balanceat Balanceat
Beginning Payments/ Endof
(DollarsinMillions) ofPeriod Accruals Credits(2) Period
2022
Accruedrebates(1) $10,331 43,026 (41,068) 12,289
Accruedreturns 520 444 (315) 649
Accruedpromotions 3 5 (7) 1
Subtotal $10,854 43,475 (41,390) 12,939
Reservefordoubtfulaccounts 50 0 (6) 44
Reserveforcashdiscounts 94 1,281 (1,265) 110
Total $10,998 44,756 (42,661) 13,093
2021
Accruedrebates(1) $9,837 37,922 (37,428) 10,331
Accruedreturns 460 345 (285) 520
Accruedpromotions 6 13 (16) 3
Subtotal $10,303 38,280 (37,729) 10,854
Reservefordoubtfulaccounts 52 18 (20) 50
Reserveforcashdiscounts 70 1,163 (1,139) 94
Total $10,425 39,461 (38,888) 10,998
(1) Includesreserveforcustomerrebatesof$203millionatJanuary1,2023and$218millionatJanuary2,2022,recordedasacontra
asset.
(2) Includespriorperiodadjustments
Johnson&Johnson2022AnnualReport • 37MedTechSegment
Balanceat Balanceat
Beginning Payments/ Endof
(DollarsinMillions) ofPeriod Accruals Credits Period
2022
Accruedrebates(1) $1,446 6,131 (6,107) 1,470
Accruedreturns 134 531 (531) 134
Accruedpromotions 54 102 (113) 43
Subtotal $1,634 6,764 (6,751) 1,647
Reservefordoubtfulaccounts 148 6 (29) 125
Reserveforcashdiscounts 10 99 (100) 9
Total $1,792 6,869 (6,880) 1,781
2021
Accruedrebates(1) $1,174 5,942 (5,670) 1,446
Accruedreturns 138 559 (563) 134
Accruedpromotions 52 140 (138) 54
Subtotal $1,364 6,641 (6,371) 1,634
Reservefordoubtfulaccounts 202 12 (66) 148
Reserveforcashdiscounts 9 96 (95) 10
Total $1,575 6,749 (6,532) 1,792
(1) Includesreserveforcustomerrebatesof$802millionatJanuary1,2023and$845millionatJanuary2,2022,recordedasacontra
asset.
IncomeTaxes:Incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludethe
resultsofanydifferencebetweenU.S.GAAPaccountingandtaxreporting,recordedasdeferredtaxassetsorliabilities.
TheCompanyestimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandrates.Futurechangesin
taxlawsandratesmayaffectrecordeddeferredtaxassetsandliabilities.
TheCompanyhasunrecognizedtaxbenefitsforuncertaintaxpositions.TheCompanyfollowsU.S.GAAP,which
prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof
ataxpositiontakenorexpectedtobetakeninataxreturn.Managementbelievesthatchangesintheseestimateswould
nothaveamaterialeffectontheCompany’sresultsofoperations,cashflowsorfinancialposition.
TheCompanyhasrecordeddeferredtaxliabilitiesonallundistributedearningspriortoDecember31,2017fromits
internationalsubsidiaries.TheCompanyhasnotprovideddeferredtaxesontheundistributedearningssubsequentto
January1,2018fromcertaininternationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvested.The
Companyintendstocontinuetoreinvesttheseearningsinthoseinternationaloperations.IftheCompanydecidesata
laterdatetorepatriatetheseearningstotheU.S.,theCompanywouldberequiredtoprovideforthenettaxeffectson
theseamounts.TheCompanyestimatesthatthetaxeffectofthisrepatriationwouldbeapproximately$0.5billionunder
currentlyenactedtaxlawsandregulationsandatcurrentcurrencyexchangerates.Thisamountdoesnotincludethe
possiblebenefitofU.S.foreigntaxcredits,whichmaysubstantiallyoffsetthiscost.
SeeNote1andNote8totheConsolidatedFinancialStatementsforfurtherinformationregardingincometaxes.
LegalandSelfInsuranceContingencies:TheCompanyrecordsaccrualsforvariouscontingencies,includinglegal
proceedingsandproductliabilityclaimsastheseariseinthenormalcourseofbusiness.Theaccrualsarebasedon
management’sjudgmentastotheprobabilityoflossesand,whereapplicable,actuariallydeterminedestimates.The
Companyhasselfinsurancethroughawholly-ownedcaptiveinsurancecompany.Inadditiontoaccrualsintheself
insuranceprogram,claimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe
reasonablyestimated.
TheCompanyfollowstheprovisionsofU.S.GAAPwhenrecordinglitigationrelatedcontingencies.Aliabilityisrecorded
whenalossisprobableandcanbereasonablyestimated.
38 • Johnson&Johnson2022AnnualReportSeeNotes1and19totheConsolidatedFinancialStatementsforfurtherinformationregardingproductliabilityandlegal
proceedings.
Long-LivedandIntangibleAssets:TheCompanyassesseschanges,bothqualitativelyandquantitatively,ineconomic
conditionsandmakesassumptionsregardingestimatedfuturecashflowsinevaluatingthevalueoftheCompany’s
property,plantandequipment,goodwillandintangibleassets.Astheseassumptionsandestimatesmaychangeovertime,
itmayormaynotbenecessaryfortheCompanytorecordimpairmentcharges.
EmployeeBenefitPlans:TheCompanysponsorsvariousretirementandpensionplans,includingdefinedbenefit,
definedcontributionandterminationindemnityplans,whichcovermostemployeesworldwide.Theseplansarebasedon
assumptionsforthediscountrate,expectedreturnonplanassets,mortalityrates,expectedsalaryincreases,healthcare
costtrendratesandattritionrates.SeeNote10totheConsolidatedFinancialStatementsforfurtherdetailsonthese
rates.
StockBasedCompensation:TheCompanyrecognizescompensationexpenseassociatedwiththeissuanceofequity
instrumentstoemployeesfortheirservices.Basedonthetypeofequityinstrument,thefairvalueisestimatedonthedate
ofgrantusingeithertheBlack-ScholesoptionvaluationmodeloracombinationofboththeBlack-Scholesoption
valuationmodelandMonteCarlovaluationmodel,andisexpensedinthefinancialstatementsovertheserviceperiod.The
inputassumptionsusedindeterminingfairvaluearetheexpectedlife,expectedvolatility,risk-freerateandexpected
dividendyield.Forperformanceshareunits,thefairmarketvalueiscalculatedforthetwocomponentgoalsatthedateof
grant:adjustedoperationalearningspershareandrelativetotalshareholderreturn.Thefairvaluesfortheearningsper
sharegoalofeachperformanceshareunitwasestimatedonthedateofgrantusingthefairmarketvalueofthesharesat
thetimeoftheaward,discountedfordividends,whicharenotpaidontheperformanceshareunitsduringthevesting
period.Thefairvaluefortherelativetotalshareholderreturngoalofeachperformanceshareunitwasestimatedonthe
dateofgrantusingtheMonteCarlovaluationmodel.SeeNote16totheConsolidatedFinancialStatementsforadditional
information.
NewAccountingPronouncements
RefertoNote1totheConsolidatedFinancialStatementsforrecentlyadoptedaccountingpronouncementsandrecently
issuedaccountingpronouncementsnotyetadoptedasofJanuary1,2023.
EconomicandMarketFactors
TheCompanyisawarethatitsproductsareusedinanenvironmentwhere,formorethanadecade,policymakers,
consumersandbusinesseshaveexpressedconcernsabouttherisingcostofhealthcare.Inresponsetotheseconcerns,
theCompanyhasalong-standingpolicyofpricingproductsresponsibly.Fortheperiod2012-2022,intheU.S.,the
weightedaveragecompoundannualgrowthrateoftheCompany’snetpriceincreasesforhealthcareproducts
(prescriptionandover-the-counterdrugs,hospitalandprofessionalproducts)wasbelowtheU.S.ConsumerPriceIndex
(CPI).
TheCompanyoperatesincertaincountrieswheretheeconomicconditionscontinuetopresentsignificantchallenges.The
Companycontinuestomonitorthesesituationsandtakeappropriateactions.Inflationratescontinuetohaveaneffecton
worldwideeconomiesand,consequently,onthewaycompaniesoperate.TheCompanyhasaccountedforoperationsin
ArgentinaandVenezuelaashighlyinflationary,asthepriorthree-yearcumulativeinflationratesurpassed100%.Beginning
inthefiscalsecondquarterof2022,theCompanyaccountedforoperationsinTurkeyashighlyinflationary,astheprior
three-yearcumulativeinflationratesurpassed100%.ThisdidnothaveamaterialimpacttotheCompany’sresultsinthe
period.Inthefaceofincreasingcosts,theCompanystrivestomaintainitsprofitmarginsthroughcostreductionprograms,
productivityimprovementsandperiodicpriceincreases.
Russia-UkraineWar
Althoughthelong-termimplicationsofRussia’sinvasionofUkrainearedifficulttopredictatthistime,thefinancialimpact
oftheconflictinthefiscal2022,includingaccountsreceivableorinventoryreserves,wasnotmaterial.Asofboththefiscal
yearsendingJanuary1,2023andJanuary2,2022,thebusinessoftheCompany’sUkrainesubsidiariesrepresentedless
than1%oftheCompany’sconsolidatedassetsandrevenues.AsofboththefiscalyearsendingJanuary1,2023and
January2,2022,thebusinessoftheCompany’sRussiansubsidiariesrepresentedlessthan1%oftheCompany’s
consolidatedassetsandrepresented1%ofrevenues.
InearlyMarch,theCompanytookstepstosuspendalladvertising,enrollmentinclinicaltrials,andanyadditional
investmentinRussia.Additionally,attheendofMarch,theCompanymadethedecisiontosuspendsupplyofpersonal
Johnson&Johnson2022AnnualReport • 39careproductsinRussia.TheCompanycontinuestosupplyitsotherproductsaspatientsrelyonmanyoftheproductsfor
healthcarepurposes.
TheCompanyisexposedtofluctuationsincurrencyexchangerates.A1%changeinthevalueoftheU.S.Dollaras
comparedtoallforeigncurrenciesinwhichtheCompanyhadsales,incomeorexpensein2022wouldhaveincreasedor
decreasedthetranslationofforeignsalesbyapproximately$0.5billionandnetincomebyapproximately$0.1billion.
Governmentsaroundtheworldconsidervariousproposalstomakechangestotaxlaws,whichmayincludeincreasingor
decreasingexistingstatutorytaxrates.Inconnectionwithvariousgovernmentinitiatives,companiesarerequiredto
disclosemoreinformationtotaxauthoritiesonoperationsaroundtheworld,whichmayleadtogreaterauditscrutinyof
profitsearnedinothercountries.Achangeinstatutorytaxrateinanycountrywouldresultintherevaluationofthe
Company’sdeferredtaxassetsandliabilitiesrelatedtothatparticularjurisdictionintheperiodinwhichthenewtaxlawis
enacted.ThischangewouldresultinanexpenseorbenefitrecordedtotheCompany’sConsolidatedStatementof
Earnings.TheCompanycloselymonitorstheseproposalsastheyariseinthecountrieswhereitoperates.Changestothe
statutorytaxratemayoccuratanytime,andanyrelatedexpenseorbenefitrecordedmaybematerialtothefiscalquarter
andyearinwhichthelawchangeisenacted.
TheCompanyfacesvariousworldwidehealthcarechangesthatmaycontinuetoresultinpricingpressuresthatinclude
healthcarecostcontainmentandgovernmentlegislationrelatingtosales,promotions,pricingandreimbursementof
healthcareproducts.
Changesinthebehaviorandspendingpatternsofpurchasersofhealthcareproductsandservices,includingdelaying
medicalprocedures,rationingprescriptionmedications,reducingthefrequencyofphysicianvisitsandforegoing
healthcareinsurancecoverage,asaresultofthecurrentglobaleconomicdownturn,maycontinuetoimpactthe
Company’sbusinesses.
TheCompanyalsooperatesinanenvironmentincreasinglyhostiletointellectualpropertyrights.Firmshavefiled
AbbreviatedNewDrugApplicationsorBiosimilarBiologicalProductApplicationswiththeU.S.FDAorotherwise
challengedthecoverageand/orvalidityoftheCompany’spatents,seekingtomarketgenericorbiosimilarformsofmany
oftheCompany’skeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproducts.Inthe
eventtheCompanyisnotsuccessfulindefendingthepatentclaimschallengedintheresultinglawsuits,genericor
biosimilarversionsoftheproductsatissuewillbeintroducedtothemarket,resultinginthepotentialforsubstantialmarket
shareandrevenuelossesforthoseproducts,andwhichmayresultinanon-cashimpairmentchargeinanyassociated
intangibleasset.Thereisalsoariskthatoneormorecompetitorscouldlaunchagenericorbiosimilarversionofthe
productatissuefollowingregulatoryapprovaleventhoughoneormorevalidpatentsareinplace.
LegalProceedings
Johnson&Johnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability,
intellectualproperty,commercial,employment,indemnificationandothermatters;governmentalinvestigations;andother
legalproceedingsthatarisefromtimetotimeintheordinarycourseofbusiness.
TheCompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata
liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimated.AsofJanuary1,2023,theCompanyhas
determinedthattheliabilitiesassociatedwithcertainlitigationmattersareprobableandcanbereasonablyestimated.The
Companyhasaccruedforthesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsasmight
bewarrantedbasedonnewinformationandfurtherdevelopmentsinaccordancewithASC450-20-25.Fortheseand
otherlitigationandregulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossible,theCompany
isunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsaccrued.Amountsaccruedforlegal
contingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyon
estimatesandassumptionsincludingtimingofrelatedpayments.Theabilitytomakesuchestimatesandjudgmentscanbe
affectedbyvariousfactorsincluding,amongotherthings,whetherdamagessoughtintheproceedingsare
unsubstantiatedorindeterminate;scientificandlegaldiscoveryhasnotcommencedorisnotcomplete;proceedingsarein
earlystages;matterspresentlegaluncertainties;therearesignificantfactsindispute;proceduralorjurisdictionalissues;
theuncertaintyandunpredictabilityofthenumberofpotentialclaims;abilitytoachievecomprehensivemulti-party
settlements;complexityofrelatedcross-claimsandcounterclaims;and/ortherearenumerouspartiesinvolved.Tothe
extentadverseawards,judgmentsorverdictshavebeenrenderedagainsttheCompany,theCompanydoesnotrecordan
accrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimated.
40 • Johnson&Johnson2022AnnualReportIntheCompany’sopinion,basedonitsexaminationofthesematters,itsexperiencetodateanddiscussionswithcounsel,
theultimateoutcomeoflegalproceedings,netofliabilitiesaccruedintheCompany’sbalancesheet,isnotexpectedto
haveamaterialadverseeffectontheCompany’sfinancialposition.However,theresolutionof,orincreaseinaccrualsfor,
oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectontheCompany’sresultsof
operationsandcashflowsforthatperiod.
SeeNote19totheConsolidatedFinancialStatementsincludedinItem8ofthisreportforfurtherinformationregarding
legalproceedings.
CommonStock
TheCompany’sCommonStockislistedontheNewYorkStockExchangeunderthesymbolJNJ.AsofFebruary10,
2023,therewere124,211recordholdersofCommonStockoftheCompany.
Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK
Theinformationcalledforbythisitemisincorporatedhereinbyreferenceto“Item7.Management’sDiscussionand
AnalysisofResultsofOperationsandFinancialCondition—LiquidityandCapitalResources—FinancingandMarket
Risk”ofthisReport;andNote1“SummaryofSignificantAccountingPolicies—FinancialInstruments”oftheNotesto
ConsolidatedFinancialStatementsincludedinItem8ofthisReport.
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
IndextoAuditedConsolidatedFinancialStatements
42 ConsolidatedBalanceSheets
43 ConsolidatedStatementsofEarnings
44 ConsolidatedStatementsofComprehensiveIncome
45 ConsolidatedStatementsofEquity
46 ConsolidatedStatementsofCashFlows
47 NotestoConsolidatedFinancialStatements
105 ReportofIndependentRegisteredPublicAccountingFirm(PCAOBID238)
108 Management’sReportonInternalControlOverFinancialReporting
Johnson&Johnson2022AnnualReport • 41JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
AtJanuary1,2023andJanuary2,2022
(DollarsinMillionsExceptShareandPerShareAmounts)(Note1)
2022 2021
Assets
Currentassets
Cashandcashequivalents(Notes1and2) $14,127 14,487
Marketablesecurities(Notes1and2) 9,392 17,121
Accountsreceivabletrade,lessallowancesfordoubtfulaccounts$203(2021,$230) 16,160 15,283
Inventories(Notes1and3) 12,483 10,387
Prepaidexpensesandotherreceivables 3,132 3,701
Totalcurrentassets 55,294 60,979
Property,plantandequipment,net(Notes1and4) 19,803 18,962
Intangibleassets,net(Notes1and5) 48,325 46,392
Goodwill(Notes1and5) 45,231 35,246
Deferredtaxesonincome(Note8) 9,123 10,223
Otherassets 9,602 10,216
Totalassets $187,378 182,018
LiabilitiesandShareholders’Equity
Currentliabilities
Loansandnotespayable(Note7) $12,771 3,766
Accountspayable 11,703 11,055
Accruedliabilities 11,456 13,612
Accruedrebates,returnsandpromotions 14,417 12,095
Accruedcompensationandemployeerelatedobligations 3,328 3,586
Accruedtaxesonincome(Note8) 2,127 1,112
Totalcurrentliabilities 55,802 45,226
Long-termdebt(Note7) 26,888 29,985
Deferredtaxesonincome(Note8) 6,374 7,487
Employeerelatedobligations(Notes9and10) 6,767 8,898
Long-termtaxespayable(Note1) 4,306 5,713
Otherliabilities 10,437 10,686
Totalliabilities 110,574 107,995
CommitmentsandContingencies(Note19)
Shareholders’equity
Preferredstock—withoutparvalue(authorizedandunissued2,000,000shares) — —
Commonstock—parvalue$1.00pershare(Note12)(authorized4,320,000,000shares;issued
3,119,843,000shares) 3,120 3,120
Accumulatedothercomprehensiveincome(loss)(Note13) (12,967) (13,058)
Retainedearnings 128,345 123,060
118,498 113,122
Less:commonstockheldintreasury,atcost(Note12)(506,246,000sharesand490,878,000shares) 41,694 39,099
Totalshareholders’equity 76,804 74,023
Totalliabilitiesandshareholders’equity $187,378 182,018
SeeNotestoConsolidatedFinancialStatements
42 • Johnson&Johnson2022AnnualReportJOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
(DollarsandSharesinMillionsExceptPerShareAmounts)(Note1)
2022 2021 2020
Salestocustomers $94,943 93,775 82,584
Costofproductssold 31,089 29,855 28,427
Grossprofit 63,854 63,920 54,157
Selling,marketingandadministrativeexpenses 24,765 24,659 22,084
Researchanddevelopmentexpense 14,603 14,714 12,159
In-processresearchanddevelopment(Note5) 783 900 181
Interestincome (490) (53) (111)
Interestexpense,netofportioncapitalized(Note4) 276 183 201
Other(income)expense,net 1,871 489 2,899
Restructuring(Note20) 321 252 247
Earningsbeforeprovisionfortaxesonincome 21,725 22,776 16,497
Provisionfortaxesonincome(Note8) 3,784 1,898 1,783
Netearnings $17,941 20,878 14,714
Netearningspershare(Notes1and15)
Basic $6.83 7.93 5.59
Diluted $6.73 7.81 5.51
Averagesharesoutstanding(Notes1and15)
Basic 2,625.2 2,632.1 2,632.8
Diluted 2,663.9 2,674.0 2,670.7
SeeNotestoConsolidatedFinancialStatements
Johnson&Johnson2022AnnualReport • 43JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(DollarsinMillions)(Note1)
2022 2021 2020
Netearnings $17,941 20,878 14,714
Othercomprehensiveincome(loss),netoftax
Foreigncurrencytranslation (1,796) (1,079) (233)
Securities:
Unrealizedholdinggain(loss)arisingduringperiod (24) (4) 1
Reclassificationstoearnings — — —
Netchange (24) (4) 1
Employeebenefitplans:
Priorservicecredit(cost),netofamortization (160) (169) 1,298
Gain(loss),netofamortization 1,854 4,318 (1,135)
Effectofexchangerates 111 106 (229)
Netchange 1,805 4,255 (66)
Derivatives&hedges:
Unrealizedgain(loss)arisingduringperiod 454 (199) 1,000
Reclassificationstoearnings (348) (789) (53)
Netchange 106 (988) 947
Othercomprehensiveincome(loss) 91 2,184 649
Comprehensiveincome $18,032 23,062 15,363
Thetaxeffectsinothercomprehensiveincomeforthefiscalyears2022,2021and2020respectively:ForeignCurrency
Translation;$460million,$346millionand$536million;Securities:$6millionand$1millionin2022and2021,
EmployeeBenefitPlans:$461million,$1,198millionand$21million,Derivatives&Hedges:$30million,$263million
and$252million.
SeeNotestoConsolidatedFinancialStatements
44 • Johnson&Johnson2022AnnualReportJOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EQUITY
(DollarsinMillions)(Note1)
Accumulated Common
Other Stock Treasury
Retained Comprehensive Issued Stock
Total Earnings Income(Loss) Amount Amount
Balance,December29,2019 $59,471 110,659 (15,891) 3,120 (38,417)
Netearnings 14,714 14,714
Cashdividendspaid($3.98pershare) (10,481) (10,481)
Employeecompensationandstockoptionplans 2,217 (931) 3,148
Repurchaseofcommonstock (3,221) (3,221)
Other (71) (71)
Othercomprehensiveincome(loss),netoftax 649 649
Balance,January3,2021 63,278 113,890 (15,242) 3,120 (38,490)
Netearnings 20,878 20,878
Cashdividendspaid($4.19pershare) (11,032) (11,032)
Employeecompensationandstockoptionplans 2,171 (676) 2,847
Repurchaseofcommonstock (3,456) (3,456)
Othercomprehensiveincome(loss),netoftax 2,184 2,184
Balance,January2,2022 74,023 123,060 (13,058) 3,120 (39,099)
Netearnings 17,941 17,941
Cashdividendspaid($4.45pershare) (11,682) (11,682)
Employeecompensationandstockoptionplans 2,466 (974) 3,440
Repurchaseofcommonstock (6,035) (6,035)
Othercomprehensiveincome(loss),netoftax 91 91
Balance,January1,2023 $76,804 128,345 (12,967) 3,120 (41,694)
SeeNotestoConsolidatedFinancialStatements
Johnson&Johnson2022AnnualReport • 45JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(DollarsinMillions)(Note1)
2022 2021 2020
Cashflowsfromoperatingactivities
Netearnings $17,941 20,878 14,714
Adjustmentstoreconcilenetearningstocashflowsfromoperatingactivities:
Depreciationandamortizationofpropertyandintangibles 6,970 7,390 7,231
Stockbasedcompensation 1,138 1,135 1,005
Assetwrite-downs 1,216 989 233
Contingentconsiderationreversal — — (1,148)
Netgainonsaleofassets/businesses (380) (617) (111)
Deferredtaxprovision (1,663) (2,079) (1,141)
Creditlossesandaccountsreceivableallowances (17) (48) 63
Changesinassetsandliabilities,netofeffectsfromacquisitionsanddivestitures:
(Increase)/Decreaseinaccountsreceivable (1,290) (2,402) 774
Increaseininventories (2,527) (1,248) (265)
Increaseinaccountspayableandaccruedliabilities 1,098 2,437 5,141
Decrease/(Increase)inothercurrentandnon-currentassets 687 (1,964) (3,704)
(Decrease)/Increaseinothercurrentandnon-currentliabilities (1,979) (1,061) 744
Netcashflowsfromoperatingactivities 21,194 23,410 23,536
Cashflowsfrominvestingactivities
Additionstoproperty,plantandequipment (4,009) (3,652) (3,347)
Proceedsfromthedisposalofassets/businesses,net 543 711 305
Acquisitions,netofcashacquired(Note18) (17,652) (60) (7,323)
Purchasesofinvestments (32,384) (30,394) (21,089)
Salesofinvestments 41,609 25,006 12,137
Creditsupportagreementsactivity,net (249) 214 (987)
Other(primarilylicensesandmilestones) (229) (508) (521)
Netcashusedbyinvestingactivities (12,371) (8,683) (20,825)
Cashflowsfromfinancingactivities
Dividendstoshareholders (11,682) (11,032) (10,481)
Repurchaseofcommonstock (6,035) (3,456) (3,221)
Proceedsfromshort-termdebt 16,134 1,997 3,391
Repaymentofshort-termdebt (6,550) (1,190) (2,663)
Proceedsfromlong-termdebt,netofissuancecosts 2 5 7,431
Repaymentoflong-termdebt (2,134) (1,802) (1,064)
Proceedsfromtheexerciseofstockoptions/employeewithholdingtaxonstockawards,net 1,329 1,036 1,114
Creditsupportagreementsactivity,net (28) 281 (333)
Other 93 114 (294)
Netcashusedbyfinancingactivities (8,871) (14,047) (6,120)
Effectofexchangeratechangesoncashandcashequivalents (312) (178) 89
(Decrease)/Increaseincashandcashequivalents (360) 502 (3,320)
Cashandcashequivalents,beginningofyear(Note1) 14,487 13,985 17,305
Cashandcashequivalents,endofyear(Note1) $14,127 14,487 13,985
Supplementalcashflowdata
Cashpaidduringtheyearfor:
Interest $982 990 904
Interest,netofamountcapitalized 933 941 841
Incometaxes 5,223 4,768 4,619
Supplementalscheduleofnon-cashinvestingandfinancingactivities
Treasurystockissuedforemployeecompensationandstockoptionplans,netofcashproceeds/employee
withholdingtaxonstockawards $2,114 1,811 1,937
Conversionofdebt — — 27
Acquisitions
Fairvalueofassetsacquired $18,710 61 7,755
Fairvalueofliabilitiesassumed (1,058) (1) (432)
Netcashpaidforacquisitions(Note18) $17,652 60 7,323
SeeNotestoConsolidatedFinancialStatements
46 • Johnson&Johnson2022AnnualReportNOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Summary of Significant Accounting Policies
PrinciplesofConsolidation
TheconsolidatedfinancialstatementsincludetheaccountsofJohnson&Johnsonanditssubsidiaries(theCompany).
Intercompanyaccountsandtransactionsareeliminated.Columnsandrowswithintablesmaynotaddduetorounding.
Percentageshavebeencalculatedusingactual,non-roundedfigures.
DescriptionoftheCompanyandBusinessSegments
TheCompanyhasapproximately152,700employeesworldwideengagedintheresearchanddevelopment,manufacture
andsaleofabroadrangeofproductsinthehealthcarefield.TheCompanyconductsbusinessinvirtuallyallcountriesof
theworldanditsprimaryfocusisonproductsrelatedtohumanhealthandwell-being.
TheCompanyisorganizedintothreebusinesssegments:ConsumerHealth,PharmaceuticalandMedTech.The
ConsumerHealthsegmentincludesabroadrangeofproductsusedintheBabyCare,OralCare,SkinHealth/Beauty,
Over-the-Counterpharmaceutical,Women’sHealthandWoundCaremarkets.Theseproductsaremarketedtothe
generalpublicandsoldonline(eCommerce)andtoretailoutletsanddistributorsthroughouttheworld.The
Pharmaceuticalsegmentisfocusedonthefollowingtherapeuticareas,includingImmunology,Infectiousdiseases,
Neuroscience,Oncology,PulmonaryHypertension,andCardiovascularandMetabolicdiseases.Productsinthissegment
aredistributeddirectlytoretailers,wholesalers,distributors,hospitalsandhealthcareprofessionalsforprescriptionuse.
TheMedTechsegmentincludesabroadportfolioofproductsusedintheOrthopaedic,Surgery,InterventionalSolutions
(cardiovascularandneurovascular)andVisionfields.Theseproductsaredistributedtowholesalers,hospitalsandretailers,
andusedprincipallyintheprofessionalfieldsbyphysicians,nurses,hospitals,eyecareprofessionalsandclinics.
InNovember2021,theCompanyannounceditsintentiontoseparatetheCompany’sConsumerHealthbusiness(Kenvue
asthenamefortheplannedNewConsumerHealthCompany),withtheintentiontocreateanew,publiclytraded
companybytheendofthefiscalyear2023.
NewAccountingStandards
RecentlyAdoptedAccountingStandards
Therewerenonewmaterialaccountingstandardsadoptedinfiscal2022.
RecentlyIssuedAccountingStandards
NotAdoptedasofJanuary1,2023
ASU2022-04:Liabilities-SupplierFinancePrograms(Topic405-50)–DisclosureofSupplierFinanceProgram
Obligations
Thisupdaterequiresthatabuyerinasupplierfinanceprogramdiscloseadditionalinformationabouttheprogramtoallow
financialstatementuserstobetterunderstandtheeffectoftheprogramsonanentity’sworkingcapital,liquidity,andcash
flows.ThisupdatewillbeeffectivefortheCompanyforfiscalyearsbeginningafterDecember15,2022,exceptforthe
amendmentonrollforwardinformation,whichiseffectiveforfiscalyearsbeginningafterDecember15,2023.Early
adoptionispermitted.TheCompanyiscurrentlyassessingtheimpactofthisupdateonitsdisclosuresandwilladoptthis
standardinthefiscalfirstquarterof2023.
CashEquivalents
TheCompanyclassifiesallhighlyliquidinvestmentswithstatedmaturitiesofthreemonthsorlessfromdateofpurchase
ascashequivalentsandallhighlyliquidinvestmentswithstatedmaturitiesofgreaterthanthreemonthsfromthedateof
purchaseascurrentmarketablesecurities.TheCompanyhasapolicyofmakinginvestmentsonlywithcommercial
institutionsthathaveatleastaninvestmentgradecreditrating.TheCompanyinvestsitscashprimarilyingovernment
securitiesandobligations,corporatedebtsecurities,moneymarketfundsandreverserepurchaseagreements(RRAs).
RRAsarecollateralizedbydepositsintheformofGovernmentSecuritiesandObligationsforanamountnotlessthan
102%oftheirvalue.TheCompanydoesnotrecordanassetorliabilityastheCompanyisnotpermittedtosellor
Johnson&Johnson2022AnnualReport • 47repledgetheassociatedcollateral.TheCompanyhasapolicythatthecollateralhasatleastanA(orequivalent)credit
rating.TheCompanyutilizesathirdpartycustodiantomanagetheexchangeoffundsandensurethatcollateralreceivedis
maintainedat102%ofthevalueoftheRRAsonadailybasis.RRAswithstatedmaturitiesofgreaterthanthreemonths
fromthedateofpurchaseareclassifiedasmarketablesecurities.
Investments
Investmentsclassifiedasheldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesare
reportedinearnings.Investmentsclassifiedasavailable-for-saledebtsecuritiesarecarriedatestimatedfairvaluewith
unrealizedgainsandlossesrecordedasacomponentofaccumulatedothercomprehensiveincome.Available-for-sale
securitiesavailableforcurrentoperationsareclassifiedascurrentassetsotherwise,theyareclassifiedaslongterm.
Managementdeterminestheappropriateclassificationofitsinvestmentindebtandequitysecuritiesatthetimeof
purchaseandre-evaluatessuchdeterminationateachbalancesheetdate.TheCompanyreviewsitsinvestmentsfor
impairmentandadjuststheseinvestmentstofairvaluethroughearnings,asrequired.
Property,PlantandEquipmentandDepreciation
Property,plantandequipmentarestatedatcost.TheCompanyutilizesthestraight-linemethodofdepreciationoverthe
estimatedusefullivesoftheassets:
Buildingandbuildingequipment 30years
Landandleaseholdimprovements 10-20years
Machineryandequipment 2-13years
TheCompanycapitalizescertaincomputersoftwareanddevelopmentcosts,includedinmachineryandequipment,when
incurredinconnectionwithdevelopingorobtainingcomputersoftwareforinternaluse.Capitalizedsoftwarecostsare
amortizedovertheestimatedusefullivesofthesoftware,whichgenerallyrangefrom3to8years.
TheCompanyreviewslong-livedassetstoassessrecoverabilityusingundiscountedcashflows.Whencertaineventsor
changesinoperatingoreconomicconditionsoccur,animpairmentassessmentmaybeperformedontherecoverabilityof
thecarryingvalueoftheseassets.Iftheassetisdeterminedtobeimpaired,thelossismeasuredbasedonthedifference
betweentheasset’sfairvalueanditscarryingvalue.Ifquotedmarketpricesarenotavailable,theCompanywillestimate
fairvalueusingadiscountedvalueofestimatedfuturecashflows.
Revenue Recognition
TheCompanyrecognizesrevenuefromproductsaleswhenobligationsunderthetermsofacontractwiththecustomer
aresatisfied;generally,thisoccurswiththetransferofcontrolofthegoodstocustomers.TheCompany’sglobalpayment
termsaretypicallybetween30to90days.Provisionsforcertainrebates,salesincentives,tradepromotions,coupons,
productreturns,discountstocustomersandgovernmentalclawbackprovisionsareaccountedforasvariable
considerationandrecordedasareductioninsales.TheliabilityisrecognizedwithinAccruedRebates,Returns,and
Promotionsontheconsolidatedbalancesheet.
Productdiscountsgrantedarebasedonthetermsofarrangementswithdirect,indirectandothermarketparticipants,as
wellasmarketconditions,includingconsiderationofcompetitorpricing.Rebatesareestimatedbasedoncontractual
terms,historicalexperience,patientoutcomes,trendanalysisandprojectedmarketconditionsinthevariousmarkets
served.AsignificantportionoftheliabilityrelatedtorebatesisfromthesaleoftheCompany’spharmaceuticalproducts
withintheU.S.,primarilytheManagedCare,MedicareandMedicaidprograms,whichamountedto$9.6billionand
$7.7billionasofJanuary1,2023andJanuary2,2022,respectively.TheCompanyevaluatesmarketconditionsfor
productsorgroupsofproductsprimarilythroughtheanalysisofwholesalerandotherthird-partysell-throughandmarket
researchdata,aswellasinternallygeneratedinformation.
Salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformation.Productsthatexhibitunusual
salesorreturnpatternsduetodating,competitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas
partoftheaccountingforsalesreturnaccruals.
48 • Johnson&Johnson2022AnnualReportSalesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpiration,destructioninthefield,
orinspecificareas,productrecall.Thesalesreturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarket
asapercenttogrosssales.InaccordancewiththeCompany’saccountingpolicies,theCompanygenerallyissuescredit
tocustomersforreturnedgoods.TheCompany’ssalesreturnsreservesareaccountedforinaccordancewiththe
U.S.GAAPguidanceforrevenuerecognitionwhenrightofreturnexists.Salesreturnsreservesarerecordedatfullsales
value.SalesreturnsintheConsumerHealthandPharmaceuticalsegmentsarealmostexclusivelynotresalable.Sales
returnsforcertainfranchisesintheMedTechsegmentaretypicallyresalablebutarenotmaterial.TheCompany
infrequentlyexchangesproductsfrominventoryforreturnedproducts.ThesalesreturnsreserveforthetotalCompanyhas
beenapproximately1.0%ofannualnettradesalesduringeachofthefiscalyears2022,2021and2020.
Promotionalprograms,suchasproductlistingallowancesandcooperativeadvertisingarrangements,arerecordedinthe
sameperiodasrelatedsales.Continuingpromotionalprogramsincludecouponsandvolume-basedsalesincentive
programs.Theredemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue.
Volume-basedincentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedas
productsaresold.Thesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedas
areductionofrevenue.TheCompanyalsoearnsprofit-sharepaymentsthroughcollaborativearrangementsforcertain
products,whichareincludedinsalestocustomers.Profit-sharepaymentswerelessthan2.0%ofthetotalrevenuesin
fiscalyear2022andlessthan3.0%ofthetotalrevenuesinfiscalyears2021and2020andareincludedinsalesto
customers.
SeeNote17totheConsolidatedFinancialStatementsforfurtherdisaggregationofrevenue.
ShippingandHandling
Shippingandhandlingcostsincurredwere$1.1billion,$1.1billionand$1.0billioninfiscalyears2022,2021and2020,
respectively,andareincludedinselling,marketingandadministrativeexpense.Theamountofrevenuereceivedfor
shippingandhandlingislessthan1.0%ofsalestocustomersforallperiodspresented.
Inventories
Inventoriesarestatedatthelowerofcostornetrealizablevaluedeterminedbythefirst-in,first-outmethod.
IntangibleAssetsandGoodwill
TheauthoritativeliteratureonU.S.GAAPrequiresthatgoodwillandintangibleassetswithindefinitelivesbeassessed
annuallyforimpairment.TheCompanycompleteditsannualimpairmenttestfor2022inthefiscalfourthquarter.Future
impairmenttestswillbeperformedannuallyinthefiscalfourthquarter,orsoonerifwarranted.Purchasedin-process
researchanddevelopmentisaccountedforasanindefinitelivedintangibleassetuntiltheunderlyingprojectiscompleted,
atwhichpointtheintangibleassetwillbeaccountedforasadefinitelivedintangibleasset.Ifwarrantedthepurchasedin-
processresearchanddevelopmentcouldbewrittenofforpartiallyimpaireddependingontheunderlyingprogram.
Intangibleassetsthathavefiniteusefullivescontinuetobeamortizedovertheirusefullives,andarereviewedfor
impairmentwhenwarrantedbyeconomicconditions.SeeNote5forfurtherdetailsonIntangibleAssetsandGoodwill.
FinancialInstruments
AsrequiredbyU.S.GAAP,allderivativeinstrumentsarerecordedonthebalancesheetatfairvalue.Fairvalueistheexit
pricethatwouldbereceivedtosellanassetorpaidtotransferaliability.Fairvalueisamarket-basedmeasurement
determinedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliability.Theauthoritativeliterature
establishesathree-levelhierarchytoprioritizetheinputsusedinmeasuringfairvalue,withLevel1havingthehighest
priorityandLevel3havingthelowest.Changesinthefairvalueofderivativesarerecordedeachperiodincurrentearnings
orothercomprehensiveincome,dependingonwhetherthederivativeisdesignatedaspartofahedgetransaction,andif
so,thetypeofhedgetransaction.
TheCompanydocumentsallrelationshipsbetweenhedgeditemsandderivatives.Theoverallriskmanagementstrategy
includesreasonsforundertakinghedgetransactionsandenteringintoderivatives.Theobjectivesofthisstrategyare:
(1)minimizeforeigncurrencyexposure’simpactontheCompany’sfinancialperformance;(2)protecttheCompany’scash
Johnson&Johnson2022AnnualReport • 49flowfromadversemovementsinforeignexchangerates;(3)ensuretheappropriatenessoffinancialinstruments;and
(4)managetheenterpriseriskassociatedwithfinancialinstitutions.SeeNote6foradditionalinformationonFinancial
Instruments.
Leases
TheCompanydetermineswhetheranarrangementisaleaseatcontractinceptionbyestablishingifthecontractconveys
therighttocontroltheuseofidentifiedproperty,plant,orequipmentforaperiodoftimeinexchangeforconsideration.
RightofUse(ROU)AssetsandLeaseLiabilitiesforoperatingleasesareincludedinOtherassets,Accruedliabilities,and
Otherliabilitiesontheconsolidatedbalancesheet.TheROUAssetsrepresenttherighttouseanunderlyingassetforthe
leasetermandleaseliabilitiesrepresentanobligationtomakeleasepaymentsarisingfromthelease.Commitmentsunder
financeleasesarenotsignificant,andareincludedinProperty,plantandequipment,Loansandnotespayable,andLong-
termdebtontheconsolidatedbalancesheet.
ROUAssetsandLeaseLiabilitiesarerecognizedattheleasecommencementdatebasedonthepresentvalueofall
minimumleasepaymentsovertheleaseterm.TheCompanyusesitsincrementalborrowingratebasedontheinformation
availableatcommencementdateindeterminingthepresentvalueofleasepayments,whentheimplicitrateisnotreadily
determinable.Leasetermsmayincludeoptionstoextendorterminatethelease.Theseoptionsareincludedinthelease
termwhenitisreasonablycertainthattheCompanywillexercisethatoption.Operatingleaseexpenseisrecognizedona
straight-linebasisovertheleaseterm.TheCompanyhaselectedthefollowingpolicyelectionsonadoption:useof
portfolioapproachonleasesofassetsundermasterserviceagreements,exclusionofshorttermleasesonthebalance
sheet,andnotseparatingleaseandnon-leasecomponents.
TheCompanyprimarilyhasoperatingleaseforspace,vehicles,manufacturingequipmentanddataprocessingequipment.
TheROUassetpertainingtooperatingleaseswas$1.1billionand$0.9billioninfiscalyears2022and2021,
respectively.Theleaseliabilitywas$1.3billionand$1.0billioninfiscalyears2022and2021,respectively.Theoperating
leasecostswere$0.3billioninfiscalyears2022,2021and2020,respectively.Cashpaidforamountsincludedinthe
measurementofleaseliabilitieswere$0.3billioninfiscalyears2022,2021and2020,respectively.
ProductLiability
Accrualsforproductliabilityclaimsarerecorded,onanundiscountedbasis,whenitisprobablethataliabilityhasbeen
incurredandtheamountoftheliabilitycanbereasonablyestimatedbasedonexistinginformationandactuarially
determinedestimateswhereapplicable.Theaccrualsareadjustedperiodicallyasadditionalinformationbecomes
available.TheCompanyaccruesanestimateofthelegaldefensecostsneededtodefendeachmatterwhenthosecosts
areprobableandcanbereasonablyestimated.TotheextentadverseverdictshavebeenrenderedagainsttheCompany,
theCompanydoesnotrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimated.
TheCompanyhasselfinsurancethroughawholly-ownedcaptiveinsurancecompany.Inadditiontoaccrualsintheself
insuranceprogram,claimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe
reasonablyestimated.
ResearchandDevelopment
ResearchanddevelopmentexpensesareexpensedasincurredinaccordancewithASC730,Researchand
Development.Upfrontandmilestonepaymentsmadetothirdpartiesinconnectionwithresearchanddevelopment
collaborationsareexpensedasincurreduptothepointofregulatoryapproval.Paymentsmadetothirdpartiessubsequent
toregulatoryapprovalarecapitalizedandamortizedovertheremainingusefullifeoftherelatedproduct.Amounts
capitalizedforsuchpaymentsareincludedinotherintangibles,netofaccumulatedamortization.
TheCompanyentersintocollaborativearrangements,typicallywithotherpharmaceuticalorbiotechnologycompanies,to
developandcommercializedrugcandidatesorintellectualproperty.Thesearrangementstypicallyinvolvetwo(ormore)
partieswhoareactiveparticipantsinthecollaborationandareexposedtosignificantrisksandrewardsdependentonthe
commercialsuccessoftheactivities.Thesecollaborationsusuallyinvolvevariousactivitiesbyoneormoreparties,
includingresearchanddevelopment,marketingandsellinganddistribution.Often,thesecollaborationsrequireupfront,
milestoneandroyaltyorprofitsharepayments,contingentupontheoccurrenceofcertainfutureeventslinkedtothe
successoftheassetindevelopment.Amountsduefromcollaborativepartnersrelatedtodevelopmentactivitiesare
generallyreflectedasareductionofresearchanddevelopmentexpensebecausetheperformanceofcontract
50 • Johnson&Johnson2022AnnualReportdevelopmentservicesisnotcentraltotheCompany’soperations.Ingeneral,theincomestatementpresentationforthese
collaborationsisasfollows:
Nature/TypeofCollaboration StatementofEarningsPresentation
Third-partysaleofproduct&profitsharepaymentsreceived Salestocustomers
Royalties/milestonespaidtocollaborativepartner(post- Costofproductssold
regulatoryapproval)*
Royaltiesreceivedfromcollaborativepartner Otherincome(expense),net
Upfrontpayments&milestonespaidtocollaborativepartner Researchanddevelopmentexpense
(pre-regulatoryapproval)
Researchanddevelopmentpaymentstocollaborative Researchanddevelopmentexpense
partner
Researchanddevelopmentpaymentsreceivedfrom ReductionofResearchanddevelopmentexpense
collaborativepartnerorgovernmententity
* Milestonesarecapitalizedasintangibleassetsandamortizedtocostofproductssoldovertheusefullife.
Forallyearspresented,therewasnoindividualprojectthatrepresentedgreaterthan5%ofthetotalannualconsolidated
researchanddevelopmentexpense.
TheCompanyhasanumberofproductsandcompoundsdevelopedincollaborationwithstrategicpartnersincluding
XARELTO,co-developedwithBayerHealthCareAGandIMBRUVICA,developedincollaborationandco-marketedwith
PharmacyclicsLLC,anAbbViecompany.
Separately,theCompanyhasanumberoflicensingarrangementsforproductsandcompoundsincludingDARZALEX,
licensedfromGenmabA/S.
Advertising
Costsassociatedwithadvertisingareexpensedintheyearincurredandareincludedinselling,marketingand
administrativeexpenses.Advertisingexpensesworldwide,whichcomprisedtelevision,radio,printmediaandInternet
advertising,were$2.1billion,$2.7billionand$2.1billioninfiscalyears2022,2021and2020,respectively.
IncomeTaxes
Incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludetheresultsofany
differencebetweenU.S.GAAPaccountingandtaxreporting,recordedasdeferredtaxassetsorliabilities.TheCompany
estimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandrates.Futurechangesintaxlawsand
ratesmayaffectrecordeddeferredtaxassetsandliabilitiesinthefuture.
TheCompanyhasunrecognizedtaxbenefitsforuncertaintaxpositions.TheCompanyfollowsU.S.GAAPwhich
prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof
ataxpositiontakenorexpectedtobetakeninataxreturn.Managementbelievesthatchangesintheseestimateswould
nothaveamaterialeffectontheCompany’sresultsofoperations,cashflowsorfinancialposition.
In2017,theUnitedStatesenactedintolawnewU.S.taxlegislation,theU.S.TaxCutsandJobsAct(TCJA).Thislaw
includedprovisionsforacomprehensiveoverhaulofthecorporateincometaxcode,includingareductionofthestatutory
corporatetaxratefrom35%to21%,effectiveonJanuary1,2018.TheTCJAincludedaprovisionforataxonall
previouslyundistributedearningsofU.S.companieslocatedinforeignjurisdictions.Undistributedearningsintheformof
cashandcashequivalentsweretaxedatarateof15.5%andallotherearningsweretaxedatarateof8.0%.Thistaxis
payableover8yearsandwillnotaccrueinterest.Thesepaymentsbeganin2018andwillcontinuethrough2025.The
remainingbalanceattheendofthe2022wasapproximately$6.1billion,ofwhich$4.6billionisclassifiedasnoncurrent
andreflectedas“Long-termtaxespayable”ontheCompany’sbalancesheet.Thebalanceofthisaccountisrelatedto
receivablesfromtaxauthoritiesnotexpectedtobereceivedinthenext12months.
TheTCJAalsoincludesprovisionsforataxonglobalintangiblelow-taxedincome(GILTI).GILTIisdescribedasthe
excessofaU.S.shareholder’stotalnetforeignincomeoveradeemedreturnontangibleassets,asprovidedbytheTCJA.
Johnson&Johnson2022AnnualReport • 51InJanuary2018,theFASBissuedguidancethatallowscompaniestoelectasanaccountingpolicywhethertorecordthe
taxeffectsofGILTIintheperiodthetaxliabilityisgenerated(i.e.,“periodcost”)orprovidefordeferredtaxassetsand
liabilitiesrelatedtobasisdifferencesthatexistandareexpectedtoeffecttheamountofGILTIinclusioninfutureyears
uponreversal(i.e.,“deferredmethod”).TheCompanyhaselectedtoaccountforGILTIunderthedeferredmethod.The
deferredtaxamountsrecordedarebasedontheevaluationoftemporarydifferencesthatareexpectedtoreverseasGILTI
isincurredinfutureperiods.
TheCompanyhasrecordeddeferredtaxliabilitiesonallundistributedearningspriortoDecember31,2017fromits
internationalsubsidiaries.TheCompanyhasnotprovideddeferredtaxesontheundistributedearningssubsequentto
January1,2018fromcertaininternationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvested.The
Companyintendstocontinuetoreinvesttheseearningsinthoseinternationaloperations.IftheCompanydecidesata
laterdatetorepatriatetheseearningstotheU.S.,theCompanywouldberequiredtoprovideforthenettaxeffectson
theseamounts.TheCompanyestimatesthatthetaxeffectofthisrepatriationwouldbeapproximately$0.5billionunder
currentlyenactedtaxlawsandregulationsandatcurrentcurrencyexchangerates.Thisamountdoesnotincludethe
possiblebenefitofU.S.foreigntaxcredits,whichmaysubstantiallyoffsetthiscost.
SeeNote8totheConsolidatedFinancialStatementsforfurtherinformationregardingincometaxes.
NetEarningsPerShare
Basicearningspershareiscomputedbydividingnetearningsavailabletocommonshareholdersbytheweightedaverage
numberofcommonsharesoutstandingfortheperiod.Dilutedearningspersharereflectsthepotentialdilutionthatcould
occurifsecuritieswereexercisedorconvertedintocommonstockusingthetreasurystockmethod.
UseofEstimates
Thepreparationofconsolidatedfinancialstatementsinconformitywithaccountingprinciplesgenerallyacceptedinthe
U.S.requiresmanagementtomakeestimatesandassumptionsthataffecttheamountsreported.Estimatesareusedwhen
accountingforsalesdiscounts,rebates,allowancesandincentives,productliabilities,incometaxes,withholdingtaxes,
depreciation,amortization,employeebenefits,contingenciesandintangibleassetandliabilityvaluations.Actualresults
mayormaynotdifferfromthoseestimates.
TheCompanyfollowstheprovisionsofU.S.GAAPwhenrecordinglitigationrelatedcontingencies.Aliabilityisrecorded
whenalossisprobableandcanbereasonablyestimated.Thebestestimateofalosswithinarangeisaccrued;however,
ifnoestimateintherangeisbetterthananyother,theminimumamountisaccrued.
AnnualClosingDate
TheCompanyfollowstheconceptofafiscalyear,whichendsontheSundaynearesttotheendofthemonthof
December.Normallyeachfiscalyearconsistsof52weeks,buteveryfiveorsixyearsthefiscalyearconsistsof53weeks,
andthereforeincludesadditionalshippingdays,aswasthecaseinfiscalyear2020,andwillbethecaseagaininfiscal
year2026.
Reclassification
Certainpriorperiodamountshavebeenreclassifiedtoconformtocurrentyearpresentation.
52 • Johnson&Johnson2022AnnualReport2. Cash, Cash Equivalents and Current Marketable Securities
Attheendofthefiscalyear2022and2021,cash,cashequivalentsandcurrentmarketablesecuritieswerecomprisedof:
2022
Estimated Cash& Current
Carrying Unrecognized Fair Cash Marketable
(DollarsinMillions) Amount Loss Value Equivalents Securities
Cash $4,926 — 4,926 4,926 —
U.S.Reverserepurchaseagreements 1,419 — 1,419 1,419 —
Corporatedebtsecurities(1) 873 (1) 872 — 873
Moneymarketfunds 5,368 — 5,368 5,368 —
Timedeposits(1) 446 — 446 446 —
Subtotal $13,032 (1) 13,031 12,159 873
U.S.Gov’tSecurities $9,959 (28) 9,931 1,922 8,009
U.S.Gov’tAgencies 210 (5) 205 — 205
Corporateandotherdebtsecurities 352 (1) 351 46 305
Subtotalavailableforsale(2) $10,521 (34) 10,487 1,968 8,519
Totalcash,cashequivalentsandcurrentmarketable
securities $14,127 9,392
2021
Estimated Cash& Current
Carrying Unrecognized Fair Cash Marketable
(DollarsinMillions) Amount Loss Value Equivalents Securities
Cash $2,936 — 2,936 2,936 —
Non-U.S.SovereignSecurities(1) 1,006 — 1,006 90 916
U.S.Reverserepurchaseagreements 1,659 — 1,659 1,659 —
Corporatedebtsecurities(1) 3,479 (1) 3,478 200 3,279
Moneymarketfunds 1,901 — 1,901 1,901 —
Timedeposits(1) 900 — 900 900 —
Subtotal 11,881 (1) 11,880 7,686 4,195
U.S.Gov’tSecurities $19,485 (4) 19,481 6,785 12,696
Corporateandotherdebtsecurities 246 — 246 16 230
Subtotalavailableforsale(2) $19,731 (4) 19,727 6,801 12,926
Totalcash,cashequivalentsandcurrentmarketable
securities $14,487 17,121
(1) Heldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesarereportedinearnings.
(2) Availableforsaledebtsecuritiesarereportedatfairvaluewithunrealizedgainsandlossesreportednetoftaxesinother
comprehensiveincome.
Fairvalueofgovernmentsecuritiesandobligationsandcorporatedebtsecuritieswereestimatedusingquotedbroker
pricesandsignificantotherobservableinputs.
Johnson&Johnson2022AnnualReport • 53ThecontractualmaturitiesoftheavailableforsaledebtsecuritiesatJanuary1,2023areasfollows:
Cost Fair
(DollarsinMillions) Basis Value
Duewithinoneyear $10,430 10,399
Dueafteroneyearthroughfiveyears 91 88
Dueafterfiveyearsthroughtenyears — —
Totaldebtsecurities $10,521 10,487
TheCompanyinvestsitsexcesscashinbothdepositswithmajorbanksthroughouttheworldandotherhigh-quality
moneymarketinstruments.TheCompanyhasapolicyofmakinginvestmentsonlywithcommercialinstitutionsthathaveat
leastaninvestmentgradecreditrating.
3. Inventories
Attheendoffiscalyears2022and2021,inventorieswerecomprisedof:
(DollarsinMillions) 2022 2021
Rawmaterialsandsupplies $2,070 1,592
Goodsinprocess 1,700 2,287
Finishedgoods 8,713 6,508
Totalinventories $12,483 10,387
4. Property, Plant and Equipment
Attheendoffiscalyears2022and2021,property,plantandequipmentatcostandaccumulateddepreciationwere:
(DollarsinMillions) 2022 2021
Landandlandimprovements $859 884
Buildingsandbuildingequipment 12,989 12,882
Machineryandequipment 30,431 29,774
Constructioninprogress 4,974 4,139
Totalproperty,plantandequipment,gross $49,253 47,679
Lessaccumulateddepreciation 29,450 28,717
Totalproperty,plantandequipment,net $19,803 18,962
TheCompanycapitalizesinterestexpenseaspartofthecostofconstructionoffacilitiesandequipment.Interestexpense
capitalizedinfiscalyears2022,2021and2020was$49million,$49millionand$63million,respectively.
Depreciationexpense,includingtheamortizationofcapitalizedinterestinfiscalyears2022,2021and2020was$2.7
billion,$2.7billionand$2.6billion,respectively.
Uponretirementorotherdisposalofproperty,plantandequipment,thecostsandrelatedamountsofaccumulated
depreciationoramortizationareeliminatedfromtheassetandaccumulateddepreciationaccounts,respectively.The
difference,ifany,betweenthenetassetvalueandtheproceedsarerecordedinearnings.
54 • Johnson&Johnson2022AnnualReport5. Intangible Assets and Goodwill
Attheendoffiscalyears2022and2021,thegrossandnetamountsofintangibleassetswere:
(DollarsinMillions) 2022 2021
Intangibleassetswithdefinitelives:
Patentsandtrademarks—gross $44,012 38,572
Lessaccumulatedamortization (22,266) (20,088)
Patentsandtrademarks—net(1) $21,746 18,484
Customerrelationshipsandotherintangibles—gross $22,987 23,011
Lessaccumulatedamortization (12,901) (11,925)
Customerrelationshipsandotherintangibles—net(2) $10,086 11,086
Intangibleassetswithindefinitelives:
Trademarks $6,807 6,985
Purchasedin-processresearchanddevelopment(3) 9,686 9,837
Totalintangibleassetswithindefinitelives $16,493 16,822
Totalintangibleassets—net $48,325 46,392
(1) ThechangewasprimarilyrelatedtotheintangibleassetsacquiredwiththeacquisitionofAbiomed,Inc.whichwaspartiallyoffsetby
amortizationexpenseofpreviouslyexistingintangibleassetsandtheresultofcurrencytranslationeffects.
(2) Themajorityiscomprisedofcustomerrelationships
(3) Thereductionwasprimarilyrelatedtoanintangibleassetimpairmentchargeofapproximately$0.8billionrecordedinthefiscalyear
2022relatedtoanin-processresearchanddevelopmentasset,bermekimab(JnJ-77474462),aninvestigationaldrugforthe
treatmentofAtopicDermatitis(AD)andHidradenitisSuppurativa(HS)acquiredwiththeacquisitionofXBiotech,Inc.inthefiscal
year2020.AdditionalinformationregardingefficacyoftheADandHSindicationsbecameavailablewhichledtheCompanytothe
decisiontoterminatethedevelopmentofbermekimabforADandHS.Anadditionalreductionof$0.7billionwasdrivenbyMonarch
assetsthatreachedcommercializationandarenowclassifiedashavingdefinitelives.Thiswaspartiallyoffsetbyapproximately
$1.1billionofIPR&DacquiredwithAbiomed,Inc.
GoodwillasofJanuary1,2023andJanuary2,2022,asallocatedbysegmentofbusiness,wasasfollows:
(DollarsinMillions) ConsumerHealth Pharmaceutical MedTech Total
GoodwillatJanuary3,2021 $10,336 11,009 15,048 36,393
Goodwill,relatedtoacquisitions — — — —
Goodwill,relatedtodivestitures (9) — — (9)
Currencytranslation/other (517) (429) (192) (1,138)
GoodwillatJanuary2,2022 $9,810 10,580 14,856 35,246
Goodwill,relatedtoacquisitions — — 11,056 11,056
Goodwill,relatedtodivestitures — — — —
Currencytranslation/other (626) (396) (49) (1,071)
GoodwillatJanuary1,2023 $9,184 10,184 25,863 45,231
Theweightedaverageamortizationperiodforpatentsandtrademarksis12years.Theweightedaverageamortization
periodforcustomerrelationshipsandotherintangibleassetsis21years.Theamortizationexpenseofamortizableassets
includedinCostofproductssoldwas$4.3billion,$4.7billionand$4.7billionbeforetax,forthefiscalyearsended
January1,2023,January2,2022andJanuary3,2021,respectively.Intangibleassetwrite-downsareincludedinOther
(income)expense,net.
Johnson&Johnson2022AnnualReport • 55Theestimatedamortizationexpenseforapprovedproducts,beforetax,forthefivesucceedingyearsisapproximately:
(DollarsinMillions)
2023 2024 2025 2026 2027
$4,600 4,400 3,600 3,000 2,400
SeeNote18totheConsolidatedFinancialStatementsforadditionaldetailsrelatedtoacquisitionsanddivestitures.
6. Fair Value Measurements
TheCompanyusesforwardforeignexchangecontractstomanageitsexposuretothevariabilityofcashflows,primarily
relatedtotheforeignexchangeratechangesoffutureintercompanyproductsandthird-partypurchasesofmaterials
denominatedinaforeigncurrency.TheCompanyusescrosscurrencyinterestrateswapstomanagecurrencyrisk
primarilyrelatedtoborrowings.Bothtypesofderivativesaredesignatedascashflowhedges.
Additionally,theCompanyprimarilyusesinterestrateswapsasaninstrumenttomanageinterestrateriskrelatedtofixed
rateborrowings.Thesederivativesaredesignatedasfairvaluehedges.TheCompanyusescrosscurrencyinterestrate
swapsandforwardforeignexchangecontractsdesignatedasnetinvestmenthedges.Additionally,theCompanyuses
forwardforeignexchangecontractstooffsetitsexposuretocertainforeigncurrencyassetsandliabilities.Theseforward
foreignexchangecontractsarenotdesignatedashedgesandtherefore,changesinthefairvaluesofthesederivativesare
recognizedinearnings,therebyoffsettingthecurrentearningseffectoftherelatedforeigncurrencyassetsandliabilities.
Inthefiscalfourthquarterof2022,theCompanyenteredintoforwardstartinginterestrateswapswithnotionalamounts
totaling$2.4billionincontemplationofhedginginterestrateriskassociatedwithlong-termfinancingfortheConsumer
Healthsegmentseparation.Theseforwardstartinginterestrateswapsarenotdesignatedashedgesandtherefore,
changesinthefairvaluesofthesederivativesarerecognizedinearnings.Attheendofthefiscalyear2022,thechanges
infairvaluewasnotmaterialandthereforenotincludedinthetablebelow.
TheCompanydoesnotenterintoderivativefinancialinstrumentsfortradingorspeculativepurposes,orthatcontaincredit
riskrelatedcontingentfeatures.TheCompanymaintainscreditsupportagreements(CSA)withcertainderivative
counterpartiesestablishingcollateralthresholdsbasedonrespectivecreditratingsandnettingagreements.Asof
January1,2023,thetotalamountofcashcollateralpaidbytheCompanyundertheCSAamountedto$0.8billionnet,
relatedtonetinvestmentandcashflowhedges.Onanongoingbasis,theCompanymonitorscounter-partycreditratings.
TheCompanyconsiderscreditnon-performancerisktobelow,becausetheCompanyprimarilyentersintoagreements
withcommercialinstitutionsthathaveatleastaninvestmentgradecreditrating.Refertothetableonsignificantfinancial
assetsandliabilitiesmeasuredatfairvaluecontainedinthisfootnoteforreceivablesandpayableswiththesecommercial
institutions.AsofJanuary1,2023,theCompanyhadnotionalamountsoutstandingforforwardforeignexchange
contracts,crosscurrencyinterestrateswapsandinterestrateswapsof$43.3billion,$36.2billionand$12.4billion,
respectively.AsofJanuary2,2022,theCompanyhadnotionalamountsoutstandingforforwardforeignexchange
contracts,crosscurrencyinterestrateswapsandinterestrateswapsof$45.8billion,$37.4billionand$10.0billion,
respectively.
Allderivativeinstrumentsarerecordedonthebalancesheetatfairvalue.Changesinthefairvalueofderivativesare
recordedeachperiodincurrentearningsorothercomprehensiveincome,dependingonwhetherthederivativeis
designatedaspartofahedgetransaction,andifso,thetypeofhedgetransaction.
Thedesignationasacashflowhedgeismadeattheentrancedateofthederivativecontract.Atinception,allderivatives
areexpectedtobehighlyeffective.Foreignexchangecontractsdesignatedascashflowhedgesareaccountedforunder
theforwardmethodandallgains/lossesassociatedwiththesecontractswillberecognizedintheincomestatementwhen
thehedgeditemimpactsearnings.Changesinthefairvalueofthesederivativesarerecordedinaccumulatedother
comprehensiveincomeuntiltheunderlyingtransactionaffectsearnings,andarethenreclassifiedtoearningsinthesame
accountasthehedgedtransaction.
Gainsandlossesassociatedwithinterestrateswapsandchangesinfairvalueofhedgeddebtattributabletochangesin
interestratesarerecordedtointerestexpenseintheperiodinwhichtheyoccur.Gainsandlossesonnetinvestment
hedgesareaccountedthroughthecurrencytranslationaccountwithinaccumulatedothercomprehensiveincome.The
portionexcludedfromeffectivenesstestingisrecordedthroughinterest(income)expenseusingthespotmethod.Onan
ongoingbasis,theCompanyassesseswhethereachderivativecontinuestobehighlyeffectiveinoffsettingchangesof
hedgeditems.Ifandwhenaderivativeisnolongerexpectedtobehighlyeffective,hedgeaccountingisdiscontinued.
56 • Johnson&Johnson2022AnnualReportTheCompanydesignateditsEurodenominatednotesissuedinMay2016withduedatesrangingfrom2022to2035as
anetinvestmenthedgeoftheCompany’sinvestmentsincertainofitsinternationalsubsidiariesthatusetheEuroastheir
functionalcurrencyinordertoreducethevolatilitycausedbychangesinexchangerates.
AsofJanuary1,2023,thebalanceofdeferrednetlossonderivativesincludedinaccumulatedothercomprehensive
incomewas$230millionafter-tax.Foradditionalinformation,seetheConsolidatedStatementsofComprehensiveIncome
andNote13.TheCompanyexpectsthatsubstantiallyalloftheamountsrelatedtoforwardforeignexchangecontractswill
bereclassifiedintoearningsoverthenext12monthsasaresultoftransactionsthatareexpectedtooccuroverthat
period.ThemaximumlengthoftimeoverwhichtheCompanyishedgingtransactionexposureis18months,excluding
interestratecontractsandnetinvestmenthedges.Theamountultimatelyrealizedinearningsmaydifferasforeign
exchangerateschange.Realizedgainsandlossesareultimatelydeterminedbyactualexchangeratesatmaturityofthe
derivative.
ThefollowingtableisasummaryoftheactivityrelatedtoderivativesandhedgesforthefiscalyearsendedJanuary1,
2023andJanuary2,2022,netoftax:
January1,2023 January2,2022
Costof Interest Other Costof Interest Other
Products R&D (Income) (Income) Products R&D (Income) (Income)
(DollarsinMillions) Sales Sold Expense Expense Expense Sales Sold Expense Expense Expense
Theeffectsoffairvalue,netinvestmentand
cashflowhedging:
Gain(Loss)onfairvaluehedging
relationship:
Interestrateswapscontracts:
Hedgeditems $— — — (1,098) — — — — (109) —
Derivativesdesignatedashedging
instruments — — — 1,098 — — — — 109 —
Gain(Loss)onnetinvestment
hedgingrelationship:
Crosscurrencyinterestrateswaps
contracts:
Amountofgainor(loss)recognizedin
incomeonderivativeamountexcluded
fromeffectivenesstesting $— — — 140 — — — — 174 —
Amountofgainor(loss)recognizedin
AOCI — — — 140 — — — — 174 —
Gain(Loss)oncashflowhedging
relationship:
Forwardforeignexchangecontracts:
Amountofgainor(loss)reclassifiedfrom
AOCIintoincome (72) (271) 149 — (23) 17 119 30 — 47
Amountofgainor(loss)recognizedin
AOCI 5 319 61 — (113) (94) (557) 123 — 146
Crosscurrencyinterestrateswaps
contracts:
Amountofgainor(loss)reclassifiedfrom
AOCIintoincome — — — 425 — — — — 402 —
Amountofgainor(loss)recognizedin
AOCI $— — — 42 — — — — 9 —
Johnson&Johnson2022AnnualReport • 57AsofJanuary1,2023andJanuary2,2022,thefollowingamountswererecordedontheconsolidatedbalancesheet
relatedtocumulativebasisadjustmentforfairvaluehedges
CumulativeAmountof
FairValueHedging
AdjustmentIncludedin
LineitemintheConsolidatedBalanceSheetin CarryingAmountofthe theCarryingAmountof
whichthehedgeditemisincluded HedgedLiability theHedgedLiability
January1, January2, January1, January2,
(DollarsinMillions) 2023 2022 2023 2022
Long-termDebt $8,665 $9,793 $(1,435) $(142)
ThefollowingtableistheeffectofderivativesnotdesignatedashedginginstrumentforthefiscalyearsendedJanuary1,
2023andJanuary2,2022:
LocationofGain/ Gain/(Loss)
(Loss)Recognizedin RecognizedIn
(DollarsinMillions) IncomeonDerivative IncomeonDerivative
DerivativesNotDesignatedasHedgingInstruments January1,2023 January2,2022
ForeignExchangeContracts Other(income)expense $94 (70)
ThefollowingtableistheeffectofnetinvestmenthedgesforthefiscalyearsendedJanuary1,2023andJanuary2,2022:
Gain/(Loss)
Gain/(Loss) LocationofGainor(Loss)Reclassified ReclassifiedFrom
RecognizedIn fromAccumulatedOtherComprehensive AccumulatedOCI
AccumulatedOCI IncomeIntoIncome IntoIncome
January1, January2, January1, January2,
(DollarsinMillions) 2023 2022 2023 2022
Debt $197 387 Interest(income)expense — —
CrossCurrencyinterestrateswaps $766 548 Interest(income)expense — —
TheCompanyholdsequityinvestmentswithreadilydeterminablefairvaluesandequityinvestmentswithoutreadily
determinablefairvalues.TheCompanymeasuresequityinvestmentsthatdonothavereadilydeterminablefairvaluesat
costminusimpairment,ifany,plusorminuschangesresultingfromobservablepricechangesinorderlytransactionsfor
theidenticalorasimilarinvestmentofthesameissuer.
ThefollowingtableisasummaryoftheactivityrelatedtoequityinvestmentsforthefiscalyearsendedJanuary1,2023
andJanuary2,2022:
January2,2022 January1,2023
Non
ChangesinFairValue Current
ReflectedinNet Sales/ Other
(DollarsinMillions) CarryingValue Income(1) Purchases/Other(2) CarryingValue Assets
EquityInvestmentswithreadilydeterminable
value $1,884 (538) (770) 576 576
EquityInvestmentswithoutreadily
determinablevalue $500 91 107 698 698
January3,2021 January2,2022
Non
ChangesinFairValue Current
ReflectedinNet Sales/ Other
(DollarsinMillions) CarryingValue Income(1) Purchases/Other(2) CarryingValue Assets
EquityInvestmentswithreadilydeterminable
value $1,481 198 205 1,884 1,884
EquityInvestmentswithoutreadily
determinablevalue $738 394 (632) 500 500
(1) RecordedinOtherIncome/Expense
(2) Otherincludesimpactofcurrency
58 • Johnson&Johnson2022AnnualReportForthefiscalyearsendedJanuary1,2023andJanuary2,2022forequityinvestmentswithoutreadilydeterminablemarket
values,$51millionand$28million,respectively,ofthechangesinfairvaluereflectedinnetincomeweretheresultof
impairments.Therewereoffsettingimpactsof$142millionand$422million,respectively,ofchangesinthefairvalue
reflectedinnetincomeduetochangesinobservablepricesandgainsonthedisposalofinvestments.Theimpactinfiscal
year2021,wasdrivenbythegainondisposaloftheGrailinvestment.Infiscalyear2022,theCompanysoldallofits
equityinvestmentsinargenxSEforproceedsof$0.6billion.
Fairvalueistheexitpricethatwouldbereceivedtosellanassetorpaidtotransferaliability.Fairvalueisamarket-based
measurementdeterminedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliability.In
accordancewithASC820,athree-levelhierarchytoprioritizetheinputsusedinmeasuringfairvalue.Thelevelswithinthe
hierarchyaredescribedbelowwithLevel1havingthehighestpriorityandLevel3havingthelowest.
Thefairvalueofaderivativefinancialinstrument(i.e.,forwardforeignexchangecontracts,interestratecontracts)isthe
aggregationbycurrencyofallfuturecashflowsdiscountedtoitspresentvalueattheprevailingmarketinterestratesand
subsequentlyconvertedtotheU.S.Dollaratthecurrentspotforeignexchangerate.TheCompanydoesnotbelievethat
fairvaluesofthesederivativeinstrumentsmateriallydifferfromtheamountsthatcouldberealizeduponsettlementor
maturity,orthatthechangesinfairvaluewillhaveamaterialeffectontheCompany’sresultsofoperations,cashflowsor
financialposition.TheCompanyalsoholdsequityinvestmentswhichareclassifiedasLevel1anddebtsecuritieswhich
areclassifiedasLevel2.TheCompanyholdsacquisitionrelatedcontingentliabilitiesbaseduponcertainregulatoryand
commercialevents,whichareclassifiedasLevel3,whosevaluesaredeterminedusingdiscountedcashflow
methodologiesorsimilartechniquesforwhichthedeterminationoffairvaluerequiressignificantjudgmentorestimations.
Thefollowingthreelevelsofinputsareusedtomeasurefairvalue:
Level1—Quotedpricesinactivemarketsforidenticalassetsandliabilities.
Level2—Significantotherobservableinputs.
Level3—Significantunobservableinputs.
TheCompany’ssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofthefiscalyearendedJanuary1,2023
andJanuary2,2022wereasfollows:
2022 2021
(DollarsinMillions) Level1 Level2 Level3 Total Total(1)
Derivativesdesignatedashedginginstruments:
Assets:
Forwardforeignexchangecontracts $ — 629 — 629 540
Interestratecontracts(2) — 1,534 — 1,534 796
Total $ — 2,163 — 2,163 1,336
Liabilities:
Forwardforeignexchangecontracts — 511 — 511 881
Interestratecontracts(2) — 2,778 — 2,778 979
Total $ — 3,289 — 3,289 1,860
Derivativesnotdesignatedashedginginstruments:
Assets:
Forwardforeignexchangecontracts $ — 38 — 38 24
Liabilities:
Forwardforeignexchangecontracts — 68 — 68 28
AvailableForSaleOtherInvestments:
Equityinvestments(3) 576 — — 576 1,884
Debtsecurities(4) — 10,487 — 10,487 19,727
OtherLiabilities
ContingentConsideration(5) $ 1,120 1,120 533
Johnson&Johnson2022AnnualReport • 59GrosstoNetDerivativeReconciliation
(DollarsinMillions) 2022 2021
TotalGrossAssets $2,201 1,360
CreditSupportAgreement(CSA) (2,176) (1,285)
TotalNetAsset 25 75
TotalGrossLiabilities 3,357 1,888
CreditSupportAgreement(CSA) (3,023) (1,855)
TotalNetLiabilities $334 33
Summarizedinformationaboutchangesinliabilitiesforcontingentconsiderationisasfollows:
(DollarsinMillions) 2022 2021 2020
BeginningBalance $533 633 1,715
Changesinestimatedfairvalue(6) (194) (52) (1,089)
Additions(7) 792 — 106
Payments (11) (48) (99)
EndingBalance $1,120 533 633
(1) 2021assetsandliabilitiesareallclassifiedasLevel2withtheexceptionofequityinvestmentsof$1,884million,whichareclassified
asLevel1andcontingentconsiderationof$533million,classifiedasLevel3.
(2) Includescrosscurrencyinterestrateswapsandinterestrateswaps.
(3) Classifiedasnon-currentotherassets.
(4) Classifiedascashequivalentsandcurrentmarketablesecurities.
(5) Includes$1,116million,$520millionand$594million,classifiedasnon-currentotherliabilitiesasofJanuary1,2023,January2,
2022andJanuary3,2021,respectively.Includes$4million,$13millionand$39millionclassifiedascurrentliabilitiesasof
January1,2023,January2,2022andJanuary3,2021,respectively.
(6) OngoingfairvalueadjustmentamountsarerecordedprimarilyinResearchandDevelopmentexpense.TheCompanyrecordeda
contingentconsiderationreversalof$1,148millionin2020relatedtothetimingofcertaindevelopmentalmilestonesassociatedwith
theAurisHealthacquisition.ThereversalofthecontingentconsiderationwasrecordedinOtherincomeandexpense.
(7) Infiscalyear2022,theCompanyrecorded$704millionofcontingentconsiderationrelatedtoAbiomed.
SeeNotes2and7forfinancialassetsandliabilitiesheldatcarryingamountontheConsolidatedBalanceSheet.
60 • Johnson&Johnson2022AnnualReport7. Borrowings
Thecomponentsoflong-termdebtareasfollows:
Effective Effective
(DollarsinMillions) 2022 Rate% 2021 Rate%
0.250%Notesdue2022(1BEuro1.1311)(3) $— —% $1,131(3) 0.26%
2.25%Notesdue2022 — — 1,000 2.31
6.73%Debenturesdue2023 250 6.73 250 6.73
3.375%Notesdue2023 801 3.17 802 3.18
2.05%Notesdue2023 500 2.09 499 2.09
0.650%Notesdue2024(750MMEuro1.0651)(2)/(750MMEuro1.1311)(3) 792(2) 0.68 847(3) 0.68
5.50%Notesdue2024(500MM1.2037GBP)(2)/(500MMGBP1.3485)(3) 600(2) 6.75 672(3) 6.75
2.625%Notesdue2025 749 2.63 749 2.63
0.55%Notesdue2025 918 0.57 983 0.57
2.45%Notesdue2026 1,996 2.47 1,995 2.47
2.95%Notesdue2027 877 2.96 978 2.96
0.95%Notesdue2027 1,394 0.96 1,478 0.96
1.150%Notesdue2028(750MMEuro1.0651)(2)/(750MMEuro1.1311)(3) 794(2) 1.21 843(3) 1.21
2.90%Notesdue2028 1,496 2.91 1,495 2.91
6.95%Notesdue2029 298 7.14 298 7.14
1.30%Notesdue2030 1,607 1.30 1,723 1.30
4.95%Debenturesdue2033 498 4.95 498 4.95
4.375%Notesdue2033 854 4.24 854 4.24
1.650%Notesdue2035(1.5BEuro1.0651)(2)/(1.5BEuro1.1311)(3) 1,591(2) 1.68 1,683(3) 1.68
3.55%Notesdue2036 842 3.59 974 3.59
5.95%Notesdue2037 993 5.99 993 5.99
3.625%Notesdue2037 1,336 3.64 1,475 3.64
5.85%Debenturesdue2038 697 5.85 696 5.85
3.400%Notesdue2038 992 3.42 992 3.42
4.50%Debenturesdue2040 540 4.63 540 4.63
2.10%Notesdue2040 828 2.14 974 2.14
4.85%Notesdue2041 297 4.89 297 4.89
4.50%Notesdue2043 496 4.52 496 4.52
3.70%Notesdue2046 1,976 3.74 1,975 3.74
3.75%Notesdue2047 812 3.76 971 3.76
3.500%Notesdue2048 743 3.52 743 3.52
2.250%Notesdue2050 808 2.29 983 2.29
2.450%Notesdue2060 1,055 2.49 1,222 2.49
Other 9 — 7 —
Subtotal 28,439(4) 3.04%(1) 32,116(4) 2.89%(1)
Lesscurrentportion 1,551 2,131
Totallong-termdebt $26,888 $29,985
(1) Weightedaverageeffectiverate.
(2) TranslationrateatJanuary1,2023.
(3) TranslationrateatJanuary2,2022.
Johnson&Johnson2022AnnualReport • 61(4) Theexcessofthecarryingvalueoverthefairvalueofdebtwas$1.6billionattheendoffiscalyear2022andtheexcessofthefair
valueoverthecarryingvalueofdebtwas$3.2billionattheendoffiscalyear2021.
Fairvalueofthelong-termdebtwasestimatedusingmarketprices,whichwerecorroboratedbyquotedbrokerpricesand
significantotherobservableinputs.
TheCompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwide.InSeptember2022,the
Companysecuredanew364-dayCreditFacilityof$10billion,whichexpiresonSeptember7,2023.InNovember2022,
theCompanysecuredanadditional364-dayCreditFacilityof$10billion,whichexpiresonNovember21,2023.Interest
chargedonborrowingsunderthecreditlineagreementisbasedoneithertheTermSOFRReferenceRateorother
applicablemarketratesasallowedunderthetermsoftheagreement,plusapplicablemargins.Commitmentfeesunderthe
agreementsarenotmaterial.
Throughoutfiscalyears2022and2021,theCompanycontinuedtohaveaccesstoliquiditythroughthecommercialpaper
market.Short-termborrowingsandthecurrentportionoflong-termdebtamountedtoapproximately$12.8billionand
$3.8billionattheendoffiscalyears2022and2021,respectively.Thecurrentportionofthelongtermdebtwas$1.6
billionand$2.1billionin2022and2021,respectively,andtheremainderiscommercialpaperandlocalborrowingby
internationalsubsidiaries.
ThecurrentdebtbalanceasofJanuary1,2023includes$11.2billionofcommercialpaperwhichhasaweightedaverage
interestrateof4.23%andaweightedaveragematurityofapproximatelytwomonths.
Aggregatematuritiesoflong-termdebtobligationscommencingin2023are:
(DollarsinMillions)
2023 2024 2025 2026 2027 After2027
$1,551 1,392 1,667 1,996 2,271 19,562
8. Income Taxes
Theprovisionfortaxesonincomeconsistsof:
(DollarsinMillions) 2022 2021 2020
Currentlypayable:
U.S.taxes $2,378 1,525 1,026
Internationaltaxes 3,069 2,452 1,898
Totalcurrentlypayable 5,447 3,977 2,924
Deferred:
U.S.taxes (2,081) 583 (76)
Internationaltaxes 418 (2,662) (1,065)
Totaldeferred (1,663) (2,079) (1,141)
Provisionfortaxesonincome $3,784 1,898 1,783
62 • Johnson&Johnson2022AnnualReportAcomparisonofincometaxexpenseattheU.S.statutoryrateof21%infiscalyears2022,2021and2020,tothe
Company’seffectivetaxrateisasfollows:
(DollarsinMillions) 2022 2021 2020
U.S. $5,369 6,110 4,312
International 16,356 16,666 12,185
Earningsbeforetaxesonincome: $21,725 22,776 16,497
Taxrates:
U.S.statutoryrate 21.0% 21.0 21.0
Internationaloperations(1) (4.5) (16.4) (9.9)
Consumerhealthseparation 2.2 — —
U.S.taxesoninternationalincome(2) (1.9) 6.7 2.7
Taxbenefitsfromlossoncapitalassets — (1.3) (1.2)
Taxbenefitsonshare-basedcompensation (1.3) (1.0) (1.5)
Allother(3) 1.9 (0.7) (0.3)
EffectiveRate 17.4% 8.3 10.8
(1) ForallperiodspresentedtheCompanyhassubsidiariesoperatinginPuertoRicoundervarioustaxincentives.International
operationsreflecttheimpactsofoperationsinjurisdictionswithstatutorytaxratesdifferentthantheU.S.,particularlyIreland,
SwitzerlandandPuertoRico,whichisafavorableimpactontheeffectivetaxrateascomparedwiththeU.S.statutoryrate.The2021
amountsincludethereorganizationofinternationalsubsidiaries;the2020amountsincludetheimpactofthenewtaxlegislation
enactmentinSwitzerland,bothofwhicharefurtherdescribedbelow.
(2) IncludestheimpactoftheGILTItax,theForeign-DerivedIntangibleIncomedeductionandotherforeignincomethatistaxableunder
theU.S.taxcode.The2022amountincludestheimpactofcertainprovisionsofthe2017TCJAthatbecameeffectiveinfiscal2022.
The2021amountsincludethereorganizationofinternationalsubsidiaries;the2020amountsincludetheimpactofthenewtax
legislationenactmentinSwitzerland,bothofwhicharefurtherdescribedbelow.
(3) Certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation.
Thefiscalyear2022effectivetaxrateincreased9.1%ascomparedtothefiscalyear2021effectivetaxrate.Aspartofthe
plannedseparationoftheCompany’sConsumerHealthbusiness,theCompanyhasrecognizedapproximately$0.5billion
innetincrementaltaxcostsinfiscalyear2022,whichincreasedthe2022effectivetaxratebyapproximately2.2%.
Additionally,theCompanyrecordedcertainnon-recurringfavorabletaxitemsinfiscalyear2021whichresultedinan
unfavorableimpacttotheCompany’sfiscal2022effectivetaxratewhencomparedtothepriorfiscalyear.Theseitemsare
describedbelow.TheCompany’s2022taxratealsobenefitedfromcertainprovisionsoftheTaxCutsandJobsActof
2017thatbecameeffectiveinfiscal2022,theimpairmentofbermekimabforADandHSIPR&D(forfurtherinformation
seeNote5ofthe202210-KConsolidatedFinancialStatements)andchangesinthefairvalueofsecuritiesinthe
Company’sinvestmentportfolio,bothrecordedattheU.S.statutoryrate.
Thefiscalyear2021taxratedecreasedby2.5%comparedtothefiscalyear2020taxrate,whichwasprimarilydrivenby
thefollowingitems.Infiscalyear2021,theCompanyreorganizedtheownershipstructureofcertainwholly-owned
internationalsubsidiaries.Aspartofthisreorganization,theCompanyincreasedthetaxbasisofcertainassetstofairvalue
inaccordancewithapplicablelocalregulations.Thenetimpactofthisrestructuringwasapproximately$0.6billionnet
benefitor2.7%benefittotheCompany’sannualeffectivetaxrate,comprisedofthefollowingitems:
• approximately$2.3billionoflocaldeferredtaxassetstorecordtheremeasurementofthetaxbasisoftheseassetsto
fairvalue,thisbenefithasbeenreflectedas“InternationalOperations”ontheCompany’seffectivetaxratereconciliation.
• approximately$1.7billionofU.S.deferredtaxexpenserelatingtotheGILTIdeferredtaxliabilityresultingfromthe
remeasurementofthesedeferredtaxassets.Thisexpensehasbeenreflectedas“U.S.taxoninternationalincome”on
theCompany’seffectivetaxratereconciliation.
Also,inthefiscalfourthquarterof2021,theCompanyrecognizedalossoncertainU.S.affiliatesrelatedtothepreviously
impairedbookvalueofcertainintangibles,whichreducedthe2021taxratebyapproximately1.3%whichisreflectedasa
Johnson&Johnson2022AnnualReport • 63“Taxbenefitsfromlossoncapitalassets”ontheeffectivetaxratereconciliation.Additionallyotherfiscal2021impactsto
theratewereprimarilydrivenbylitigationandacquisitionrelateditemsasfollows:
• theCompanyaccruedadditionallegalexpenses,ofapproximately$1.6billionfortalcataneffectivetaxrateof23.5%
and$0.8billionforRisperdalGynecomastiasettlementsataneffectivetaxrateof16.4%(SeeNote19tothe
ConsolidatedFinancialStatementsformoredetails).
• theCompanyrecordedapartialIPR&Dchargeof$0.9billionfortheOttavaintangibleasset(acquiredwiththeAuris
Healthacquisitionin2019)ataneffectiverateof22.4%.
Infiscalyear2019,SwitzerlandenactedtheFederalActonTaxReformandAHVFinancing(TRAF)andbecameeffective
forfiscalyear2020.TheFederaltransitionalprovisionsofTRAFallowcompanies,undercertainconditions,toadjustthe
taxbasisincertainassetstofairvalue(i.e.,“step-up”)tobedepreciatedandamortizedresultinginanincrementalSwiss
taxdeductionoverthetransitionalperiod.
TRAFalsoprovidesforparameterswhichenabletheSwisscantonstoestablishlocalizedtaxratesandregulationsfor
companies.Thenewcantonaltaxparametersincludefavorabletaxbenefitsforpatentsandadditionalresearchand
developmenttaxdeductions.ThecantonaltransitionalprovisionsofTRAFallowedcompaniestoelecteither1)taxbasis
step-upsimilartotheFederaltransitionbenefitor2)alternativestatutorytaxrateforaperiodnottoexceed5years.The
CompanyhasoperationslocatedinvariousSwisscantons.
Duringthefiscalyear2020,thefinalcantonwheretheCompanymaintainssignificantoperationsenactedTRAF
legislation.Additionally,theCompanyreceivedrulingsfromtheSwissFederalandcantonaltaxauthoritiesintheremaining
jurisdictionswhereithassignificantoperations.TheserulingsresultedintheCompanyrevisingitsestimateonthetax
basisadjustment(i.e.,“step-up”)foritsassetsandasaresult,theCompanyrecordedadditionaldeferredtaxbenefitsin
2020.TheCompanyrecognizedanetbenefitinthefiscalyear2020forSwissTaxReformofapproximately$0.4billionor
2.6%benefittotheCompany’sannualeffectivetaxrate,comprisedofthefollowingitems:
• approximately$0.3billiontaxbenefitrelatingtotheremeasurementofSwissdeferredtaxassetsandliabilitiesforthe
changeintheFederalandcantonaltaxrates,whereenactmentoccurredinthefiscalyear2020;thisbenefithasbeen
reflectedas“InternationalOperations”ontheCompany’seffectivetaxratereconciliation.
• a$450milliondeferredtaxassetrelatedtotheestimatedvalueofaFederaltaxbasisstep-upoftheCompany’sSwiss
subsidiaries’assetsasdescribedabove;thisbenefithasbeenreflectedas“InternationalOperations”ontheCompany’s
effectivetaxratereconciliation.
• approximately$0.3billionofU.S.deferredtaxexpenserelatingtotheGILTIdeferredtaxliabilityresultingfromthe
remeasurementoftheSwissdeferredtaxassetsandliabilitiesinthefiscalyear2020.Thisbenefithasbeenreflectedas
“U.S.taxoninternationalincome”ontheCompany’seffectivetaxratereconciliation.
TheCompanydoesnotexpecttoreceivefuturerulingsregardingthetransitionalprovisionsofTRAF.
Also,inthefiscalyear2020,theCompanyrecognizedacapitallossoncertainU.S.affiliatesrelatedtothepreviously
impairedbookvalueofcertainintangibles,whichreducedthe2020taxratebyapproximately1.2%whichisreflectedasa
“Taxbenefitsfromlossoncapitalassets”ontheeffectivetaxratereconciliation.Inaddition,inthefiscalyear2020,the
Companyhadlowerincomeinhighertaxjurisdictions,primarilydrivenby:
• theimpactoftheaccrualoflitigationcostsrelatedtotalcfor$4.0billionwhichreducedtheU.S.earningsbeforetaxes
ataneffectivetaxrateof23.5%;
• theaccrualofadditionallegalcosts,includinganadditional$1.0billionassociatedwitharevisedagreementinprinciple
tosettleopioidlitigationataneffectivetaxrateof21.4%
TheCompanyalsoreducedthecontingentconsiderationliabilityrelatedtotheAurisHealthacquisitionin2019and
reversedsomeofitsunrecognizedtaxbenefitsduetothecompletionofseveralyearsoftaxexaminationsincertain
jurisdictionsduringthefiscalyear2020.
64 • Johnson&Johnson2022AnnualReportTemporarydifferencesandcarryforwardsattheendoffiscalyears2022and2021wereasfollows:
2022 2021
DeferredTax DeferredTax(1)
(DollarsinMillions) Asset Liability Asset Liability
Employeerelatedobligations $725 1,244
Stockbasedcompensation 687 679
Depreciationofproperty,plantandequipment (858) (876)
Goodwillandintangibles (4,271)(3) (2,659)(2)
R&Dcapitalizedfortax 2,611 1,664
Reserves&liabilities 2,761 2,882
Incomereportedfortaxpurposes 2,045 2,566
Netrealizableoperatinglosscarryforwards(4) 1,260 1,720
Undistributedforeignearnings 1,565 (1,693) 1,015 (1,461)
Globalintangiblelow-taxedincome (3,547) (4,853)
Miscellaneousinternational 1,053 (65) 870 (39)
MiscellaneousU.S. 476 (16)
Totaldeferredincometaxes $13,183 (10,434) 12,640 (9,904)
(1) Certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation.
(2) Amountisinclusiveofthe$2.3billiondeferredtaxassetestablishedaspartofthereorganizedownershipstructureof
certainwholly-ownedinternationalsubsidiaries,aspreviouslydescribed.
(3) Amountisinclusiveofthe$1.8billiondeferredtaxliabilityduetotheacquisitionofAbiomed.
(4) Netofvaluationallowancesof$0.9billioninboth2022and2021.
TheCompanyhaswholly-ownedinternationalsubsidiariesthathavecumulativenetlosses.TheCompanybelievesthatitis
morelikelythannotthatthesesubsidiarieswillgeneratefuturetaxableincomesufficienttoutilizethesedeferredtaxassets.
However,incertainjurisdictions,valuationallowanceshavebeenrecordedagainstdeferredtaxassetsforloss
carryforwardsthatarenotmorelikelythannottoberealized.
Thefollowingtablesummarizestheactivityrelatedtounrecognizedtaxbenefits:
(DollarsinMillions) 2022 2021 2020
Beginningofyear $3,323 3,373 3,853
Increasesrelatedtocurrentyeartaxpositions 523 242 265
Increasesrelatedtopriorperiodtaxpositions 143 23 668
Decreasesrelatedtopriorperiodtaxpositions (148) (128) (551)
Settlements (1) (187) (839)
Lapseofstatuteoflimitations (11) — (23)
Endofyear $3,829 3,323 3,373
Theunrecognizedtaxbenefitsof$3.8billionatJanuary1,2023,ifrecognized,wouldaffecttheCompany’sannualeffectivetax
rate.TheCompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxauditsinprogresswith
anumberoftaxauthorities.WithrespecttotheUnitedStates,theIRShascompleteditsauditforthetaxyearsthrough2012
andiscurrentlyauditingtaxyears2013through2016.Inthefiscalyear2020,theCompanymadeitsfinalpaymentsfor
approximately$0.7billiontotheU.S.Treasuryrelatedtothefinalsettlementof2010-2012taxauditliability.
InothermajorjurisdictionswheretheCompanyconductsbusiness,theyearsthatremainopentotaxauditsgobacktothe
year2008.TheCompanybelievesitispossiblethatsometaxauditsmaybecompletedoverthenexttwelvemonthsby
taxingauthoritiesinsomejurisdictions,includingintheUnitedStates.However,theCompanyisnotabletoprovidea
reasonablyreliableestimateofthetimingofanyotherfuturetaxpaymentsorchangeinuncertaintaxpositions,ifany.
TheCompanyclassifiesliabilitiesforunrecognizedtaxbenefitsandrelatedinterestandpenaltiesaslong-termliabilities.
Interestexpenseandpenaltiesrelatedtounrecognizedtaxbenefitsareclassifiedasincometaxexpense.TheCompany
Johnson&Johnson2022AnnualReport • 65recognizedaftertaxinterestexpenseof$139million,$44millionand$32millioninfiscalyears2022,2021and2020,
respectively.Thetotalamountofaccruedinterestwas$651millionand$512millioninfiscalyears2022and2021,
respectively.
9. Employee Related Obligations
Attheendoffiscal2022andfiscal2021,employeerelatedobligationsrecordedontheConsolidatedBalanceSheets
were:
(DollarsinMillions) 2022 2021
Pensionbenefits $2,698 4,088
Postretirementbenefits 1,734 2,069
Postemploymentbenefits 2,832 3,117
Deferredcompensation 100 181
Totalemployeeobligations 7,364 9,455
Lesscurrentbenefitspayable 597 557
Employeerelatedobligations—non-current $6,767 8,898
Prepaidemployeerelatedobligationsof$4,581millionand$4,436millionfor2022and2021,respectively,areincluded
inOtherassetsontheConsolidatedBalanceSheets.
10. Pensions and Other Benefit Plans
TheCompanysponsorsvariousretirementandpensionplans,includingdefinedbenefit,definedcontributionand
terminationindemnityplans,whichcovermostemployeesworldwide.TheCompanyalsoprovidespost-retirement
benefits,primarilyhealthcare,toalleligibleU.S.retiredemployeesandtheirdependents.
Manyinternationalemployeesarecoveredbygovernment-sponsoredprogramsandthecosttotheCompanyisnot
significant.
IntheU.S,non-unionpensionbenefitsforemployeeshiredbeforeJanuary1,2015areprimarilybasedontheemployee’s
compensationduringthelastfiveyearsbeforeretirementandthenumberofyearsofservice(theFinalAveragePay
formula).U.S.pensionbenefitsforemployeeshiredafter2014,arecalculatedusingadifferentformulabasedonemployee
compensationovertotalyearsofservice(theRetirementValueformula).
InJanuary2021,theCompanyannouncedthat,effectiveonJanuary1,2026,alleligibleU.S.non-unionemployees,
regardlessofhiredate,willearnbenefitsundertheRetirementValueformula.Thisamendmentdoesnotaffectthebenefits
accruedundertheFinalAveragePayformulaforservicebeforeJanuary1,2026.
Internationalsubsidiarieshaveplansunderwhichfundsaredepositedwithtrustees,annuitiesarepurchasedundergroup
contracts,orreservesareprovided.
TheCompanydoesnotfundretireehealthcarebenefitsinadvanceandhastherighttomodifytheseplansinthefuture.
In2022and2021theCompanyusedDecember31,2022andDecember31,2021,respectively,asthemeasurement
dateforallU.S.andinternationalretirementandotherbenefitplans.
NetperiodicbenefitcostsfortheCompany’sdefinedbenefitretirementplansandotherbenefitplansfor2022,2021and
2020includethefollowingcomponents:
RetirementPlans OtherBenefitPlans
(DollarsinMillions) 2022 2021 2020 2022 2021 2020
Servicecost $1,327 1,421 1,380 320 309 287
Interestcost 911 770 955 105 81 133
Expectedreturnonplanassets (2,757) (2,645) (2,461) (8) (7) (7)
Amortizationofpriorservicecost (184) (181) 2 (5) (31) (31)
Recognizedactuariallosses(gains) 655 1,257 891 121 151 142
Curtailmentsandsettlements 1 1 23 — — —
Netperiodicbenefitcost(credit) $(47) 623 790 533 503 524
66 • Johnson&Johnson2022AnnualReportTheservicecostcomponentofnetperiodicbenefitcostispresentedinthesamelineitemsontheConsolidated
StatementofEarningswhereotheremployeecompensationcostsarereported,includingCostofproductssold,Research
anddevelopmentexpense,andSelling,marketingandadministrativeexpenses.Allothercomponentsofnetperiodic
benefitcostarepresentedaspartofOther(income)expense,netontheConsolidatedStatementofEarnings.
UnrecognizedgainsandlossesfortheU.S.pensionplansareamortizedovertheaverageremainingfutureserviceforeach
plan.Forplanswithnoactiveemployees,theyareamortizedovertheaveragelifeexpectancy.Theamortizationofgains
andlossesfortheotherU.S.benefitplansisdeterminedbyusinga10%corridorofthegreaterofthemarketvalueof
assetsortheaccumulatedpostretirementbenefitobligation.Totalunamortizedgainsandlossesinexcessofthecorridor
areamortizedovertheaverageremainingfutureservice.
Priorservicecosts/benefitsfortheU.S.pensionplansareamortizedovertheaverageremainingfutureserviceofplan
participantsatthetimeoftheplanamendment.Priorservicecost/benefitfortheotherU.S.benefitplansisamortizedover
theaverageremainingservicetofulleligibilityageofplanparticipantsatthetimeoftheplanamendment.
Thefollowingtablerepresentstheweighted-averageactuarialassumptions:
RetirementPlans OtherBenefitPlans
WorldwideBenefitPlans 2022 2021 2020 2022 2021 2020
NetPeriodicBenefitCost
Servicecostdiscountrate 2.46% 2.14 2.82 2.59 2.09 3.04
Interestcostdiscountrate 2.80% 2.34 3.13 2.64 2.33 3.08
Rateofincreaseincompensationlevels 4.02% 4.01 4.00 4.21 4.25 4.25
Expectedlong-termrateofreturnonplanassets 7.25% 7.71 8.12
BenefitObligation
Discountrate 5.01% 2.49 2.14 5.42 2.68 2.23
Rateofincreaseincompensationlevels 4.00% 4.01 4.00 4.21 4.21 4.27
TheCompany’sdiscountratesaredeterminedbyconsideringcurrentyieldcurvesrepresentinghighquality,long-term
fixedincomeinstruments.Theresultingdiscountratesareconsistentwiththedurationofplanliabilities.TheCompany’s
methodologyindeterminingserviceandinterestcostusesdurationspecificspotratesalongthatyieldcurvetotheplans’
liabilitycashflows.
TheexpectedratesofreturnonplanassetassumptionsrepresenttheCompany’sassessmentoflong-termreturnson
diversifiedinvestmentportfoliosglobally.Theassessmentisdeterminedusingprojectionsfromexternalfinancialsources,
long-termhistoricalaverages,actualreturnsbyassetclassandthevariousassetclassallocationsbymarket.
Thefollowingtabledisplaystheassumedhealthcarecosttrendrates,forallindividuals:
HealthcarePlans 2022 2021
Healthcarecosttrendrateassumedfornextyear 5.99% 5.33%
Ratetowhichthecosttrendrateisassumedtodecline(ultimatetrend) 4.01% 3.73%
Yeartheratereachestheultimatetrendrate 2047 2046
Johnson&Johnson2022AnnualReport • 67Thefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatfiscalyear-end
2022and2021fortheCompany’sdefinedbenefitretirementplansandotherpost-retirementplans:
OtherBenefit
RetirementPlans Plans
(DollarsinMillions) 2022 2021 2022 2021
ChangeinBenefitObligation
Projectedbenefitobligation—beginningofyear $41,582 43,300 4,878 5,028
Servicecost 1,327 1,421 320 309
Interestcost 911 770 105 81
Planparticipantcontributions 67 67 — —
Amendments 7 5 — —
Actuarial(gains)losses(1) (12,213) (2,132) (704) (188)
Divestitures&acquisitions — (2) — —
Curtailments,settlements&restructuring (7) (7) — —
Benefitspaidfromplan (1,228) (1,157) (393) (348)
Effectofexchangerates (815) (683) (9) (4)
Projectedbenefitobligation—endofyear $29,631 41,582 4,197 4,878
ChangeinPlanAssets
Planassetsatfairvalue—beginningofyear $41,930 38,195 102 90
Actualreturn(loss)onplanassets (8,665) 4,439 (17) 17
Companycontributions 270 969 386 343
Planparticipantcontributions 67 67 — —
Settlements (5) (7) — —
Divestitures&acquisitions — (2) — —
Benefitspaidfromplanassets (1,228) (1,157) (393) (348)
Effectofexchangerates (855) (574) — —
Planassetsatfairvalue—endofyear $31,514 41,930 78 102
Fundedstatus—endofyear $1,883 348 (4,119) (4,776)
AmountsRecognizedintheCompany’sBalanceSheetconsistofthefollowing:
Non-currentassets $4,581 4,436 — —
Currentliabilities (132) (115) (461) (438)
Non-currentliabilities (2,566) (3,973) (3,658) (4,338)
Totalrecognizedintheconsolidatedbalancesheet—endofyear $1,883 348 (4,119) (4,776)
AmountsRecognizedinAccumulatedOtherComprehensiveIncomeconsistof
thefollowing:
Netactuarialloss $3,948 5,539 239 1,113
Priorservicecost(credit)(1) (1,417) (1,610) (7) (13)
Unrecognizednettransitionobligation — — — —
Totalbeforetaxeffects $2,531 3,929 232 1,100
AccumulatedBenefitObligations—endofyear $28,023 39,049
(1) Theactuarialgainforretirementplansin2022and2021wasprimarilyrelatedtoincreasesindiscountrates.
68 • Johnson&Johnson2022AnnualReportOtherBenefit
RetirementPlans Plans
(DollarsinMillions) 2022 2021 2022 2021
AmountsRecognizedinNetPeriodicBenefitCostandOtherComprehensive
Income
Netperiodicbenefitcost(credit) $(47) 623 533 503
Netactuarial(gain)loss (793) (3,927) (751) (199)
Amortizationofnetactuarialloss (655) (1,257) (121) (151)
Priorservicecost(credit) 7 5 — —
Amortizationofpriorservice(cost)credit 183 181 5 31
Effectofexchangerates (140) (136) (1) —
Totalloss/(income)recognizedinothercomprehensiveincome,beforetax $(1,398) (5,134) (868) (319)
Totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome $(1,445) (4,511) (335) 184
TheCompanyplanstocontinuetofunditsU.S.QualifiedPlanstocomplywiththePensionProtectionActof2006.
InternationalPlansarefundedinaccordancewithlocalregulations.Additionaldiscretionarycontributionsaremadewhen
deemedappropriatetomeetthelong-termobligationsoftheplans.Forcertainplans,fundingisnotacommonpractice,as
fundingprovidesnoeconomicbenefit.Consequently,theCompanyhasseveralpensionplansthatarenotfunded.
In2022,theCompanycontributed$119millionand$151milliontoitsU.S.andinternationalpensionplans,respectively.
ThefollowingtabledisplaysthefundedstatusoftheCompany’sU.S.Qualified&Non-Qualifiedpensionplansand
internationalfundedandunfundedpensionplansatDecember31,2022andDecember31,2021,respectively:
U.S.Plans InternationalPlans
QualifiedPlans Non-QualifiedPlans FundedPlans UnfundedPlans
(DollarsinMillions) 2022 2021 2022 2021 2022 2021 2022 2021
PlanAssets $20,937 27,944 — — 10,577 13,986 — —
ProjectedBenefitObligation 18,394 25,041 1,937 2,703 9,024 13,428 276 410
AccumulatedBenefitObligation 17,696 23,985 1,872 2,479 8,202 12,212 253 373
Over(Under)FundedStatus
ProjectedBenefitObligation $2,543 2,903 (1,937) (2,703) 1,553 558 (276) (410)
AccumulatedBenefitObligation 3,241 3,959 (1,872) (2,479) 2,375 1,774 (253) (373)
Planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligation,projected
benefitobligationandplanassetsof$2.9billion,$2.9billionand$0.3billion,respectively,attheendof2022,and$3.9
billion,$4.2billionand$0.3billion,respectively,attheendof2021.
ThefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromtheCompany’sretirementandotherbenefitplans:
(DollarsinMillions) 2023 2024 2025 2026 2027 2028-2032
Projectedfuturebenefitpayments
Retirementplans $1,445 1,457 1,532 1,609 1,708 10,034
Otherbenefitplans $471 485 433 447 462 2,539
Thefollowingtabledisplaystheprojectedfutureminimumcontributionstotheunfundedretirementplans.Theseamounts
donotincludeanydiscretionarycontributionsthattheCompanymayelecttomakeinthefuture.
(DollarsinMillions) 2023 2024 2025 2026 2027 2028-2032
Projectedfuturecontributions $123 128 136 141 146 816
Johnson&Johnson2022AnnualReport • 69Eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationand
investmentofthepensionplans.Indetermininginvestmentpolicies,strategiesandgoals,eachcommitteeorboard
considersfactorsincluding,localpensionrulesandregulations;localtaxregulations;availabilityofinvestmentvehicles
(separateaccounts,commingledaccounts,insurancefunds,etc.);fundedstatusoftheplans;ratioofactivestoretirees;
durationofliabilities;andotherrelevantfactorsincluding:diversification,liquidityoflocalmarketsandliquidityofbase
currency.AmajorityoftheCompany’spensionfundsareopentonewentrantsandareexpectedtobeon-goingplans.
Permittedinvestmentsareprimarilyliquidand/orlisted,withlittlerelianceonilliquidandnon-traditionalinvestmentssuch
ashedgefunds.
TheCompany’sretirementplanassetallocationattheendof2022and2021andtargetallocationsfor2023areas
follows:
Percentof Target
PlanAssets Allocation
2022 2021 2023
WorldwideRetirementPlans
Equitysecurities 62% 65% 61%
Debtsecurities 38 35 39
Totalplanassets 100% 100% 100%
DeterminationofFairValueofPlanAssets
ThePlanhasanestablishedandwell-documentedprocessfordeterminingfairvalues.Fairvalueisbaseduponquoted
marketprices,whereavailable.Iflistedpricesorquotesarenotavailable,fairvalueisbaseduponmodelsthatprimarily
use,asinputs,market-basedorindependentlysourcedmarketparameters,includingyieldcurves,interestrates,volatilities,
equityordebtprices,foreignexchangeratesandcreditcurves.
WhilethePlanbelievesitsvaluationmethodsareappropriateandconsistentwithothermarketparticipants,theuseof
differentmethodologiesorassumptionstodeterminethefairvalueofcertainfinancialinstrumentscouldresultinadifferent
estimateoffairvalueatthereportingdate.
ValuationHierarchy
Theauthoritativeliteratureestablishesathree-levelhierarchytoprioritizetheinputsusedinmeasuringfairvalue.Thelevels
withinthehierarchyaredescribedinthetablebelowwithLevel1havingthehighestpriorityandLevel3havingthelowest.
TheNetAssetValue(NAV)isbasedonthevalueoftheunderlyingassetsownedbythefund,minusitsliabilities,andthen
dividedbythenumberofsharesoutstanding.
Afinancialinstrument’scategorizationwithinthevaluationhierarchyisbaseduponthelowestlevelofinputthatis
significanttothefairvaluemeasurement.
Followingisadescriptionofthevaluationmethodologiesusedfortheinvestmentsmeasuredatfairvalue.
• Short-terminvestmentfunds—Cashandquotedshort-terminstrumentsarevaluedattheclosingpriceortheamount
heldondepositbythecustodianbank.OtherinvestmentsarethroughinvestmentvehiclesvaluedusingtheNAV
providedbytheadministratorofthefund.TheNAVisaquotedpriceinamarketthatisnotactiveandclassifiedas
Level2.
• Governmentandagencysecurities—Alimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedon
themajormarketonwhichtheindividualsecuritiesaretraded.Wherequotedpricesareavailableinanactivemarket,
theinvestmentsareclassifiedwithinLevel1ofthevaluationhierarchy.Ifquotedmarketpricesarenotavailableforthe
specificsecurity,thenfairvaluesareestimatedbyusingpricingmodels,quotedpricesofsecuritieswithsimilar
characteristicsordiscountedcashflows.Whenquotedmarketpricesforasecurityarenotavailableinanactivemarket,
theyareclassifiedasLevel2.
• Debtinstruments—Alimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedonthemajormarket
onwhichtheindividualsecuritiesaretraded.Wherequotedpricesareavailableinanactivemarket,theinvestmentsare
classifiedasLevel1.Ifquotedmarketpricesarenotavailableforthespecificsecurity,thenfairvaluesareestimatedby
70 • Johnson&Johnson2022AnnualReportusingpricingmodels,quotedpricesofsecuritieswithsimilarcharacteristicsordiscountedcashflowsandareclassified
asLevel2.Level3debtinstrumentsarepricedbasedonunobservableinputs.
• Equitysecurities—Equitysecuritiesarevaluedattheclosingpricereportedonthemajormarketonwhichtheindividual
securitiesaretraded.SubstantiallyallequitysecuritiesareclassifiedwithinLevel1ofthevaluationhierarchy.
• Commingledfunds—TheseinvestmentvehiclesarevaluedusingtheNAVprovidedbythefundadministrator.Assetsin
theLevel2categoryhaveaquotedmarketprice.
• Otherassets—Otherassetsarerepresentedprimarilybylimitedpartnerships.Theseinvestmentvehiclesarevalued
usingtheNAVprovidedbythefundadministrator.Otherassetsthatareexchangelistedandactivelytradedare
classifiedasLevel1,whileinactivelytradedassetsareclassifiedasLevel2.
ThefollowingtablesetsforththeRetirementPlans’investmentsmeasuredatfairvalueasofDecember31,2022and
December31,2021:
QuotedPrices Significant
inActive Other Significant Investments
Marketsfor Observable Unobservable Measuredat
IdenticalAssets Inputs Inputs(1) NetAsset
(Level1) (Level2) (Level3) Value TotalAssets
(DollarsinMillions) 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021
Short-terminvestmentfunds $33 102 13 1,033 — — — — 46 1,135
Governmentandagencysecurities — — 5,863 7,016 — — — — 5,863 7,016
Debtinstruments — — 3,681 3,505 — — — — 3,681 3,505
Equitysecurities 8,846 14,107 2 2 — — — — 8,848 14,109
Commingledfunds — — 4,362 5,496 56 105 6,106 8,708 10,524 14,309
Otherassets — — 33 34 13 15 2,506 1,807 2,552 1,856
Investmentsatfairvalue $8,879 14,209 13,954 17,086 69 120 8,612 10,515 31,514 41,930
(1) TheactivityfortheLevel3assetsisnotsignificantforallyearspresented.
TheCompany’sOtherBenefitPlansareunfundedexceptforU.S.commingledfunds(Level2)of$78millionand$102
millionatDecember31,2022andDecember31,2021,respectively.
ThefairvalueofJohnson&JohnsonCommonStockdirectlyheldinplanassetswas$21million(0.1%oftotalplan
assets)atDecember31,2022and$385million(0.9%oftotalplanassets)atDecember31,2021.
11. Savings Plan
TheCompanyhasvoluntary401(k)savingsplansdesignedtoenhancetheexistingretirementprogramscoveringeligible
employees.TheCompanymatchesapercentageofeachemployee’scontributionsconsistentwiththeprovisionsofthe
planforwhichhe/sheiseligible.TotalCompanymatchingcontributionstotheplanswere$275million,$256millionand
$243millioninfiscalyears2022,2021and2020,respectively.
Johnson&Johnson2022AnnualReport • 7112. Capital and Treasury Stock
Changesintreasurystockwere:
TreasuryStock
(AmountsinMillionsExceptTreasuryStockSharesinThousands) Shares Amount
BalanceatDecember29,2019 487,336 $38,417
Employeecompensationandstockoptionplans (21,765) (3,148)
Repurchaseofcommonstock 21,760 3,221
BalanceatJanuary3,2021 487,331 38,490
Employeecompensationandstockoptionplans (17,399) (2,847)
Repurchaseofcommonstock 20,946 3,456
BalanceatJanuary2,2022 490,878 39,099
Employeecompensationandstockoptionplans (20,007) (3,440)
Repurchaseofcommonstock 35,375 6,035
BalanceatJanuary1,2023 506,246 $41,694
Aggregatesharesofcommonstockissuedwereapproximately3,119,843,000sharesattheendoffiscalyears2022,
2021and2020.
Cashdividendspaidwere$4.45pershareinfiscalyear2022,comparedwithdividendsof$4.19pershareinfiscalyear
2021,and$3.98pershareinfiscalyear2020.
OnJanuary3,2023,theBoardofDirectorsdeclaredaregularcashdividendof$1.13pershare,payableonMarch7,
2023toshareholdersofrecordasofFebruary21,2023.
OnSeptember14,2022,theCompanyannouncedthatitsBoardofDirectorsapprovedasharerepurchaseprogram,
authorizingtheCompanytopurchaseupto$5.0billionoftheCompany’ssharesofcommonstock.Sharerepurchases
maybemadeatmanagement’sdiscretionfromtimetotimeontheopenmarketorthroughprivatelynegotiated
transactions.Therepurchaseprogramhasnotimelimitandmaybesuspendedforperiodsordiscontinuedatanytime.
ThroughJanuary1,2023,approximately$2.5billionhasbeenrepurchasedundertheprogram.
13. Accumulated Other Comprehensive Income (Loss)
Componentsofothercomprehensiveincome(loss)consistofthefollowing:
Total
Gain/(Loss) Accumulated
Foreign Gain/(Loss) Employee On Other
Currency On Benefit Derivatives Comprehensive
(DollarsinMillions) Translation Securities Plans &Hedges Income(Loss)
December29,2019 $(8,705) — (6,891) (295) (15,891)
Net2020changes (233) 1 (66) 947 649
January3,2021 (8,938) 1 (6,957) 652 (15,242)
Net2021changes (1,079) (4) 4,255 (988) 2,184
January2,2022 (10,017) (3) (2,702) (336) (13,058)
Net2022changes (1,796) (24) 1,805 106 91
January1,2023 $(11,813) (27) (897) (230) (12,967)
Amountsinaccumulatedothercomprehensiveincomearepresentednetoftherelatedtaximpact.Foreigncurrency
translationisnotadjustedforincometaxeswhereitrelatestopermanentinvestmentsininternationalsubsidiaries.For
additionaldetailsoncomprehensiveincomeseetheConsolidatedStatementsofComprehensiveIncome.
DetailsonreclassificationsoutofAccumulatedOtherComprehensiveIncome:
Gain/(Loss)OnSecurities—reclassificationsreleasedtoOther(income)expense,net.
72 • Johnson&Johnson2022AnnualReportEmployeeBenefitPlans—reclassificationsareincludedinnetperiodicbenefitcost.SeeNote10foradditionaldetails.
Gain/(Loss)OnDerivatives&Hedges-reclassificationstoearningsarerecordedinthesameaccountasthehedged
transaction.SeeNote6foradditionaldetails.
14. International Currency Translation
Fortranslationofitssubsidiariesoperatinginnon-U.S.Dollarcurrencies,theCompanyhasdeterminedthatthelocal
currenciesofitsinternationalsubsidiariesarethefunctionalcurrenciesexceptthoseinhighlyinflationaryeconomies,which
aredefinedasthosewhichhavehadcompoundcumulativeratesofinflationof100%ormoreduringthepastthreeyears,
orwhereasubstantialportionofitscashflowsarenotinthelocalcurrency.ForthemajorityoftheCompany’ssubsidiaries
thelocalcurrencyisthefunctionalcurrency.
Inconsolidatinginternationalsubsidiaries,balancesheetcurrencyeffectsarerecordedasacomponentofaccumulated
othercomprehensiveincome.Theothercurrentandnon-currentassetslinewithintheStatementofCashflowsincludes
theimpactofforeigncurrencytranslation.Thisequityaccountincludestheresultsoftranslatingcertainbalancesheet
assetsandliabilitiesatcurrentexchangeratesandsomeaccountsathistoricalrates,exceptforthoselocatedinhighly
inflationaryeconomies,(ArgentinaandVenezuela).Beginninginthefiscalsecondquarterof2022,theCompanyalso
accountedforoperationsinTurkeyashighlyinflationary.Thetranslationofbalancesheetaccountsforhighlyinflationary
economiesarereflectedintheoperatingresults.
Arollforwardofthechangesduringfiscalyears2022,2021and2020forforeigncurrencytranslationadjustmentsis
includedinNote13.
NetcurrencytransactiongainsandlossesincludedinOther(income)expensewerelossesof$328million,$236million
and$209millioninfiscalyears2022,2021and2020,respectively.
15. Earnings Per Share
Thefollowingisareconciliationofbasicnetearningspersharetodilutednetearningspershareforthefiscalyearsended
January1,2023,January2,2022andJanuary3,2021:
(InMillionsExceptPerShareAmounts) 2022 2021 2020
Basicnetearningspershare $6.83 7.93 5.59
Averagesharesoutstanding—basic 2,625.2 2,632.1 2,632.8
Potentialsharesexercisableunderstockoptionplans 140.1 138.0 118.3
Less:sharesrepurchasedundertreasurystockmethod (101.4) (96.1) (80.4)
Adjustedaveragesharesoutstanding—diluted 2,663.9 2,674.0 2,670.7
Dilutednetearningspershare $6.73 7.81 5.51
Thedilutednetearningspersharecalculationforthefiscalyears2022and2021includedallsharesrelatedtostock
options,astheexercisepriceoftheseoptionswaslessthantheaveragemarketvalueoftheCompany’sstock.
Thedilutednetearningspersharecalculationforfiscalyear2020excluded18millionsharesrelatedtostockoptions,as
theexercisepriceoftheseoptionswasgreaterthantheaveragemarketvalueoftheCompany’sstock.
16. Common Stock, Stock Option Plans and Stock Compensation Agreements
AtJanuary1,2023,theCompanyhadonestock-basedcompensationplan.Thesharesoutstandingareforcontracts
undertheCompany’s2012Long-TermIncentivePlanandthe2022Long-TermIncentivePlan.The2012Long-Term
IncentivePlanexpiredonApril26,2022.Allawards(stockoptions,restrictedsharesunitsandperformanceshareunits)
grantedsubsequenttothatdatewereunderthe2022Long-TermIncentivePlan.Underthe2022Long-TermIncentive
Plan,theCompanymayissueupto150millionsharesofcommonstock,ofwhichupto110millionsharesofcommon
stockmaybeissuedsubjecttostockoptionsorstockappreciationrightsandupto40millionsharesofcommonstock
maybeissuedsubjecttofullvalueawards.Awardswillgenerallybecountedona1-for-1basisagainstthesharereserve,
providedthatifmorethan40millionfullvalueawardsaregranted,eachfullvalueawardinexcessof40millionwillbe
countedona5-for-1basisagainstthesharereserve.Sharesavailableforfuturegrantsunderthe2022Long-Term
IncentivePlanwere150millionattheendoffiscalyear2022.
Johnson&Johnson2022AnnualReport • 73Thecompensationcostthathasbeenchargedagainstincomefortheseplanswas$1,138million,$1,135millionand
$1,005millionforfiscalyears2022,2021and2020,respectively.Thetotalincometaxbenefitrecognizedintheincome
statementforshare-basedcompensationcostswas$196million,$218millionand$210millionforfiscalyears2022,
2021and2020,respectively.TheCompanyalsorecognizedadditionalincometaxbenefitsof$282million,$223million
and$248millionforfiscalyears2022,2021and2020,respectively,forwhichoptionswereexercisedorrestrictedshares
werevested.Thetotalunrecognizedcompensationcostwas$939million,$862millionand$804millionforfiscalyears
2022,2021and2020,respectively.Theweightedaverageperiodforthiscosttoberecognizedwas1.80years,
1.78yearsand1.76yearsforfiscalyears2022,2021,and2020,respectively.Share-basedcompensationcosts
capitalizedaspartofinventorywereinsignificantinallperiods.
TheCompanysettlesemployeebenefitequityissuanceswithtreasuryshares.Treasurysharesarereplenishedthrough
marketpurchasesthroughouttheyearforthenumberofsharesusedtosettleemployeebenefitequityissuances.
StockOptions
Stockoptionsexpire10yearsfromthedateofgrantandvestoverserviceperiodsthatrangefrom6monthsto4years.All
optionsaregrantedattheaverageofthehighandlowpricesoftheCompany’sCommonStockontheNewYorkStock
Exchangeonthedateofgrant.
ThefairvalueofeachoptionawardwasestimatedonthedateofgrantusingtheBlack-Scholesoptionvaluationmodel
thatusestheassumptionsnotedinthefollowingtable.For2022,2021,and2020grants,expectedvolatilityrepresentsa
blendedrateof10-yearweeklyhistoricaloverallvolatilityrate,anda5-weekaverageimpliedvolatilityratebasedonat-the-
moneytradedJohnson&Johnsonoptionswithalifeof2years.Forallgrants,historicaldataisusedtodeterminethe
expectedlifeoftheoption.Therisk-freeratewasbasedontheU.S.Treasuryyieldcurveineffectatthetimeofgrant.
Theaveragefairvalueofoptionsgrantedwas$23.23,$20.86and$16.42,infiscalyears2022,2021and2020,
respectively.Thefairvaluewasestimatedbasedontheweightedaverageassumptionsof:
2022 2021 2020
Risk-freerate 1.98% 0.83% 1.47%
Expectedvolatility 18.00% 18.59% 15.33%
Expectedlife(inyears) 7.0 7.0 7.0
Expecteddividendyield 2.70% 2.50% 2.60%
AsummaryofoptionactivityunderthePlanasofJanuary1,2023,January2,2022andJanuary3,2021,andchanges
duringtheyearsendingonthosedatesispresentedbelow:
Aggregate
Intrinsic
Weighted Value
Outstanding Average (Dollarsin
(SharesinThousands) Shares ExercisePrice Millions)
SharesatDecember29,2019 111,637 $105.63 $4,478
Optionsgranted 20,723 151.41
Optionsexercised (16,275) 86.05
Optionscanceled/forfeited (1,835) 137.62
SharesatJanuary3,2021 114,250 116.22 4,703
Optionsgranted 18,525 164.62
Optionsexercised (13,248) 97.48
Optionscanceled/forfeited (2,166) 149.75
SharesatJanuary2,2022 117,361 125.36 5,364
Optionsgranted 19,809 165.89
Optionsexercised (16,310) 100.15
Optionscanceled/forfeited (2,188) 160.56
SharesatJanuary1,2023 118,672 $134.95 $4,949
74 • Johnson&Johnson2022AnnualReportThetotalintrinsicvalueofoptionsexercisedwas$1,228million,$919millionand$1,021millioninfiscalyears2022,
2021and2020,respectively.
ThefollowingtablesummarizesstockoptionsoutstandingandexercisableatJanuary1,2023:
(SharesinThousands) Outstanding Exercisable
Weighted Weighted
Average Average
Average Exercise Exercise
ExercisePriceRange Options Life(1) Price Options Price
$72.54-$100.48 17,221 1.5 $93.07 17,221 $93.07
$101.87-$115.67 22,039 3.6 $108.78 22,039 $108.78
$129.51-$141.06 24,870 5.7 $130.88 24,228 $130.85
$151.41-$164.62 35,465 7.6 $157.75 150 $156.21
$164.63-$165.89 19,077 9.1 $165.89 23 $165.89
118,672 5.8 $134.95 63,661 $113.06
(1) Averagecontractualliferemaininginyears.
StockoptionsoutstandingatJanuary2,2022andJanuary3,2021were117,361andanaveragelifeof5.8yearsand
114,250andanaveragelifeof6.0years,respectively.StockoptionsexercisableatJanuary2,2022andJanuary3,2021
were62,742atanaveragepriceof$104.42and61,289atanaveragepriceof$96.97,respectively.
RestrictedShareUnitsandPerformance ShareUnits
TheCompanygrantsrestrictedshareunitswhichvestoverserviceperiodsthatrangefrom6monthsto3years.The
Companyalsograntsperformanceshareunits,whicharepaidinsharesofJohnson&JohnsonCommonStockafterthe
endofathree-yearperformanceperiod.Performancesharesweregrantedwithtwoequally-weightedgoalsthatdirectly
alignwithorhelpdrivelong-termtotalshareholderreturn:adjustedoperationalearningspershareandrelativetotal
shareholderreturn.Thenumberofsharesactuallyearnedattheendofthethree-yearperiodwillvary,basedonlyonactual
performance,from0%to200%ofthetargetnumberofperformanceshareunitsgranted.
AsummaryoftherestrictedshareunitsandperformanceshareunitsactivityunderthePlansasofJanuary1,2023is
presentedbelow:
Outstanding Outstanding
Restricted Performance
(SharesinThousands) ShareUnits ShareUnits
SharesatJanuary2,2022 14,122 2,312
Granted 5,154 753
Issued (4,866) (637)
Canceled/forfeited/adjusted (794) (71)
SharesatJanuary1,2023 13,616 2,357
Theaveragefairvalueoftherestrictedshareunitsgrantedwas$153.67,$152.62and$139.58infiscalyears2022,
2021and2020,respectively,usingthefairmarketvalueatthedateofgrant.Thefairvalueofrestrictedshareunitswas
discountedfordividends,whicharenotpaidontherestrictedshareunitsduringthevestingperiod.Thefairvalueof
restrictedshareunitsissuedwas$591million,$611millionand$650millionin2022,2021and2020,respectively.
Theweightedaveragefairvalueoftheperformanceshareunitsgrantedwas$170.46,$179.35and$160.54infiscal
years2022,2021and2020,calculatedusingtheweightedaveragefairmarketvalueforeachofthecomponentgoalsat
thedateofgrant.
Thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedonthedateof
grantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividends,whicharenotpaidonthe
performanceshareunitsduringthevestingperiod.Thefairvaluefortherelativetotalshareholderreturngoalofeach
performanceshareunitwasestimatedonthedateofgrantusingtheMonteCarlovaluationmodel.Thefairvalueof
performanceshareunitsissuedwas$94million,$83millionand$91millioninfiscalyears2022,2021and2020,
respectively.
Johnson&Johnson2022AnnualReport • 7517. Segments of Business* and Geographic Areas
SalestoCustomers %Change
(DollarsinMillions) 2022 2021 2020 ’22vs.’21 ’21vs.’20
CONSUMERHEALTH(1)
OTC
U.S. $2,782 2,594 2,460 7.3% 5.4
International 3,249 3,034 2,761 7.1 9.9
Worldwide 6,031 5,627 5,221 7.2 7.8
SkinHealth/Beauty
U.S. 2,337 2,400 2,350 (2.6) 2.1
International 2,015 2,141 2,100 (5.9) 1.9
Worldwide 4,352 4,541 4,450 (4.2) 2.0
OralCare
U.S. 635 637 683 (0.3) (6.7)
International 871 1,008 958 (13.6) 5.1
Worldwide 1,505 1,645 1,641 (8.5) 0.2
BabyCare
U.S. 357 378 376 (5.5) 0.5
International 1,104 1,188 1,141 (7.1) 4.1
Worldwide 1,461 1,566 1,517 (6.7) 3.2
Women’sHealth
U.S. 13 13 13 1.7 (1.6)
International 891 905 888 (1.5) 1.8
Worldwide 904 917 901 (1.5) 1.8
WoundCare/Other
U.S. 475 495 480 (4.0) 3.1
International 224 243 240 (8.0) 1.7
Worldwide 700 739 720 (5.3) 2.6
TOTALCONSUMERHEALTH
U.S. 6,599 6,516 6,362 1.3 2.4
International 8,354 8,519 8,088 (1.9) 5.3
Worldwide 14,953 15,035 14,450 (0.5) 4.0
76 • Johnson&Johnson2022AnnualReportSalestoCustomers %Change
(DollarsinMillions) 2022 2021 2020 ’22vs.’21 ’21vs.’20
PHARMACEUTICAL(1)
Immunology
U.S. 11,036 10,843 10,175 1.8 6.6
International 5,899 5,907 4,880 (0.1) 21.0
Worldwide 16,935 16,750 15,055 1.1 11.3
REMICADE
U.S. 1,417 2,019 2,508 (29.8) (19.5)
U.S.Exports 204 236 346 (13.6) (31.9)
International 722 935 893 (22.8) 4.8
Worldwide 2,343 3,190 3,747 (26.6) (14.9)
SIMPONI/SIMPONIARIA
U.S. 1,166 1,127 1,155 3.5 (2.4)
International 1,017 1,148 1,088 (11.4) 5.5
Worldwide 2,184 2,276 2,243 (4.0) 1.4
STELARA
U.S. 6,388 5,938 5,240 7.6 13.3
International 3,335 3,196 2,467 4.4 29.6
Worldwide 9,723 9,134 7,707 6.5 18.5
TREMFYA
U.S. 1,844 1,503 926 22.7 62.3
International 824 624 421 32.0 48.2
Worldwide 2,668 2,127 1,347 25.4 57.9
OTHERIMMUNOLOGY
U.S. 17 21 — (18.4) **
International 0 3 11 ** (73.3)
Worldwide 17 24 11 (28.2) **
InfectiousDiseases
U.S. 1,680 2,249 1,735 (25.3) 29.7
International 3,769 3,576 1,808 5.4 97.8
Worldwide 5,449 5,825 3,543 (6.5) 64.4
COVID-19VACCINE
U.S. 120 634 — (81.1) **
International 2,059 1,751 — 17.6 **
Worldwide 2,179 2,385 — (8.6) **
EDURANT/rilpivirine
U.S. 36 41 44 (10.8) (7.6)
International 972 953 920 2.0 3.6
Worldwide 1,008 994 964 1.5 3.1
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
U.S. 1,494 1,508 1,587 (1.0) (4.9)
International 449 575 597 (21.9) (3.6)
Worldwide 1,943 2,083 2,184 (6.7) (4.6)
Johnson&Johnson2022AnnualReport • 77SalestoCustomers %Change
(DollarsinMillions) 2022 2021 2020 ’22vs.’21 ’21vs.’20
OTHERINFECTIOUSDISEASES
U.S. 30 66 104 (55.5) (36.0)
International 289 297 292 (2.6) 1.7
Worldwide 318 363 396 (12.3) (8.3)
Neuroscience
U.S. 3,570 3,347 3,091 6.7 8.3
International 3,323 3,641 3,435 (8.7) 6.0
Worldwide 6,893 6,988 6,526 (1.4) 7.1
CONCERTA/methylphenidate
U.S. 151 172 183 (12.5) (5.8)
International 493 495 439 (0.4) 12.8
Worldwide 644 667 622 (3.5) 7.3
INVEGASUSTENNA/XEPLION/INVEGATRINZA/TREVICTA
U.S. 2,714 2,550 2,314 6.5 10.2
International 1,426 1,472 1,339 (3.1) 10.0
Worldwide 4,140 4,022 3,653 3.0 10.1
RISPERDALCONSTA
U.S. 257 287 296 (10.4) (2.9)
International 228 305 346 (25.3) (11.8)
Worldwide 485 592 642 (18.1) (7.7)
OTHERNEUROSCIENCE
U.S. 447 338 298 32.4 13.3
International 1,176 1,368 1,312 (14.1) 4.3
Worldwide 1,623 1,706 1,610 (4.9) 6.0
Oncology
U.S. 6,930 5,958 5,092 16.3 17.0
International 9,052 8,590 7,275 5.4 18.1
Worldwide 15,983 14,548 12,367 9.9 17.6
DARZALEX
U.S. 4,210 3,169 2,232 32.8 42.0
International 3,767 2,854 1,958 32.0 45.8
Worldwide 7,977 6,023 4,190 32.4 43.8
ERLEADA
U.S. 968 813 583 19.2 39.3
International 913 478 176 ** **
Worldwide 1,881 1,291 760 45.7 70.0
IMBRUVICA
U.S. 1,390 1,747 1,821 (20.4) (4.0)
International 2,394 2,622 2,307 (8.7) 13.6
Worldwide 3,784 4,369 4,128 (13.4) 5.8
ZYTIGA/abirateroneacetate
U.S. 74 119 373 (37.8) (68.1)
International 1,696 2,178 2,097 (22.1) 3.9
Worldwide 1,770 2,297 2,470 (22.9) (7.0)
78 • Johnson&Johnson2022AnnualReportSalestoCustomers %Change
(DollarsinMillions) 2022 2021 2020 ’22vs.’21 ’21vs.’20
OTHERONCOLOGY
U.S. 289 110 83 ** 31.7
International 283 458 738 (38.3) (37.9)
Worldwide 571 568 821 0.6 (30.8)
PulmonaryHypertension
U.S. 2,346 2,365 2,133 (0.8) 10.9
International 1,071 1,085 1,015 (1.3) 6.9
Worldwide 3,417 3,450 3,148 (1.0) 9.6
OPSUMIT
U.S. 1,132 1,147 1,008 (1.3) 13.7
International 651 672 631 (3.2) 6.6
Worldwide 1,783 1,819 1,639 (2.0) 11.0
UPTRAVI
U.S. 1,104 1,056 955 4.5 10.5
International 218 181 138 20.4 31.1
Worldwide 1,322 1,237 1,093 6.9 13.1
OTHER
U.S. 110 163 169 (32.3) (3.7)
International 202 232 247 (12.8) (5.9)
Worldwide 313 395 416 (20.8) (5.0)
Cardiovascular/Metabolism/Other
U.S. 3,042 3,192 3,509 (4.7) (9.0)
International 845 927 1,025 (8.9) (9.6)
Worldwide 3,887 4,119 4,534 (5.6) (9.2)
XARELTO
U.S. 2,473 2,438 2,345 1.4 4.0
International — — — — —
Worldwide 2,473 2,438 2,345 1.4 4.0
INVOKANA/INVOKAMET
U.S. 193 308 564 (37.4) (45.4)
International 255 254 231 0.1 9.9
Worldwide 448 563 795 (20.4) (29.3)
OTHER(2)
U.S. 376 446 600 (15.5) (25.7)
International 590 673 794 (12.3) (15.2)
Worldwide 966 1,119 1,394 (13.6) (19.7)
TOTALPHARMACEUTICAL
U.S. 28,604 27,954 25,735 2.3 8.6
International 23,959 23,726 19,440 1.0 22.0
Worldwide 52,563 51,680 45,175 1.7 14.4
Johnson&Johnson2022AnnualReport • 79SalestoCustomers %Change
(DollarsinMillions) 2022 2021 2020 ’22vs.’21 ’21vs.’20
MEDTECH*(3)
InterventionalSolutions
U.S. 2,169 1,836 1,452 18.2 26.4
International 2,131 2,135 1,594 (0.2) 34.0
Worldwide 4,300 3,971 3,046 8.3 30.4
Orthopaedics
U.S. 5,321 5,126 4,779 3.8 7.3
International 3,267 3,462 2,984 (5.6) 16.0
Worldwide 8,587 8,588 7,763 0.0 10.6
HIPS
U.S. 943 878 793 7.3 10.7
International 571 602 487 (5.1) 23.6
Worldwide 1,514 1,480 1,280 2.3 15.6
KNEES
U.S. 851 787 743 8.2 5.9
International 508 538 427 (5.7) 26.1
Worldwide 1,359 1,325 1,170 2.6 13.3
TRAUMA
U.S. 1,882 1,819 1,648 3.5 10.4
International 989 1,066 966 (7.2) 10.4
Worldwide 2,871 2,885 2,614 (0.5) 10.4
SPINE,SPORTS&OTHER
U.S. 1,645 1,642 1,595 0.2 2.9
International 1,198 1,256 1,104 (4.6) 13.8
Worldwide 2,843 2,898 2,699 (1.9) 7.4
Surgery
U.S. 3,897 3,867 3,249 0.8 19.0
International 5,793 5,945 4,983 (2.6) 19.3
Worldwide 9,690 9,812 8,232 (1.2) 19.2
ADVANCED
U.S. 1,784 1,761 1,535 1.3 14.9
International 2,785 2,861 2,304 (2.6) 24.1
Worldwide 4,569 4,622 3,839 (1.1) 20.4
GENERAL
U.S. 2,113 2,105 1,714 0.4 22.7
International 3,008 3,085 2,679 (2.5) 15.2
Worldwide 5,121 5,190 4,392 (1.3) 18.1
Vision
U.S. 1,990 1,857 1,557 7.2 19.3
International 2,859 2,831 2,362 1.0 19.8
Worldwide 4,849 4,688 3,919 3.4 19.6
CONTACTLENSES/OTHER
U.S. 1,522 1,398 1,213 8.9 15.2
International 2,022 2,043 1,781 (1.0) 14.7
Worldwide 3,543 3,440 2,994 3.0 14.9
80 • Johnson&Johnson2022AnnualReportSalestoCustomers %Change
(DollarsinMillions) 2022 2021 2020 ’22vs.’21 ’21vs.’20
SURGICAL
U.S. 468 459 344 2.0 33.5
International 837 788 581 6.2 35.7
Worldwide 1,306 1,248 925 4.6 34.9
TOTALMEDTECH
U.S. 13,377 12,686 11,036 5.4 14.9
International 14,050 14,374 11,923 (2.3) 20.6
Worldwide 27,427 27,060 22,959 1.4 17.9
WORLDWIDE
U.S. 48,580 47,156 43,133 3.0 9.3
International 46,363 46,619 39,451 (0.6) 18.2
Worldwide $94,943 93,775 82,584 1.3% 13.6
* Certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation
** Percentagegreaterthan100%ornotmeaningful
(1) Approximately$0.4billioninboththefiscal2021and2020,ofcertaininternationalOTCproducts,primarilyinChina,were
reclassifiedfromthePharmaceuticalsegmenttotheConsumerHealthsegmentbasedonoperationalchanges
(2) InclusiveofPROCRIT/EPREXwhichwaspreviouslydisclosedseparately
(3) PreviouslyreferredtoasMedicalDevices
Income(Loss)BeforeTax* IdentifiableAssets
(DollarsinMillions) 2022(3) 2021(4) 2020(5) 2022 2021
ConsumerHealth $2,930 1,573 (852) $24,068 25,081
Pharmaceutical 15,901 17,969 15,250 58,436 64,376
MedTech 4,607 4,373 3,044 70,956 53,372
Total 23,438 23,915 17,442 153,460 142,829
Less:Expensenotallocatedtosegments(1) 624 1,072 945
Less:ConsumerHealthseparationcosts 1,089 67
Generalcorporate(2) 33,918 39,189
Worldwidetotal $21,725 22,776 16,497 $187,378 182,018
* Incomebeforetaxofapproximately$0.2billionand$0.2billioninthefiscalyears2021and2020,respectively,hasbeenreclassified
ascertaininternationalOTCproducts,primarilyinChina,werereclassifiedfromthePharmaceuticalsegmenttotheConsumerHealth
segmentbasedonoperationalchanges
AdditionstoProperty, Depreciationand
Plant&Equipment Amortization
(DollarsinMillions) 2022 2021 2020 2022 2021 2020
ConsumerHealth $323 331 248 $658 759 785
Pharmaceutical 1,374 1,198 863 3,687 4,029 4,006
MedTech 2,120 1,933 1,980 2,302 2,286 2,140
Segmentstotal 3,817 3,462 3,091 6,647 7,074 6,931
Generalcorporate 192 190 256 323 316 300
Worldwidetotal $4,009 3,652 3,347 $6,970 7,390 7,231
Johnson&Johnson2022AnnualReport • 81SalestoCustomers Long-LivedAssets(6)
(DollarsinMillions) 2022 2021 2020 2022 2021
UnitedStates $48,580 47,156 43,133 $66,283 48,586
Europe 23,449 23,594 18,980 38,774 43,257
WesternHemisphereexcludingU.S. 6,125 5,750 5,335 2,737 2,708
Asia-Pacific,Africa 16,789 17,275 15,136 4,431 5,035
Segmentstotal 94,943 93,775 82,584 112,225 99,586
Generalcorporate 1,134 1,014
Othernonlong-livedassets 74,019 81,418
Worldwidetotal $94,943 93,775 82,584 $187,378 182,018
SeeNote1foradescriptionofthesegmentsinwhichtheCompanyoperates.
Exportsalesarenotsignificant.Infiscalyear2022,theCompanyutilizedthreewholesalersdistributingproductsforall
threesegmentsthatrepresentedapproximately16.5%,13.0%and12.0%ofthetotalconsolidatedrevenues.Infiscalyear
2021,theCompanyhadthreewholesalersdistributingproductsforallthreesegmentsthatrepresentedapproximately
14.0%,11.0%and11.0%ofthetotalconsolidatedrevenues.Infiscalyear2020,theCompanyhadthreewholesalers
distributingproductsforallthreesegmentsthatrepresentedapproximately16.0%,12.0%,and12.0%ofthetotal
consolidatedrevenues.
(1) Amountsnotallocatedtosegmentsincludeinterest(income)expenseandgeneralcorporate(income)expense.
(2) Generalcorporateincludescash,cashequivalentsandmarketablesecurities.
(3) ConsumerHealthincludes:
• Litigationexpenseof$0.2billion
• Arestructuringrelatedchargeof$0.1billion
Pharmaceuticalincludes:
• One-timeCOVID-19Vaccinemanufacturingexitrelatedcostsof$1.5billion
• Anintangibleassetimpairmentchargeofapproximately$0.8billionrelatedtoanin-processresearchand
developmentasset,bermekimab(JnJ-77474462),aninvestigationaldrugforthetreatmentofAtopicDermatitis(AD)
andHidradenitisSuppurativa(HS)acquiredwiththeacquisitionofXBiotech,Inc.inthefiscalyear2020.Additional
informationregardingefficacyoftheADandHSindicationsbecameavailablewhichledtheCompanytothedecision
toterminatethedevelopmentofbermekimabforADandHS
• Litigationexpenseof$0.1billion
• Lossof$0.7billionrelatedtothechangeinthefairvalueofsecurities
• Arestructuringrelatedchargeof$0.1billion
MedTechincludes:
• Litigationexpenseof$0.6billionprimarilyforpelvicmeshrelatedcosts
• Arestructuringrelatedchargeof$0.3billion
• Acquisitionandintegrationrelatedcostsof$0.3billionprimarilyrelatedtotheacquisitionofAbiomed
• AMedicalDeviceRegulationchargeof$0.3billion
(4) ConsumerHealthincludes:
• Litigationexpenseof$1.6billion,primarilytalcrelatedcosts
• Arestructuringrelatedchargeof$0.1billion
Pharmaceuticalincludes:
• Litigationexpenseof$0.6billion,primarilyrelatedtoRisperdalGynecomastia
• Divestituregainsof$0.6billion
• Gainsof$0.5billionrelatedtothechangeinthefairvalueofsecurities
• Arestructuringrelatedchargeof$0.1billion
82 • Johnson&Johnson2022AnnualReportMedTechincludes:
• Arestructuringrelatedchargeof$0.3billion
• Anin-processresearchanddevelopmentexpenseof$0.9billionrelatedtoOttava
• AMedicalDeviceRegulationchargeof$0.2billion
• Litigationexpenseof$0.1billion
(5) ConsumerHealthincludes:
• Litigationexpenseof$3.9billion,primarilytalcrelatedcostsandcertainsettlements.
Pharmaceuticalincludes:
• Litigationexpenseof$0.8billion,primarilyrelatedtotheagreementinprincipletosettleopioidlitigation
• Againof$0.5billionrelatedtothechangeinthefairvalueofsecurities
• Arestructuringrelatedchargeof$0.1billion
MedTechincludes:
• Acontingentconsiderationreversalof$1.1billionrelatedtothetimingofcertaindevelopmentalmilestones
associatedwiththeAurisHealthacquisition.
• Litigationexpenseof$0.3billion
• Arestructuringrelatedchargeof$0.3billion
• Anin-processresearchanddevelopmentexpenseof$0.2billion
• AMedicalDeviceRegulationchargeof$0.1billion
(6) Long-livedassetsincludeproperty,plantandequipment,netforfiscalyears2022,and2021of$19,803and
$18,962,respectively,andintangibleassetsandgoodwill,netforfiscalyears2022and2021of$93,556and
$81,638,respectively.
18. Acquisitions and Divestitures
Duringthefiscalyear2022,certainbusinesseswereacquiredfor$17.7billionincashand$1.1billionofliabilities
assumed.Theseacquisitionswereaccountedforusingtheacquisitionmethodand,accordingly,resultsofoperationshave
beenincludedinthefinancialstatementsfromtheirrespectivedatesofacquisition.
Theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedto$17.3billionandhas
beenassignedtoidentifiableintangibleassets,withanyresidualrecordedtogoodwill.
Thefiscalyear2022acquisitionsprimarilyincludedAbiomed,Inc.(Abiomed).Theremainingacquisitionswerenot
material.
OnDecember22,2022,theCompanycompletedtheacquisitionofAbiomed,aleading,first-to-marketproviderof
cardiovascularmedicaltechnologywithafirst-in-kindportfolioforthetreatmentofcoronaryarterydiseaseandheartfailure
whichalsohasanextensiveinnovationpipelineoflife-savingtechnologies.ThetransactionbroadenstheCompany’s
positionasagrowingcardiovascularinnovator,advancingthestandardofcareinheartfailureandrecovery,oneof
healthcare’slargestareasofunmetneed.Thetransactionwasaccountedforasabusinesscombinationandtheresultsof
operationswereincludedintheMedTechsegmentasofthedateoftheacquisition.Theacquisitionwascompleted
throughatenderofferforalloutstandingshares.Theconsiderationpaidintheacquisitionconsistedofanupfrontpayment
of$380.00pershareincash,amountingto$17.1billion,netofcashacquired,aswellasanon-tradeablecontingent
valueright(“CVR”)entitlingtheholdertoreceiveupto$35.00pershareincash(whichwithrespecttotheCVRstotal
approximately$1.6billionintheaggregate)ifcertaincommercialandclinicalmilestonesareachieved.Thecorresponding
enterprisevalue(withouttakingintoaccounttheCVRs)ofapproximately$16.5billionincludescash,cashequivalentsand
marketablesecuritiesacquired.
ThemilestonesoftheCVRconsistof:
a.$17.50pershare,payableifnetsalesforAbiomedproductsexceeds$3.7billionduringJohnson&Johnson’sfiscal
secondquarterof2027throughfiscalfirstquarterof2028,orifthisthresholdisnotmetduringthisperiodandis
subsequentlymetduringanyrollingfourquarterperioduptotheendofJohnson&Johnson’sfiscalfirstquarterof
2029,$8.75pershare;
b.$7.50persharepayableuponFDApremarketapplicationapprovaloftheuseofImpella®productsinST-elevated
myocardialinfarction(STEMI)patientswithoutcardiogenicshockbyJanuary1,2028;and
Johnson&Johnson2022AnnualReport • 83c.$10.00persharepayableuponthefirstpublicationofaClassIrecommendationfortheuseofImpella®products
inhighriskPCIorSTEMIwithorwithoutcardiogenicshockwithinfouryearsfromtheirrespectiveclinicalendpoint
publicationdates,butinallcasesnolaterthanDecember31,2029.
Thefairvalueoftheacquisitionwasallocatedtoassetsacquiredof$19.9billion(netof$0.3billioncashacquired),
primarilytogoodwillfor$10.9billion,amortizableintangibleassetsfor$6.6billion,IPR&Dfor$1.1billion,marketable
securitiesof$0.6billionandliabilitiesassumedof$2.8billion,whichincludesthefairvalueofthecontingent
considerationmentionedabovefor$0.7billionanddeferredtaxesof$1.8billion.Thegoodwillisprimarilyattributableto
thecommercialaccelerationandexpansionoftheportfolioandisnotexpectedtobedeductiblefortaxpurposes.The
contingentconsiderationwasrecordedinOtherLiabilitiesontheConsolidatedBalanceSheet.
AstheacquisitionoccurredinDecember2022,theCompanyisstillfinalizingtheallocationofthepurchasepricetothe
individualassetsacquiredandliabilitiesassumed.Theallocationofthepurchasepriceincludedinthecurrentperiod
balancesheetisbasedonthebestestimateofmanagementandispreliminaryandsubjecttochange.Toassist
managementintheallocation,theCompanyengagedvaluationspecialiststoprepareappraisals.TheCompanywillfinalize
theamountsrecognizedastheinformationnecessarytocompletetheanalysisisobtained.TheCompanyexpectsto
finalizetheseamountsassoonaspossiblebutnolaterthanoneyearfromtheacquisitiondate.
Theamortizableintangibleassetswereprimarilycomprisedofalreadyin-marketproductsoftheImpella®platformwithan
averageweightedlifeof14years.TheIPR&Dassetswerevaluedfortechnologyprogramsforunapprovedproducts.The
valueoftheIPR&Dwascalculatedusingprobability-adjustedcashflowprojectionsdiscountedfortheriskinherentinsuch
projects.Theprobabilityofsuccessfactorrangedfrom52%to70%.Thediscountrateappliedwas9.5%.
In2022,theCompanyrecordedacquisitionrelatedcostsbeforetaxofapproximately$0.3billion,whichwasrecordedin
Other(income)/expense.
Duringfiscalyear2021,theCompanydidnotmakeanymaterialacquisitions.
Duringfiscalyear2020,certainbusinesseswereacquiredfor$7.3billionincashand$0.4billionofliabilitiesassumed.
Theseacquisitionswereaccountedforusingtheacquisitionmethodand,accordingly,resultsofoperationshavebeen
includedinthefinancialstatementsfromtheirrespectivedatesofacquisition.
Theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedto$7.5billionandhas
beenassignedtoidentifiableintangibleassets,withanyresidualrecordedtogoodwill.
Thefiscalyear2020acquisitionsprimarilyincluded:allrightstotheinvestigationalcompoundbermekimab,whichhas
multipledermatologicalindications,alongwithcertainemployeesfromXBiotechInc.(XBiotech),Momenta
Pharmaceuticals,Inc.(Momenta),acompanythatdiscoversanddevelopsnoveltherapiesforimmune-mediateddiseases
andtheoutstandingsharesinVerbSurgicalInc.,acompanywithsignificantroboticsanddatasciencecapabilities.
Duringthefiscalfirstquarterof2020,theCompanycompletedtheacquisitionofallrightstotheinvestigationalcompound
bermekimab,whichhasmultipledermatologicalindications,alongwithcertainemployeesfromXBiotechInc.,fora
purchasepriceof$0.8billion.Thefairvalueoftheacquisitionwasallocatedprimarilytonon-amortizableintangibleassets,
primarilyIPR&D,for$0.8billionapplyingaprobabilityofsuccessfactorthatrangedfrom20%to60%toreflectinherent
development,regulatoryandcommercialriskforthedifferentindications.Thediscountrateappliedwasapproximately
16%.ThetransactionwasaccountedforasabusinesscombinationandincludedinthePharmaceuticalsegment.Infiscal
2022,theCompanyrecordedanintangibleassetimpairmentchargeofapproximately$0.8billionrelatedtothisin-
processresearchanddevelopmentasset.
Additionally,inthefiscalfirstquarterof2020,theCompanycompletedtheacquisitionofalloutstandingsharesinVerb
SurgicalInc.,acompanywithsignificantroboticsanddatasciencecapabilities,includingthosesharespreviouslyheldby
Verily.ThetransactionwasaccountedforasabusinesscombinationandincludedintheMedTechsegment.Thefairvalue
oftheacquisitionwasallocatedprimarilytonon-amortizableintangibleassets,primarilyIPR&D,for$0.4billion,goodwillfor
$0.2billion,otherassetsof$0.2billionandliabilitiesassumedof$0.3billion.ThefairvalueoftheCompany’spreviously
heldequityinvestmentinVerbSurgicalInc.was$0.4billion.
OnOctober1,2020,theCompanycompletedtheacquisitionofMomentaforapurchasepriceofapproximately
$6.1billion,netofcashacquired.Thefairvalueoftheacquisitionwasallocatedprimarilytonon-amortizableintangible
assets(IPR&D)of$6.0billion,goodwillof$1.2billion,otherassetsof$0.5billionandliabilitiesof$1.6billion.Theassets
acquiredareintendedtoaddresssubstantialunmetmedicalneedinmaternal-fetaldisorders,neuro-inflammatory
disorders,rheumatology,dermatologyandautoimmunehematology.Dependingontheasset,probabilityofsuccess
factorsrangingfrom20%to77%wereusedinthefairvaluecalculationtoreflectinherentdevelopmentandregulatory
84 • Johnson&Johnson2022AnnualReportriskoftheIPR&D.Thediscountrateappliedwasapproximately13%.Thegoodwillisprimarilyattributabletosynergies
expectedtoarisefromthebusinessacquisitionandisnotexpectedtobedeductiblefortaxpurposes.Thetransactionwas
accountedforasabusinesscombinationandincludedinthePharmaceuticalsegment.
InaccordancewithU.S.GAAPstandardsrelatedtobusinesscombinations,andgoodwillandotherintangibleassets,
supplementalproformainformationforfiscalyears2022,2021and2020isnotprovided,astheimpactofthe
aforementionedacquisitionsdidnothaveamaterialeffectontheCompany’sresultsofoperations.
Divestitures
Duringfiscalyear2022,theCompanydidnotmakeanymaterialdivestitures.
Duringfiscalyear2021,inseparatetransactions,theCompanydivestedtwobrandsoutsidetheU.S.withinthe
Pharmaceuticalsegment.TheCompanyrecognizedapre-taxgainrecordedinOther(income)expense,net,of
approximately$0.6billion.
Duringfiscalyear2020,theCompanysold11.8millionsharesofIdorsiaLTD(Idorsia),orits8.3%ownershipinthe
companyatthattime.ThetransactionresultedingrossproceedsofapproximatelyCHF337million($357million)based
onasalespriceofCHF28.55/shareandresultedinanimmaterialnetloss.Attheendoffiscal2020,theCompanyhad
rightstoapproximately38.7millionsharesthroughaconvertibleloanwithaprincipalamountofCHF445million(dueJune
2027).Duringfiscalyear2021,theCompanyconvertedCHF110million($120million)ofthisloanintoapproximately
9.6millionsharesofIdorsiawhichwerereflectedatfairvalueasofJanuary2,2022.Duringthefiscalthirdquarterof
2021,theCompany’sundrawncreditfacilitywithIdorsiawasterminated.
19. Legal Proceedings
Johnson&Johnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability;
intellectualproperty;commercial;indemnificationandothermatters;governmentalinvestigations;andotherlegal
proceedingsthatarisefromtimetotimeintheordinarycourseoftheirbusiness.
TheCompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata
liabilitywillbeincurred,andtheamountofthelosscanbereasonablyestimated.AsofJanuary1,2023,theCompanyhas
determinedthattheliabilitiesassociatedwithcertainlitigationmattersareprobableandcanbereasonablyestimated.The
Companyhasaccruedforthesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsasmight
bewarrantedbasedonnewinformationandfurtherdevelopmentsinaccordancewithASC450-20-25.Fortheseand
otherlitigationandregulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossible,theCompany
isunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsaccrued.Amountsaccruedforlegal
contingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyon
estimatesandassumptionsincludingtimingofrelatedpayments.Theabilitytomakesuchestimatesandjudgmentscanbe
affectedbyvariousfactorsincluding,amongotherthings,whetherdamagessoughtintheproceedingsare
unsubstantiatedorindeterminate;scientificandlegaldiscoveryhasnotcommencedorisnotcomplete;proceedingsarein
earlystages;matterspresentlegaluncertainties;therearesignificantfactsindispute;proceduralorjurisdictionalissues;
theuncertaintyandunpredictabilityofthenumberofpotentialclaims;abilitytoachievecomprehensivemulti-party
settlements;complexityofrelatedcross-claimsandcounterclaims;and/ortherearenumerouspartiesinvolved.Tothe
extentadverseawards,judgmentsorverdictshavebeenrenderedagainsttheCompany,theCompanydoesnotrecordan
accrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimated.
IntheCompany’sopinion,basedonitsexaminationofthesematters,itsexperiencetodateanddiscussionswithcounsel,
theultimateoutcomeoflegalproceedings,netofliabilitiesaccruedintheCompany’sbalancesheet,isnotexpectedto
haveamaterialadverseeffectontheCompany’sfinancialposition.However,theresolutionof,orincreaseinaccrualsfor,
oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectontheCompany’sresultsof
operationsandcashflowsforthatperiod.
PRODUCTLIABILITY
TheCompanyandcertainofitssubsidiariesareinvolvedinnumerousproductliabilityclaimsandlawsuitsinvolving
multipleproducts.Claimantsinthesecasesseeksubstantialcompensatoryand,whereavailable,punitivedamages.While
theCompanybelievesithassubstantialdefenses,itisnotfeasibletopredicttheultimateoutcomeoflitigation.Fromtime
totime,evenifithassubstantialdefenses,theCompanyconsidersisolatedsettlementsbasedonavarietyof
circumstances.TheCompanyhasestablishedaccrualsforproductliabilityclaimsandlawsuitsincompliancewith
Johnson&Johnson2022AnnualReport • 85ASC450-20basedoncurrentlyavailableinformation,whichinsomecasesmaybelimited.TheCompanyaccruesan
estimateofthelegaldefensecostsneededtodefendeachmatterwhenthosecostsareprobableandcanbereasonably
estimated.Forcertainofthesematters,theCompanyhasaccruedadditionalamountssuchasestimatedcostsassociated
withsettlements,damagesandotherlosses.Productliabilityaccrualscanrepresentprojectedproductliabilityfor
thousandsofclaimsaroundtheworld,eachindifferentlitigationenvironmentsandwithdifferentfactpatterns.Changesto
theaccrualsmayberequiredinthefutureasadditionalinformationbecomesavailable.
Themostsignificantofthesecasesinclude:theDePuyASRXLAcetabularSystemandDePuyASRHipResurfacing
System;thePINNACLEAcetabularCupSystem;pelvicmeshes;RISPERDAL;bodypowderscontainingtalc,primarily
JOHNSON’SBabyPowder;ETHICONPHYSIOMESHFlexibleCompositeMesh;ELMIRON;andTYLENOL.Asof
January1,2023,intheUnitedStatestherewereapproximately170plaintiffswithdirectclaimsinpendinglawsuits
regardinginjuriesallegedlyduetotheDePuyASRXLAcetabularSystemandDePuyASRHipResurfacingSystem;1,400
withrespecttothePINNACLEAcetabularCupSystem;9,000withrespecttopelvicmeshes;1,100withrespectto
RISPERDAL;40,300withrespecttobodypowderscontainingtalc;2,100withrespecttoETHICONPHYSIOMESH
FlexibleCompositeMesh;2,000withrespecttoELMIRON;and170withrespecttoTYLENOL.Thenumberofpending
lawsuitsisexpectedtofluctuateascertainlawsuitsaresettledordismissedandadditionallawsuitsarefiled.
InAugust2010,DePuyOrthopaedics,Inc.(DePuy)announcedaworldwidevoluntaryrecallofitsASRXLAcetabular
SystemandDePuyASRHipResurfacingSystem(ASRHip)usedinhipreplacementsurgery.Claimsforpersonalinjury
havebeenmadeagainstDePuyandtheCompany.CasesfiledinfederalcourtsintheUnitedStateshavebeenorganized
asamulti-districtlitigationintheUnitedStatesDistrictCourtfortheNorthernDistrictofOhio.Litigationhasalsobeen
filedincountriesoutsideoftheUnitedStates,primarilyintheUnitedKingdom,Canada,Australia,Ireland,Germany,India
andItaly.InNovember2013,DePuyreachedanagreementwithaCourt-appointedcommitteeoflawyersrepresenting
ASRHipplaintiffstoestablishaprogramtosettleclaimswitheligibleASRHippatientsintheUnitedStateswhohad
surgerytoreplacetheirASRHips,knownasrevisionsurgery,asofAugust2013.DePuyreachedadditionalagreementsin
February2015andMarch2017,whichfurtherextendedthesettlementprogramtoincludeASRHippatientswhohad
revisionsurgeriesafterAugust2013andpriortoFebruary15,2017.Thissettlementprogramhasresolvedmorethan
10,000claims,therebybringingtoresolutionsignificantASRHiplitigationactivityintheUnitedStates.However,lawsuits
intheUnitedStatesremain,andthesettlementprogramdoesnotaddresslitigationoutsideoftheUnitedStates.In
Australia,aclassactionsettlementwasreachedthatresolvedtheclaimsofthemajorityofASRHippatientsinthat
country.InCanada,theCompanyhasreachedagreementstosettletheclassactionsfiledinthatcountry.TheCompany
continuestoreceiveinformationwithrespecttopotentialadditionalcostsassociatedwiththisrecallonaworldwidebasis.
TheCompanyhasestablishedaccrualsforthecostsassociatedwiththeUnitedStatessettlementprogramandASRHip-
relatedproductliabilitylitigation.
ClaimsforpersonalinjuryhavealsobeenmadeagainstDePuyOrthopaedics,Inc.andtheCompany(collectively,DePuy)
relatingtothePINNACLEAcetabularCupSystemusedinhipreplacementsurgery.Productliabilitylawsuitscontinueto
befiled,andtheCompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberof
cases.MostcasesfiledinfederalcourtsintheUnitedStateshavebeenorganizedasamulti-districtlitigationinthe
UnitedStatesDistrictCourtfortheNorthernDistrictofTexas(TexasMDL).BeginningonJune1,2022,theJudicialPanel
onMultidistrictLitigationceasedtransferofnewcasesintotheTexasMDL,andtherearenowcasespendinginfederal
courtoutsidetheTexasMDL.LitigationalsohasbeenfiledinstatecourtsandincountriesoutsideoftheUnitedStates.
Priorto2019,severaladverseverdictshadbeenrenderedagainstDePuy,oneofwhichwasreversedonappealand
remandedforretrial.Duringthefirstquarterof2019,DePuyestablishedaUnitedStatessettlementprogramtoresolve
thesecases.Aspartofthesettlementprogram,adverseverdictshavebeensettled.TheCompanyhasestablishedan
accrualforproductliabilitylitigationassociatedwiththePINNACLEAcetabularCupSystemandtherelatedsettlement
program.
ClaimsforpersonalinjuryhavebeenmadeagainstEthicon,Inc.(Ethicon)andtheCompanyarisingoutofEthicon’spelvic
meshdevicesusedtotreatstressurinaryincontinenceandpelvicorganprolapse.TheCompanycontinuestoreceive
informationwithrespecttopotentialcostsandadditionalcases.CasesfiledinfederalcourtsintheUnitedStateshad
beenorganizedasamulti-districtlitigation(MDL)intheUnitedStatesDistrictCourtfortheSouthernDistrictofWest
Virginia.InMarch2021,theMDLCourtenteredanorderclosingtheMDL.TheMDLCourthasremandedcasesfortrialto
thejurisdictionswherethecasewasoriginallyfiledandadditionalpelvicmeshlawsuitshavebeenfiled,andremain,
outsideoftheMDL.TheCompanyhassettledorotherwiseresolvedthemajorityoftheUnitedStatescasesandthe
estimatedcostsassociatedwiththesesettlementsandtheremainingcasesarereflectedintheCompany’saccruals.In
addition,classactionsandindividualpersonalinjurycasesorclaimsseekingdamagesforallegedinjuryresultingfrom
Ethicon’spelvicmeshdeviceshavebeencommencedinvariouscountriesoutsideoftheUnitedStates,includingclaims
andcasesintheUnitedKingdom,theNetherlands,Belgium,France,Ireland,Italy,SpainandSloveniaandclassactionsin
Israel,Australia,CanadaandSouthAfrica.InNovember2019,theFederalCourtofAustraliaissuedajudgmentregarding
86 • Johnson&Johnson2022AnnualReportitsfindingswithrespecttoliabilityinrelationtothethreeLeadApplicantsandgenerallyinrelationtothedesign,
manufacture,preandpost-marketassessmentsandtesting,andsupplyandpromotionofthedevicesinAustraliausedto
treatstressurinaryincontinenceandpelvicorganprolapse.InSeptember2022,afterexhaustingitsappeals,theCompany
reachedanin-principleagreementtoresolvethetwopelvicmeshclassactionsinAustralia,pendingFederalCourt
approval.InNovember2022,theapplicationforapprovalofthesettlementwasfiled,andahearingonthesettlementhas
beenscheduledfortheendofFebruary2023.TheclassactionsinCanadawerediscontinuedin2020asaresultofa
settlementofagroupofcasesandanagreementtoresolvetheIsraeliclassactionwasreachedinMay2021.Theparties
intheIsraeliclassactionarecurrentlyfinalizingthetermsofthesettlement.Amotiontoapprovethesettlementwasfiled
withtheCourt.TheCompanyhasestablishedaccrualswithrespecttoproductliabilitylitigationassociatedwithEthicon’s
pelvicmeshproducts.
FollowingaJune2016worldwidemarketwithdrawalofETHICONPHYSIOMESHFlexibleCompositeMesh
(Physiomesh),claimsforpersonalinjuryhavebeenmadeagainstEthicon,Inc.(Ethicon)andtheCompanyalleging
personalinjuryarisingoutoftheuseofthisherniameshdevice.CasesfiledinfederalcourtsintheUnitedStateshave
beenorganizedasamulti-districtlitigation(MDL)intheUnitedStatesDistrictCourtfortheNorthernDistrictofGeorgia.A
multi-countylitigation(MCL)alsohasbeenformedinNewJerseystatecourtandassignedtoAtlanticCountyforcases
pendinginNewJersey.InadditiontothemattersintheMDLandMCL,thereareadditionallawsuitspendinginthe
UnitedStatesDistrictCourtfortheSouthernDistrictofOhio,whicharepartoftheMDLforpolypropylenemeshdevices
manufacturedbyC.R.Bard,Inc.,andlawsuitspendingintwoNewJerseyMCLsformedforProceed/ProceedVentral
PatchandProleneHerniasystems,andlawsuitspendingoutsidetheUnitedStates.InMay2021,Ethiconandlead
counselfortheplaintiffsenteredintoatermsheettoresolveapproximately3,600Physiomeshcases(covering
approximately4,300plaintiffs)pendingintheMDLandMCLatthattime.Amastersettlementagreement(MSA)was
enteredintoinSeptember2021andincludes3,729casesintheMDLandMCL.Alldeadlinesandtrialsettingsinthose
proceedingsarecurrentlystayedpendingthecompletionofthesettlementagreement.OfthecasessubjecttotheMSA,
2,236havebeendismissedwithprejudice.Post-settlementcasesinthePhysiomeshMDLandMCLaresubjecttodocket
controlordersrequiringearlyexpertreportsanddiscoveryrequirements.AsofJanuary2023,thereareapproximately208
activecasessubjecttotheseorderswhicharebeingreviewedandevaluated.
ClaimshavealsobeenfiledagainstEthiconandtheCompanyallegingpersonalinjuriesarisingfromthePROCEEDMesh
andPROCEEDVentralPatchherniameshproducts.InMarch2019,theNewJerseySupremeCourtenteredanorder
consolidatingthesecasespendinginNewJerseyasanMCLinAtlanticCountySuperiorCourt.Additionalcaseshave
beenfiledinvariousfederalandstatecourtsintheUnitedStates,andinjurisdictionsoutsidetheUnitedStates.
EthiconandtheCompanyalsohavebeensubjecttoclaimsforpersonalinjuriesarisingfromthePROLENEPolypropylene
HerniaSystem.InJanuary2020,theNewJerseySupremeCourtcreatedanMCLinAtlanticCountySuperiorCourtto
handlesuchcases.CasesinvolvingthisproducthavealsobeenfiledinotherfederalandstatecourtsintheUnitedStates.
InOctober2022,anagreementinprinciple,subjecttovariousconditions,wasreachedtosettlethemajorityofthe
pendingcasesinvolvingProceed,ProceedVentralPatch,ProleneHerniaSystemandrelatedmulti-layeredmeshproducts.
AlllitigationactivitiesinthetwoNewJerseyMCLsarestayedpendingresolutionoftheproposedsettlement.Futurecases
thatarefiledintheNewJerseyMCLswillbesubjecttodocketcontrolordersrequiringearlyexpertreportsanddiscovery
requirements.
TheCompanyhasestablishedaccrualswithrespecttoproductliabilitylitigationassociatedwithETHICON
PHYSIOMESHFlexibleCompositeMesh,PROCEEDMeshandPROCEEDVentralPatch,andPROLENEPolypropylene
HerniaSystemproducts.
ClaimsforpersonalinjuryhavebeenmadeagainstJanssenPharmaceuticals,Inc.andtheCompanyarisingoutoftheuse
ofRISPERDAL,andrelatedcompounds,indicatedforthetreatmentofschizophrenia,acutemanicormixedepisodes
associatedwithbipolarIdisorderandirritabilityassociatedwithautism.Lawsuitsprimarilyhavebeenfiledinstatecourtsin
Pennsylvania,California,andMissouri.OtheractionsarependinginvariouscourtsintheUnitedStatesandCanada.
Productliabilitylawsuitscontinuetobefiled,andtheCompanycontinuestoreceiveinformationwithrespecttopotential
costsandtheanticipatednumberofcases.TheCompanyhassuccessfullydefendedanumberofthesecasesbutthere
havebeenverdictsagainsttheCompany,includingaverdictinOctober2019of$8.0billionofpunitivedamagesrelated
tooneplaintiff,whichthetrialjudgereducedto$6.8millioninJanuary2020.InSeptember2021,theCompanyentered
intoasettlementinprinciplewiththecounselrepresentingplaintiffsinthismatterandinsubstantiallyalloftheoutstanding
casesintheUnitedStates.ThecostsassociatedwiththisandothersettlementsarereflectedintheCompany’saccruals.
ClaimsforpersonalinjuryarisingoutoftheuseofXARELTO,anoralanticoagulant,havebeenmadeagainstJanssen
Pharmaceuticals,Inc.(JPI);theCompany;andJPI’scollaborationpartnerforXARELTO,BayerHealthcareAG,andcertain
Johnson&Johnson2022AnnualReport • 87ofitsaffiliates.CasesfiledinfederalcourtsintheUnitedStateshavebeenorganizedasamulti-districtlitigationinthe
UnitedStatesDistrictCourtfortheEasternDistrictofLouisiana.Inaddition,caseswerefiledinstatecourtsacrossthe
UnitedStates.ManyofthesecaseswereconsolidatedintoastatemasstortlitigationinPhiladelphia,Pennsylvaniaandin
acoordinatedproceedinginLosAngeles,California.ClassactionlawsuitsalsohavebeenfiledinCanada.InMarch2019,
JPIandtheCompanyannouncedanagreementinprincipletosettletheXARELTOcasesintheUnitedStates;the
settlementagreementwasexecutedinMay2019,thesettlementbecamefinalinDecember2019,andthesettlementwas
fundedinJanuary2020.ThisresolvedthemajorityofcasespendingintheUnitedStates.TheCompanyhasestablished
accrualsforitscostsassociatedwiththeUnitedStatessettlementprogramandXARELTOrelatedproductliability
litigation.
AsignificantnumberofpersonalinjuryclaimsallegingthattalccausescancerweremadeagainstJohnson&Johnson
ConsumerInc.andtheCompanyarisingoutoftheuseofbodypowderscontainingtalc,primarilyJOHNSON’SBaby
Powder.Thenumberofthesepersonalinjurylawsuits,filedinstateandfederalcourtsintheUnitedStatesaswellas
outsideoftheUnitedStates,continuedtoincrease.
Intalccasesthatpreviouslyhavegonetotrial,theCompanyhasobtainedanumberofdefenseverdicts,buttherealso
havebeenverdictsagainsttheCompany,manyofwhichhavebeenreversedonappeal.InJune2020,theMissouriCourt
ofAppealsreversedinpartandaffirmedinpartaJuly2018verdictof$4.7billioninInghamv.Johnson&Johnson,etal.,
No.ED207476(Mo.App.),reducingtheoverallawardto$2.1billion.Anapplicationfortransferofthecasetothe
MissouriSupremeCourtwassubsequentlydeniedandinJune2021,apetitionforcertiorari,seekingareviewofthe
InghamdecisionbytheUnitedStatesSupremeCourt,wasdenied.InJune2021,theCompanypaidtheaward,which,
includinginterest,totaledapproximately$2.5billion.Thefactsandcircumstances,includingthetermsoftheaward,were
uniquetotheInghamdecisionandnotrepresentativeofotherclaimsbroughtagainsttheCompany.TheCompany
continuestobelievethatithasstronglegalgroundstocontesttheothertalcverdictsthatithasappealed.
NotwithstandingtheCompany’sconfidenceinthesafetyofitstalcproducts,incertaincircumstancestheCompanyhas
settledcases.
InOctober2021,Johnson&JohnsonConsumerInc.(OldJJCI)implementedacorporaterestructuring(the2021
CorporateRestructuring).Asaresultofthatrestructuring,OldJJCIceasedtoexistandthreenewentitieswerecreated:
(a)LTLManagementLLC,aNorthCarolinalimitedliabilitycompany(LTLorDebtor);(b)RoyaltyA&MLLC,aNorth
CarolinalimitedliabilitycompanyandadirectsubsidiaryofLTL(RAM);and(c)theDebtor’sdirectparent,Johnson&
JohnsonConsumerInc.,aNewJerseycompany(NewJJCI).TheDebtorreceivedcertainofOldJJCI’sassetsandbecame
solelyresponsibleforthetalc-relatedliabilitiesofOldJJCI,includingallliabilitiesrelatedinanywaytoinjuryordamage,or
allegedinjuryordamage,sustainedorincurredinthepurchaseoruseof,orexposureto,talc,includingtalccontainedin
anyproduct,ortotheriskof,orresponsibilityfor,anysuchdamageorinjury,exceptforanyliabilitiesforwhichthe
exclusiveremedyisprovidedunderaworkers’compensationstatuteoract(theTalc-RelatedLiabilities).
InOctober2021,notwithstandingtheCompany’sconfidenceinthesafetyofitstalcproducts,theDebtorfiledavoluntary
petitionwiththeUnitedStatesBankruptcyCourtfortheWesternDistrictofNorthCarolina,CharlotteDivision,seeking
reliefunderchapter11oftheBankruptcyCode(theLTLBankruptcyCase).AsaresultoftheLTLBankruptcyCase,the
NorthCarolinaBankruptcyCourtenteredatemporaryrestrainingorderstayingalllitigationagainstLTLandOldJJCI.On
November15,2021,theNorthCarolinaBankruptcyCourtconfirmedthescopeofthestay,issuingaPreliminaryInjunction
(PI)prohibitingandenjoiningthecommencementandprosecutionoftalc-relatedclaimsagainstLTL,OldJJCI,NewJJCI,
theCompany,otheroftheircorporateaffiliates,identifiedretailers,insurancecompanies,andcertainotherparties(the
ProtectedParties).TheLTLBankruptcyCasewastransferredtotheUnitedStatesBankruptcyCourtfortheDistrictof
NewJerseyinNovember2021,andthatcourtextendedthePIthroughtheendofFebruary2022.Claimantsfiledmotions
todismisstheLTLBankruptcyCaseand,followingamultipledayhearing,theNewJerseyBankruptcyCourtdeniedthose
motionsbyorderissuedinMarch2022.TheNewJerseyBankruptcyCourtsimultaneouslyissuedanotherorderextending
thestayastotheProtectedParties.Theclaimantssubsequentlyfilednoticesofappealastothedenialofthemotionsto
dismissandtheextensionofthestay.InMay2022,theThirdCircuitCourtofAppealsgrantedthepetitionstoappeal.The
briefingandoralargumentontheappealwerecompletedinSeptember2022.OnJanuary30,2023,theThirdCircuit
reversedtheBankruptcyCourt’srulingandremandedtotheBankruptcyCourttodismisstheLTLbankruptcy.LTLfileda
petitionforrehearingonthedecision.
WhiletheNewJerseyBankruptcyCourt’sordereffectivelystaysalloftheCompany’stalc-relatedpersonalinjurylitigation,
LTLhasagreedtoliftthestayonasmallnumberofappealswhereappealbondshavebeenfiled.
TheCompanyhasagreedtoprovidefundingtoLTLforthepaymentofamountstheNewJerseyBankruptcyCourt
determinesareowedbyLTLandtheestablishmentofa$2billiontrustinfurtheranceofthispurpose.TheCompanyhas
establishedareserveforapproximately$2billioninconnectionwiththeaforementionedtrust.Afterandasaresultofthe
88 • Johnson&Johnson2022AnnualReportfilingoftheLTLBankruptcyCase,theCompanyde-consolidatedLTL,whichisarelatedparty.Theimpactofthede-
consolidationisnotmaterialtotheCompany.ThepartieshavenotyetreachedaresolutionofalltalcmattersintheLTL
BankruptcyCase,andtheCompanyisunabletoestimatethepossiblelossorrangeoflossbeyondtheamountaccrued.
AclassactionadvancingclaimsrelatingtoindustrialtalcwasfiledagainsttheCompanyandothersinNewJerseystate
courtinMay2022(theEdleyClassAction).TheEdleyClassActionasserts,amongotherthings,thattheCompany
fraudulentlydefendedpastasbestospersonalinjurylawsuitsarisingfromexposuretoindustrialtalcmined,milled,and
manufacturedbeforeJanuary6,1989bytheCompany’sthenwhollyownedsubsidiary,WindsorMinerals,Inc.,whichis
currentlyadebtorintheImerysBankruptcydescribedhereafter.TheCompanyremovedtheEdleyClassActiontofederal
courtintheDistrictofNewJersey.InJuly2022,ImerysfiledamotionintheImerysBankruptcytostaytheEdleyClass
Action,whichwasdeniedinAugust2022.InOctober2022,theCompanyfiledmotionstodismissandtodeny
certificationofaclasstopursuetheEdleyClassActionintheNewJerseyDistrictCourt.
InFebruary2019,theCompany’stalcsupplier,ImerysTalcAmerica,Inc.andtwoofitsaffiliates,ImerysTalcVermont,Inc.
andImerysTalcCanada,Inc.(collectively,Imerys)filedavoluntarypetitionunderchapter11oftheUnitedStatesCode
(theBankruptcyCode)intheUnitedStatesBankruptcyCourtfortheDistrictofDelaware(ImerysBankruptcy).TheImerys
BankruptcyrelatestoImerys’spotentialliabilityforpersonalinjuryfromexposuretotalcumpowdersoldbyImerys.Inits
bankruptcy,ImerysallegesithasclaimsagainsttheCompanyforindemnificationandrightstojointinsuranceproceeds.In
May2020,Imerys,itsparentImerysS.A.,theTortClaimants’Committee(TCC),andtheFutureClaimants’Representative
(FCR)(collectively,thePlanProponents)filedtheirPlanofReorganization(thePlan)andtheDisclosureStatementrelated
thereto.ThePlanProponentshavesincefilednumerousamendmentstothePlanandDisclosureStatement.Ahearingon
thePlanProponent’sDisclosureStatementwasheldinJanuary2021,andtheCourtenteredanorderapprovingthe
DisclosureStatement,allowingImerystoproceedwithsolicitingvotesonthePlan.
InMarch2021,theCompanyvotedtorejectthePlanandoptedoutoftheconsensualreleasesinthePlan.InApril2021,
thePlanProponentsannouncedthePlanhadreceivedtherequisitenumberofacceptingvotestoconfirmthePlan.The
Companychallengedcertainimproprietieswithrespecttoportionsofthevoteandsoughttodisqualifythosevotes.In
October2021,theBankruptcyCourtissuedarulingdeemingthousandsofvotesaswithdrawn.
InOctober2021,ImeryscancelledtheconfirmationhearingonthePlan.Imerys,theTCC,theFCR,certainofImerys’s
insurers,andcertainpartiesintheCyprusMineschapter11case(describedbelow)(collectivelytheMediationParties)
agreedtoengageinmediation.ThemostrecenttermofthemediationendedonDecember31,2022.
InJuly2021,ImeryscommencedanadversaryproceedingagainsttheCompanyintheImerysBankruptcy(theImerys
AdversaryProceeding).TheImerysAdversaryProceedingsought,amongotherthings,certaindeclarationswithrespectto
theindemnificationobligationsallegedlyowedbytheCompanytoImerys.TheTCCandFCRsimultaneouslyfiledamotion
fortemporaryrestrainingorderandpreliminaryinjunctionseekingtoenjointheCompanyfromundergoingacorporate
restructuringthatwouldseparatetheCompany’stalcliabilitiesfromitsotherassets.TheBankruptcyCourtdeniedthe
motion.TheCompanythereafterfiledamotiontodismisstheadversaryproceeding.TheBankruptcyCourthasnotyet
decidedthemotiontodismiss.InOctober2021,theCompanyfiledaNoticeofBankruptcyFilingandStayof
ProceedingsclarifyingthattheautomaticstayarisinguponthefilingoftheLTLBankruptcyCaseshouldapplytothe
ImerysAdversaryProceeding.
InJune2020,CyprusMinesCorporationanditsparent,CyprusAmaxMineralsCompany(CAMC)(together,Cyprus),
whichhadownedcertainImerystalcmines,filedanadversaryproceedingagainsttheCompanyandImerysintheImerys
Bankruptcyseekingadeclarationofindemnityrightsundercertaincontractualagreements(theCyprusAdversary
Proceeding).TheCompanydeniessuchindemnificationisowed,andfiledamotiontodismisstheadversarycomplaint.In
February2021,Cyprusfiledavoluntarypetitionforreliefunderchapter11oftheBankruptcyCodeandfileditsDisclosure
StatementandPlan(theCyprusPlan).TheCyprusPlancontemplatesasettlementwithImerysandtalcclaimantswhere
CypruswouldmakeamonetarycontributiontoatrustestablishedundertheImerysPlaninexchangeforaninjunction
againsttalcclaimsassertedagainstitandcertainprotectedparties.CyprushasnotyetsoughtapprovalofitsDisclosure
StatementandPlan.Cyprus,alongwiththeTCCandFCRappointedintheCypruschapter11case,haveagreedto
participateinthemediationwiththeMediationParties.InOctober2021,theCompanyfiledaNoticeofBankruptcyFiling
andStayofProceedingsclarifyingthattheautomaticstayarisinguponthefilingoftheLTLBankruptcyCaseshouldapply
totheCyprusAdversaryProceeding.InJune2022,CypruscommencedanAdversaryProceedinginitschapter11case
seekinganorderenforcingtheautomaticstaybyenjoiningpartiesfromcommencingorcontinuing“talc-relatedclaims”
againstCAMC.InJune2022,thecourtenteredapreliminaryinjunctionorderenjoiningclaimantsfrompursuingtalc-
relatedclaimsagainstCAMCthroughJanuary2023.
Johnson&Johnson2022AnnualReport • 89InFebruary2021,severaloftheCompany’sinsurersinvolvedincoveragelitigationinNewJerseyStateCourt(the
CoverageAction)filedamotionintheImerysBankruptcyCourtproceedingseekingadeterminationthattheautomatic
staydoesnotapplytotheCoverageActionand,inthealternative,seekingrelieffromtheautomaticstaytoallowthemto
continuetolitigatetheirclaimsintheCoverageAction.InMarch2021,theCompanyfiledalimitedresponseand
reservationofrightswithrespecttothemotion.TheCourtenteredanagreedordermodifyingthestaytoallowthe
litigationintheCoverageActiontocontinue.InOctober2021,LTLfiledaNoticeofBankruptcyFilingandStayof
ProceedingsclarifyingthattheautomaticstayarisinguponthefilingoftheLTLBankruptcyCaseshouldapplytothe
CoverageAction.InMarch2022,theNewJerseyBankruptcyCourtruledthattheLTLautomaticstayappliedtothe
CoverageAction.
InFebruary2018,asecuritiesclassactionlawsuitwasfiledagainsttheCompanyandcertainnamedofficersinthe
UnitedStatesDistrictCourtfortheDistrictofNewJersey,allegingthattheCompanyviolatedthefederalsecuritieslawsby
failingtodiscloseallegedasbestoscontaminationinbodypowderscontainingtalc,primarilyJOHNSON’SBabyPowder,
andthatpurchasersoftheCompany’ssharessufferedlossesasaresult.Plaintiffisseekingdamages.InApril2019,the
CompanymovedtodismissthecomplaintandbriefingonthemotionwascompleteasofAugust2019.InDecember2019,
theCourtdenied,inpart,themotiontodismiss.InMarch2020,theCompanyansweredthecomplaint.InApril2021,
briefingonPlaintiff’smotionforclasscertificationwascompleted.InJuly2021,theCompanyfiledanoticeofsupplemental
authorityinoppositiontoPlaintiff’smotionforclasscertification,andPlaintifffiledaresponse.InDecember2021,the
Companyfiledamotiontosupplementtheclasscertificationrecord,andinJanuary2022,Plaintiffresponded.In
March2022,LTLaskedtheNewJerseyBankruptcyCourttostaythesecuritiesclassaction.InApril2022,Defendantsfiled
asecondmotiontosupplementtheclasscertificationrecord.InMay2022,theNewJerseyBankruptcyCourtenteredan
orderstayingthesecuritiesclassaction.PlaintiffhasappealedtheBankruptcyCourt’sorder.
AlawsuitwasbroughtagainsttheCompanyintheSuperiorCourtofCaliforniafortheCountyofSanDiegoalleging
violationsofCalifornia’sConsumerLegalRemediesAct(CLRA)relatingtoJOHNSON’SBabyPowder.Inthatlawsuit,the
plaintiffsallegethattheCompanyviolatedtheCLRAbyfailingtoproviderequiredProposition65warnings.InJuly2019,
theCompanyfiledanoticeofremovaltotheUnitedStatesDistrictCourtfortheSouthernDistrictofCaliforniaand
plaintiffsfiledasecondamendedcomplaintshortlythereafter.InOctober2019,theCompanymovedtodismissthe
secondamendedcomplaintforfailuretostateaclaimuponwhichreliefmaybegranted.Inresponsetothosemotions,
plaintiffsfiledathirdamendedcomplaint.InDecember2019,theCompanymovedtodismissthethirdamendedcomplaint
forfailuretostateaclaimuponwhichreliefmaybegranted.InApril2020,theCourtgrantedthemotiontodismissbut
grantedleavetoamend.InMay2020,plaintiffsfiledaFourthAmendedComplaintbutindicatedthattheywouldbefilinga
motionforleavetofileafifthamendedcomplaint.PlaintiffsfiledaFifthAmendedComplaintinAugust2020.TheCompany
movedtodismisstheFifthAmendedComplaintforfailuretostateaclaimuponwhichreliefmaybegranted.In
January2021,theCourtissuedanOrderandopinionrulingintheCompany’sfavorandgrantingthemotiontodismiss
withprejudice.InFebruary2021,PlaintiffsfiledaNoticeofAppealwiththeNinthCircuit.Plaintiffsfiledtheiropeningbrief
inJuly2021.ThecompanyfileditsresponsivebriefinOctober2021.InOctober2021,NoticeofSuggestionof
BankruptcywasfiledwiththeNinthCircuit.AbankruptcystaywasimposedinDecember2021,andtheCourtheldthe
replydeadlineinabeyance.InFebruary2022,theBankruptcyCourtissuedanorderextendingthestay.Theappeal
continuestobeheldinabeyance,withtheCompanybeingrequiredtofileperiodicstatusupdates.
Inaddition,theCompanyhasreceivedinquiries,subpoenas,andrequeststoproducedocumentsregardingtalcmatters
andtheLTLBankruptcyCasefromvariousgovernmentalauthorities.TheCompanyhasproduceddocumentsand
respondedtoinquiries,andwillcontinuetocooperatewithgovernmentinquiries.
ClaimsforpersonalinjuryhavebeenmadeagainstanumberofJohnson&Johnsoncompanies,includingJanssen
Pharmaceuticals,Inc.andtheCompany,arisingoutoftheuseofINVOKANA,aprescriptionmedicationindicatedto
improveglycemiccontrolinadultswithType2diabetes.InDecember2016,lawsuitsfiledinfederalcourtsinthe
UnitedStateswereorganizedasamulti-districtlitigationintheUnitedStatesDistrictCourtfortheDistrictofNewJersey.
Caseshavealsobeenfiledinstatecourts.ClassactionlawsuitshavebeenfiledinCanada.Productliabilitylawsuits
continuetobefiled,andtheCompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipated
numberofcases.TheCompanyhassettledorotherwiseresolvedmanyofthecasesandclaimsintheUnitedStatesand
thecostsassociatedwiththesesettlementsarereflectedintheCompany’saccruals.
ClaimsforpersonalinjuryhavebeenmadeagainstanumberofJohnson&Johnsoncompanies,includingJanssen
Pharmaceuticals,Inc.andtheCompany,arisingoutoftheuseofELMIRON,aprescriptionmedicationindicatedforthe
reliefofbladderpainordiscomfortassociatedwithinterstitialcystitis.Theselawsuits,whichallegethatELMIRON
contributestothedevelopmentofpermanentretinalinjuryandvisionloss,havebeenfiledinbothstateandfederalcourts
acrosstheUnitedStates.InDecember2020,lawsuitsfiledinfederalcourtsintheUnitedStates,includingputativeclass
90 • Johnson&Johnson2022AnnualReportactioncasesseekingmedicalmonitoring,wereorganizedasamulti-districtlitigationintheUnitedStatesDistrictCourtfor
theDistrictofNewJersey.Inaddition,caseshavebeenfiledinvariousstatecourtsofNewJersey,whichhavebeen
coordinatedinamulti-countylitigationinBergenCounty,aswellastheCourtofCommonPleasinPhiladelphia,which
havebeencoordinatedandgrantedmasstortdesignation.Inaddition,threeclassactionlawsuitshavebeenfiledin
Canada.Productliabilitylawsuitscontinuetobefiled,andtheCompanycontinuestoreceiveinformationwithrespectto
potentialcostsandtheanticipatednumberofcases.TheCompanyhasestablishedaccrualsfordefenseandindemnity
costsassociatedwithELMIRONrelatedproductliabilitylitigation.
ClaimsforpersonalinjuryhavebeenmadeagainstJohnsonandJohnsonConsumerInc.(JJCI),arisingoutoftheuseof
TYLENOL,anover-the-counterpainmedication,allegingthatprenatalexposuretoacetaminophenisassociatedwiththe
developmentofautismspectrumdisorderand/orattention-deficit/hyperactivitydisorder.InOctober2022,lawsuitsfiledin
federalcourtsintheUnitedStateswereorganizedasamulti-districtlitigationintheUnitedStatesDistrictCourtforthe
SouthernDistrictofNewYork.Inaddition,lawsuitshavebeenfiledinCanada.Productliabilitylawsuitscontinuetobe
filed,andtheCompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberof
cases.TheCompanyhasestablishedaccrualsfordefensecostsassociatedwithTYLENOLrelatedproductliability
litigation.
INTELLECTUALPROPERTY
CertainsubsidiariesoftheCompanyaresubject,fromtimetotime,tolegalproceedingsandclaimsrelatedtopatent,
trademarkandotherintellectualpropertymattersarisingoutoftheirbusinesses.Manyofthesemattersinvolvechallenges
tothecoverageand/orvalidityofthepatentsonvariousproductsandallegationsthatcertainoftheCompany’sproducts
infringethepatentsofthirdparties.Althoughthesesubsidiariesbelievethattheyhavesubstantialdefensestothese
challengesandallegationswithrespecttoallsignificantpatents,therecanbenoassuranceastotheoutcomeofthese
matters.Alossinanyofthesecasescouldadverselyaffecttheabilityofthesesubsidiariestoselltheirproducts,resultin
lossofsalesduetolossofmarketexclusivity,requirethepaymentofpastdamagesandfutureroyalties,andmayresultin
anon-cashimpairmentchargeforanyassociatedintangibleasset.Significantmattersaredescribedbelow.
MedTech
InAugust2018,IntuitiveSurgical,Inc.andIntuitiveSurgicalOperations,Inc.(collectively,Intuitive)filedapatent
infringementsuitagainstAurisHealth,Inc.(Auris)inUnitedStatesDistrictCourtfortheDistrictofDelaware.Inthesuit,
IntuitiveallegeswillfulinfringementofU.S.PatentNos.6,522,906(’906);6,800,056(’056);8,142,447(’447);and
9,452,276(’276)basedonAuris’MONARCHPlatform.AurisfiledIPRPetitionswiththeU.S.PatentandTrademark
Office(USPTO)regardingthe’056,’447,’276and’906patents.InDecember2019,theUSPTOdeniedreviewofthe
’056patent.InFebruaryandMarch2020,theUSPTOinstitutedreviewofthe’447,and’906patentsanddeniedreview
ofthe’276patent.InMarch2021,theUSPTOruledthatthechallengedclaimsofthe’447and’906patentsarenot
invalid.Aurisappealed,andinApril2022,theUnitedStatesCourtofAppealsfortheFederalCircuitvacatedthedecision
thatthe’447patentwasnotinvalidandremandedthedecisiontotheUSPTOforfurtherreview.InMay2022,the
UnitedStatesCourtofAppealsfortheFederalCircuitconfirmedtherulingthatclaim53ofthe’906patentwasnot
invalid,vacatedthedecisionthattheremainingclaimsofthe’906patentwerenotinvalidandremandedthedecisionto
theUSPTOforfurtherreview.Aurisfiledarequestforreexaminationofthe’276patentinNovember2021,andin
January2022,theUSPTOgrantedthereexaminationrequest.TrialisscheduledtobegininSeptember2023.
InAugust2019,RSBSpineLLC(RSBSpine)filedapatentinfringementsuitagainstDePuySynthes,Inc.inthe
UnitedStatesDistrictCourtfortheDistrictofDelaware.InOctober2019,RSBSpineamendedthecomplainttochange
thenameddefendantstoDePuySynthesSales,Inc.andDePuySynthesProducts,Inc.Inthesuit,RSBSpinealleges
willfulinfringementofU.S.PatentNos.6,984,234(’234)and9,713,537(’537)byoneormoreofthefollowingproducts:
ZERO-P-VASpacer,ZERO-PSpacer,ZERO-PNATURALPlate,SYNFIXLRSpacerandSYNFIXEvolutionSystem.RSB
Spineseeksmonetarydamagesandinjunctiverelief.InNovember2019,thesuitwasconsolidatedforpre-trialpurposes
withotherpatentinfringementsuitsbroughtbyRSBSpineintheUnitedStatesDistrictCourtfortheDistrictofDelaware
againstLifeSpine,Inc.,MedactaUSA,Inc.,andPrecisionSpine,Inc.InJune2022,DePuyfiledpotentiallydispositive
summaryjudgmentmotionsthatthe’234patentisinvalidasanticipatedandthe’537patentisnotinfringed.In
November2022,theCourtgrantedDePuy’ssummaryjudgmentmotionthatthe’234patentisinvalidasanticipatedand
deniedDePuy’smotionthatthe’537patentisnotinfringed.InDecember2022,theCourtconductedajurytrialonthe
’537patentwherethejuryfoundthatthe’537patentwasnotliterallyinfringed,butthatDePuyinfringedunderthe
doctrineofequivalents(DOE).ThejuryawardedRSB$12millionindamagessubjecttopost-trialmotionsandappeals.
Johnson&Johnson2022AnnualReport • 91InOctober2020,RasmussenInstruments,LLC(Rasmussen)filedapatentinfringementsuitagainstDePuySynthes
Products,Inc.,DePuySynthesSales,Inc.andMedicalDeviceBusinessServices,Inc.(collectively,DePuy)inthe
UnitedStatesDistrictCourtfortheDistrictofMassachusetts.RasmussenallegesthatDePuywillfullyinfringesU.S.Patent
Nos.9,492,180(’180)and10,517,583(’583)bymakingandsellingtheAttuneBalancedSizer.InApril2021,
RasmussensoughtpermissiontoamenditsinfringementcontentionstoallegethatDePuyalsowillfullyinfringesthe
’583patentbymakingandsellingtheAttuneBalancingBlocks.Rasmussenseekstrebledamagesforwillfulinfringement.
TrialconcludedinMarch2022,withthejuryreturningaverdictinfavorofRasmussen,findingwillfulinfringementofthe
’180patent,andawardingdamagesintheamountof$20million.DePuychallengedtheverdictinitspost-trialmotions.In
July2022,ahearingwasheldonthepost-trialmotions.
Pharmaceutical
LitigationAgainstFilersofAbbreviatedNewDrugApplications(ANDAs)
ThefollowingsummarizeslawsuitstheCompany’ssubsidiarieshavebroughtagainstgenericcompaniesthathavefiled
ANDAswiththeU.S.FDAorundertakensimilarregulatoryprocessesoutsideoftheUnitedStates,seekingtomarket
genericformsofproductssoldbyvarioussubsidiariesoftheCompanypriortoexpirationoftheapplicablepatents
coveringthoseproducts.TheseANDAstypicallyincludeallegationsofnon-infringementandinvalidityoftheapplicable
patents.TheInterPartesReview(IPR)processwiththeUSPTO,createdunderthe2011AmericaInventsAct,isalso
beingusedattimesbygenericcompaniesinconjunctionwithANDAsandlawsuits,tochallengetheapplicablepatents.In
theeventtheCompany’ssubsidiariesarenotsuccessfulinanaction,ortheautomaticstatutorystayoftheANDAsexpires
beforetheUnitedStatesDistrictCourtrulingsareobtained,thegenericcompaniesinvolvedwouldhavetheability,upon
approvaloftheU.S.FDA,tointroducegenericversionsoftheirproductstothemarket,resultinginthepotentialfor
substantialmarketshareandrevenuelossesfortheapplicableproducts,andwhichmayresultinanon-cashimpairment
chargeinanyassociatedintangibleasset.Inaddition,fromtimetotime,theCompany’ssubsidiariesmaysettlethesetypes
ofactionsandsuchsettlementscaninvolvetheintroductionofgenericversionsoftheproductsatissuetothemarket
priortotheexpirationoftherelevantpatents.
ZYTIGA
BeginninginJanuary2019,JanssenInc.,JanssenOncology,Inc.,andBTGInternationalLtd.(collectively,Janssen)
initiatedStatementsofClaimunderSection6ofthePatentedMedicines(NoticeofCompliance)RegulationsinCanada
againstApotexInc.(Apotex),PharmascienceInc.(Pharmascience)andDr.Reddy’sLaboratoriesLtd.andDr.Reddy’s
Laboratories,Inc.(collectively,DRL)inresponsetothoseparties’filingofAbbreviatedNewDrugSubmissions(ANDS)
seekingapprovaltomarketgenericversionsofZYTIGAbeforetheexpirationoftheCanadianPatentNo.2,661,422
(’422).ThetrialintheseactionsconcludedinNovember2020,andtheCourtissuedadecisionholdingthe’422patent
invalidinJanuary2021.InFebruary2021,Janssenappealedthedecision.Theappealhearingtookplacein
September2022.InNovember2022,Janssen’sappealwasdismissed.
InApril2021,July2021andApril2022,respectively,Apotex,DRLandPharmascienceinitiatedStatementsofClaim
underSection8ofthePatentedMedicines(NoticeofCompliance)RegulationsagainstJanssenseekingdamagesin
respectofthosepartiesgenericZytigatablets.TrialsagainstApotexandDRLarescheduledforJune2023.Atrialdatefor
thePharmascienceactionhasnotbeenset.
XARELTO
BeginninginMarch2021,JanssenPharmaceuticals,Inc.(JPI)andBayerPharmaAGandBayerAG(collectively,Bayer)
filedpatentinfringementlawsuitsintheUnitedStatesDistrictCourtfortheDistrictofDelawareagainstanumberof
genericcompanieswhofiledANDAsseekingapprovaltomarketgenericversionsofXARELTO(2.5mg)beforeexpiration
ofU.S.PatentNo.10,828,310(’310).Thefollowinggenericdrugcompaniesarenameddefendants:Dr.Reddy’s
Laboratories,Inc.andDr.Reddy’sLaboratories,Ltd.;LupinLimitedandLupinPharmaceuticals,Inc.;TaroPharmaceutical
IndustriesLtd.andTaroPharmaceuticalsU.S.A.,Inc.;andTevaPharmaceuticalsUSA,Inc.InOctober2021,thecourt
consolidatedtheDelawarelawsuitsforallpurposes,includingtrial.TrialfortheconsolidatedDelawarelawsuitsis
scheduledtobegininMay2023.
InJuly2021,JPIandBayerfiledapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheNorthernDistrict
ofWestVirginiaagainstMylanPharmaceuticalsInc.andMylanInc.(collectively,Mylan)whichfiledanANDAseeking
approvaltomarketagenericversionofXARELTO(2.5mg)beforeexpirationofthe’310patent.InAugust2021,JPIand
BayerfiledamotionbeforetheUnitedStatesJudicialPanelonMultidistrictLitigation(theMDLpanel)totransferthis
92 • Johnson&Johnson2022AnnualReportlawsuittotheUnitedStatesDistrictCourtfortheDistrictofDelawareforcoordinatedandconsolidatedpretrial
proceedings.InDecember2021,theMDLpanelgrantedthemotion.InAugust2022,afterreceivingasecondnotice
letterfromMylanregardingthesameANDA,JPIandBayerfiledasecondpatentinfringementlawsuitintheUnitedStates
DistrictCourtfortheNorthernDistrictofWestVirginiaagainstMylan.InSeptember2022,Mylanmovedtodismissthe
secondlawsuit.InSeptember2022,theMDLpaneltransferredthesecondlawsuittotheDistrictofDelaware.Notrial
datehasbeensetforthesetwolawsuits.InOctober2022,Mylanvoluntarilywithdrewitsmotiontodismiss.
Ineachoftheselawsuits,JPIandBayerareseekinganorderenjoiningdefendantsfrommarketingtheirgenericversionof
XARELTO(2.5mg)beforetheexpirationofthe’310patent.InJanuary2023,thecourtissuedanorderstayingthe
lawsuitsuntilafterafinalwrittendecisionisissuedintheInterPartesReviewproceedingsonthe’310patent.
InFebruary2022,MylanPharmaceuticalsInc.filedaPetitionforInterPartesReview(IPR)withtheUnitedStatesPatent
andTrademarkOffice(USPTO),seekingtoinvalidatethe’310patent.InAugust2022,thePatentTrialandAppealBoard
(PTAB)issuedadecisioninstitutingIPR.
InSeptember2022,InvaGenPharmaceuticals,Inc.filedaPetitionforIPRwiththeUSPTOseekingtoinvalidatethe
’310patent.AlsoinSeptember2022,TevaPharmaceuticalsUSA,Inc.filedaPetitionforIPRwiththeUSPTOseekingto
invalidatethe’310patent.InOctober2022,thePTABissueddecisionsinstitutingIPRinbothproceedingsandjoining
themwiththeearlierIPRproceedingfiledbyMylanPharmaceuticalsInc.
InSeptember2022,JPI,Bayer,andBayerIntellectualPropertyGmbH(BIP)initiatedapatentinfringementlawsuitinthe
UnitedStatesDistrictCourtfortheDistrictofNewJerseyagainstUSVPrivateLimited(USV),whofiledanANDAseeking
approvaltomarketgenericversionsofXARELTO(2.5mg,10mg,15mg,and20mg)beforetheexpirationofthe
‘310patentandU.S.PatentNo.9,539,218(’218).JPI,Bayer,andBIPareseekinganorderenjoiningUSVfrommarketing
itsgenericversionofXARELTO(2.5mg)beforetheexpirationofthe’310patent,anditsgenericversionsofXARELTO
(10mg,15mg,and20mg)beforetheexpirationofthe’218patent.InNovember2022,theMDLpaneltransferredthis
lawsuittotheUnitedStatesDistrictCourtfortheDistrictofDelaware.
InSeptember2022,JPI,BayerAG,andBIPinitiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourtfor
theDistrictofNewJerseyagainstMankindPharmaLimited(Mankind),whofiledanANDAseekingapprovaltomarket
genericversionsofXARELTO(10mg,15mg,and20mg)beforetheexpirationofthe’218patent.JPI,BayerAG,andBIP
areseekinganorderenjoiningMankindfrommarketingitsgenericversionsofXARELTObeforetheexpirationofthe
’218patent.
InNovember2022,JPI,Bayer,andBIPinitiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourtforthe
DistrictofDelawareagainstEpicPharma,LLC(Epic),whofiledanANDAseekingapprovaltomarketgenericversionsof
XARELTO(2.5mg,10mg,15mg,and20mg)beforetheexpirationofthe’310patentandthe’218patent.JPI,Bayer,
andBIPareseekinganorderenjoiningEpicfrommarketingitsgenericversionofXARELTO(2.5mg)beforetheexpiration
ofthe’310patent,anditsgenericversionsofXARELTO(10mg,15mg,and20mg)beforetheexpirationofthe
’218patent.
InDecember2022,JPIandBayerinitiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrict
ofDelawareagainstApotexInc.andApotexCorp.(collectively,Apotex),whofiledanANDAseekingapprovaltomarket
genericversionsofXARELTO(2.5mg)beforetheexpirationofthe’310patent.JPIandBayerareseekinganorder
enjoiningApotexfrommarketingitsgenericversionofXARELTO(2.5mg)beforetheexpirationofthe’310patent.
OPSUMIT
InMay2020,JanssenInc.(Janssen)andActelionPharmaceuticalsLtd(Actelion)initiatedaStatementofClaimunder
Section6ofthePatentedMedicines(NoticeofCompliance)RegulationsagainstSandozCanadaInc.(Sandoz)inCanada
inresponsetoSandoz’sfilingofanANDSseekingapprovaltomarketagenericversionofOPSUMIT10mg,beforethe
expirationofCanadianPatentNo.2,659,770(’770).Sandozstipulatedtoinfringementofthe’770patent.Trialagainst
SandozontheissueofvalidityconcludedinFebruary2022,andinMay2022,theCourtissuedadecisioninfavorof
JanssenandActelion.InJune2022,Sandozappealedthedecision.
InMay2020,JanssenandActelioninitiatedaStatementofClaimunderSection6ofthePatentedMedicines(Noticeof
Compliance)RegulationsagainstApotexInc.(Apotex)inCanadainresponsetoApotex’sfilingofanANDSseeking
approvaltomarketagenericversionofOPSUMIT10mg,beforetheexpirationofthe’770patent.Apotexstipulatedto
validityofthe’770patent.TrialagainstApotexontheissueofinfringementconcludedinMarch2022,andinMay2022,
theCourtissuedadecisioninfavorofJanssenandActelion.InJune2022,Apotexappealedthedecision.
Johnson&Johnson2022AnnualReport • 93InJanuary2023,JanssenandActelioninitiatedaStatementofClaimunderSection6ofthePatentedMedicines(Notice
ofCompliance)RegulationsagainstGenericMedicalPartnersInc.(GMP)inCanadainresponsetoGMP’sfilingofan
ANDSseekingapprovaltomarketagenericversionofOPSUMIT10mg,beforetheexpirationofCanadianPatentNos.
2,659,770and2,621,273.
IneachoftheseCanadianactions,JanssenandActelionareseekinganorderenjoiningthedefendantsfrommarketing
theirgenericversionsofOPSUMITbeforetheexpirationoftherelevantpatents.
InJanuary2023,ActelionPharmaceuticalsLtdandActelionPharmaceuticalsUS,Inc.(collectively,Actelion)initiateda
patentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictofNewJerseyagainstSunPharmaceutical
IndustriesLimitedandSunPharmaceuticalIndustries,Inc.(collectively,Sun)whofiledanANDAseekingapprovalto
marketagenericversionofOPSUMITbeforetheexpirationofU.S.PatentNos.7,094,781(’781)and10,946,015(’015).
ActelionisseekinganorderenjoiningSunfrommarketingtheirgenericversionsofOPSUMITbeforetheexpirationofthe
’781and’015patents.
INVEGASUSTENNA
InJanuary2018,JanssenPharmaceuticaNVandJanssenPharmaceuticals,Inc.(collectively,Janssen)initiatedapatent
infringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictofNewJerseyagainstTevaPharmaceuticalsUSA,
Inc.(Teva),whichfiledanANDAseekingapprovaltomarketagenericversionofINVEGASUSTENNAbeforethe
expirationofU.S.PatentNo.9,439,906(’906).TrialconcludedinOctober2020.InOctober2021,thecourtissueda
decisioninJanssen’sfavor.Tevahasappealedthedecision.
InAugust2019,JansseninitiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictof
NewJerseyagainstMylanLaboratoriesLimited(Mylan),whichfiledanANDAseekingapprovaltomarketagenericversion
ofINVEGASUSTENNAbeforetheexpirationofthe’906patent.Pursuanttoanagreementbytheparties,judgmentin
favorofJanssenwasenteredinDecember2021.Mylanappealed.
InDecember2019,JansseninitiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourtsfortheDistrictsof
NewJerseyandDelawareagainstPharmascienceInc.,MallinckrodtPLCandSpecgxLLC(collectively,Pharmascience),
whichfiledanANDAseekingapprovaltomarketagenericversionofINVEGASUSTENNAbeforetheexpirationofthe
’906patent.
InNovember2021,JansseninitiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictof
DelawareagainstTolmar,Inc.,TolmarTherapeutics,Inc.,TolmarPharmaceuticals,Inc.andTolmarHolding,Inc.
(collectively,Tolmar),whichfiledanANDAseekingapprovaltomarketagenericversionofINVEGASUSTENNAbefore
theexpirationofthe’906patent.AtrialisscheduledtobegininOctober2023.
InFebruary2022,JansseninitiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictof
NewJerseyagainstAccordHealthcare,Inc.,AccordHealthcare,Ltd.andIntasPharmaceuticals,Ltd.(collectively,Accord),
whofiledanANDAseekingapprovaltomarketagenericversionofINVEGASUSTENNAbeforetheexpirationofthe
’906patent.
IneachoftheseU.S.lawsuits,Janssenisseekinganorderenjoiningthedefendantfrommarketingagenericversionof
INVEGASUSTENNAbeforetheexpirationoftherelevantpatents.
InFebruary2018,JanssenInc.andJanssenPharmaceuticaNV(collectively,JanssenCanada)initiatedaStatementof
ClaimunderSection6ofthePatentedMedicines(NoticeofCompliance)RegulationsagainstTevaCanadaLimited
(TevaCanada)inresponsetoTeva’sfilingofanANDSseekingapprovaltomarketagenericversionofINVEGA
SUSTENNAbeforetheexpirationofCanadianPatentNos.2,309,629(’629)and2,655,335(’335).Janssensubsequently
discontinuedtheportionofthelawsuitrelatingtothe’629patent.InMay2020,theCanadianFederalCourtissueda
PublicJudgmentandReasonsdeclaringthatTevaCanada’sgenericversionofINVEGASUSTENNA,ifapproved,would
infringecertainclaimsofthe’335patentandthattheclaimsofthe’335patentarenotinvalid.TevaCanadaappealed.
InNovember2020,JanssenCanadainitiatedaStatementofClaimunderSection6ofthePatentedMedicines(Noticeof
Compliance)RegulationsagainstPharmascienceInc.inresponsetoPharmascienceInc.’sfilingofanANDSseeking
approvaltomarketagenericversionofINVEGASUSTENNAbeforetheexpirationofthe’335patent.Asummarytrialon
theissueofinfringementtookplaceinNovember2021.InJanuary2022,theCourtissuedadecisioninfavorofJanssen
ontheissueofinfringement.Pharmasciencefiledanappeal.InMarch2022,JanssenCanadainitiatedaStatementof
ClaimunderSection6ofthePatentedMedicines(NoticeofCompliance)RegulationsagainstPharmascienceinresponse
toPharmascience’sfilingofanANDSseekingapprovaltomarketagenericversionofanadditionalstrengthof
94 • Johnson&Johnson2022AnnualReportINVEGASUSTENNAbeforetheexpirationofthe’335patent.TheactionhasbeenconsolidatedwiththeNovember2020
actionfortrial,whichtookplaceinJuly2022.InAugust2022,theCourtissuedadecisionfindingtheclaimsof
the’335patentarenotinvalid.Pharmascienceappealed.
InJanuary2021,JanssenCanadainitiatedaStatementofClaimunderSection6ofthePatentedMedicines(Noticeof
Compliance)RegulationsagainstApotexInc.(Apotex)inresponsetoApotex’sfilingofanANDS(originalANDS)seeking
approvaltomarketagenericversionofINVEGASUSTENNAbeforetheexpirationofthe’335patent.Asummarytrialon
theissueofinfringementtookplaceinDecember2021.InJanuary2022,theCourtissuedadecisioninfavorofJanssen
ontheissueofinfringement.Apotexappealed.
InJune2022,JanssenCanadainitiatedStatementsofClaimunderSection6ofthePatentedMedicines(Noticeof
Compliance)RegulationsagainstApotexinresponsetoApotex’sNoticeofAllegationofinvaliditywithrespecttothe
originalANDSandinresponsetoApotex’sfilingofanANDSseekingapprovaltomarketagenericversionofanadditional
strengthofINVEGASUSTENNAbeforetheexpirationofthe’335patent.AtrialisscheduledtobegininMarch2024.
IneachoftheseCanadianlawsuits,JanssenCanadaisseekinganorderenjoiningthedefendantfrommarketingageneric
versionofINVEGASUSTENNAbeforetheexpirationoftherelevantpatents.
INVEGATRINZA
InSeptember2020,JanssenPharmaceuticals,Inc.,JanssenPharmaceuticaNV,andJanssenResearch&Development,
LLC(collectively,Janssen)initiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictof
NewJerseyagainstMylanLaboratoriesLimited,MylanPharmaceuticalsInc.,andMylanInstitutionalLLC(collectively,
Mylan).MylanfiledanANDAseekingapprovaltomarketgenericversionsofINVEGATRINZA(546mg)beforeexpiration
ofU.S.PatentNo.10,143,693(’693)relatingtoINVEGATRINZA(546mg).
InAugust2021,JansseninitiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictofNew
JerseyagainstMylan.MylanfiledanANDAseekingapprovaltomarketgenericversionsofINVEGATRINZA(819mg)
beforeexpirationofthe’693patent.
InOctober2021,JansseninitiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictofNew
JerseyagainstMylan.MylanfiledanANDAseekingapprovaltomarketgenericversionsofINVEGATRINZA(273mgand
410mg)beforeexpirationofthe’693patent.
InJanuary2022,thecourtconsolidatedthethreecasesintothecasefiledinSeptember2020.Ineachofthese
consolidatedcases,JanssenisseekinganorderenjoiningMylanfrommarketingitsgenericversionsofINVEGATRINZA
beforeexpirationofthe’693patent.TrialwasconductedinNovemberandDecember2022,andpost-trialbriefingis
proceeding.ClosingargumentswillbeheldinMarch2023.
IMBRUVICA
InMarch2019,PharmacyclicsLLC(Pharmacyclics)andJanssenBiotech,Inc.(JBI)filedapatentinfringementlawsuitin
theUnitedStatesDistrictCourtfortheDistrictofDelawareagainstAlvogenPineBrookLLCandNatcoPharmaLtd.
(collectively,Alvogen),whichfiledanANDAseekingapprovaltomarketgenericversionsofIMBRUVICAtablets,asserting
infringementofU.S.PatentNos.7,514,444;8,003,309;8,476,284;8,497,277;8,697,711;8,753,403;8,754,090;
8,754,091;8,952,015;8,957,079;9,181,257;9,296,753;9,655,857;9,725,455;10,010,507;10,106,548;and
10,125,140.InJune2019,PharmacyclicsandJBIamendedtheircomplaintagainstAlvogentofurtherallegeinfringement
ofU.S.PatentNo.10,213,386.
TrialagainstAlvogentookplaceinOctober2020.InAugust2021,theDistrictCourtissuedadecisioninfavorof
PharmacyclicsandJanssenfindingtheassertedclaimsagainstAlvogentobeinfringedandnotinvalid.InNovember2022,
theUnitedStatesCourtofAppealsfortheFederalCircuitaffirmedtheDistrictCourt’sdecision.
InSeptember2021,PharmacyclicsandJanssenInc.(JanssenCanada)initiatedStatementsofClaimunderSection6of
thePatentedMedicines(NoticeofCompliance)RegulationsagainstNatcoPharma(Canada)Inc.(Natco)inresponseto
Natco’sfilingoftwoANDSsseekingapprovaltomarketgenericversionsofIMBRUVICAcapsulesbeforetheexpirationof
CanadianPatentNos.2,663,116(’116);2,928,721(’721);2,800,913(’913);3,007,787(’787);3,007,788(’788);
2,875,986(’986);and3,022,256(’256).Inthislawsuit,PharmacyclicsandJanssenCanadaareseekinganorder
enjoiningNatcofrommarketingitsgenericversionofIMBRUVICAbeforetheexpirationoftherelevantpatents.Trialis
scheduledtobegininJuly2023.
Johnson&Johnson2022AnnualReport • 95InOctober2022,PharmacyclicsandJanssenCanadainitiatedasecondStatementofClaimunderSection6ofthe
PatentedMedicines(NoticeofCompliance)RegulationsagainstNatcoinresponsetoNatco’sfilingofanANDSseeking
approvaltomarketagenericversionofIMBRUVICAcapsulesbeforetheexpirationofthe’116,’721,’913,’787,and’788
patentsandCanadianPatentNo.2,851,808.Inthislawsuit,PharmacyclicsandJanssenCanadaareseekinganorder
enjoiningNatcofrommarketingitsgenericversionofIMBRUVICAcapsulesbeforetheexpirationoftherelevantpatents.
TrialinthissecondactionisscheduledtobegininAugust2024.
InFebruary2023,PharmacyclicsandJanssenCanadainitiatedaStatementofClaimunderSection6ofthePatented
Medicines(NoticeofCompliance)RegulationsagainstSandozCanadaInc.(Sandoz)inresponsetoSandoz’sfilingofan
ANDSseekingapprovaltomarketagenericversionofIMBRUVICAcapsulesbeforetheexpirationofthe’116,’913,’787,
and’788patents.AlsoinFebruary2023,PharmacyclicsandJansseninitiatedaStatementofClaimunderSection8.2of
thePatentedMedicines(NoticeofCompliance)RegulationsagainstSandozassertingthe’721and’256patents,which
arealsolistedinHealthCanada’sPatentRegisterforIMBRUVICA.Intheselawsuits,PharmacyclicsandJanssenCanada
areseekinganorderenjoiningSandozfrommarketingitsgenericversionofIMBRUVICAcapsulesbeforetheexpirationof
therelevantpatents.Atrialdatefortheseactionshasnotbeenset.
SYMTUZA
InNovember2021,JanssenProducts,L.P.andJanssenSciencesIrelandUnlimitedCompany(collectively,Janssen)and
GileadSciences,Inc.andGileadSciencesIrelandUC(collectively,Gilead)initiatedapatentinfringementlawsuitinthe
UnitedStatesDistrictCourtfortheDistrictofDelawareagainstLupinLimited,LupinPharmaceuticals,Inc.,MSN
LaboratoriesPrivateLtd.,MSNLifeSciencesPrivateLtd.,andMSNPharmaceuticalsInc.(collectively,Lupin),whichfiled
anANDAseekingapprovaltomarketagenericversionofSYMTUZAbeforetheexpirationofU.S.PatentNos.10,039,718
(’718)and10,786,518(’518).ThetrialisscheduledtobegininOctober2023.
InOctober2022,JanssenProducts,L.P.andJanssenSciencesIrelandUnlimitedCompany(collectively,Janssen)and
GileadSciences,Inc.andGileadSciencesIrelandUC(collectively,Gilead)initiatedapatentinfringementlawsuitinthe
UnitedStatesDistrictCourtfortheDistrictofDelawareagainstApotexInc.andApotexCorp.(collectively,Apotex),which
filedanANDAseekingapprovaltomarketagenericversionofSYMTUZAbeforetheexpirationofthe’718and’518
patents.
IneachoftheseU.S.lawsuits,Janssenisseekinganorderenjoiningthedefendantfrommarketingagenericversionof
SYMTUZAbeforetheexpirationoftherelevantpatents.
ERLEADA
InMay2022,AragonPharmaceuticals,Inc.andJanssenBiotech,Inc.(collectively,Janssen)andSloanKetteringInstitute
forCancerResearch(SKI)initiatedpatentinfringementlawsuitsinUnitedStatesDistrictCourtfortheDistrictsof
NewJerseyandDelawareagainstLupinLimitedandLupinPharmaceuticals,Inc.(collectively,Lupin),whichfiledanANDA
seekingapprovaltomarketagenericversionofERLEADAbeforetheexpirationofU.S.PatentNo.9,481,663(’663).In
August2022,JanssenandSKIfiledafirstamendedcomplaintagainstLupinaddingU.S.PatentNos.9,884,054(’054),
10,052,314(’314),10,702,508(’508)and10,849,888(’888)tothesuit.JanssenandSKIareseekinganorderenjoining
LupinfrommarketingitsgenericversionofERLEADAbeforetheexpirationofthe’663,’054,’314,’508,and’888patents.
InAugust2022,JanssenandSKIvoluntarilydismissedtheDelawarecomplaint.TheNewJerseyactionisproceeding.
InMay2022,JanssenandSKIinitiatedapatentinfringementlawsuitinUnitedStatesDistrictCourtfortheDistrictof
NewJerseyagainstZydusWorldwideDMCC,ZydusPharmaceuticals(USA),Inc.,andZydusLifesciencesLimited
(collectively,Zydus),whichfiledanANDAseekingapprovaltomarketagenericversionofERLEADAbeforetheexpiration
ofthe’663,’054,’314,’508,and’888patents.JanssenandSKIareseekinganorderenjoiningZydusfrommarketingits
genericversionofERLEADAbeforetheexpirationofthe’663,’054,’314,’508,and’888patents.
InMay2022,Janssen,TheRegentsoftheUniversityofCalifornia(UC),andSKIinitiatedpatentinfringementlawsuitsin
UnitedStatesDistrictCourtfortheDistrictsofNewJerseyandDelawareagainstSandozInc.(Sandoz),whichfiledan
ANDAseekingapprovaltomarketagenericversionofERLEADAbeforetheexpirationofthe’663patentandU.S.Patent
Nos.8,445,507(’507),8,802,689(’689),9,338,159(’159),and9,987,261(’261).InAugust2022,Janssen,UC,and
SKIfiledafirstamendedcomplaintagainstSandozaddingthe’054,’314,’508,and’888patentstothesuit.InAugust
2022,Janssen,UC,andSKIvoluntarilydismissedtheDelawarecomplaint.InDecember2022,Janssen,UC,andSKIfiled
asecondamendedcomplaintagainstSandozwithdrawingthe’054,’314,’508,and’888patentsfromthesuitwithout
prejudice.Janssen,UC,andSKIareseekinganorderenjoiningSandozfrommarketingitsgenericversionofERLEADA
beforetheexpirationofthe’663,’507,’689,’159,and’261patents.TheNewJerseyactionisproceeding.
96 • Johnson&Johnson2022AnnualReportInMay2022,Janssen,UC,andSKIinitiatedpatentinfringementlawsuitsinUnitedStatesDistrictCourtfortheDistrictsof
NewJerseyandDelawareagainstEugiaPharmaSpecialitiesLimited,AurobindoPharmaUSA,Inc.,andAuromedics
PharmaLLC(collectively,Eugia),whichfiledanANDAseekingapprovaltomarketagenericversionofERLEADAbefore
theexpirationofthe’663,’507,’689,’159and’261patents.InSeptember2022,Janssen,UC,andSKIfiledafirst
amendedcomplaintagainstEugiaaddingU.S.PatentNos.9,884,054(’054),10,052,314(’314),10,702,508(’508)and
10,849,888(’888)tothesuit.InSeptember2022,Janssen,UC,andSKIvoluntarilydismissedtheDelawarecomplaint.
Janssen,UC,andSKIareseekinganorderenjoiningEugiafrommarketingitsgenericversionofERLEADAbeforethe
expirationofthe’663,’507,’689,’159,’261,’054,’314,’508,and’888patents.TheNewJerseyactionisproceeding.
InMay2022,Janssen,UC,andSKIinitiatedpatentinfringementlawsuitsinUnitedStatesDistrictCourtfortheDistrictsof
NewJerseyandDelawareagainstHeteroLabsLimitedUnitVandHeteroUSA,Inc.(collectively,Hetero),whichfiledan
ANDAseekingapprovaltomarketagenericversionofERLEADAbeforetheexpirationofthe’663,’507,’054,’314,’508,
and’888patents.Janssen,UC,andSKIareseekinganorderenjoiningHeterofrommarketingitsgenericversionof
ERLEADAbeforetheexpirationofthe’663,’507,’054,’314,’508and’888patents.InAugust2022,Janssen,UC,and
SKIvoluntarilydismissedtheDelawarecomplaint.TheNewJerseyactionisproceeding.
UPTRAVI
InAugust2022,ActelionPharmaceuticalsLtd,andJanssenInc.(collectively,Janssen)andNipponShinyakuCo.(Nippon
Shinyaku)initiatedaStatementofClaimunderSection6ofthePatentedMedicines(NoticeofCompliance)Regulations
againstSandozCanadaInc.inresponsetoSandoz’sfilingofanANDSseekingapprovaltomarketgenericversionsof
UPTRAVItabletsbeforetheexpirationofCanadianPatentNos.2,731,370and2,764,475.Inthislawsuit,Janssenand
NipponShinyakuareseekinganorderenjoiningSandozfrommarketingitsgenericversionofUPTRAVIbeforethe
expirationoftherelevantpatents.AtrialisscheduledtobegininMay2024.
InNovember2022,ActelionPharmaceuticalsUSInc.andActelionPharmaceuticalsLtd(collectively,Actelion)andNippon
ShinyakuCo.,Ltd.(NipponShinyaku)initiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourtforthe
DistrictofDelawareagainstAlembicPharmaceuticalsLimitedandAlembicPharmaceuticalsInc.(collectively,Alembic)
whofiledanANDAseekingapprovaltomarketgenericversionsofUPTRAVIinjectionforintravenoususebeforeexpiration
ofU.S.PatentNos.8,791,122(’122)and9,284,280(’280)relatingtoUPTRAVI.Inthislawsuit,ActelionandNippon
ShinyakuareseekinganorderenjoiningAlembicfrommarketingagenericversionofUPTRAVIbeforetheexpirationofthe
relevantpatents.Atrialdatehasnotbeenset.
InFebruary2023,ActelionandNipponShinyakuinitiatedapatentinfringementlawsuitintheUnitedStatesDistrictCourt
fortheDistrictofDelawareagainstLupinLtd.andLupinPharmaceuticals,Inc.(collectively,Lupin)whofiledanANDA
seekingapprovaltomarketgenericversionsofUPTRAVIinjectionforintravenoususebeforeexpirationofthe’122and
’280patentsrelatingtoUPTRAVI.Inthislawsuit,ActelionandNipponShinyakuareseekinganorderenjoiningLupinfrom
marketingagenericversionofUPTRAVIbeforetheexpirationoftherelevantpatents.Atrialdatehasnotbeenset.
OtherLitigation
InNovember2021,JanssenPharmaceuticaN.V.(Janssen)providedtoAlkermesPharmaIrelandLimited,ElanPharma
InternationalLimited,andElanDrugDelivery,Inc.three-months’noticeofterminationofaLicenseAgreementbyand
amongElanPharmaceuticalResearchCorp.,d/b/aNanosystems,ElanPharmaInternationalLimitedandJanssen,
executedinMarch,1999.InNovember2021,JanssenalsoprovidedtoAlkermesPharmaIrelandLimitedthree-months’
noticeofterminationofaLicenseAgreementbetweenElanPharmaInternationalLimitedandJanssenexecutedinJuly
2003.InApril2022,inresponsetothesenotices,AlkermesPharmaIrelandLimited(Alkermes)initiatedarbitrationinthe
InternationalInstituteforConflictPreventionandResolution.ThepartiesexchangedopeningbriefsinJuly2022and
responsivebriefsinSeptember2022.InDecember2022,theArbitrationTribunalissuedanInterimDecisionfindingthat
Janssenmayterminatetheagreements,butitmaynotcontinuetosellproductsdevelopedduringthetermofthe
agreementswithoutcontinuingtopayroyaltiestoAlkermes.
GOVERNMENTPROCEEDINGS
Likeothercompaniesinthepharmaceutical,consumerhealthandmedicaldevicesindustries,theCompanyandcertainof
itssubsidiariesaresubjecttoextensiveregulationbynational,stateandlocalgovernmentagenciesintheUnitedStates
andothercountriesinwhichtheyoperate.Suchregulationhasbeenthebasisofgovernmentinvestigationsandlitigations.
Themostsignificantlitigationbroughtby,andinvestigationsconductedby,governmentagenciesarelistedbelow.Itis
possiblethatcriminalchargesandsubstantialfinesand/orcivilpenaltiesordamagescouldresultfromgovernment
investigationsorlitigation.
Johnson&Johnson2022AnnualReport • 97AverageWholesalePrice(AWP)Litigation
TheCompanyandseveralofitspharmaceuticalsubsidiaries(theJ&JAWPDefendants),alongwithnumerousother
pharmaceuticalcompanies,werenamedasdefendantsinaseriesoflawsuitsinstateandfederalcourtsinvolving
allegationsthatthepricingandmarketingofcertainpharmaceuticalproductsamountedtofraudulentandotherwise
actionableconductbecause,amongotherthings,thecompaniesallegedlyreportedaninflatedAverageWholesalePrice
(AWP)forthedrugsatissue.PayorsallegedthattheyusedthoseAWPsincalculatingproviderreimbursementlevels.The
plaintiffsinthesecasesincludedthreeclassesofprivatepersonsorentitiesthatpaidforanyportionofthepurchaseof
thedrugsatissuebasedonAWP,andstategovernmententitiesthatmadeMedicaidpaymentsforthedrugsatissue
basedonAWP.Manyofthesecases,bothfederalactionsandstateactionsremovedtofederalcourt,wereconsolidated
forpre-trialpurposesinamulti-districtlitigationintheUnitedStatesDistrictCourtfortheDistrictofMassachusetts,where
allclaimsagainsttheJ&JAWPDefendantswereultimatelydismissed.TheJ&JAWPDefendantsalsoprevailedinacase
broughtbytheCommonwealthofPennsylvania.OtherAWPcaseshavebeenresolvedthroughcourtorderorsettlement.
ThecasebroughtbyIllinoiswassettledaftertrial.InNewJersey,aputativeclassactionbaseduponAWPallegationsis
pendingagainstCentocor,Inc.andOrthoBiotechInc.(bothnowJanssenBiotech,Inc.),theCompanyandALZA
Corporation.Allothercaseshavebeenresolved.
OpioidLitigation
Beginningin2014andcontinuingtothepresent,theCompanyandJanssenPharmaceuticals,Inc.(JPI),alongwithother
pharmaceuticalcompanies,havebeennamedincloseto3,500lawsuitsrelatedtothemarketingofopioids,including
DURAGESIC,NUCYNTAandNUCYNTAER.Thesuitsalsoraiseallegationsrelatedtopreviouslyownedactive
pharmaceuticalingredientsuppliersubsidiaries,TasmanianAlkaloidsPty,Ltd.andNoramco,Inc.(bothsubsidiarieswere
divestedin2016).Themajorityofthecaseshavebeenfiledbystateandlocalgovernments.Similarlawsuitshavealso
beenfiledbyprivateplaintiffsandorganizations,includingbutnotlimitedtothefollowing:individualplaintiffsonbehalfof
childrenbornwithNeonatalAbstinenceSyndrome;hospitals;andhealthinsurers/payors.Todate,complaintsagainst
pharmaceuticalmanufacturers,includingtheCompanyandJPI,havebeenfiledbythestateAttorneysGeneralin
Arkansas,Florida,Idaho,Illinois,Kentucky,Louisiana,Mississippi,Missouri,Nevada,NewHampshire,NewJersey,New
Mexico,NewYork,Ohio,Oklahoma,SouthDakota,Texas,WashingtonandWestVirginia.Complaintsagainstthe
manufacturersalsohavebeenfiledinstateorfederalcourtbycity,countyandlocalgovernmentagenciesineverystate
butAlaska.TheGovernmentofPuertoRicofiledsuitinSuperiorCourtofSanJuan.
TheCompany,JPIandotherpharmaceuticalcompanieshadalsoreceivedsubpoenasorrequestsforinformationrelated
toopioidsmarketingpracticesfromthefollowingstateAttorneysGeneral:Alaska,Indiana,Montana,NewHampshire,
SouthCarolina,Tennessee,TexasandWashington.InSeptember2017,theCompanyandJPIwerecontactedbythe
TexasandColoradoAttorneyGeneral’sOfficesonbehalfofapproximately38statesregardingamulti-stateAttorney
Generalinvestigation.
In2019,thetrialinthematterfiledbytheOklahomaAttorneyGeneralresultedinajudgmentagainsttheCompanyandJPI
intheamountof$465million.TheCompanyandJPIappealedthejudgment,andinNovember2021,theOklahoma
SupremeCourtreversedthetrialcourt’sjudgmentanddirectedentryofjudgmentforDefendants.InOctober2019the
CompanyandJPIannouncedasettlementofthefirstcasesetfortrialintheMDLwithtwocountiesinOhio.InApril2021,
threeCaliforniacountiesandtheCityofOaklandcommencedatrialinCaliforniastatecourtagainsttheCompanyandJPI,
andotheraffiliates,aswellasthreeotherpharmaceuticalmanufacturers.ThetrialconcludedinOctober2021,andin
December2021,theCourtenteredafinaltrialjudgmentinfavorofDefendantsonallclaims.InFebruary2022,Plaintiffs’
motiontosetasideandvacatethejudgmentwasdenied.Plaintiffsappealedthejudgment,butlaterfiledarequestto
dismisstheappealafterelectingtoparticipateinthenationalsettlementagreement.
InOctober2019,theCompanyannouncedaproposedagreementinprinciplethatwouldincludetheCompanypaying
$4billionassettlementofthesemattersthathadnotbeentriedorsettled.InOctober2020,theCompanyagreedto
contributeuptoanadditional$1billiontoanall-insettlementamountthatwouldresolveopioidlawsuitsfiledandfuture
claimsbystates,cities,countiesandtribalgovernments,foratotalof$5billionwhichhasbeenaccrued,subjectto
variousconditionsandanagreementbeingfinalized.Thisagreementisnotanadmissionofliabilityorwrong-doing.In
July2021,theCompanyannouncedthatthetermsoftheagreementtosettlethestateandsubdivisionclaimshadbeen
finalizedandapproximatelyhalfoftheall-insettlementwasexpectedtobepaidbytheendoffiscalyear2022,depending
uponthelevelofparticipationbythestatesandtheirsubdivisions.Thetermsprovidedaperiodoftimeforstatestoelect
toparticipateintheagreementand,thereafter,aperiodforthesubdivisionsoftheparticipatingstatestoopt-in.Basedon
expectedparticipation,theCompanycommittedinadvancetoproceedwiththesettlementinfiveoftheparticipating
states(NewYork,Texas,Florida,Nevada,andNewMexico)andwithtribalgovernments.BylateFebruary2022,45states,
98 • Johnson&Johnson2022AnnualReportfiveterritories,theDistrictofColumbia,andthevastmajorityofeligiblesubdivisionshadelectedtoparticipateinthe
settlement,andtheCompanyconfirmedthatthelevelofparticipationwassufficienttoproceedwiththeagreementasto
allparticipants.TheagreementwaseffectiveinApril2022.AlsoinApril2022,theCompanyenteredintosettlement
agreementswiththestatesofAlabamaandWestVirginiaandtheirparticipatingsubdivisions.InJuly2022,theCompany
reachedasettlementagreementwithalllitigatingOklahomasubdivisions,andinSeptember2022,theCompanysettled
withtheStateofNewHampshireanditsparticipatingsubdivisions.Consequently,bytheendofthefiscalyear2022,the
CompanyhadsettledtheopioidclaimsadvancedbyallstatesexceptWashington.
Thereareapproximately60casesremainingpost-settlementinvariousstatecourts.Thereareapproximately570
remainingfederalcasesagainsttheCompanyandJPIcoordinatedinafederalMulti-DistrictLitigation(MDL)pendingin
theU.S.DistrictCourtfortheNorthernDistrictofOhio,andapproximately20additionalcasespendingagainstthe
CompanyandJPIinotherfederalcourts.Inaddition,theProvinceofBritishColumbiafiledsuitagainsttheCompanyand
itsCanadianaffiliateJanssenInc.,andmanyotherindustrymembers,inCanada,andisseekingtohavethataction
certifiedasanoptinclassactiononbehalfofotherprovincial/territorialandthefederalgovernmentsinCanada.Additional
proposedclassactionshavebeenfiledinCanadaagainsttheCompanyandJanssenInc.,andmanyotherindustry
members,byandonbehalfofpeoplewhousedopioids(forpersonalinjuries),municipalitiesandFirstNationsbands.In
October2019,anantitrustcomplaintwasfiledbyprivateplaintiffsinfederalcourtinTennesseeandispendingtransferto
theMDL.Theseactionsallegeavarietyofclaimsrelatedtoopioidmarketingpractices,includingfalseadvertising,unfair
competition,publicnuisance,consumerfraudviolations,deceptiveactsandpractices,falseclaimsandunjustenrichment.
Thesuitsgenerallyseekpenaltiesand/orinjunctiveandmonetaryreliefand,insomeofthesuits,theplaintiffsareseeking
jointandseveralliabilityamongthedefendants.Anadversejudgmentinanyoftheselawsuitscouldresultintheimposition
oflargemonetarypenaltiesandsignificantdamagesincluding,punitivedamages,costofabatement,substantialfines,
equitableremediesandothersanctions.
InAugust2019,theCompanyreceivedagrandjurysubpoenafromtheUnitedStatesAttorney’sOfficefortheEastern
DistrictofNewYorkfordocumentsrelatedtotheCompany’santi-diversionpoliciesandproceduresanddistributionofits
opioidmedications,inwhattheCompanyunderstandstobepartofabroaderinvestigationintomanufacturers’and
distributors’monitoringprogramsandreportingundertheControlledSubstancesAct.
FromJune2017throughDecember2019,theCompany’sBoardofDirectorsreceivedaseriesofshareholderdemand
lettersallegingbreachesoffiduciarydutiesrelatedtothemarketingofopioids.TheBoardretainedindependentcounselto
investigatetheallegationsinthedemands,andinApril2020,independentcounseldeliveredareporttotheBoard
recommendingthattheCompanyrejecttheshareholderdemandsandtakethestepsthatarenecessaryorappropriateto
securedismissalofrelatedderivativelitigation.TheBoardunanimouslyadoptedtherecommendationsoftheindependent
counsel’sreport.
InNovember2019,oneoftheshareholderswhosentademandfiledaderivativecomplaintagainsttheCompanyasthe
nominaldefendantandcertaincurrentandformerdirectorsandofficersasdefendantsintheSuperiorCourtofNew
Jersey.Thecomplaintallegesbreachesoffiduciarydutiesrelatedtothemarketingofopioids,andthattheCompanyhas
suffereddamagesasaresultofthoseallegedbreaches.Aseriesofadditionalderivativecomplaintsmakingsimilar
allegationsagainstthesameandsimilardefendantswerefiledinNewJerseystateandfederalcourtsin2019and2020.
By2022,allbuttwostatecourtcaseshadbeenvoluntarilydismissed.InFebruary2022,thestatecourtgrantedthe
Company’smotiontodismissoneofthetwocases,andtheshareholderthatbroughtthesecondcasefiledanoticeof
dismissal.Theshareholderwhosecomplaintwasdismissedfiledamotionforreconsideration.InMay2022,thestatecourt
heldoralargumentonthemotionforreconsiderationandsubsequentlydeniedthemotion.Theshareholderhasappealed
thestatecourt’sdismissalorder.
Other
InAugust2012,DePuyOrthopaedics,Inc.,DePuy,Inc.(nowknownasDePuySynthes,Inc.),andJohnson&Johnson
Services,Inc.(collectivelyDePuy)receivedaninformalrequestfromtheUnitedStatesAttorney’sOfficefortheDistrictof
MassachusettsandtheCivilDivisionoftheUnitedStatesDepartmentofJustice(theUnitedStates)fortheproductionof
materialsrelatingtotheDePuyASRXLHipdevice.InJuly2014,theUnitedStatesnotifiedtheUnitedStatesDistrict
CourtfortheDistrictofMassachusettsthatithaddeclinedtointerveneinaquitamcasefiledpursuanttotheFalseClaims
Actagainstthecompaniesconcerningthehipdevices.InFebruary2016,theDistrictCourtgrantedthecompanies’
motiontodismisswithprejudice,unsealedthequitamcomplaint,anddeniedthequitamrelators’requestforleavetofilea
furtheramendedcomplaint.ThequitamrelatorsappealedthecasetotheUnitedStatesCourtofAppealsfortheFirst
Circuit.InJuly2017,theFirstCircuitaffirmedtheDistrictCourt’sdismissalinpart,reversedinpart,andaffirmedthe
decisiontodenytherelators’requesttofileathirdamendedcomplaint.InMarch2021,DePuyfileditsmotiontostrikeand
Johnson&Johnson2022AnnualReport • 99dismisstherelators’secondamendedcomplaint;theDistrictCourtdeniedDePuy’smotiontostrikeanddismissin
July2021.DePuyfiledamotionforreconsiderationoftheDistrictCourt’sJuly2021ruling.InNovember2021,theDistrict
CourtgrantedDePuy’smotionforreconsiderationanddismissedthecasewithprejudice.TheDistrictCourt’sorderwas
unsealedinDecember2021.Therelatorsfiledseveralpost-dismissalmotions,includingaJanuary2022omnibusmotion
forreconsideration,whichtheDistrictCourtdenied.FollowingtheDistrictCourt’sorderdismissingthecasewith
prejudice,DePuyfiledaDecember2021motionseekingtherecoveryofattorneys’feesandcosts,whichtheDistrict
Courtdeniedexceptastocosts.TheRelatorshaveappealedtheDistrictCourt’sdismissalofthecasetotheFirstCircuit.
Thebriefingontheappealiscomplete,theFirstCircuitheldoralargumentonDecember6,2022,andtheFirstCircuit’s
decisionremainspending.
InOctober2012,theCompanywascontactedbytheCaliforniaAttorneyGeneral’sofficeregardingamulti-stateAttorney
Generalinvestigationofthemarketingofsurgicalmeshproductsforherniaandurogynecologicalpurposesbythe
Company’ssubsidiary,Ethicon,Inc.(Ethicon).InMay2016,CaliforniaandWashingtonfiledcivilcomplaintsagainstthe
Company,EthiconandEthiconUS,LLCallegingviolationsoftheirconsumerprotectionstatutes.Similarcomplaintswere
filedagainstthecompaniesbythefollowingstates:Kentucky,Mississippi,WestVirginiaandOregon.InApril2019,the
CompanyandEthiconsettledtheWashingtoncase.InOctober2019,theCompanyandEthiconsettledthemulti-state
investigationwith41otherstatesandtheDistrictofColumbia.InApril2020,theCompanysettledtheWestVirginiacase.
InOctober2020,theCompanysettledwiththeAttorneyGeneralofOregon.InNovember2020,theCompanysettled
withtheAttorneyGeneralofMississippi.TrialintheKentuckymatterisscheduledforJune2023.TheCaliforniacase
startedtrialinJuly2019andconcludedinSeptember2019.InJanuary2020,theCourtinCaliforniaissuedastatementof
decision,findinginfavoroftheStateofCalifornia,andawardedcivilpenaltiesintheamountof$344million.InApril2020,
theCourtinCaliforniadeniedtheCompany’smotionforanewtrial.InAugust2020,theCourtenteredjudgmentwith
respecttothepenaltiesof$344million,butdeniedtheAttorneyGeneral’srequestforinjunctiverelief.TheCompany
appealedthepenaltyjudgment.InApril2022,theCourtofAppealsreducedthejudgmentto$302million,butotherwise
deniedtheappeal.InJuly2022,theSupremeCourtofCaliforniadeniedtheCompany’spetitiontoreviewtheCourtof
Appealsdecision,andtheCompanyrecordedachargetoreflectthejudgmentinthesecondquarterof2022.In
November2022,theCompanypetitionedtheUnitedStatesSupremeCourtforreview.
InJune2014,theMississippiAttorneyGeneralfiledacomplaintinChanceryCourtofTheFirstJudicialDistrictofHinds
County,MississippiagainsttheCompanyandJohnson&JohnsonConsumerCompanies,Inc.(nowknownasJohnson&
JohnsonConsumerInc.)(collectively,JJCI).ThecomplaintallegesthatJJCIviolatedtheMississippiConsumerProtection
Actbyfailingtodiscloseallegedhealthrisksassociatedwithfemaleconsumers’useoftalccontainedinJOHNSON’S
BabyPowderandJOHNSON’SShowertoShower(aproductdivestedin2012)andseeksinjunctiveandmonetaryrelief.
TheCompanyandJJCImovedforsummaryjudgmentonthegroundsthattheState’sclaimwasbarredbypreemption,
whichthetrialcourtdenied.TheMississippiSupremeCourtgrantedtheCompanyandJJCI’srequesttofilean
interlocutoryappealofthedenialofthemotionforsummaryjudgmentinlate2019.Briefingandoralargumentwere
completed.Thereafter,theCourtrejectedtheinterlocutoryappealinApril2021andremandedthemattertothetrialcourt.
InAugust2021,JJCIfiledaPetitionforWritofCertiorariintheUnitedStatesSupremeCourtastotheMississippi
SupremeCourt’srulingofApril2021.InDecember2021theUnitedStatesSupremeCourtdeniedthePetitionforWritof
Certiorari.AftertheMississippiSupremeCourtremandedthemattertothetrialcourt,theStatemovedforatrialsetting.
JJCIobjectedtoanytrialsettingasbarredbythestayarisingfromtheLTLBankruptcyCase,referencedabove,whilethe
Statearguedthatthestaydidnotapply.InJanuary2022,theCourtgrantedtheState’smotionfortrialsettingand
directedthepartiestoconsultwiththeCourtadministratortosecureatrialdate.InFebruary2022,thetrialcourtsetthe
casefortrialtobegininFebruary2023.However,giventheeffortstoresolvetalc-relatedclaimsintheLTLBankruptcy
Case,theCompanyandtheStateagreedtoatemporarystayofdiscoveryuntilMay2022.Thetemporarystayexpiredin
May2022.LTLthereaftermovedtoenjoinprosecutionofthecaseintheLTLBankruptcyCase.InOctober2022,the
bankruptcycourtissuedanorderstayingthecase.TheStatefiledanappealtotheThirdCircuitconcerningthestayorder.
InJanuary2020,theStateofNewMexicofiledaconsumerprotectioncaseallegingthattheCompanydeceptively
marketedandsolditstalcumpowderproductsbymakingmisrepresentationsaboutthesafetyoftheproductsandthe
presenceofcarcinogens,includingasbestos.TheStateofNewMexicofiledanAmendedComplaintinMarch2020.The
CompanymovedtodismisscertainoftheclaimsintheAmendedComplaint,whichwasgranted.TheCompanythenfiled
amotionforpartialjudgmentonthepleadingsinDecember2020,whichwasdenied.InMarch2022,theNewMexico
courtdeniedtheCompany’smotiontocompeltheStateofNewMexicotoengageindiscoveryofstateagenciesand
deniedtheCompany’srequestforinterlocutoryappealofthatdecision.TheCompanythenfiledaPetitionforWritof
SuperintendingControlandaRequestforaStaytotheNewMexicoSupremeCourtontheissueoftheStateof
NewMexico’sdiscoveryobligations.InApril2022,inviewoftheeffortstoresolvetalc-relatedclaimsintheLTL
BankruptcyCase,theCompanyandtheStateagreedtoa60-daystayofallmattersexceptforthependingwritbeforethe
100 • Johnson&Johnson2022AnnualReportNewMexicoSupremeCourt,whichexpiredinJune2022.Thereafter,theCompanymovedtoenjoinprosecutionofthe
caseintheLTLBankruptcyCase.InOctober2022,thebankruptcycourtissuedanorderstayingthecase.InDecember
2022,theStatefiledanappealtotheThirdCircuitconcerningthestayorder.Separately,inSeptember2022,the
NewMexicoSupremeCourtgrantedtheCompany’srequestforastaypendingfurtherbriefingonthescopeoftheState
ofNewMexico’sdiscoveryobligations.
Forty-twostatesandtheDistrictofColumbiahavecommencedajointinvestigationintotheCompany’smarketingofits
talcumpowderproducts.Atthistime,themulti-stategrouphasnotassertedanyclaimsagainsttheCompany.Fivestates
haveissuedCivilInvestigativeDemandsseekingdocumentsandotherinformation.TheCompanyhasproduced
documentstoArizona,NorthCarolina,Texas,andWashingtonandenteredintoconfidentialityagreements.TheCompany
hasnotreceivedanyfollowuprequestsfromthosestates.InMarch2022,eachoftheforty-twostates(including
MississippiandNewMexico)agreedtomediationoftheirclaimsintheLTLBankruptcyCase.InJuly2022,NewMexico
andMississippiindicatedtheywouldnolongervoluntarilysubmittofurthermediationintheLTLBankruptcyandwould
proceedwiththeirrespectivecasesinstatecourt.LTLmovedtheNewJerseyBankruptcyCourtforanorderstaying
furtherproceedingsinthosetwoactions,whichtheBankruptcyCourtgrantedinOctober2022.InDecember2022,the
BankruptcyCourtallowedNewMexicoandMississippitofileadirectappealofitsstay.
InJuly2016,theCompanyandJanssenProducts,LPwereservedwithaquitamcomplaintpursuanttotheFalseClaims
ActfiledintheUnitedStatesDistrictCourtfortheDistrictofNewJerseyallegingtheoff-labelpromotionoftwoHIV
products,PREZISTAandINTELENCE,andanti-kickbackviolationsinconnectionwiththepromotionoftheseproducts.
ThecomplaintwasfiledundersealinDecember2012.Thefederalandstategovernmentshavedeclinedtointervene,and
thelawsuitisbeingprosecutedbytherelators.TheCourtdeniedsummaryjudgmentonallclaimsinDecember2021.
DaubertmotionsweregrantedinpartanddeniedinpartinJanuary2022,andthecaseisproceedingtotrial.
InMarch2017,JanssenBiotech,Inc.(JBI)receivedaCivilInvestigativeDemandfromtheUnitedStatesDepartmentof
JusticeregardingaFalseClaimsActinvestigationconcerningmanagementandadvisoryservicesprovidedto
rheumatologyandgastroenterologypracticesthatpurchasedREMICADEorSIMPONIARIA.InAugust2019,the
UnitedStatesDepartmentofJusticenotifiedJBIthatitwasclosingtheinvestigation.Subsequently,theUnitedStates
DistrictCourtfortheDistrictofMassachusettsunsealedaquitamFalseClaimsActcomplaint,whichwasservedonthe
Company.TheDepartmentofJusticehaddeclinedtointerveneinthequitamlawsuitinAugust2019.TheCompanyfiled
amotiontodismiss,whichwasgrantedinpartanddeniedinpart.Discoveryisunderway.
InAprilandSeptember2017,theCompanyreceivedsubpoenasfromtheUnitedStatesAttorneyfortheDistrictof
MassachusettsseekingdocumentsbroadlyrelatingtopharmaceuticalcopaymentsupportprogramsforDARZALEX,
OLYSIO,REMICADE,SIMPONI,STELARAandZYTIGA.ThesubpoenasalsoseekdocumentsrelatingtoAverage
ManufacturerPriceandBestPricereportingtotheCenterforMedicareandMedicaidServicesrelatedtothoseproducts,
aswellasrebatepaymentstostateMedicaidagencies.TheCompanyhasprovideddocumentsinresponsetothe
subpoenas.
InJune2017,theCompanyreceivedasubpoenafromtheUnitedStatesAttorney’sOfficefortheDistrictof
MassachusettsseekinginformationregardingpracticespertainingtothesterilizationofDePuySynthes,Inc.(DePuy)spinal
implantsatthreehospitalsinBostonaswellasinteractionsofemployeesofCompanysubsidiarieswithphysiciansat
thesehospitals.TheCompanyandDePuyfullycooperatedwiththegovernment’sinvestigation.InJanuary2023,the
Company,DePuySynthes,Inc.,andDePuySynthesSalesInc.enteredintoasettlementagreementwiththeUnitedStates
resolvingthematterforanimmaterialamount.
InJuly2018,thePublicProsecutionServiceinRiodeJaneiroandrepresentativesfromtheBrazilianantitrustauthority
CADEinspectedtheofficesofmorethan30companiesincludingJohnson&JohnsondoBrasilIndústriaeComérciode
ProdutosparaSaúdeLtda.Theauthoritiesappeartobeinvestigatingallegationsofpossibleanti-competitivebehaviorand
possibleimproperpaymentsinthemedicaldeviceindustry.TheCompanycontinuestorespondtoinquiriesregardingthe
ForeignCorruptPracticesActfromtheUnitedStatesDepartmentofJusticeandtheUnitedStatesSecuritiesand
ExchangeCommission.
Fromtimetotime,theCompanyhasreceivedrequestsfromavarietyofUnitedStatesCongressionalCommitteesto
produceinformationrelevanttoongoingcongressionalinquiries.ItisthepolicyofJohnson&Johnsontocooperatewith
theseinquiriesbyproducingtherequestedinformation.
Johnson&Johnson2022AnnualReport • 101GENERALLITIGATION
BeginninginSeptember2017,multiplepurportedclassactionswerefiledonbehalfofindirectpurchasersofREMICADE
againsttheCompanyandJanssenBiotech,Inc.(collectively,Janssen)allegingthatJanssenhasviolatedfederalantitrust
lawsthroughitscontractingstrategiesforREMICADE.Thecaseswereconsolidatedforpre-trialpurposesasInre
REMICADEAntitrustLitigationinUnitedStatesDistrictCourtfortheEasternDistrictofPennsylvania.Thiscasewassettled
inFebruary2022.ThefinalapprovalhearingisscheduledforFebruary2023.
InJune2019,theUnitedStatesFederalTradeCommission(FTC)issuedaCivilInvestigativeDemandtotheCompany
andJanssenBiotech,Inc.(collectively,Janssen)inconnectionwithitsinvestigationofwhetherJanssen’sREMICADE
contractingpracticesviolatefederalantitrustlaws.TheCompanyhasproduceddocumentsandinformationresponsiveto
theCivilInvestigativeDemand.JanssenisinongoingdiscussionswiththeFTCstaffregardingitsinquiry.
InFebruary2022,theUnitedStatesFederalTradeCommission(FTC)issuedCivilInvestigativeDemandstoJohnson&
JohnsonandJanssenBiotech,Inc.(collectively,Janssen)inconnectionwithitsinvestigationofwhetheradvertising
practicesforREMICADEviolatefederallaw.JanssenhasproduceddocumentsandinformationresponsivetotheCivil
InvestigativeDemands.JanssenisinongoingdiscussionswiththeFTCstaffregardingtheinquiry.
InJune2022,GenmabA/SfiledaNoticeforArbitrationwithInternationalInstituteforConflictPreventionandResolution
(CPR)againstJanssenBiotech,Inc.seekingmilestonesandanextendedroyaltytermforDarzalexFASPRO.Janssenfiled
itsNoticeofDefenseinJuly2022.GenmabandJanssenhavecross-movedforearlydispositionofthearbitration.
ArgumentwashadinJanuary2023.
InOctober2017,certainUnitedStatesservicemembersandtheirfamiliesbroughtacomplaintagainstanumberof
pharmaceuticalandmedicaldevicescompanies,includingJohnson&JohnsonandcertainofitssubsidiariesinUnited
StatesDistrictCourtfortheDistrictofColumbia,allegingthatthedefendantsviolatedtheUnitedStatesAnti-Terrorism
Act.Thecomplaintallegesthatthedefendantsprovidedfundingforterroristorganizationsthroughtheirsalespractices
pursuanttopharmaceuticalandmedicaldevicecontractswiththeIraqiMinistryofHealth.InJuly2020,theDistrictCourt
dismissedthecomplaint.InJanuary2022,theUnitedStatesCourtofAppealsfortheDistrictofColumbiaCircuitreversed
theDistrictCourt’sdecision.InFebruary2022,defendantspetitionedforrehearingenbanc.
InOctober2018,twoseparateputativeclassactionswerefiledagainstActelionPharmaceuticalLtd.,Actelion
PharmaceuticalsU.S.,Inc.,andActelionClinicalResearch,Inc.(collectivelyActelion)inUnitedStatesDistrictCourtforthe
DistrictofMarylandandUnitedStatesDistrictCourtfortheDistrictofColumbia.ThecomplaintsallegethatActelion
violatedstateandfederalantitrustandunfaircompetitionlawsbyallegedlyrefusingtosupplygenericpharmaceutical
manufacturerswithsamplesofTRACLEER.TRACLEERissubjecttoaRiskEvaluationandMitigationStrategyrequiredby
theFoodandDrugAdministration,whichimposesrestrictionsondistributionoftheproduct.InJanuary2019,theplaintiffs
dismissedtheDistrictofColumbiacaseandfiledaconsolidatedcomplaintintheUnitedStatesDistrictCourtforthe
DistrictofMaryland.InOctober2019,theCourtgrantedActelion’smotiontodismisstheamendedcomplaint.In
April2021,theUnitedStatesCourtofAppealsfortheFourthCircuitreversedandremanded.Discoveryisongoing.
InMay2019,aclassactionantitrustcomplaintwasfiledagainstJanssenR&DIreland(Janssen)andJohnson&Johnsonin
theUnitedStatesDistrictCourtfortheNorthernDistrictofCalifornia.ThecomplaintallegesthatJanssenviolatedfederal
andstateantitrustandconsumerprotectionlawsbyagreeingtoexclusivityprovisionsinitsagreementswithGilead
concerningthedevelopmentandmarketingofcombinationantiretroviraltherapies(cART)totreatHIV.Thecomplaintalso
allegesthatGileadenteredintosimilaragreementswithBristol-MyersSquibbandJapanTobacco.InMarch2020,the
Courtgrantedinpartanddeniedinpartdefendants’motionstodismiss.Plaintiffsfiledanamendedcomplaintin
April2020.Defendantsmovedtodismisstheamendedcomplaint.InJuly2020,theCourtgrantedinpartanddeniedin
parttherenewedmotiontodismiss.InDecember2021,severalinsurancecompaniesandotherpayersfiledindividual
“Opt-Out”complaintscontainingallegationssimilartotheoriginalcomplaint.InSeptember2022,theCourtgrantedin
partanddeniedinpartplaintiff’smotionforclasscertification.InJanuary2023,theCourtgrantedinpartanddeniedin
partdefendants’motionforsummaryjudgment.TrialisscheduledforMay2023.
InOctober2019,InnovativeHealth,LLCfiledacomplaintagainstBiosenseWebster,Inc.(BWI)intheUnitedStates
DistrictCourtfortheMiddleDistrictofCalifornia.ThecomplaintallegesthatcertainofBWI’sbusinesspracticesand
contractualtermsviolatetheantitrustlawsoftheUnitedStatesandtheStateofCaliforniabyrestrictingcompetitioninthe
saleofHighDensityMappingCathetersandUltrasoundCatheters.InJanuary2020,BWIfiledamotiontodismissthe
complaint.InAugust2020,theCourtgrantedinpartanddeniedinpartBWI’smotiontodismiss.InDecember2021,
BWIfiledamotionforsummaryjudgment.InMarch2022,theCourtgrantedBWI’smotionforsummaryjudgment.In
April2022,InnovativeappealedthisrulingtotheUnitedStatesCourtofAppealsfortheNinthCircuit.
102 • Johnson&Johnson2022AnnualReportInNovember2019,theCompanyreceivedademandforindemnificationfromPfizerInc.(Pfizer),pursuanttothe2006
StockandAssetPurchaseAgreementbetweentheCompanyandPfizer.AlsoinNovember2019,Johnson&JohnsonInc.
receivednoticereservingrightstoclaimindemnificationfromSanofiConsumerHealth,Inc.(Sanofi),pursuanttothe2016
AssetPurchaseAgreementbetweenJohnson&JohnsonInc.andSanofi.InJanuary2020,Johnson&Johnsonreceiveda
demandforindemnificationfromBoehringerIngelheimPharmaceuticals,Inc.(BoehringerIngelheim),pursuanttothe2006
AssetPurchaseAgreementamongtheCompany,Pfizer,andBoehringerIngelheim.InNovember2022,Johnson&
JohnsonreceivedademandforindemnificationfromGlaxoSmithKlineLLC(GSK),pursuanttothe2006StockandAsset
PurchaseAgreementbetweentheCompanyandPfizer,andcertain1993,1998,and2002agreementsbetweenGlaxo
WellcomeandWarner-Lambertentities.Thenoticesseekindemnificationforlegalclaimsrelatedtoover-the-counter
ZANTAC(ranitidine)products.PlaintiffsintheunderlyingactionsallegethatZANTACandotherover-the-counter
ranitidinemedicationscontainunsafelevelsofNDMA(N-nitrosodimethylamine)andcancauseand/orhavecausedvarious
cancersinpatientsusingtheproducts,andseekinjunctiveandmonetaryrelief.TheCompanyandJohnson&JohnsonInc.
havealsobeennamedinputativeclassactionsfiledinCanadawithsimilarallegationsregardingZANTACorranitidine
use.Johnson&JohnsonInc.wasalsonamedasadefendantalongwithothermanufacturersinvariouspersonalinjury
actionsinCanadarelatedtoZANTACproducts.Johnson&JohnsonInc.hasprovidedSanofinoticereservingrightsto
claimindemnificationpursuanttothe2016AssetPurchaseAgreementrelatedtotheclassactionsandpersonalinjury
actions.
InOctober2020,FortisAdvisorsLLC(Fortis),initscapacityasrepresentativeoftheformerstockholdersofAurisHealth
Inc.(Auris),filedacomplaintagainsttheCompany,EthiconInc.,andcertainnamedofficersandemployees(collectively,
Ethicon)intheCourtofChanceryoftheStateofDelaware.Thecomplaintallegesbreachofcontract,fraud,andother
causesofactionagainstEthiconinconnectionwithEthicon’sacquisitionofAurisin2019.Thecomplaintseeksdamages
andotherrelief.InDecember2021,theCourtgrantedinpartanddeniedinpartdefendants’motiontodismisscertain
causesofaction.Allclaimsagainsttheindividualdefendantsweredismissed.ThetrialisscheduledforJanuary2024.
InJune2022,JanssenPharmaceuticals,Inc.filedaDemandforArbitrationagainstEmergentBiosolutionsInc.etal
(“EBSI”)withtheAmericanArbitrationAssociation,allegingthatEBSIbreachedtheparties’ManufacturingServices
AgreementfortheCompany’sCOVID-19vaccine.InJuly2022,Emergentfileditsansweringstatementand
counterclaims.
InOctober2022,JanssenPharmaceuticals,Inc.filedaDemandforArbitrationagainstMerckSharp&DohmeCorp.with
theAmericanArbitrationAssociationpursuanttotheParties’agreementsrelatingtoproductionofdrugsubstanceand
drugproductfortheCompany’sCOVID-19vaccine.AlsoinOctober2022,Merckfileditsanswerandcounterclaims.
BeginninginMay2021,multipleputativeclassactionswerefiledinstateandfederalcourts(California,Florida,NewYork,
andNewJersey)againstvariousJohnson&Johnsonentitiesallegingviolationsofstateconsumerfraudstatutesbasedon
nondisclosureofallegedbenzenecontaminationofcertainNeutrogenaandAveenosunscreenproductsandthe
affirmativepromotionofthoseproductsas“safe”;and,inatleastonecase,allegingastrictliabilitymanufacturingdefect
andfailuretowarnclaims,assertingthatthenamedplaintiffssufferedunspecifiedinjuriesasaresultofallegedexposure
tobenzene.TheJudicialPanelonMulti-DistrictLitigationhasconsolidatedallpendingactions,exceptoneproductliability
caseandonecasependinginNewJerseystatecourt,intheUnitedStatesDistrictCourtfortheSouthernDistrictof
Florida,FortLauderdaleDivision.InOctober2021,theCompanyreachedanagreementinprincipleforthesettlementofa
nationwideclass,encompassingtheclaimsoftheconsolidatedactions,subjecttoapprovalbytheFloridafederalCourt.In
December2021,plaintiffsintheconsolidatedactionsfiledamotionforpreliminaryapprovalofanationwideclass
settlement.ThesettlementwaspreliminarilyapprovedbythecourtinMarch2022.
TheCompany(subsequentlysubstitutedbyJohnson&JohnsonConsumerInc.(JJCI))alongwithmorethan120other
companies,isadefendantinacostrecoveryandcontributionactionbroughtbyOccidentalChemicalCorporationin
June2018intheUnitedStatesDistrictCourtfortheDistrictofNewJersey,relatedtotheclean-upofasectionofthe
LowerPassaicRiverinNewJersey.
TheCompanyoritssubsidiariesarealsopartiestovariousproceedingsbroughtundertheComprehensiveEnvironmental
Response,Compensation,andLiabilityAct,commonlyknownasSuperfund,andcomparablestate,localorforeignlawsin
whichtheprimaryreliefsoughtisthecostofpastand/orfutureremediation.
Johnson&Johnson2022AnnualReport • 10320. Restructuring
Inthefiscalsecondquarterof2018,theCompanyannouncedplanstoimplementaseriesofactionsacrossitsGlobal
SupplyChainthatareintendedtofocusresourcesandincreaseinvestmentsinthecriticalcapabilities,technologiesand
solutionsnecessarytomanufactureandsupplyitsproductportfolio,enhanceagilityanddrivegrowth.TheGlobalSupply
Chainactionsincludeexpandingtheuseofstrategiccollaborationsandbolsteringinitiativestoreducecomplexity,improve
cost-competitiveness,enhancecapabilitiesandoptimizetheSupplyChainnetwork.Infiscalyear2022,theCompany
recordedapre-taxchargeof$0.5billion,whichisincludedonthefollowinglinesoftheConsolidatedStatementof
Earnings,$0.3billioninrestructuring,$0.1billioninother(income)expenseand$0.1billionincostofproductssold.Total
projectcostsofapproximately$2.2billionhavebeenrecordedsincetherestructuringwasannounced.Theprogramwas
completedinthefiscalfourthquarterof2022.
Thefollowingtablesummarizestheseverancechargesandtheassociatedspendingundertheseinitiativesthroughthe
fiscalyearended2022:
(DollarsinMillions) Severance AssetWrite-offs/Sales Other(2) Total
Reservebalance,January3,2021 $135 — 9 144
2021activity (23) — 16 (7)
Reservebalance,January2,2022 112 — 25 137
Currentyearactivity:
Charges — 15 448 463
Cashsettlements (37) 44(3) (439) (432)
Settlednoncash — (59) (59)
Reservebalance,January1,2023(1) $75 — 34 109
(1) Althoughtherestructuringprogramhasbeencompletedinthefiscalyear2022,theCompanyexpectsthatseverancechargeswill
continuebeyondthatdate.ThereservebalanceasofJanuary1,2023isrecordedintheEmployeeRelatedObligationaccountinthe
ConsolidatedBalanceSheet.
(2) Otherincludesprojectexpensesuchassalariesforemployeessupportingtheseinitiativesandconsultingexpenses.
(3) Representsgainonsaleofassets
104 • Johnson&Johnson2022AnnualReportReport of Independent Registered Public
Accounting Firm
TotheBoardofDirectorsandShareholdersofJohnson&Johnson
OpinionsontheFinancialStatementsandInternalControloverFinancialReporting
WehaveauditedtheaccompanyingconsolidatedbalancesheetsofJohnson&Johnsonanditssubsidiaries(the
“Company”)asofJanuary1,2023andJanuary2,2022,andtherelatedconsolidatedstatementsofearnings,of
comprehensiveincome,ofequityandofcashflowsforeachofthethreefiscalyearsintheperiodendedJanuary1,2023,
includingtherelatednotes(collectivelyreferredtoasthe“consolidatedfinancialstatements”).Wealsohaveauditedthe
Company’sinternalcontroloverfinancialreportingasofJanuary1,2023,basedoncriteriaestablishedinInternalControl-
IntegratedFramework(2013)issuedbytheCommitteeofSponsoringOrganizationsoftheTreadwayCommission
(COSO).
Inouropinion,theconsolidatedfinancialstatementsreferredtoabovepresentfairly,inallmaterialrespects,thefinancial
positionoftheCompanyasofJanuary1,2023andJanuary2,2022,andtheresultsofitsoperationsanditscashflows
foreachofthethreefiscalyearsintheperiodendedJanuary1,2023inconformitywithaccountingprinciplesgenerally
acceptedintheUnitedStatesofAmerica.Alsoinouropinion,theCompanymaintained,inallmaterialrespects,effective
internalcontroloverfinancialreportingasofJanuary1,2023,basedoncriteriaestablishedinInternalControl-Integrated
Framework(2013)issuedbytheCOSO.
BasisforOpinions
TheCompany’smanagementisresponsiblefortheseconsolidatedfinancialstatements,formaintainingeffectiveinternal
controloverfinancialreporting,andforitsassessmentoftheeffectivenessofinternalcontroloverfinancialreporting,
includedintheaccompanyingManagement’sReportonInternalControlOverFinancialReporting.Ourresponsibilityisto
expressopinionsontheCompany’sconsolidatedfinancialstatementsandontheCompany’sinternalcontroloverfinancial
reportingbasedonouraudits.WeareapublicaccountingfirmregisteredwiththePublicCompanyAccountingOversight
Board(UnitedStates)(PCAOB)andarerequiredtobeindependentwithrespecttotheCompanyinaccordancewiththe
U.S.federalsecuritieslawsandtheapplicablerulesandregulationsoftheSecuritiesandExchangeCommissionandthe
PCAOB.
WeconductedourauditsinaccordancewiththestandardsofthePCAOB.Thosestandardsrequirethatweplanand
performtheauditstoobtainreasonableassuranceaboutwhethertheconsolidatedfinancialstatementsarefreeofmaterial
misstatement,whetherduetoerrororfraud,andwhethereffectiveinternalcontroloverfinancialreportingwasmaintained
inallmaterialrespects.
Ourauditsoftheconsolidatedfinancialstatementsincludedperformingprocedurestoassesstherisksofmaterial
misstatementoftheconsolidatedfinancialstatements,whetherduetoerrororfraud,andperformingproceduresthat
respondtothoserisks.Suchproceduresincludedexamining,onatestbasis,evidenceregardingtheamountsand
disclosuresintheconsolidatedfinancialstatements.Ourauditsalsoincludedevaluatingtheaccountingprinciplesused
andsignificantestimatesmadebymanagement,aswellasevaluatingtheoverallpresentationoftheconsolidatedfinancial
statements.Ourauditofinternalcontroloverfinancialreportingincludedobtaininganunderstandingofinternalcontrol
overfinancialreporting,assessingtheriskthatamaterialweaknessexists,andtestingandevaluatingthedesignand
operatingeffectivenessofinternalcontrolbasedontheassessedrisk.Ourauditsalsoincludedperformingsuchother
proceduresasweconsiderednecessaryinthecircumstances.Webelievethatourauditsprovideareasonablebasisfor
ouropinions.
AsdescribedinManagement’sReportonInternalControlOverFinancialReporting,managementhasexcludedAbiomed,
Inc.,(“Abiomed”)fromitsassessmentofinternalcontroloverfinancialreportingasofJanuary1,2023,becauseitwas
acquiredbytheCompanyinabusinesscombinationduring2022.WehavealsoexcludedAbiomedfromourauditof
internalcontroloverfinancialreporting.Abiomedisawholly-ownedsubsidiarywhosetotalassetsandtotalsalesexcluded
frommanagement’sassessmentandourauditofinternalcontroloverfinancialreportingrepresentlessthan1%ofeachof
therelatedconsolidatedfinancialstatementamountsasofandforthefiscalyearendedJanuary1,2023.
DefinitionandLimitationsofInternalControloverFinancialReporting
Acompany’sinternalcontroloverfinancialreportingisaprocessdesignedtoprovidereasonableassuranceregardingthe
reliabilityoffinancialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewith
Johnson&Johnson2022AnnualReport • 105generallyacceptedaccountingprinciples.Acompany’sinternalcontroloverfinancialreportingincludesthosepoliciesand
proceduresthat(i)pertaintothemaintenanceofrecordsthat,inreasonabledetail,accuratelyandfairlyreflectthe
transactionsanddispositionsoftheassetsofthecompany;(ii)providereasonableassurancethattransactionsare
recordedasnecessarytopermitpreparationoffinancialstatementsinaccordancewithgenerallyacceptedaccounting
principles,andthatreceiptsandexpendituresofthecompanyarebeingmadeonlyinaccordancewithauthorizationsof
managementanddirectorsofthecompany;and(iii)providereasonableassuranceregardingpreventionortimelydetection
ofunauthorizedacquisition,use,ordispositionofthecompany’sassetsthatcouldhaveamaterialeffectonthefinancial
statements.
Becauseofitsinherentlimitations,internalcontroloverfinancialreportingmaynotpreventordetectmisstatements.Also,
projectionsofanyevaluationofeffectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequate
becauseofchangesinconditions,orthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate.
CriticalAuditMatters
Thecriticalauditmatterscommunicatedbelowaremattersarisingfromthecurrentperiodauditoftheconsolidated
financialstatementsthatwerecommunicatedorrequiredtobecommunicatedtotheauditcommitteeandthat(i)relateto
accountsordisclosuresthatarematerialtotheconsolidatedfinancialstatementsand(ii)involvedourespecially
challenging,subjective,orcomplexjudgments.Thecommunicationofcriticalauditmattersdoesnotalterinanywayour
opinionontheconsolidatedfinancialstatements,takenasawhole,andwearenot,bycommunicatingthecriticalaudit
mattersbelow,providingseparateopinionsonthecriticalauditmattersorontheaccountsordisclosurestowhichthey
relate.
U.S.PharmaceuticalRebateReserves-ManagedCare,MedicareandMedicaid
AsdescribedinNote1totheconsolidatedfinancialstatements,theCompanyrecognizesrevenuefromproductsales
whenobligationsunderthetermsofacontractwiththecustomeraresatisfied.Rebatesanddiscountsprovidedto
customersareaccountedforasvariableconsiderationandrecordedasareductioninsales.Theliabilityforsuchrebates
anddiscountsisrecognizedwithinAccruedRebates,Returns,andPromotionsontheconsolidatedbalancesheet.A
significantportionoftheliabilityrelatedtorebatesisfromthesaleofpharmaceuticalgoodswithintheU.S.,primarilythe
ManagedCare,MedicareandMedicaidprograms,whichamountedto$9.6billionasofJanuary1,2023.Forsignificant
rebateprograms,whichincludetheU.S.ManagedCare,MedicareandMedicaidrebateprograms,rebatesanddiscounts
estimatedbymanagementarebasedoncontractualterms,historicalexperience,patientoutcomes,trendanalysis,and
projectedmarketconditionsintheU.S.pharmaceuticalmarket.
TheprincipalconsiderationsforourdeterminationthatperformingproceduresrelatingtoU.S.pharmaceuticalrebate
reserves—ManagedCare,MedicareandMedicaidisacriticalauditmatterarethesignificantjudgmentbymanagement
duetothesignificantmeasurementuncertaintyinvolvedindevelopingthesereservesandthehighdegreeofauditor
judgment,subjectivityandauditeffortinperformingproceduresandevaluatingtheassumptionsrelatedtocontractual
terms,historicalexperience,patientoutcomes,trendanalysis,andprojectedmarketconditionsintheU.S.pharmaceutical
market.
Addressingthematterinvolvedperformingproceduresandevaluatingauditevidenceinconnectionwithformingour
overallopinionontheconsolidatedfinancialstatements.Theseproceduresincludedtestingtheeffectivenessofcontrols
relatingtoU.S.pharmaceuticalrebatereserves—ManagedCare,MedicareandMedicaid,includingcontrolsoverthe
assumptionsusedtoestimatetheserebates.Theseproceduresalsoincluded,amongothers,(i)developingan
independentestimateoftherebatesbyutilizingthirdpartyinformationonpriceandmarketconditionsintheU.S.
pharmaceuticalmarket,thetermsofthespecificrebateprograms,andthehistoricalexperienceandtrendanalysisof
actualrebateclaimspaid;(ii)testingrebateclaimsprocessedbytheCompany,includingevaluatingthoseclaimsfor
consistencywiththecontractualandmandatedtermsoftheCompany’srebatearrangements;and(iii)comparingthe
independentestimatestomanagement’sestimates.
LitigationContingencies-Talc
AsdescribedinNotes1and19totheconsolidatedfinancialstatements,theCompanyrecordsaccrualsforloss
contingenciesassociatedwithlegalmatters,includingtalc,whenitisprobablethataliabilitywillbeincurredandthe
amountofthelosscanbereasonablyestimated.Totheextentadverseawards,judgments,orverdictshavebeenrendered
againsttheCompany,managementdoesnotrecordanaccrualuntilalossisdeterminedtobeprobableandcanbe
reasonablyestimated.Forthesematters,managementisunabletoestimatethepossiblelossorrangeoflossbeyondthe
106 • Johnson&Johnson2022AnnualReportamountsaccrued.Amountsaccruedforlegalcontingenciesoftenresultfromacomplexseriesofjudgmentsaboutfuture
eventsanduncertaintiesthatrelyheavilyonestimatesandassumptionsincludingtimingofrelatedpayments.Theabilityto
makesuchestimatesandjudgmentscanbeaffectedbyvariousfactors,including,amongotherthings,whetherdamages
soughtintheproceedingsareunsubstantiatedorindeterminate;scientificandlegaldiscoveryhasnotcommencedoris
notcomplete;proceedingsareinearlystages;matterspresentlegaluncertainties;therearesignificantfactsindispute;
proceduralorjurisdictionalissues;theuncertaintyandunpredictabilityofthenumberofpotentialclaims;abilitytoachieve
comprehensivemulti-partysettlements;complexityofrelatedcross-claimsandcounterclaims;and/ortherearenumerous
partiesinvolved.ManagementcontinuestobelievethattheCompanyhasstronglegalgroundstocontestthetalcverdicts
ithasappealed.Notwithstandingmanagement’sconfidenceinthesafetyoftheCompany’stalcproducts,incertain
circumstancestheCompanyhassettledcases.InOctober2021,Johnson&JohnsonConsumerInc.(OldJJCI),awholly-
ownedsubsidiaryofJohnson&Johnson,implementedacorporaterestructuringandcreatedasubsidiary,LTL
ManagementLLC(LTL),whichbecamesolelyresponsibleforthetalc-relatedliabilities,andanothersubsidiary,NewJJCI,
whichbecameresponsiblefortheremainingbusinessofOldJJCI.LTLfiledavoluntarypetition,seekingreliefunder
chapter11oftheBankruptcyCode.AsaresultoftheLTLbankruptcycase,theCourtenteredatemporaryrestraining
orderstayingalllitigationagainstLTLandOldJJCI.OnNovember15,2021,theNorthCarolinaBankruptcyCourt
confirmedthescopeofthestay,issuingaPreliminaryInjunction(PI)prohibitingandenjoiningthecommencementand
prosecutionoftalc-relatedclaimsagainstLTL,OldJJCI,NewJJCI,Johnson&Johnson,otheroftheircorporateaffiliates,
identifiedretailers,insurancecompanies,andcertainotherparties.TheLTLBankruptcyCasewastransferredtothe
UnitedStatesBankruptcyCourtfortheDistrictofNewJerseyinNovember2021,andthatcourtextendedthePIthrough
theendofFebruary2022.ClaimantsfiledmotionstodismisstheLTLBankruptcyCaseand,followingamultipleday
hearing,theNewJerseyBankruptcyCourtdeniedthosemotionsbyorderissuedinMarch2022.TheNewJersey
BankruptcyCourtsimultaneouslyissuedanotherorderextendingthestayastotheProtectedParties.Theclaimants
subsequentlyfilednoticesofappealastothedenialofthemotionstodismissandtheextensionofthestay.InMay
2022,theThirdCircuitCourtofAppealsgrantedthepetitionstoappeal.Thebriefingandoralargumentontheappeal
werecompletedinSeptember2022.OnJanuary30,2023,theThirdCircuitreversedtheBankruptcyCourt’srulingand
remandedtotheBankruptcyCourttodismisstheLTLbankruptcy.LTLhasfiledapetitionforrehearingonthedecision.
Theprincipalconsiderationsforourdeterminationthatperformingproceduresrelatingtothetalclitigationisacriticalaudit
matterarethesignificantjudgmentbymanagementwhenassessingthelikelihoodofalossbeingincurredandwhen
determiningwhetherareasonableestimateofthelossorrangeoflossforthefutureandexistingtalcclaimscanbemade,
whichinturnledtoahighdegreeofauditorjudgment,subjectivityandeffortinperformingproceduresandevaluating
management’sassessmentofthelosscontingenciesassociatedwiththislitigation.
Addressingthematterinvolvedperformingproceduresandevaluatingauditevidenceinconnectionwithformingour
overallopinionontheconsolidatedfinancialstatements.Theseproceduresincludedtestingtheeffectivenessofcontrols
relatingtomanagement’sevaluationofthetalclitigation,includingcontrolsoverdeterminingwhetheralossisprobable
andwhethertheamountoflosscanbereasonablyestimated,aswellasfinancialstatementdisclosures.These
proceduresalsoincluded,amongothers,(i)gaininganunderstandingoftheCompany’sprocessaroundtheaccounting
andreportingforthetalclitigation;(ii)discussingthestatusofsignificantknownactualandpotentiallitigationandthe
ongoingLTLbankruptcyproceedingswiththeCompany’sin-houselegalcounsel,aswellasexternalcounselwhen
deemednecessary;(iii)obtainingandevaluatingthelettersofauditinquirywithinternalandexternallegalcounselfor
significantlitigation;(iv)evaluatingthereasonablenessofmanagement’sassessmentregardingwhetheranunfavorable
outcomeisreasonablypossibleorprobableandreasonablyestimable;and(v)evaluatingthesufficiencyoftheCompany’s
litigationcontingenciesdisclosures.
/s/PricewaterhouseCoopersLLP
FlorhamPark,NewJersey
February16,2023
WehaveservedastheCompany’sauditorsinceatleast1920.Wehavenotbeenabletodeterminethespecificyearwe
beganservingasauditoroftheCompany.
Johnson&Johnson2022AnnualReport • 107Management’s Report on Internal Control Over
Financial Reporting
UnderSection404oftheSarbanes-OxleyActof2002,managementisrequiredtoassesstheeffectivenessofthe
Company’sinternalcontroloverfinancialreportingasoftheendofeachfiscalyearandreport,basedonthatassessment,
whethertheCompany’sinternalcontroloverfinancialreportingiseffective.
ManagementoftheCompanyisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancial
reporting.TheCompany’sinternalcontroloverfinancialreportingisdesignedtoprovidereasonableassuranceastothe
reliabilityoftheCompany’sfinancialreportingandthepreparationofexternalfinancialstatementsinaccordancewith
generallyacceptedaccountingprinciples.
Internalcontrolsoverfinancialreporting,nomatterhowwelldesigned,haveinherentlimitations.Therefore,internalcontrol
overfinancialreportingdeterminedtobeeffectivecanprovideonlyreasonableassurancewithrespecttofinancial
statementpreparationandmaynotpreventordetectallmisstatements.Moreover,projectionsofanyevaluationof
effectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequatebecauseofchangesin
conditions,orthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate.
TheCompany’smanagementhasassessedtheeffectivenessoftheCompany’sinternalcontroloverfinancialreportingas
ofJanuary1,2023.Inmakingthisassessment,theCompanyusedthecriteriaestablishedbytheCommitteeof
SponsoringOrganizationsoftheTreadwayCommission(COSO)in“InternalControl-IntegratedFramework(2013).”
Thesecriteriaareintheareasofcontrolenvironment,riskassessment,controlactivities,informationandcommunication,
andmonitoring.TheCompany’sassessmentincludedextensivedocumenting,evaluatingandtestingthedesignand
operatingeffectivenessofitsinternalcontrolsoverfinancialreporting.
TheCompanyacquiredAbiomed,Inc.(Abiomed),inabusinesscombinationinDecember2022.Abiomed’stotalassets,
excludingintangibleassetsandgoodwill,andtotalsalesrepresentedlessthan1%ofeachoftherelatedconsolidated
financialstatementamountsasofandforthefiscalyearendedJanuary1,2023.Astheacquisitionoccurredinthefiscal
year2022,thescopeoftheCompany’sassessmentofthedesignandeffectivenessofinternalcontroloverfinancial
reportingforthefiscalyear2022excludedtheabovementionedacquisition.Thisexclusionisinaccordancewiththe
SEC’sgeneralguidancethatanassessmentofarecentlyacquiredbusinessmaybeomittedfromthescopeintheyearof
acquisition.
BasedontheCompany’sprocessesandassessment,asdescribedabove,managementhasconcludedthat,asof
January1,2023,theCompany’sinternalcontroloverfinancialreportingwaseffective.
TheeffectivenessoftheCompany’sinternalcontroloverfinancialreportingasofJanuary1,2023hasbeenauditedby
PricewaterhouseCoopersLLP,anindependentregisteredpublicaccountingfirm,asstatedintheirreport,whichappears
herein.
/s/J.Duato /s/JosephJ.Wolk
JoaquinDuato JosephJ.Wolk
Chairman,BoardofDirectors ExecutiveVicePresident,
ChiefExecutiveOfficer ChiefFinancialOfficer
108 • Johnson&Johnson2022AnnualReportShareholder Return Performance Graphs
SetforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnontheCompany’sCommonStockfor
periodsoffiveyearsandtenyearsendingJanuary1,2023,againstthecumulativetotalreturnoftheStandard&Poor’s
500StockIndex,theStandard&Poor’sPharmaceuticalIndexandtheStandard&Poor’sHealthcareEquipmentIndex.
Thegraphsandtablesassumethat$100wasinvestedonDecember31,2017andDecember31,2012ineachofthe
Company’sCommonStock,theStandard&Poor’s500StockIndex,theStandard&Poor’sPharmaceuticalIndexandthe
Standard&Poor’sHealthcareEquipmentIndexandthatalldividendswerereinvested.
5YearShareholderReturn
PerformanceJ&Jvs.Indices
$230
Johnson & Johnson
$210
S&P 500 Index
$190
S&P Pharmaceu(cid:2)cal Index
$170
S&P Healthcare Equipment
$150
Index
5-Year CAGR $130
J&J 7.6%
$110
S&P 500 9.4%
S&P Pharm 12.8%
$90
S&P H/C Equip 11.4% 2017 2018 2019 2020 2021 2022
2017 2018 2019 2020 2021 2022
Johnson&Johnson $100.00 $94.86 $110.24 $122.20 $136.19 $144.32
S&P500Index $100.00 $95.61 $125.70 $148.81 $191.48 $156.77
S&PPharmaceuticalIndex $100.00 $108.09 $124.40 $133.76 $168.21 $182.43
S&PHealthcareEquipmentIndex $100.00 $116.24 $150.32 $176.83 $211.05 $171.25
10YearShareholderReturn
PerformanceJ&Jvs.Indices
$550
Johnson & Johnson
$500
S&P 500 Index $450
$400
S&P Pharmaceu(cid:2)cal Index
$350
S&P Healthcare Equipment $300
Index
$250
10-Year CAGR
$200
J&J 12.7%
S&P 500 12.5% $150
S&P Pharm 13.5%
$100
S&P H/C Equip 15.1% 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
Johnson&Johnson $100.00 $134.62 $157.95 $159.78 $184.26 $229.23 $217.46 $252.71 $280.13 $312.20 $330.83
S&P500Index $100.00 $132.37 $150.47 $152.53 $170.76 $208.02 $198.87 $261.47 $309.54 $398.32 $326.12
S&PPharmaceuticalIndex $100.00 $135.23 $165.27 $174.84 $172.10 $193.74 $209.41 $241.01 $259.15 $325.89 $353.44
S&PHealthcareEquipmentIndex $100.00 $127.69 $161.24 $170.87 $181.95 $238.17 $276.85 $358.03 $421.16 $502.66 $407.86
Johnson&Johnson2022AnnualReport • 109Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL DISCLOSURE
Notapplicable.
Item 9A. CONTROLS AND PROCEDURES
DisclosureControlsandProcedures.AttheendoftheperiodcoveredbythisReport,theCompanyevaluatedthe
effectivenessofthedesignandoperationofitsdisclosurecontrolsandprocedures.TheCompany’sdisclosurecontrols
andproceduresaredesignedtoensurethatinformationrequiredtobedisclosedbytheCompanyinthereportsthatit
filesorsubmitsundertheExchangeActisrecorded,processed,summarizedandreportedwithinthetimeperiods
specifiedintheSEC’srulesandforms.Disclosurecontrolsandproceduresinclude,withoutlimitation,controlsand
proceduresdesignedtoensurethatinformationrequiredtobedisclosedbytheCompanyinthereportsthatitfilesor
submitsundertheExchangeActisaccumulatedandcommunicatedtotheCompany’smanagement,includingitsprincipal
executiveandprincipalfinancialofficers,orpersonsperformingsimilarfunctions,asappropriatetoallowtimelydecisions
regardingrequireddisclosure.JoaquinDuato,ChairmanandChiefExecutiveOfficer,andJosephJ.Wolk,ExecutiveVice
President,ChiefFinancialOfficer,reviewedandparticipatedinthisevaluation.Basedonthisevaluation,Messrs.Duato
andWolkconcludedthat,asoftheendoftheperiodcoveredbythisReport,theCompany’sdisclosurecontrolsand
procedureswereeffective.
ReportsonInternalControlOverFinancialReporting.Theinformationcalledforbythisitemisincorporatedhereinby
referenceto“Management’sReportonInternalControlOverFinancialReporting”,andtheattestationregardinginternal
controlsoverfinancialreportingincludedinthe“ReportofIndependentRegisteredPublicAccountingFirm”includedin
Item8ofthisReport.
ChangesinInternalControlOverFinancialReporting.DuringthefiscalquarterendedJanuary1,2023,therewereno
changesintheCompany’sinternalcontroloverfinancialreportingidentifiedinconnectionwiththeevaluationrequired
underRules13a-15and15d-15undertheExchangeActthathavemateriallyaffected,orarereasonablylikelyto
materiallyaffect,theCompany’sinternalcontroloverfinancialreporting.TheCompanycontinuestomonitorandassess
theeffectivenessofthedesignandoperationofitsdisclosurecontrolsandprocedures.
TheCompanyisimplementingamulti-year,enterprise-wideinitiativetointegrate,simplifyandstandardizeprocessesand
systemsforthehumanresources,informationtechnology,procurement,supplychainandfinancefunctions.Theseare
enhancementstosupportthegrowthoftheCompany’sfinancialsharedservicecapabilitiesandstandardizefinancial
systems.ThisinitiativeisnotinresponsetoanyidentifieddeficiencyorweaknessintheCompany’sinternalcontrolover
financialreporting.Inresponsetothisinitiative,theCompanyhasandwillcontinuetoalignandstreamlinethedesignand
operationofitsfinancialcontrolenvironment.
Item 9B. OTHER INFORMATION
Notapplicable.
Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT
PREVENT INSPECTIONS
Notapplicable.
110 • Johnson&Johnson2022AnnualReportPART III
Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE
GOVERNANCE
TheinformationcalledforbythisitemisincorporatedhereinbyreferencetothediscussionoftheAuditCommitteeunder
thecaption“Item1.ElectionofDirectors-BoardCommittees”;andthematerialunderthecaptions“Item1.Electionof
Directors”and,ifapplicable,“StockOwnershipandSection16Compliance–DelinquentSection16(a)Reports”inthe
ProxyStatement;andthematerialunderthecaption“ExecutiveOfficersoftheRegistrant”inPartIofthisReport.
TheCompany’sCodeofBusinessConduct,whichcoversallemployees(includingtheChiefExecutiveOfficer,Chief
FinancialOfficerandController),meetstherequirementsoftheSECrulespromulgatedunderSection406ofthe
Sarbanes-OxleyActof2002.TheCodeofBusinessConductisavailableontheCompany’swebsiteatwww.jnj.com/
code-of-business-conduct,andcopiesareavailabletoshareholderswithoutchargeuponwrittenrequesttotheSecretary
attheCompany’sprincipalexecutiveoffices.AnysubstantiveamendmenttotheCodeofBusinessConductoranywaiver
oftheCodegrantedtotheChiefExecutiveOfficer,theChiefFinancialOfficerortheControllerwillbepostedonthe
Company’swebsiteatwww.investor.jnj.com/gov.cfmwithinfivebusinessdays(andretainedonthewebsiteforatleastone
year).
Inaddition,theCompanyhasadoptedaCodeofBusinessConduct&EthicsforMembersoftheBoardofDirectorsand
ExecutiveOfficers.TheCodeofBusinessConduct&EthicsforMembersoftheBoardofDirectorsandExecutiveOfficers
isavailableontheCompany’swebsiteatwww.investor.jnj.com/gov/boardconduct.cfm,andcopiesareavailableto
shareholderswithoutchargeuponwrittenrequesttotheSecretaryattheCompany’sprincipalexecutiveoffices.Any
substantiveamendmenttotheCodeoranywaiveroftheCodegrantedtoanymemberoftheBoardofDirectorsorany
executiveofficerwillbepostedontheCompany’swebsiteatwww.investor.jnj.com/gov.cfmwithinfivebusinessdays(and
retainedonthewebsiteforatleastoneyear).
Item 11. EXECUTIVE COMPENSATION
Theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptions“Item1.
ElectionofDirectors–DirectorCompensation,”and“Item2.Compensation&BenefitsCommitteeReport,”
“CompensationDiscussionandAnalysis”and“ExecutiveCompensationTables”intheProxyStatement.
Thematerialincorporatedhereinbyreferencetothematerialunderthecaption“Compensation&BenefitsCommittee
Report”intheProxyStatementshallbedeemedfurnished,andnotfiled,inthisReportandshallnotbedeemed
incorporatedbyreferenceintoanyfilingundertheSecuritiesActof1933,asamended,ortheSecuritiesExchangeActof
1934,asamended,asaresultofthisfurnishing,excepttotheextentthattheCompanyspecificallyincorporatesitby
reference.
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT AND RELATED STOCKHOLDER MATTERS
Theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaption“Item1.
StockOwnershipandSection16Compliance”intheProxyStatement;andNote16“CommonStock,StockOptionPlans
andStockCompensationAgreements”oftheNotestoConsolidatedFinancialStatementsinItem8ofthisReport.
Johnson&Johnson2022AnnualReport • 111Equity Compensation Plan Information
ThefollowingtableprovidescertaininformationasofJanuary1,2023concerningthesharesoftheCompany’sCommon
Stockthatmaybeissuedunderexistingequitycompensationplans.
Numberof
Securitiesto
beIssuedUpon WeightedAverage NumberofSecurities
Exerciseof ExercisePriceof RemainingAvailablefor
Outstanding Outstanding FutureIssuanceUnderEquity
PlanCategory OptionsandRights OptionsandRights CompensationPlans(2)(3)
EquityCompensationPlansApprovedbySecurity
Holders(1) 134,644,525 $118.94 149,652,710
EquityCompensationPlansNotApprovedbySecurity
Holders — — —
Total 134,644,525 $118.94 149,652,710
(1) IncludedinthiscategoryarethefollowingequitycompensationplanswhichhavebeenapprovedbytheCompany’sshareholders:
2012Long-TermIncentivePlanand2022Long-TermIncentivePlan.
(2) Thiscolumnexcludessharesreflectedunderthecolumn“NumberofSecuritiestobeIssuedUponExerciseofOutstandingOptions
andRights.”
(3) The2012Long-TermIncentivePlanexpiredApril26,2022.Alloptionsandrestrictedsharesgrantedsubsequenttothatdatewere
underthe2022Long-TermIncentivePlan.
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND
DIRECTOR INDEPENDENCE
Theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptions“Item1.
ElectionofDirectors-DirectorIndependence”and“RelatedPersonTransactions”intheProxyStatement.
Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaption“Item3.
RatificationofAppointmentofIndependentRegisteredPublicAccountingFirm”intheProxyStatement.
112 • Johnson&Johnson2022AnnualReportPART IV
Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
Thefollowingdocumentsarefiledaspartofthisreport:
1. FinancialStatements
ConsolidatedBalanceSheetsatendofFiscalYears2022and2021
ConsolidatedStatementsofEarningsforFiscalYears2022,2021and2020
ConsolidatedStatementsofComprehensiveIncomeforFiscalYears2022,2021and2020
ConsolidatedStatementsofEquityforFiscalYears2022,2021and2020
ConsolidatedStatementsofCashFlowsforFiscalYears2022,2021and2020
NotestoConsolidatedFinancialStatements
ReportofIndependentRegisteredPublicAccountingFirm
Allschedulesareomittedbecausetheyarenotapplicableortherequiredinformationisincludedinthefinancial
statementsornotes.
2. ExhibitsRequiredtobeFiledbyItem60lofRegulationS-K
TheinformationcalledforbythisitemisincorporatedhereinbyreferencetotheExhibitIndexinthisReport.
Item 16. FORM 10-K SUMMARY
RegistrantsmayvoluntarilyincludeasummaryofinformationrequiredbyForm10-KunderthisItem16.TheCompanyhas
electednottoincludesuchsummaryinformation.
Johnson&Johnson2022AnnualReport • 113SIGNATURES
PursuanttotherequirementsofSection13oftheSecuritiesExchangeActof1934,theregistranthasdulycausedthis
Reporttobesignedonitsbehalfbytheundersigned,thereuntodulyauthorized.
Date:February16,2023
JOHNSON&JOHNSON
(Registrant)
By /s/J.Duato
J.Duato,ChairmanoftheBoard
andChiefExecutiveOfficer
PursuanttotherequirementsoftheSecuritiesExchangeActof1934,thisreporthasbeensignedbelowbythefollowing
personsonbehalfoftheregistrantandinthecapacitiesandonthedatesindicated.
Signature Title Date
/s/J.Duato ChairmanoftheBoard February16,2023
J.Duato ChiefExecutiveOfficer
(PrincipalExecutiveOfficer)
/s/J.J.Wolk
ChiefFinancialOfficer February16,2023
J.J.Wolk (PrincipalFinancialOfficer)
/s/R.J.DeckerJr.
ControllerandChiefAccountingOfficer February16,2023
R.J.DeckerJr. (PrincipalAccountingOfficer)
/s/D.Adamczyk
Director February16,2023
D.Adamczyk
/s/M.C.Beckerle
Director February16,2023
M.C.Beckerle
/s/D.S.Davis
Director February16,2023
D.S.Davis
/s/I.E.L.Davis
Director February16,2023
I.E.L.Davis
/s/J.A.Doudna
Director February16,2023
J.A.Doudna
/s/M.A.Hewson
Director February16,2023
M.A.Hewson
/s/H.Joly
Director February16,2023
H.Joly
/s/M.B.McClellan
Director February16,2023
M.B.McClellan
114 • Johnson&Johnson2022AnnualReportSignature Title Date
/s/A.M.Mulcahy Director February16,2023
A.M.Mulcahy
/s/A.E.Washington
Director February16,2023
A.E.Washington
/s/M.A.Weinberger Director February16,2023
M.A.Weinberger
/s/N.Y.West Director February16,2023
N.Y.West
Johnson&Johnson2022AnnualReport • 115EXHIBIT INDEX
Reg.S-K
ExhibitTable
ItemNo. DescriptionofExhibit
2(i) AgreementandPlanofMerger,datedasofOctober31,2022,byandamongJohnson&Johnson,AthosMergerSub,Inc.and
ABIOMED,Inc.–IncorporatedhereinbyreferencetoExhibit2.1oftheRegistrant’sForm8-KCurrentReportfiledNovember1,
2022.†
3(i) RestatedCertificateofIncorporationeffectiveFebruary19,2016—IncorporatedhereinbyreferencetoExhibit3(i)ofthe
Registrant’sForm10-KAnnualReportforthefiscalyearendedJanuary3,2016.
3(ii) CertificateofAmendmenttotheCertificateofIncorporationofJohnson&JohnsoneffectiveApril30,2020—Incorporatedherein
byreferencetoExhibit3.1oftheRegistrant’sForm8-KCurrentReportfiledApril29,2020.
3(iii) By-LawsoftheCompany,asamendedeffectiveJune9,2020—IncorporatedhereinbyreferencetoExhibit3.1ofthe
Registrant’sForm8-KCurrentReportfiledJune10,2020.
4(a) UpontherequestoftheSecuritiesandExchangeCommission,theRegistrantwillfurnishacopyofallinstrumentsdefiningthe
rightsofholdersoflong-termdebtoftheRegistrant.
4(b) DescriptionofSecuritiesRegisteredPursuanttoSection12oftheSecuritiesExchangeActof1934—Incorporatedhereinby
referencetoExhibit4.1oftheRegistrant’sForm8-KCurrentReportfiledAugust12,2020.
10(a) 2005Long-TermIncentivePlan—IncorporatedhereinbyreferencetoExhibit4oftheRegistrant’sS-8RegistrationStatement
filedonMay10,2005(fileno.333-124785).*
10(b) FormofStockOptionCertificateunderthe2005Long-TermIncentivePlan—IncorporatedhereinbyreferencetoExhibit10.1of
theRegistrant’sForm8-KCurrentReportfiledJanuary13,2012.*
10(c) 2012Long-TermIncentivePlan—IncorporatedhereinbyreferencetoAppendixAoftheRegistrant’sProxyStatementfiledon
March15,2017.*
10(d) FormofStockOptionCertificate,RestrictedShareUnitCertificateandPerformanceShareUnitCertificateunderthe2012
Long-TermIncentivePlan—IncorporatedhereinbyreferencetoExhibits10.2,10.3and10.4oftheRegistrant’sForm10-Q
QuarterlyReportforthequarterendedApril1,2012.*
10(e) GlobalNonQualifiedStockOptionAwardAgreement,GlobalRestrictedShareUnitAwardAgreementandGlobalPerformance
ShareUnitAwardAgreementunderthe2012Long-TermIncentivePlan—IncorporatedhereinbyreferencetoExhibits10.1,
10.2and10.3oftheRegistrant’sForm10-QQuarterlyReportforthequarterendedApril1,2018.*
10(f) Johnson&JohnsonExecutiveIncentivePlan(AmendedasofNovember28,2018)—Incorporatedhereinbyreferenceto
Exhibit10(a)oftheRegistrant’sForm10-QQuarterlyReportforthequarterendedMarch31,2019.*
10(g) DomesticDeferredCompensation(CertificateofExtraCompensation)Plan—IncorporatedhereinbyreferencetoExhibit10(g)
oftheRegistrant’sForm10-KAnnualReportfortheyearendedDecember28,2003.*
10(h) AmendmentstotheCertificateofExtraCompensationPlaneffectiveasofJanuary1,2009—Incorporatedhereinbyreferenceto
Exhibit10(j)oftheRegistrant’sForm10-KAnnualReportfortheyearendedDecember28,2008.*
10(i) 2009CertificatesofLong-TermPerformancePlan—IncorporatedhereinbyreferencetoExhibit10.1oftheRegistrant’s
Form10-QQuarterlyReportforthequarterendedSeptember27,2009.*
10(j) AmendedandRestatedDeferredFeePlanforDirectors(AmendedasofJanuary17,2012)—Incorporatedhereinbyreference
toExhibit10(k)oftheRegistrant’sForm10-KAnnualReportforthefiscalyearendedJanuary1,2012.*
10(k) TheJohnson&JohnsonExecutiveIncomeDeferralPlanAmendedandRestatedEffectiveJanuary1,2010—Incorporatedherein
byreferencetoExhibit10.1oftheRegistrant’sForm10-QQuarterlyReportforthequarterendedSeptember30,2012.*
10(l) TheJohnson&JohnsonExcessSavingsPlan(amendedandrestatedasofJanuary1,2022)—Filedwiththisdocument.*
10(m) ExcessBenefitPlanofJohnson&JohnsonandAffiliatedCompanies(amendedandrestatedasofJanuary1,2020)—
incorporatedbyreferencetoExhibit10(n)oftheRegistrant’sForm10-KAnnualReportforthefiscalyearendedJanuary3,
2021.*
10(n)** ExecutiveLifePlanAgreement—IncorporatedhereinbyreferencetoExhibit10(i)oftheRegistrant’sForm10-KAnnualReport
forthefiscalyearendedJanuary3,1993.*
10(o) ExecutiveLifePlanAgreementClosureLetter—IncorporatedhereinbyreferencetoExhibit10.1oftheRegistrant’sForm10-Q
QuarterlyReportforthequarterendedMarch29,2015.*
10(p) 2022Long-TermIncentivePlan—IncorporatedbyreferencetoAppendixAoftheRegistrant’sProxyStatementfiledon
March16,2022.*
10(q) SeverancePayPlanofJohnson&JohnsonandU.S.AffiliatedCompanies,AmendedandRestatedasofOctober1,2014—
IncorporatedhereinbyreferencetoExhibit10.1oftheRegistrant’sForm10-QQuarterlyReportforthequarterended
September28,2014.*
116 • Johnson&Johnson2022AnnualReportReg.S-K
ExhibitTable
ItemNo. DescriptionofExhibit
10(r) FirstAmendmenttotheSeverancePayPlanofJohnson&JohnsonandU.S.AffiliatedCompanies(asamendedandrestated
effectiveOctober1,2014)—IncorporatedhereinbyreferencetoExhibit10.1oftheRegistrant’sForm10-QQuarterlyReport
forthequarterendedJune28,2015.*
10(s) SecondAmendmenttotheSeverancePayPlanofJohnson&JohnsonandU.S.AffiliatedCompanies(asamendedandrestated
effectiveOctober1,2014)—IncorporatedhereinbyreferencetoExhibit10(x)oftheRegistrant’sForm10-KAnnualReportfor
thefiscalyearendedJanuary3,2016.*
10(t) ContingentValueRightsAgreement,datedasofDecember22,2022,byandbetweenJohnson&JohnsonandAmericanStock
Transfer&TrustCompany,LLC–IncorporatedhereinbyreferencetoExhibit10.1oftheRegistrant’sForm8-KCurrentReport
filedDecember22,2022.†
21 Subsidiaries—Filedwiththisdocument.
23 ConsentofIndependentRegisteredPublicAccountingFirm—Filedwiththisdocument.
31.1 CertificationofChiefExecutiveOfficerPursuanttoSection302oftheSarbanes-OxleyAct—Filedwiththisdocument.
31.2 CertificationofChiefFinancialOfficerPursuanttoSection302oftheSarbanes-OxleyAct—Filedwiththisdocument.
32.1 CertificationofChiefExecutiveOfficerPursuanttoSection906oftheSarbanes-OxleyAct—Furnishedwiththisdocument.
32.2 CertificationofChiefFinancialOfficerPursuanttoSection906oftheSarbanes-OxleyAct—Furnishedwiththisdocument.
Exhibit101:
EX-101.INS InstanceDocument—theinstancedocumentdoesnotappearintheInteractiveDataFilebecauseitsXBRLtagsareembedded
withintheInlineXBRLdocument
EX-101.SCH InlineXBRLTaxonomyExtensionSchema
EX-101.CAL InlineXBRLTaxonomyExtensionCalculationLinkbase
EX-101.LAB InlineXBRLTaxonomyExtensionLabelLinkbase
EX-101.PRE InlineXBRLTaxonomyExtensionPresentationLinkbase
EX-101.DEF InlineXBRLTaxonomyExtensionDefinitionDocument
Exhibit104: CoverPageInteractiveDataFile––thecoverpageinteractivedatafiledoesnotappearintheInteractiveDataFilebecauseits
XBRLtagsareembeddedwithintheInlineXBRLdocument.
* Managementcontractorcompensatoryplan.
**Paperfiling.
† CertainexhibitsandscheduleshavebeenomittedpursuanttoItem601(b)(2)(ii)or601(b)(10)(iv)ofRegulationS-K,asapplicable.
AcopyofanyoftheExhibitslistedabovewillbeprovidedwithoutchargetoanyshareholdersubmittingawrittenrequest
specifyingthedesiredexhibit(s)totheSecretaryattheprincipalexecutiveofficesoftheCompany.Pursuantto
Item601(b)(4)(iii)(A)ofRegulationS-K,theCompanyhasnotfiledasexhibitstothisForm10-Kcertainlong-termdebt
instruments,includingindentures,underwhichthetotalamountofsecuritiesauthorizeddoesnotexceed10%ofthetotal
assetsoftheCompanyanditssubsidiariesonaconsolidatedbasis.TheCompanyherebyagreestofurnishacopyofany
suchinstrumenttotheSECuponrequest.
ThefollowingExhibits,indicatedasbeingfiledwiththisdocument,areomittedfromtheprintedversionofthis2022
AnnualReport.
Exhibit10(l)
Exhibit21
Exhibit23
Johnson&Johnson2022AnnualReport • 117[THISPAGEINTENTIONALLYLEFTBLANK]Exhibit31.1
CERTIFICATIONOFCHIEFEXECUTIVEOFFICER
PURSUANTTOSECTION302OFTHESARBANES-OXLEYACT
I,JoaquinDuato,certifythat:
1.IhavereviewedthisAnnualReportonForm10-KforthefiscalyearendedJanuary1,2023(the“report”)ofJohnson&
Johnson(the“Company”);
2.Basedonmyknowledge,thisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostateamaterial
factnecessarytomakethestatementsmade,inlightofthecircumstancesunderwhichsuchstatementsweremade,not
misleadingwithrespecttotheperiodcoveredbythisreport;
3.Basedonmyknowledge,thefinancialstatements,andotherfinancialinformationincludedinthisreport,fairlypresentin
allmaterialrespectsthefinancialcondition,resultsofoperationsandcashflowsoftheCompanyasof,andfor,theperiods
presentedinthisreport;
4.TheCompany’sothercertifyingofficer(s)andIareresponsibleforestablishingandmaintainingdisclosurecontrolsand
procedures(asdefinedinExchangeActRules13a-15(e)and15d-15(e))andinternalcontroloverfinancialreporting(as
definedinExchangeActRules13a-15(f)and15d-15(f))fortheCompanyandhave:
(a)Designedsuchdisclosurecontrolsandprocedures,orcausedsuchdisclosurecontrolsandproceduresto
bedesignedunderoursupervision,toensurethatmaterialinformationrelatingtotheCompany,includingits
consolidatedsubsidiaries,ismadeknowntousbyotherswithinthoseentities,particularlyduringtheperiodinwhich
thisreportisbeingprepared;
(b)Designedsuchinternalcontroloverfinancialreporting,orcausedsuchinternalcontroloverfinancial
reportingtobedesignedunderoursupervision,toprovidereasonableassuranceregardingthereliabilityoffinancial
reportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerallyaccepted
accountingprinciples;
(c)EvaluatedtheeffectivenessoftheCompany’sdisclosurecontrolsandproceduresandpresentedinthis
reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandprocedures,asoftheendoftheperiod
coveredbythisreportbasedonsuchevaluation;and
(d)DisclosedinthisreportanychangeintheCompany’sinternalcontroloverfinancialreportingthatoccurred
duringtheCompany’smostrecentfiscalquarter(theCompany’sfourthfiscalquarterinthecaseofanannualreport)
thathasmateriallyaffected,orisreasonablylikelytomateriallyaffect,theCompany’sinternalcontroloverfinancial
reporting;and
5.TheCompany’sothercertifyingofficer(s)andIhavedisclosed,basedonourmostrecentevaluationofinternalcontrol
overfinancialreporting,totheCompany’sauditorsandtheauditcommitteeoftheCompany’sboardofdirectors(or
personsperformingtheequivalentfunctions):
(a)Allsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover
financialreportingwhicharereasonablylikelytoadverselyaffecttheCompany’sabilitytorecord,process,summarize
andreportfinancialinformation;and
(b)Anyfraud,whetherornotmaterial,thatinvolvesmanagementorotheremployeeswhohaveasignificantrole
intheCompany’sinternalcontroloverfinancialreporting.
/s/JoaquinDuato
JoaquinDuato
ChiefExecutiveOfficer
Date:February16,2023
Johnson&Johnson2022AnnualReportExhibit31.2
CERTIFICATIONOFCHIEFFINANCIALOFFICER
PURSUANTTOSECTION302OFTHESARBANES-OXLEYACT
I,JosephJ.Wolkcertifythat:
1.IhavereviewedthisAnnualReportonForm10-KforthefiscalyearendedJanuary1,2023(the“report”)ofJohnson&
Johnson(the“Company”);
2.Basedonmyknowledge,thisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostateamaterial
factnecessarytomakethestatementsmade,inlightofthecircumstancesunderwhichsuchstatementsweremade,not
misleadingwithrespecttotheperiodcoveredbythisreport;
3.Basedonmyknowledge,thefinancialstatements,andotherfinancialinformationincludedinthisreport,fairlypresentin
allmaterialrespectsthefinancialcondition,resultsofoperationsandcashflowsoftheCompanyasof,andfor,theperiods
presentedinthisreport;
4.TheCompany’sothercertifyingofficer(s)andIareresponsibleforestablishingandmaintainingdisclosurecontrolsand
procedures(asdefinedinExchangeActRules13a-15(e)and15d-15(e))andinternalcontroloverfinancialreporting(as
definedinExchangeActRules13a-15(f)and15d-15(f))fortheCompanyandhave:
(a)Designedsuchdisclosurecontrolsandprocedures,orcausedsuchdisclosurecontrolsandproceduresto
bedesignedunderoursupervision,toensurethatmaterialinformationrelatingtotheCompany,includingits
consolidatedsubsidiaries,ismadeknowntousbyotherswithinthoseentities,particularlyduringtheperiodinwhich
thisreportisbeingprepared;
(b)Designedsuchinternalcontroloverfinancialreporting,orcausedsuchinternalcontroloverfinancial
reportingtobedesignedunderoursupervision,toprovidereasonableassuranceregardingthereliabilityoffinancial
reportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerallyaccepted
accountingprinciples;
(c)EvaluatedtheeffectivenessoftheCompany’sdisclosurecontrolsandproceduresandpresentedinthis
reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandprocedures,asoftheendoftheperiod
coveredbythisreportbasedonsuchevaluation;and
(d)DisclosedinthisreportanychangeintheCompany’sinternalcontroloverfinancialreportingthatoccurred
duringtheCompany’smostrecentfiscalquarter(theCompany’sfourthfiscalquarterinthecaseofanannualreport)
thathasmateriallyaffected,orisreasonablylikelytomateriallyaffect,theCompany’sinternalcontroloverfinancial
reporting;and
5.TheCompany’sothercertifyingofficer(s)andIhavedisclosed,basedonourmostrecentevaluationofinternalcontrol
overfinancialreporting,totheCompany’sauditorsandtheauditcommitteeoftheCompany’sboardofdirectors(or
personsperformingtheequivalentfunctions):
(a)Allsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover
financialreportingwhicharereasonablylikelytoadverselyaffecttheCompany’sabilitytorecord,process,summarize
andreportfinancialinformation;and
(b)Anyfraud,whetherornotmaterial,thatinvolvesmanagementorotheremployeeswhohaveasignificantrole
intheCompany’sinternalcontroloverfinancialreporting.
/s/JosephJ.Wolk
JosephJ.Wolk
ChiefFinancialOfficer
Date:February16,2023
Johnson&Johnson2022AnnualReportExhibit32.1
CERTIFICATIONOFCHIEFEXECUTIVEOFFICER
PURSUANTTOSECTION906OFTHESARBANES-OXLEYACT
Theundersigned,JoaquinDuato,theChiefExecutiveOfficerofJohnson&Johnson,aNewJerseycorporation(the
“Company”),pursuantto18U.S.C.1350,asadoptedpursuanttoSection906oftheSarbanes-OxleyActof2002,
herebycertifiesthat,tothebestofmyknowledge:
(1)theCompany’sAnnualReportonForm10-KforthefiscalyearendedJanuary1,2023(the“Report”)fullycomplies
withtherequirementsofSection13(a)oftheSecuritiesExchangeActof1934;and
(2)theinformationcontainedintheReportfairlypresents,inallmaterialrespects,thefinancialconditionandresultsof
operationsoftheCompany.
/s/JoaquinDuato
JoaquinDuato
ChiefExecutiveOfficer
Dated:February16,2023
ThiscertificationisbeingfurnishedtotheSECwiththisReportonForm10-KpursuanttoSection906oftheSarbanes-
OxleyActof2002andshallnot,excepttotheextentrequiredbysuchAct,bedeemedfiledbytheCompanyforpurposes
ofSection18oftheSecuritiesExchangeActof1934,asamended,orotherwisesubjecttotheliabilityofthatsection.
Johnson&Johnson2022AnnualReportExhibit32.2
CERTIFICATIONOFCHIEFFINANCIALOFFICER
PURSUANTTOSECTION906OFTHESARBANES-OXLEYACT
Theundersigned,JosephJ.Wolk,theChiefFinancialOfficerofJohnson&Johnson,aNewJerseycorporation(the
“Company”),pursuantto18U.S.C.1350,asadoptedpursuanttoSection906oftheSarbanes-OxleyActof2002,
herebycertifiesthat,tothebestofmyknowledge:
(1)theCompany’sAnnualReportonForm10-KforthefiscalyearendedJanuary1,2023(the“Report”)fullycomplies
withtherequirementsofSection13(a)oftheSecuritiesExchangeActof1934;and
(2)theinformationcontainedintheReportfairlypresents,inallmaterialrespects,thefinancialconditionandresultsof
operationsoftheCompany.
/s/JosephJ.Wolk
JosephJ.Wolk
ChiefFinancialOfficer
Dated:February16,2023
ThiscertificationisbeingfurnishedtotheSECwiththisReportonForm10-KpursuanttoSection906oftheSarbanes-
OxleyActof2002andshallnot,excepttotheextentrequiredbysuchAct,bedeemedfiledbytheCompanyforpurposes
ofSection18oftheSecuritiesExchangeActof1934,asamended,orotherwisesubjecttotheliabilityofthatsection.
Johnson&Johnson2022AnnualReport[THISPAGEINTENTIONALLYLEFTBLANK][THISPAGEINTENTIONALLYLEFTBLANK]Thetablesbelowareprovidedtoreconcilecertainnon-GAAPfinancialdisclosuresinthe2022
Chairman’sLetter.
ReconciliationofNon-GAAPFinancialMeasures
%
(DollarsinMillionsExceptPerShareData) 2022 2021 change
NetEarnings,aftertax-asreported $17,941 $20,878
Pre-taxAdjustments
IntangibleAssetAmortizationexpense 4,305 4,697
Litigationrelated 866 2,328
IPR&D 783 900
Restructuringrelated 463 473
Acquisition,integrationanddivestiturerelated 196 (478)
(Gains)/lossesonsecurities 690 (533)
MedicalDeviceRegulation 296 234
COVID-19Vaccinerelatedcosts 1,474 —
ConsumerHealthseparationcosts 1,089 67
Other (7) —
TaxAdjustments
Taximpactonspecialitemadjustments (1,592) (1,281)
ConsumerHealthseparationtaxrelatedcosts 494 —
Taxlegislationandothertaxrelated 40 (1,090)
AdjustedNetEarnings,aftertax $27,038 $26,195 3.2%
Averagesharesoutstanding(Diluted) 2,663.9 2,674.0
Adjustednetearningspershare(Diluted) $10.15 $9.80 3.6%
Operationaladjustednetearningspershare(Diluted) $10.70 9.2%
Growth%
Inc./
SalesGrowth%2022vs.2021 (Dec.)
WWtotalasreported 1.3%
Operational 6.1%
Currency (4.8)%Board of Directors Senior Management
JOAQUINDUATO JOAQUINDUATO*
Chairman,BoardofDirectors ChiefExecutiveOfficer;
Chairman,ExecutiveCommittee
DARIUSADAMCZYK
ChairmanandChiefExecutiveOfficer,
VANESSABROADHURST*
HoneywellInternational
ExecutiveVicePresident,GlobalCorporateAffairs
MARYC.BECKERLE
ROBERTJ.DECKERJR.
ChiefExecutiveOfficer,HuntsmanCancerInstitute
CorporateController;ChiefAccountingOfficer
attheUniversityofUtah;
DistinguishedProfessorofBiology,
PETERM.FASOLO*
CollegeofScience,UniversityofUtah
ExecutiveVicePresident,ChiefHumanResourcesOfficer
D.SCOTTDAVIS
FormerChairmanandChiefExecutiveOfficer, ELIZABETHFORMINARD*
UnitedParcelService,Inc. ExecutiveVicePresident,GeneralCounsel
IANE.L.DAVIS WILLIAMN.HAIT*
FormerNon-ExecutiveChairman, ExecutiveVicePresident,ChiefExternalInnovationand
Rolls-RoyceHoldingsplc; MedicalSafetyOfficer;InterimHeadJanssenR&D
FormerChairmanandWorldwideManagingDirector,
McKinsey&Company MARCLARKINS
CorporateSecretary;
JENNIFERA.DOUDNA
WorldwideVicePresident,CorporateGovernance
ProfessorofChemistry;ProfessorofBiochemistry
&MolecularBiology;
ASHLEYMcEVOY*
LiKaShingChancellor’sProfessorinBiomedical
ExecutiveVicePresident,WorldwideChairman,
andHealth,UniversityofCalifornia,Berkeley
MedTech
MARILLYNA.HEWSON
THIBAUTMONGON*
FormerChairandChiefExecutiveOfficer,
ExecutiveVicePresident,WorldwideChairman,
LockheedMartinCorporation
ConsumerHealth;CEODesignate,ThePlanned
PAULAA.JOHNSON NewConsumerHealthCompany
President,WellesleyCollege
JAMESSWANSON*
HUBERTJOLY
ExecutiveVicePresident,ChiefInformationOfficer
FormerChairmanandChiefExecutiveOfficer,
BestBuyCo.,Inc.
JENNIFERTAUBERT*
MARKB.McCLELLAN ExecutiveVicePresident,WorldwideChairman,
Director,Duke-RobertJ.Margolis,MD, Pharmaceuticals
CenterforHealthPolicy,DukeUniversity
DUANEVANARSDALE
ANNEM.MULCAHY
Treasurer
FormerChairmanandChiefExecutiveOfficer,
XeroxCorporation KATHRYNE.WENGEL*
ExecutiveVicePresident,ChiefTechnicalOperations
A.EUGENEWASHINGTON
&RiskOfficer
DukeUniversity’sChancellorforHealthAffairs;
PresidentandChiefExecutiveOfficer,
JOSEPHJ.WOLK*
DukeUniversityHealthSystem
ExecutiveVicePresident,ChiefFinancialOfficer
MARKA.WEINBERGER
FormerChairmanandChiefExecutiveOfficer, *Member,ExecutiveCommittee
Ernst&Young
NADJAY.WEST
FormerLieutenantGeneral,U.S.Army
Johnson&Johnson2022AnnualReportPRINCIPALOFFICE STOCKLISTING JOHNSON&JOHNSONONLINE
OneJohnson&JohnsonPlaza Johnson&JohnsonCommonStock
NewBrunswick,NewJersey08933 ListedonNewYorkStockExchange Ourwebsite:www.jnj.com
(732)524-0400 StockSymbol:JNJ
http://www.jnj.com/media-center
2023ANNUALMEETINGOFSHAREHOLDERS SHAREHOLDERRELATIONSCONTACT
Thursday,April27,2023 MarcLarkins
CorporateSecretary www.facebook.com/jnj
10:00a.m.(EasternStandardTime)
(732)524-2455
Meetingheldvirtuallyat www.twitter.com/JNJNews
www.twitter.com/JNJCares
www.virtualshareholdermeeting.com/JNJ2023. INVESTORRELATIONSCONTACT
Allshareholdersasoftherecorddateof JessicaMoore
www.youtube.com/jnj
February28,2023areinvitedtoattend. VicePresident,InvestorRelations
(800)950-5089
AformalNoticeofAnnualMeeting,
investor-relations@its.jnj.com http://www.linkedin.com/company/
ProxyStatementandproxyhavebeen
johnson-&-johnson
madeavailabletoshareholders.
STOCKTRANSFERAGENTANDREGISTRAR
2022ANNUALREPORTONFORM10-KAND Questionsregardingstockholdings,
2023PROXYSTATEMENT certificatereplacement/transfer,dividends
Johnson&Johnson’sAnnualReportonForm10-K andaddresschangesshouldbedirectedto
forthefiscalyearendedJanuary1,2023is ourstocktransferagentandregistrarat:
Thelatestnews,conferenceannouncements,
includedinthisAnnualReportinitsentirety,with ComputershareTrustCompany,N.A.
pressreleasesandCompanyperformance
theexceptionofcertainexhibits.TheForm10-K, P.O.Box3006
completewithallofitsexhibits,isavailableonour Providence,RI02490-3006
informationcanbefoundatinvestor.jnj.com.
websiteatwww.investor.jnj.com/sec.cfm,andthe Overnightmail: Theinformationonthesewebsitesshouldnot
SEC’swebsiteatwww.sec.gov. ComputershareTrustCompany,N.A. bedeemedtobepartofthisAnnualReport.
150RoyalStreet,Suite101
Shareholdersmayalsoobtaincopiesofthe
Canton,MA02021
exhibits,our2022AnnualReporton
(800)328-9033or(781)575-2718
Form10-Kandour2023ProxyStatement,
withoutcharge,uponwrittenrequesttothe Shareholderwebsite:
www.computershare.com/investor
OfficeoftheCorporateSecretaryatour
principalofficeaddress,orbycalling
DividendReinvestmentPlan
(800)950-5089.
ThePlanallowsforfullorpartialdividend
ELECTRONICDELIVERYNOTIFICATION reinvestmentandadditionalcash
investmentsupto$50,000peryearin
The2023ProxyStatementandour2022Annual
Johnson&JohnsonCommonStockwithout
Reportareavailableonourwebsite
pershareorservicechargesonstock
investor.jnj.com/asm.Shareholderswhoreceive
purchases.Ifyouareinterestedin
papercopiesofourProxyStatementandAnnual
participatinginthePlanandneedan
Reportbymailcanelecttoreceiveinsteadane-
enrollmentformand/ormoreinformation,
mailmessagewithalinktothosedocumentsonthe
pleasecallthePlanadministrator,
Internet.Registeredshareholdersmayenrollin
ComputershareTrustCompany,N.A.at
electronicdeliveryat:www.computershare-na.com/
(800)328-9033or(781)575-2718 C132107
green.Beneficialshareholders(whoholdsharesof
(outsidetheU.S.)oraccessonlineat
Johnson&JohnsonCommonStockthroughabank,
www.computershare.com/investor.
brokerorotherholderofrecord)generallycan
enrollforelectronicdeliveryat:
HearingImpaired ©Johnson&Johnson2023.Allrights
enroll.icsdelivery.com/jnj.
Shareholderswhohaveinquiriesregarding reserved.
stock-relatedmatterscancommunicate
directlywithComputershareTrustCompany,
N.A.viaatelecommunicationsdevice(TDD).
Thetelephonenumberforthisserviceis
(800)952-9245or(781)575-2692
(outsidetheU.S.).